Acacia Research-(CBMX)-die CombiIMatrix- Vogelgrippe Play & rebounder 2006 ??? - 500 Beiträge pro Seite

[whyso]

Wer kennt sie nicht-"die Vogelgrppe" problematik-und auch alle firmen die an die Medikamentenbehandlung hierfür arbeiten kennt man auch irgendwie mit am Rande-aber wer kennt die Firma CMBX-die mit ein bereits zugelassene Erkennungsprodukt für verschiedene arten der Krankheitsausbruch (auch für Sars & HIV Identifizierungen geeignet) schon auf dem Markt agiert???

Prüfgeräte können bald wieder sehr "SEXY" werden am US Markt-falls die Avian Flu Entwicklung sich weiter ausbreitet wie bis dato
http://worldnetdaily.com/news/article.asp?ARTICLE_ID=47583

Kanada ist auch nicht mehr soweit weg von die Amerikanische Heimat:
http://www.inspection.gc.ca/english/anima/heasan/disemala/av…

Einmal ein "solchen Räumungsfall" im herzen von Amerika-DANN BOOM-ist ein Army Einsatz mit deren bereits zugelassene "Gerätschaft" http://biz.yahoo.com/bw/050928/285187.html?.v=1
von Vertriebspartner COMBIMATRIX nicht mehr allzuweit Entfernt die anderen würden dann brav folgen.

Ein starke "rebounder" Anstieg wäre alleine aus sicht der Charttechnik dann schon fällig:


Mit ein gesamte MK von 70,19 Mio.USD & mit nur knapp 39 Mio Shares draussen -das schmeckt irgendwie nach ein drastiche Unterbewertung

Was heute (für manche Anlegern) wie Blei im Depot liegt, könnte morgen auf einmal richtig schönen "flügeln" bekommen-ich bin lieber vorher dabei!!!

Viele Grüße & good trades mit die COMBIMATRIX,
Whyso

P.S. Last, but not least-die Cooperation zwischen Novavavax(NVAX) & CBMX http://biz.yahoo.com/bw/051109/20051109005217.html?.v=1 wird sich sicherlich für beide Indischen CEO`s mit die besten Internationale verbindungen auch langfristig auszahlen

[whyso]

N`abend hier etwas aktuelle "Lesematerial" zum Thema Combimatrix:

Hot Stocks Investor - CombiMatrix für Mutige- 09:32 08.11.05

Alle Aktien in dieser Nachricht: ACACIA RESEARCH-COMB.


Die Experten von "Hot Stocks Investor" halten die Aktie von CombiMatrix (ISIN US0038812089/ WKN 164630) für den mutigen Anleger für interessant.

Nach Ansicht der Experten könnte CombiMatrix von der aktuellen H5N1-Diskussion profitieren. Das Unternehmen habe sich auf die Herstellung von Microarrays zur beschleunigten und einfacheren Identifizierung von DNA spezialisiert. Nun habe die Gesellschaft auch für den H5N1-Virus Microarrays für einen schnellen DNA-Abgleich entwickelt. Damit könnten in weniger als vier Stunden die Grippeviren nachgewiesen werden. Zudem könne der Microarray auch Mutationen und Veränderungen sichtbar machen, wodurch neue Stämme bzw. Unterstämme leicht identifiziert werden könnten.

Mutige Anleger steigen bei der CombiMatrix-Aktie mit einer kleinen Position ein, raten die Experten von "Hot Stocks Investor".

http://www.aktiencheck.de/analysen/artikel.m?id=1105040&menu…

CombiMatrix bei Schwäche kaufen 02.11.2005 Der Aktionär


Die Experten vom Anlegermagazin "Der Aktionär" raten, die Aktie von CombiMatrix (ISIN US0038812089 / WKN 164630) bei Schwäche zu kaufen.

Der Titel habe in der letzten Woche an einem Tag einen Kurssprung von 60% vollzogen. Hintergrund des rasanten Kursanstiegs sei eine Meldung des Unternehmens gewesen, wonach es einen sogenannten Microarray entwickelt habe. Dieser solle Grippeviren viel schneller als bisher identifizieren können. Zu den Viren gehöre auch der Vogelgrippevirus H5N1.

Nach Ansicht der Experten dürfte sich der positive Trend bei Vogelgrippe-Werten fortsetzen, wovon auch CombiMatrix profitieren sollte.

Bei Schwäche können sich Anleger einige Stücke der CombiMatrix-Aktie ins Depot legen, so die Experten von "Der Aktionär".
http://www.aktiencheck.de/analysen/artikel.m?id=1096115&menu…

Combimatrix Turnaround-Chance 15.09.2005 Biotech-Report

Für die Experten vom "Biotech-Report" stellt die Aktie von Combimatrix (ISIN US0038812089 / WKN 164630) eine Turnaround-Chance dar.

Combimatrix sei eine Tochter der Acacia Research Corpoartion und habe sich auf die Entwicklung von Nano-Biochips, sogenannte Microarrys, spezialisiert.

Seit 2001 bestehe eine auf 15 Jahre angelegte Kooperation mit Roche. Die Schweizer würden die Chips für diagnostische Zwecke verwenden und zum Teil auch weiterentwickeln und verkaufen. Dafür erhalte Combimatrix Lizenzgebühren und werde an den Verkaufserlösen beteiligt.


Für das US-Militär forsche die US-Firma an Chips, die chemische Kampfstoffe erkennen und anschließend analysieren sollten.

In 2004 habe die Gesellschaft einen Umsatz in Höhe von 19,6 Mio. USD generiert (davon seien 17,3 Mio. USD aus einer Einmalzahlung von Roche). In 2005 dürften ca. 6,9 Mio. USD durch die Bücher gehen, 2006 dann ca. 10 Mio. USD und 2007 20 Mio. USD. Das EPS dürfte wegen hohen Forschungs- und Entwicklungsaufwendungen in diesem Jahr nach Ansicht von Analysten bei -0,44 USD liegen. 2006 werde dann ein EPS von -0,39 USD und 2007 von -0,21 USD geschätzt. Die Gewinnzone solle 2008 erreicht werden. Dann sollte ein Gewinn je Aktie von 0,15 USD erwirtschaftet werden.

Zuletzt habe die Aktie herbe Kursverluste hinnehmen müssen, was nicht zuletzt an der schlechten Stimmung gegenüber Nanotech-Werten gelegen haben dürfte. Doch die Chancen für eine Trendwende stünden nach Ansicht der Experten nicht schlecht: So liege die Marktkapitalisierung des Titels bei nur noch 52 Mio. USD, während das Unternehmen zum Ende des ersten Halbjahres über 55 Mio. USD an Cash-Mitteln verfügt habe.

Sehr risikobereite Anleger spekulieren auf den Turnaround und legen sich einige Stücke der Combimatrix-Aktie als Beimischung ins Depot, so die Experten vom "Biotech-Report".

http://www.aktiencheck.de/analysen/artikel.m?id=1017806&menu…

CombiMatrix Group to Receive $10.5 Million from Acacia Research Registered Direct Offering 16.09.2005 13:02

Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) today announced that it has obtained commitments to purchase approximately $10.5 million of its Acacia Research-CombiMatrix common stock in a registered direct offering. Under the terms of the transaction, Acacia will sell approximately 6.4 million shares of its Acacia Research-CombiMatrix common stock at $1.65 per share to a select group of accredited investors and grant to such investors five year warrants for the purchase of an aggregate of approximately 1.6 million shares of common stock at an exercise price of $2.40 per share. Piper Jaffray&Co. acted as exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The shares of common stock may only be offered by means of a prospectus. Copies of the prospectus supplement and accompanying base prospectus can be obtained from Piper Jaffray&Co. at 405 Lexington Avenue, 58th Floor, New York, New York 10174-5899, fax [phone].

ABOUT ACACIA RESEARCH COPORATION

Acacia Research Corporation (Nachrichten) comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 33 patent portfolios, which include over 120 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement&synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption&product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason

http://www.finanznachrichten.de/nachrichten-2005-09/artikel-…

Die Aktie kann man zurzeit für 1,50 ins Depot legen

Good trades & gute chancen sollte man nützen!
Whyso

[kgv1]

Hallo W,
ich sehe du hast mein lieblings Aktie auch noch entdeckt.
Typisch CBMX, heute Schwach, morgen Stark.
Kgv1

[kgv1]

Die schlafen noch,
Kgv1

[whyso]

Ja nee, ist klar...-


Mit CBMX stehen wir auch ganz am Anfang von die Entwicklung, sowie bei NVAX-sie werden sich gegenseitig nach oben "zerren"...die Platform für 06` wird jetzt erst gelegt.

Warten & freuen ist nun angesagt!
Whyso

[whyso]

CombiMatrix Enters into Distribution Agreement with Singapore-Based Cell Sciences Thursday December 1, 3:03 pm ET ....
Cell Sciences to Distribute Arrays Including CombiMatrix`s New Influenza Array (also v. good for NVAX)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Dec. 1, 2005--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has entered into a non-exclusive distribution agreement with Cell Sciences Pte Ltd, a wholly owned subsidiary of the CyGenics Group, to distribute CombiMatrix products and services in Singapore, Malaysia, Thailand, Philippines, Hong Kong, and Indonesia. Under the terms of the agreement, Cell Sciences will market and sell CustomArrays(TM) and CatalogArrays(TM), including the recently introduced Influenza Research Microarray.
"We are very pleased to have expanded our distribution network into South East Asia," said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix. "I am confident that by joining forces with Cell Sciences, we can accelerate sales growth and enhance our collective market share."

"Cell Sciences has identified CombiMatrix`s platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology," said Dr. John Khong, Vice President & General Manager, Cell Sciences. "This has a huge market potential in the Asia Pacific region and we look forward to a long and fruitful relationship. In addition, we are impressed with CombiMatrix`s recently launched influenza array. As we enter the flu season, and focus on H5N1 intensifies, we anticipate increased interest in this array."

[whyso]

Keiner da?
Schade KGV alte junge-da hast du heute was verpasst in Amiland

Der Druck im Kessel wird jetzt weiter anhalten, bis weit über die $3,5 Marke, check it out (leider nicht Verlinkbar)

http://stockcharts.com/def/servlet/SC.web?c=Cbmx,uu[h,a]dacl…

Dort angekommen können sie ein kleinen Verschnaufspause einlegen, der Anstieg ist jetzt wirklich mehr als überfällig!

GN8-Whyso

[kgv1]

Na alte Schwede, bin da, und freue mich in aller Stille.
http://stockcharts.com/gallery/?CBMX
Kgv1

[kgv1]

CombiMatrix`s platform technology....
by: mpetisth1
Long-Term Sentiment: Strong Buy 12/01/05 09:34 am
Msg: 21342 of 21414

"I am CONFIDENT that by joining forces with Cell Sciences, we can ACCELERATE SALES GROWTH and enhance our collective MARKET SHARE." "Cell Sciences has identified CombiMatrix`s platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology," said Mr Steven Fang, Group CEO, CyGenics. "This has a HUGE MARKET POTENTIAL in the Asia Pacific region and we look forward to a long and fruitful relationship."

http://www.acnnewswire.net/article.asp?Art_ID=30903&lang=

Big revenue in 2006 $$$$$$

[whyso]

Das verstehe ich wirklich gar nicht, wie kann man nuur dieser Aktie zu mickrigen 1,65 aus sein Depot verkaufen z.Zt

11:35:27 1,65 2000
11:28:05 1,69 300
11:03:27 1,70 2500
10:31:52 1,69 500
10:14:14 1,69 590
09:48:33 1,69 589
09:41:47 bG 1,66 6000 ???
09:03:43 1,67 1003

Die fangen dooch erst an zu laufen, die story & Aussichten sind jetzt von alle feinsten, und manche verlassen das Boot bevor es überhaupt aus dem Hafen gekommen ist...
Naja, jeder muss es selbstverständlich selber wissen!

Ich denke wir werden hier "viel Musik" erleben im Kurs von CBMX demnächst,
Whyso

[kgv1]

Re: Broker advice raise sell limit orde
by: callmanagementthenprofit (45/the friendly skies) 12/01/05 05:36 pm
Msg: 21412 of 21484

That is very, very good advice.

Asia has an enormous contingent of trading firms who will start accumulating positions in CBMX all month long due to this development today.

Today`s news is affirmation of Combimatrix`s significant progress in the multi-national adoption of their platform technology which until now was at best relegated by most to mere educated speculation.

No hype intended but what lay ahead for Combimatrix will make NVAX and the other penny stock companies small potatoes by comparison.

While Combimatrix is not a H5N1-influenza play, per se, it is not a 1-trick pony, flavor-of-the-season trade either like most other stocks are that have attracted all the speculative money and momentum over the "buzz" surrounding Avian Flu.

What that fast trader money which bull raided the stock earlier did not understand and failed to consider, as some of us have read of those numerous posters who sold during and after the retracement and encouraged everyone else to do the same, was the ongoing developments and progress of Combimatrix`s other multi-national developments addressing not just Avian Flu detection but all strains for influenza and Avian Flu mutation, including all types of cancers, viruses, and other insideous diseases.

Let us be reminded and repeat as nescessary that, unlike other Avian Flu plays, Combimatrix is a multi-faceted biotechnology company with a virtual monopoly on a platform that is already slated to become a new standard for wide scale disease detection and analysis for high efficacy, next generation therapies.

Some of the highest calibre names in medicine and science have recently either joined Combimatrix and signed on or voiced support for their science and platform.

The great thing now is that nearly everyone has left Combimatrix stock for other plays which were benefitting entirely from momentum caused by media "buzz" over influenza alone.

The point?! There is an armada of potential buyers which will rotate out of those other 1-trick pony plays to come into CBMX. We now know that the "potential" that Combimatrix possesses is enormous as confirmed by today`s news and among other ongoing company developments.


Kgv1

[whyso]

http://www.deraktionaer.de/xist4c/web/Combimatrix---Spiel-au…

Sehr gut zusammengfefasst Ich freue mich auf 2006 mit CBMX & NVAX
Späte erkenntnis-ist jedenfalls besser als gar keins!
Whyso

[kgv1]

Yahoooo calling

Impressed and disappointed
by: query_handling
Long-Term Sentiment: Strong Buy 12/04/05 06:06 am
Msg: 21546 of 21553

I`m impressed and disappointed about Combimatrix 2005.
Impressed about the pipeline. At least 3 new products should make it to the market the next 2 quarters. I expect the BTS System, the High Density Array and the first CMD Tool. With the 3 new products the company will erase all doubts about its positive future. A handful of products of such a high technical standard will most likely open doors to big life science companies for partnerships and into the portfolios of fund managers. All of this will help to increase sales and pps.
With a good sentiment one can say that an investment in CBMX should result in a big pay back. At this moment I don`t see any more risk. 6-12 months ago it was not like that but now with multiple products ready for launch the fair value of this company is at least $70 million. Break even by 3rd quarter 2006 is most likely.

I`m also disappointed. The sales strategy was wrong. It was a wrong decision of the current management. The CusomArray sales could be twice or three times as high with a better sales strategy. The management paniked once they realised it is not working this way and what followed was a financing at very unfavourable conditions.
No one is without failures. Overall the management did a very good job. Important is that now the checks and balances work.

The management has build a very strong fundament. Many other companies that are trading at 5x higher values are built on sand. CBMX is built on concrete.
Still to come the next 4 weeks is an update about CMD and the announcement of a contract with a Fortune 500 company in Japan. The CEO mentioned in one of his earlier calls that both will happen before year end.
January 2006 promises a big run in the pps.

[kgv1]

"CombiMatrix`s belief is that, for a variety of reasons, the world needs the ability to design new vaccines and to produce them much more rapidly than it can today," said Amit Kumar, Ph.D., President and CEO of CombiMatrix. "Reasons include the possibility of rapidly evolving natural threats such as bird flu and SARS as well as increased terrorist activity throughout the world. Novavax is working on technology to greatly speed vaccine development and production. Now CombiMatrix has the potential to make contributions to vaccine response as well. This procedure will be useful for other vaccine development programs in the future. This collaboration fits synergistically with our efforts in DNA arrays, defense-related work, drug development, and diagnostics."

[whyso]

Good linkhttp://www.otcbb.com/asp/Info_Center.asp

It just keeps getting better:


Acacia Units License Matsushita Electric Patents


12-05-05 07:52 AM EST
NEWPORT BEACH, Calif. -(Dow Jones)- Three more Acacia Research Corp. (ACTG) units licensed Matsushita Electric Industrial Co. (MC) technologies to settle patent infringement lawsuits.

In a press release Monday, Acacia said the contracts cover audio/video enhancement and synchronization technology, as well as image resolution enhancement technology.

IP Innovation LLC, AV Technologies LLC and New Medium Technologies LLC signed the latest round of licensing contracts. Matsushita`s complaints against these businesses were pending in the U.S. District Court for the Northern District of Illinois Eastern Division.

In mid-September, Acacia`s KY Data Systems LLC unit signed a non-exclusive license for Matsushita`s interactive television patents.

All four units are part of Acacia Technologies group.

Company Web site: http://www.acaciaresearch.com

-Eamon Beltran; Dow Jones Newswires; 201-938-5400; [e-mail]

(END) Dow Jones Newswires

12-05-050752ET

Copyright (c) 2005 Dow Jones & Company, Inc.

Copyright (C) 2005 Dow Jones & Company, Inc. All Rights
http://news.morningstar.com/news/DJ/M12/D05/200512050752DOWJ…

[whyso]

examples of "Other Current Assets"

COMBIMATRIX GROUP

During the three and nine months ended September 30, 2005,
the CombiMatrix groups operating activities included
the recognition of
$1.5 million and
$4.4 million in revenues,
including
$973,000 and
$3.0 million in government contract revenues under its two-year,
$5.9 million contract with the Department of Defense
to further the development of the CombiMatrix groups array technology
for the detection of biological threat agents, and
$490,000 and
$1.4 million in CustomArrayTM product, capital equipment and service revenues,

respectively.

The CombiMatrix group is negotiating additional contracts
with the government, which if successful will
extend the amount of revenues to be earned
beyond what is currently obligated
under its existing Department of Defense contract
which was originally award in March 2004.

http://biz.yahoo.com/e/051107/actg10-q.html
-------

5-Aug-05 10-Q

COMBIMATRIX GROUP

During the three and six months ended June 30, 2005,
the CombiMatrix group`s operating activities included
the recognition of
$1.9 million and
$2.9 million in revenues,
including
$1.3 million and
$2.0 million in government contract revenues under its two-year,
$5.9 million contract with the Department of Defense
to further the development of the CombiMatrix group`s array technology
for the detection of biological threat agents, and
$576,000 and
$914,000 in CustomArray(TM) product, capital equipment and service revenues, respectively.
CustomArray(TM) product, capital equipment and service revenues
increased 70% over the prior quarter and
have increased each quarter since the launch of CustomArray(TM) in March of 2004,

signaling continued growth of the CombiMatrix`s business and
acceptance of its products and services in the marketplace.

http://biz.yahoo.com/e/050805/actg10-q.html
-------

15-Mar-05 10-Q

All payments received to date from Furuno and Toppan, totaling
$3.4 million, have been classified as deferred revenues.

$306,000 from the sale of a genomics array synthesizer system
and related array products to two institutions in Japan.

http://biz.yahoo.com/e/050315/actg10-k.html
========

<

Cash Burn gap to be made up by:

Continued Milestone payments,
New Gov`t Contract payments,
New BioDectector sales,
New Custom Synthesizer sales,
New CMD Lab Services,
New CMD Cancer Arrays,
New Partnering deals,
CustomArray sales,
Bird Flu Array sales,
NVAX agreement,
World-wide Distribution network sales.

and probably a surprise or two we can`t anticipate.
(like Roche showing renewed interest in MatrixArray or
Intel or ST actually releasing a Combi-based product.)

long and strong-let the turn-around begin

[whyso]

Merill mit 3,06% CBMX im Depot

http://www.amex.com/?href=/othProd/prodInf/OpPiIndComp.jsp?P…

Gestern für 1,45€ zu haben!
Whyso

[kgv1]

So wird geshortet:

"To short a stock you are effectively selling something you DO NOT own. Shares are loaned to you by your broker, you sell them, the cash goes in your margin account and I believe is "restricted" from other use. When you buy the stock back at your lower price (presumably) the money for that purchase is taken from those "restricted" funds...and you get what is left over....PROFIT!!!"

Einfach-oder?
Halt die anteile fest, eh basta!
Kgv1

[whyso]

Acacia Technologies Acquires Patents for Information Monitoring Technology Monday December 12, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Dec. 12, 2005--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has acquired patents relating to technology that can be used to monitor and diagnose information, and alert users of changes based upon user based criteria.

"As Acacia`s licensing success grows, we are attracting more companies and inventors that want us to license and enforce their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "The Information Monitoring technology is the 33rd patented technology that we have acquired this year," concluded Mr. Ryan

The technology, which can be incorporated into software products, can be used to monitor infrastructure components such as hardware, servers, networks, and operating systems, and can also be used for information monitoring and other information databases.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 35 patent portfolios, which include over 130 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
Acacia Research Corporation
Rob Stewart (Investor Relations), 949-480-8300
Fax: [phone]
[e-mail]

@KGV, verstehst du das??? only good news-und trotzdem fallende Kurse??? aber nicht mehr lange sagt mir mein Gefühl

Ich kaufe jedenfalls immer noch kräftig dazu,
Grüße & UP
Whyso

[whyso]

Tagesentwicklung (weil ich das vergessen habe mit die Charts beim Threaderöffnung)

und der Link nach USA über Marketwatch:
http://www.marketwatch.com/tools/quotes/quotes.asp?symb=cbmx…

Bis dann über die 2$ Marke wieder,
Whyso

[whyso]

Mit Dank an dem edlen spender...

Nochmal 2k in FSE zu 1,40 (der Makler ging beim reinstellen direkt auf ask 1,45 -meine leichte stürheit hat soeben 100€ gespaart ) so nicht freundschen!

Habt ihr das gelesen
http://biz.yahoo.com/bw/051214/20051214005230.html?.v=1


Jetzt iist CBMX an die Reihe...

Steigende Grüße,
Whyso

[whyso]

1,60 USD (1,39E)
Ready for take off???
Whyso

[nort.]

whyso,

ich lege ja auch schon zu... erstmal in kleineren Paketchen und wenn sich die Story anfängt zu bestätigen, kann man auch noch mitgehen. Die Basis ist ja schon vorhanden...

Was für CBMX spricht sind folgende Gründe:

- NVAX Kooperation --> Vogelgrippephantasie. Durch die Kooperation mit NVAX kann CBMX an der VLP Technologie, die die herkümmliche Technologie auf Ei-Basis für Impfstoffe ablösen kann.

- H1N5 Microarrays --> Durch diese kann der H1N5 Virus innerhalb weniger Minuten nachgwiesen werden. Ebenfalls kann bei einer Mutation (hatten wir ursprünglich nicht H1N9?) das Verfahren schnell angepasst werden. Analog NVAX

- Terrorabwähr --> CBMX arbeitet eng mit der US-Regierung zusammen. Sie sind an Regierungsprojekten beteiligt u.a. für Terrorabwehr - Nachweis von Biokampfmitteln

- Nanophantasie --> Ist für mich eher ein Schmakerl. Noch ein zuschwaches Pflänzechen... Entwicklung von neuen Material(oberflächen)

- Unter einen $ sollte es nicht gehen, da meines Wissens nach die Deplazierung von der Nasdaq droht. Das werden einige nicht wollen... Somit sollten wir hier einen Boden haben.

- Der Chart bietet eine schöne GAP bis 3$ oder mehr.

- Der Chart geht sein 1,5 Jahren nicht mehr mit Acacia Technologis. Für mich etwas unverständlich. Entweder kommt Acacia zurück oder CBMX hoch. Wahrscheinlich wird die Wahrheit in der Mitte zu finden sein.

- US-Boards benennen CBMX als Basis 2006. Hier braut sich zumindest was zusammen.

- Umsätze ziehen an, Marketing und Forschungsausgaben steigen... Trotzdem ist das finanzielle Ergebnis nicht gut. Ist aber im Kurs meiner Meinung nach schon enthalten

- Analyseservices ziehen an (analog Analytik Jena): Gammelfleisch, Grippe, Wasserverschmutzung (China, Bodensee), HIV (Ansteckungsraten ziehen an), ...

- Sonstige Kooperationen mit: Roche, Nasa (soll da nicht das Marsprogramm groß aufgezogen werden?), ...

Was mir noch fehlt sind Insiderkäufe. Hier kann ich keine finden. Acacia Technologis wird verkauft ;-) Wenn die noch kommen, sollte es kein Halten mehr geben...

Reicht das erstmal?

nort

[nort.]

Congress seeks $3.8 billion for avian flu

By Joanne Kenen Sun Dec 18,10:23 PM ET

WASHINGTON (Reuters) - U.S. lawmakers on Sunday tentatively agreed to earmark $3.78 billion to prepare for a possible avian flu epidemic, about half what the Senate and White House had wanted for stockpiling anti-viral drugs and vaccines and helping communities plan for a health crisis.

The Senate had wanted $8 billion, and
President Bush last month requested $7 billion but faced resistance from fiscal conservatives.

The bill does not include a provision sought by Senate Majority Leader Bill Frist, a Tennessee Republican, that would protect vaccine, drug and medical device makers against lawsuits in a public health or bioterror emergency.

But Frist aides said the bill`s text was not finalized and would not rule out including a liability measure very late Sunday night or early Monday.

The bird flu funds were included in a defense spending bill, and the fate of that bill was uncertain in the Senate.

The House aimed to vote on it very early Monday and the Senate would then take it up later in the week. But it contains many controversial provisions, including opening up the Arctic National Wildlife Refuge in Alaska, and some Democrats and possibly some Republican moderates may try to block it.

Democrats in Congress had urged quick approval of the full $8 billion, which would also be used to step up worldwide surveillance of the disease and help localities cope with an outbreak. But with Congress already reeling under Hurricane Katrina cleanup and huge budget deficits, conservatives did not want to spend the full amount at this time without cutting other federal spending.

For the past several years, avian flu has been killing poultry flocks in Asia and the animal disease has been spreading globally.

At least 139 people have been infected with avian flu and about half have died. But scientists fear a pandemic-style human outbreak if the virus mutates in a way that allows person-to-person transmission.

[nort.]

Weiteres Vogelgrippe-Opfer

In Indonesien ist nach Angaben des Gesundheitsministeriums ein achtjähriger Junge an Vogelgrippe gestorben. Ein Ministeriumssprecher in Jakarta teilte mit, eine Bestätigung durch die Weltgesundheitsorganisation (WHO) stehe noch aus.

Das Kind sei in der vergangenen Woche in einem dicht besiedelten Wohngebiet der Hauptstadt gestorben. Unbekannt sei, ob der Junge Kontakt mit Vögeln gehabt habe. Ein WHO-Labor in Hongkong hat bisher neun Todesfälle durch das Vogelgrippe-Virus H5N1 in Indonesien bestätigt.

WHO-Koordinator David Nabarro sagte zum Abschluss eines zweitägigen Indonesien-Besuchs, es gebe keine Hinweise dafür, dass Vogelgrippe von Mensch zu Mensch übertragen worden sei. Die hohe Bevölkerungsdichte und die große Zahl von Geflügel machten es aber wahrscheinlich, das eine Pandemie in Indonesien beginnen könnte. "Wir sind darüber sehr besorgt", sagte er.

Bisher haben sich in Asien meist Menschen mit Vogelgrippe angesteckt, die sehr engen Kontakt zu Vögeln hatten. Mindestens 71 Menschen starben an der Krankheit.

[whyso]

Guten morgen Nort

was für ein Satz

19 Dec 2005
Chinese Authorities have confirmed that a 35-year-old man from Jiangxi (south east province) has H5N1 avian flu infection. He became ill on 4th December, with a high temperature, and then developed pneumonia.

The man is in intensive care.

Near the man`s house, ducks infected with the H5 virus were found. His relatives and close friends have been placed under medical observation.

This is the sixth confirmed case of a human infected with bird flu in China. So far, two have died.

Chinese authorities are considering culling the whole nation`s farmed live poultry stock, over 10 billion chickens.

So far, human cases of bird flu infection have been found in the following areas of China:
-- Anhui
-- Guangxi
-- Hunan
-- Jiangxi
-- Liaoning


Um Zehn Billionen Hühern etwas visueller darzustellen muss man die jetzt folgende Rechnung vor Augen haben:

Deutsche Staatsverschuldung:
Die heutige Verschuldung der Bundesrepublik Deutschland beträgt in diesem Augenblick etwa 1.609.439.966.559 Euro.
In Worten: 1 Billion, 609 Milliarden, 439 Millionen, 966 Tausend, 559 Euro !

Chinas Problem ist tatsächlich erheblich größer als sie bisher zugegeben haben, wenn sie diese drastische Maßnahmen jetzt schon in Erwägung ziehen...

Stay tuned-wir stehen hier ganz am Anfang,
Whyso

[whyso]

Ich bleibe dabei, der Rebound ist nicht weit entfernt, und es wird auch GEWALTIG ausfallen wenn es eintrifft....

http://www.researchandmarkets.com/search.asp?q=Nvax&cat_id=0

[nort.]

[posting]19.334.414 von whyso am 19.12.05 12:14:06[/posting]Es wird nichts anderes behauptet

[nort.]

Flu season arrives in U.S.

http://news.yahoo.com/s/nm/20051216/hl_nm/flu_season_dc;_ylt…

"Flu season usually peaks in the United States in February and March."

[nort.]

EILMELDUNG - Vogelgrippe greift auf der Krim weiter um sich
13:57 | 19/ 12/ 2005

Druckversion

KIEW, 19. Dezember (RIA Nowosti). Auf dem gesamten Territorium der Krim wird in dieser Woche Quarantäne angeordnet, um die weitere Ausbreitung von Vogelgrippe auf der Halbinsel zu verhindern. Das teilte am Montag der ukrainische Fernsehsender TNT unter Berufung auf Quellen im Ministerium für Agrarpolitik der Ukraine mit.

Den Angaben zufolge besteht der Minister für Agrarpolitik, Alexander Baranowski, auf der baldigsten Einführung der Quarantäne. Nur mit dieser Maßname könne die Ausbreitung des Vogelgrippe-Virus auf der Krim gestoppt und das Übergreifen der Seuche auf weitere Gebiete verhindert werden.

Die Infektion wurde bis Montagmorgen in 15 Ortschaften der Krim nachgewiesen. Das Virus H5N1 auf der Krim war von einem russischen und einem Londoner Labor bestätigt worden. Eine Gruppe von Fachleuten hat bisher mindestens 60 000 Hühner, Enten und Gänse vernichtet.

Trotz der Quarantäne, die bereits in einzelnen Rayons eingeführt wurde, greift Vogelgrippe weiter um sich.



http://de.rian.ru/world/20051219/42556023.html

[whyso]

[posting]19.334.685 von nort. am 19.12.05 12:37:14[/posting]@nort,
die kommende Flu Saison in Amiland wird Benzin auf NVAX`s & CBMX`s bereits angezündeten Feuer giessen...
Whyso

[whyso]

and don`t forget...
http://www.forbes.com/2005/12/16/amgen-merck-insmed-cx_pk_12…

[nort.]

Artikel drucken Fenster schliessen
Combimatrix - Spiel auf Zeit

Mit einer speziellen Technologie von Combimatrix können synthetische Impftsoffe künftig wesentlich schneller hergestellt werden. In der Bilanz werden jetzt die Erfolge der vergangenen Monate deutlich sichtbar.



Von Martin Weiß

Die Vogelgrippe breitet sich in Asien derzeit mit einer hohen Geschwindigkeit aus. Nicht selten sind auch Menschen von der Krankheit betroffen. Insgesamt arbeiten weltweit neun Pharmaunternehmen an einem Impfstoff, um die Epidemie in den Griff zu bekommen. Allerdings ist das gar nicht so leicht, denn das Virus kann andere Erreger in sein Erbgut aufnehmen und sich damit in relativ kurzer Zeit verändern. Ein vormals geeigneter Impfstoff kann nach einer Mutation seine Wirksamkeit komplett verlieren. Das US-Unternehmen Novavax - der aktionär berichtete in Ausgabe 44/05 - hat erste Erfolge in der Entwicklung eines Impfstoffes gegen das H5N1-Virus erzielt. Allerdings befindet man sich erst in der präklinischen Phase. Das Produkt wäre damit erst in vielen Jahren auf dem Markt.
Combimatrix macht`s möglich

Die Zusammenarbeit mit Combimatrix könnte den Entwicklungsprozess allerdings enorm beschleunigen. Der Hersteller von Biochips ist im Besitz einer Technologie, mit der die Herstellung synthetischer Impfstoffe deutlich schneller als bisher möglich ist. Zudem kann man damit die genetische Zusammensetzung exakt kontrollieren und so schneller auf Mutationen reagieren. Für Combimatrix läuft es gut in diesem Jahr: Im August hat man seinen ersten DNA-Synthesizer auf den Markt gebracht. Mit ihm können Unternehmen in ihren eigenen Forschungszentren Mikrodatenträger mit biomolekularen Informationen anlegen. Im dritten Quartal erhielt man einen weiteren Auftrag von der Air Force zur Entwicklung und Produktion eines Biochips zum Aufspüren von Krankheitserregern, die sich auf Atemwege und Wunden ausbreiten.
Umsatzschub

Die Erfolge der vergangenen Monate haben das Zahlenwerk von Combimatrix spürbar beeinflusst. So stieg der Umsatz im dritten Quartal 2005 gegenüber dem Vorjahreszeitraum um 94 Prozent auf 1,40 Millionen Dollar. Zwei Drittel davon erzielte Combimatrix mit Regierungsaufträgen. Der Verlust blieb mit 3,88 Millionen Dollar auf dem Niveau des Vorjahresquartals. Mit einem Cash-Bestand von 24,7 Millionen Dollar verfügt man zudem ein über ein solides finanzielles Polster.
Nicht zögern

Die Combimatrix-Aktie reagierte auf die Kooperation mit Novavax mit einem deutlichen Kurssprung, jedoch konnte der Abwärtstrend nicht endgültig gebrochen werden. Allerdings verhinderte die Unterstützung bei 1,50 Euro weitere Rücksetzer. Anleger scheinen das ganze Potenzial des Unternehmens bislang nicht erkannt zu haben. Wer auf die Zukunft von Combimatrix setzen will, sollte beim aktuellen Kurs nicht zögern. Der Wert empfiehlt sich jedoch ausschließlich für spekulative Investoren.

Artikel aus DER AKTIONÄR 49/05

[kgv1]

Strong Buy 2006

http://stconsultant.blogspot.com/2005/10/bush-to-push-for-ma…
Min 4E bis Juni 2006,
Kgv1

[kgv1]

Whyso-BM

[nort.]

CBMX & NVAX has the solution ...


...patients suffering from the H5N1 flu strain and treated with Tamiflu had died, including two who developed resistance.

The reports increase suggested levels of resistance to nearly 10 per cent, or three out of the 31 known human cases of H5N1 treated with Tamiflu, which is marketed by Roche of Switzerland.

The study raises new questions about the drug...

http://news.ft.com/cms/s/fd320708-724f-11da-9ff7-0000779e234…

[whyso]

N`abend zusammen!

Diese Kursverlauf ist jenseits von "NORMAL", hier sind eindeutig Hedge fonds kräftig zugange..das schöne ist wenn sie sich "satt gesaugt haben" wird der Kurs sich genauso schnell gen Norden drehen-ich glaube der Boden ist nicht mehr weit Entfernt
http://www.magnum.com/hedgefunds/strategies.asp

CBMX hat meiner Meinung nach das Zeug Renner 06 zu werden mit NVAX zusammen!
Die Eckdaten:Marktkapital.56,15 Mio.USD- Stücke 39 Mio.

Die Unterbewertung wird hoffentlich sehr bald ersichtlich,
Viele Grüße,
Whyso

[nort.]

schöne Zusammenfassung über CBMX:

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…




http://www.businessweek.com/magazine/content/05_12/c3925096_…

http://books.google.com/books?q=Combimatrix&lr=&ie=UTF-8

http://www.eet.com/news/semi/showArticle.jhtml?articleID=174…

http://www.msnbc.msn.com/id/8552323/

http://www.isotron.net/pdf/nano.pdf

http://www.asu.edu/news/research/smartdrugs_082605.htm

http://www.asu.edu/news/printedition/documents/082605.pdf

http://www.aidsinfonyc.org/tag/tx/pipeline2005.html

http://www.japancorp.net/Article.Asp?Art_ID=8064

http://www.ece.ucsb.edu/courses/ECE594/594F_F05Gossard/More%…

regarding NVAX & CBMX:

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=… sid=1602900656&mid=20203

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=… sid=1602900656&mid=20210

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=… sid=1602900656&mid=20211

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=… sid=1602900656&mid=20209

[kgv1]

FTD von Whyso aus der NVAX Forum

Vogelgrippe-Opfer sterben trotz Tamiflu

VON Nicole Kohnert, Berlin, und Martin Virtel, Hamburg 23.12.2005

Gefährliches Virus entwickelte in Vietnam Resistenz gegen Grippemedikament · Weitere Vorfälle in Indonesien

In Vietnam sind zwei mit dem Vogelgrippevirus H5N1 infizierte Patienten gestorben, obwohl sie mit dem bekannten Gegenmittel Tamiflu behandelt wurden. „Diese Beobachtungen deuten darauf hin, dass sich bei der zurzeit empfohlenen Behandlung mit dem Mittel Tamiflu eine Resistenz entwickeln kann“, schreiben Forscher der Universität Oxford in einer Studie, die gestern in dem amerikanischen Fachmagazin „New England Journal of Medicine“ veröffentlicht wurde.

Tamiflu-resistente Mutationen von H5N1 waren bereits zuvor aufgetreten. Bislang waren die widerstandsfähigen Erreger allerdings zugleich nicht tödlich für Menschen und weniger infektiös als das Original. Dem gestern veröffentlichten Bericht zufolge hatte eine 13-jährige vietnamesische Patientin aber zunächst auf die Behandlung mit Tamiflu reagiert. Danach hatte sich die Krankheit wieder verschlimmert, das Mädchen war schließlich nach acht Tagen gestorben. Der andere Patient überlebte zwei Wochen.

Die zwei Todesfälle könnten auf isolierte Mutationen zurückzuführen sein. Die resistenten Viren haben möglicherweise den Tod ihrer Opfer nicht lange überlebt. Vielleicht ist der Befund aus Vietnam aber auch ein erster Hinweis auf einen neuen resistenten Virenstamm.

„Es ist nicht überraschend, dass es eine Resistenz gegen Tamiflu gibt“, sagte eine Sprecherin des Robert-Koch-Instituts in Berlin. „Neu ist, dass es ein mutiertes Virus gibt, das die Ursache für den Tod der beiden Mädchen sein könnte.“

Ärzte eines Krankenhauses in der vietnamesischen Hauptstadt Ho-Chi-Minh-Stadt berichten in derselben Zeitschrift, dass acht Vogelgrippepatienten mit Tamiflu behandelt wurden und vier von ihnen dennoch starben. Bei zwei Mädchen habe das Virus Resistenzen entwickelt. In der Zeitschrift rufen Mediziner auf, neben Tamiflu auch andere Medikamente zu nutzen.

Das vom Schweizer Pharmakonzern Roche hergestellte Medikament gilt als bestes Mittel gegen eine mögliche menschliche Grippeepidemie, die sich aus dem Tierseuchenvirus H5N1 entwickeln könnte. Allein in Deutschland haben die Behörden deswegen im Durchschnitt für zehn Prozent der Bevölkerung das Grippemittel gekauft. Pläne für den Fall einer Epidemie mit Tamiflu-resistenten Viren gibt es nicht; bis zur massenhaften Verfügbarkeit einer Impfung vergehen nach Ausbruch einer Epidemie mehrere Monate.

„Diese Studie zeigt erneut, wie bedrohlich das Virus ist“, sagte der Virologe Professor John Oxford der BBC. Es müsse mehr Geld investiert werden, um zusätzliche Medikamente gegen die Krankheit zu entwickeln. Sie zeige auch, dass das Virus in manchen Menschen schnell mutieren könne, um resistent gegen Tamiflu zu werden.

Das Vogelgrippevirus ist derzeit nicht von Mensch zu Mensch übertragbar. Wer sich beim Kontakt mit Vögeln infiziert, stirbt allerdings mit hoher Wahrscheinlichkeit: Das Vogelgrippevirus vom Typ H5N1 hat seit 2003 bisher insgesamt 71 Menschen in Indonesien, Thailand, Vietnam, China und Kambodscha getötet, über die Hälfte der Infizierten. Experten befürchten jedoch eine Mutation des Virus zu einer Variante, die sehr tödlich bleibt und direkt von Mensch zu Mensch übertragen werden kann. Diese Mutation könnte eine Pandemie mit Millionen Opfern auf der ganzen Welt auslösen.

Der Tamiflu-Hersteller Roche warnte vor Hysterie. „Das ist derzeit keine pandemische Variante“, sagte David Ready, Leiter der Roche-Grippepandemie-Task-Force, in einer Telefonkonferenz. Der Aktienkurs von Roche, der infolge der Angst vor einer Pandemie in den vergangenen Monaten deutlich zugelegt hatte, gab gestern um 0,8 Prozent nach.

Bisher seien 138 Infektionen mit H5N1 bekannt geworden, von denen 31 mit Tamiflu behandelt wurden, so Roche. Bereits im Oktober hatte ein 14-jähriges vietnamesisches Mädchen eine Infektion mit H5N1 nach der Behandlung mit Tamiflu überlebt. Allerdings wurde danach in ihrem Körper eine gegen das Mittel resistente Variante des Virus gefunden.

Die Weltgesundheitsorganisation bestätigte zwei weitere Vogelgrippe-Todesfälle in Indonesien. Opfer seien ein achtjähriger Junge und ein 39 Jahre alter Mann. Damit starben im vergangenen halben Jahr insgesamt elf Menschen in Indonesien an der Vogelgrippe.

[nort.]

CBMX shed 28% over the quarter, including a gap down on huge volume following the recent stock sale announcement, and is down 58% YTD. The company has completed about 68% of its contract to develop biological threat detection technology for the DoD, which generated a gross margin of only 6% last quarter. While technology developed under the agreement may have much greater long-term significance for CBMX than its current financial impact suggests, replacing more of this revenue with microarray product sales, which showed a gross margin of 68%, puts the company on a much better track toward profitability. Whether it can continue to grow product sales at such a strong rate once it builds a larger base remains to be seen.

[whyso]

Wow, das sind top Numbers Nort-du bist immer sehr tüchtig unterwegs, dass muss ich schon sagen

Hier ist ein recht "informativer Link" nach drüben
http://www.pinksheets.com/quote/quote.jsp?symbol=CBMX
Bis später (muss schnell zum Flughafen)
Whyso

[whyso]

Tja, wiedermal ein Dank an dem edlen Spender(hoffe ich das er/sie dass ist zumindest)...

14:28:08 1,17 8200 zu 1,17 und den Chart (ausgebombt) völlig egal welche version davon man anschaut:


@Andre Kostolany,
ich habe mich-(gegen ihren guten Rat)-entschieden diese fallende messer doch noch aufzufangen um die
1,17 "we will see, ob das gut geht, oder auch nicht!

So, und jetzt "wiedermal" zurück zum Tee trinken,
Whyso

[whyso]

Ich schätze der letzendlichen Ausbruch ist nicht mehr weit Entfernt

-----------------------
Peking (Reuters) - China hat der Weltgesundheitsorganisation (WHO) nach deren Angaben bislang noch keine Proben von mit der Vogelgrippe infizierten Tieren geliefert. Am Donnerstag hatte China über den dritten Vogelgrippe-Toten in dem Land berichtet.

Die WHO habe China um Übersendung von Proben gebeten, was bislang aber noch nicht passiert sei, erklärte die WHO. Warum die chinesische Regierung nur schriftliche Informationen und kein Material für Labortests geliefert habe, sei unklar, sagte der WHO-Sprecher in Peking, Roy Wadia, am Freitag.

China hat sich bisher nur bereit erklärt, Virus-Proben von erkrankten Menschen zugänglich zu machen. "Tier-Viren könnten aber wichtiger sein, weil dieser Erreger immer noch vor allem bei Tieren zu beobachten ist", erklärte Wadia.

Die amtliche Nachrichtenagentur Xinhua hatte am Donnerstag den Tod einer Fabrikarbeiterin aus der südöstlichen Provinz Fujian gemeldet. In der Provinz war die Krankheit nach offizieller Darstellung bisher nicht unter Tieren ausgebrochen.

Insgesamt erlagen der Vogelgrippe in Asien seit 2003 mehr als 70 Menschen. Wissenschaftler befürchten, das Virus könne mutieren und dann von Menschen zu Mensch übertragen werden.
http://de.today.reuters.com/news/newsArticle.aspx?type=topNe…

Meiner Prognose: CBMX wird sich selbst wieder entdecken im frühen 2006, und es wird mich nicht wundern wenn NVAX die Firma komplett übernehmen wird

We will see...Guten Rutsch allerseits,
Whyso

P.S. die letzte CBMX aktien 2005 hätte man heute haben können für schlappe 1,15 ...

[nort.]

Aus yahoo Forum...

nasdaq.com

CBMX

High Volume alert!

Overall Summary

BULLISH:
Probability - Intermediate trend possibly bullish, Sideways trend near lower support.
Probability - Oversold, odds favor long trades.
Probability - Short term strong pullback, pullback may start to slow.
Probability - Mild bullish 3 day chart pattern with Strong 3 day accumulation.
Confirmation - Extreme bullish 1 day moneyflow
Probability - Strong Down trend (1 month), may start to turn sideways.
Confirmation - at support

BEARISH: None

SUMMARY:
5 bullish probability indicators. 10, (Score)
2 bullish confirmation indicators. Very Strong Outperform, short term (1-6 wks)

No bearish indicators. 100%, Bullish vs. 0%, Bearish



Upside Trade

Trade indicators for long trades.

TRADE QUALITY: 95%, Excellent
Good trade quality is a combination of good profit, profit/loss ratio and target potential.

TARGET 1 Price: 1.67 Profit: 22.8% , for a typical rally.

Profit/Loss Ratio: 4.5 : 1 - Excellent

TARGET 1 POTENTIAL: Good, there are 1 resistance areas on the way to Target 1.

TARGET 2 Price: 1.81 Profit: 33.1% ,

Profit/Loss Ratio: 6.5 : 1 - Excellent for an extreme rally.


http://www.nasdaq.com/asp/stock_consultant.asp?&symbol=cbmx&…

Could this be the last of the Bargain Basement Prices?

Looks like it wants to break out,
yet it looks like most are waiting confirmation of "The Reversal",
before Stepping up and Buying in, in a BIG way.

Kind of a Catch-22, isn`t it?

They want to buy, but they don`t want to get burned.

What that old saying?
No Guts, No Glory.

On the other hand:
He who hesistates ...
live to fight another day.


6 months from now, will $1.36
look like a Steal,
or a ceiling that`s out of reach?

Nasdaq.com seems to thinks $1.36
is a no-brainer for longs.
They think CBMX IS OVERSOLD!

Imagine that; I been saying that for months!

[whyso]

The Key words for CBMX in 2006: -EARLY DETECTION -

Early detection would buy time in forestalling the further spread of the virus — a situation no one wants.

“Initially, wild birds are primarily victims. Someday they may become vectors. We don’t know how that will play out,” Ip said. “What I would like to see is the virus stopped before it gets to America so we don’t see the last reel of this film played out in North America.”

http://www.msnbc.msn.com/id/10624217/

[nort.]

U.S. Biochips Demand to Reach $2.1 Billion in 2008

U.S. demand for biochip products and services is projected
to increase 20 percent annually to $2.1 billion in 2008.

Biochips (or microarrays) will account for $875 million
of this amount, with the remaining $1.2 billion divided
among related instruments, reagents and other consumables,
software, and services.

Growth will be led by uses in drug discovery and
epidemiological research, with protein analysis and
gene expression profiling providing the fastest expanding applications.

DNA chips will continue to generate broad usage in genomic research.
However, sales of laboratory and protein chips will expand faster
as pharmaceutical researchers shift the focus of
drug discovery toward proteomics.

By 2013, protein chips will account for the largest demand
among microarrays, at over $1 billion.

Demand for biochip instruments is projected to grow over
13 percent annually from 2003.

Growth opportunities for detection, sample preparation
and hybridization equipment will continue to expand
as pharmaceutical and other life science researchers
diversify into proteomic investigations.

The market for biochip-related services is projected
to reach $600 million in 2008, up 19 percent annually
from 2003.

Subscription rights to use proprietary technologies and systems,
along with contract research in the area of drug discovery,
will continue to make up the largest share of demand.

[nort.]

CombiMatrix Expands Catalog Microarray Product Line By Launching microRNA arrays
Wednesday January 4, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 4, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has launched a series of catalog microarrays specifically designed for microRNA analysis. MicroRNAs (miRNAs) are small, RNA molecules encoded in the genomes of plants and animals. These highly conserved, ~21-mer RNAs regulate the expression of genes and are believed to be critical to controlling physiology in areas that include neural development, viral disease, and cancer.

Each miRNA is thought to regulate multiple genes, and since hundreds of miRNA genes are predicted to be present in higher eukaryotes the potential regulatory circuitry afforded by miRNAs is enormous. There is evidence that miRNAs may act as key regulators of processes as diverse as early development, cell proliferation and cell death, apoptosis and fat metabolism, and cell differentiation.

"CombiMatrix`s portfolio of miRNAs includes arrays that can be used in studies for human, dog, rat, mouse, and other plants and animals. This portfolio will grow throughout 2006," said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix. "The versatility of our platform technology enables us to launch a large number of arrays and will facilitate the update of each array as new miRNA sequences are discovered. Consequently, our miRNA arrays will be the most up-to-date and comprehensive arrays available on the market."


"As we enter 2006, we plan to launch a number of new products and services, including arrays and equipment," said Dr. Amit Kumar, President and CEO of CombiMatrix. "These products and services will address established markets as well as emerging markets including molecular diagnostics and defense applications."



ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 38 patent portfolios, which include over 140 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[gehtsjetztendlich]

bin seit heute mit 1k zu 1,22€ dabei....

[nort.]

Glückwunsch

[nort.]

Haufenweise BUY-Optionen von CBMX ausgegeben zu $1.37 und $6.94.


A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:52:06 ACACIA RESEARCH CORP ACTG DEBOOM FRED A Director 15,000 $6.94 86,400 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:52:06 ACACIA RESEARCH CORP ACTG DEBOOM FRED A Director 15,000 $1.37 74,736 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:35:55 ACACIA RESEARCH CORP ACTG GRAZIADIO G LOUIS III Director 15,000 $6.94 82,000 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:35:55 ACACIA RESEARCH CORP ACTG GRAZIADIO G LOUIS III Director 15,000 $1.37 72,280 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:34:20 ACACIA RESEARCH CORP ACTG FRYKMAN EDWARD W Director 15,000 $6.94 80,600 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:34:20 ACACIA RESEARCH CORP ACTG FRYKMAN EDWARD W Director 15,000 $1.37 74,736 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:31:01 ACACIA RESEARCH CORP ACTG CURRIE F RIDGON Director 15,000 $6.94 59,000 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:31:01 ACACIA RESEARCH CORP ACTG CURRIE F RIDGON Director 15,000 $1.37 142,500 D View
A Stock Option (Right To Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:29:26 ACACIA RESEARCH CORP ACTG AKIN THOMAS B Director 15,000 $6.94 86,400 D View
A Stock Option (Right to Buy) 2006-01-03 N/A 2016-01-03 2006-01-04
18:29:26 ACACIA RESEARCH CORP ACTG AKIN THOMAS B Director 15,000 $1.37 129,736 D View
M Stock Option (Right to Buy) 2005-12-01 N/A 2013-01-07 2005-12-01
14:04:58 ACACIA RESEARCH CORP ACTG CURRIE F RIDGON Director 2,000 $2.00 44,000 D View

[nort.]

[posting]19.543.330 von gehtsjetztendlich am 05.01.06 11:38:42[/posting]übrigens, gutes timing

[nort.]

Schaut Euch die Tendenz des Profits an...

http://www.nasdaq.com/asp/ExtendFund.asp?CompanyID=1231&NumP…

[nort.]

und die Gewichtung von CBMX steigt

Index Components as of: 01/05/06
Company Name Symbol % Weighting
pSivida Ltd. (ADS) PSDV 4.50%
Arrowhead Research ARWR 3.98%
Cabot Corp CBT 3.96%
Headwaters Inc. HW 3.93%
Tegal Corp TGAL 3.93%
Nve Corp NVEC 3.92%
Fei Co FEIC 3.91%
Acacia Research-Combimatrix CBMX 3.86%
Veeco Instruments VECO 3.84%
Ultratech Inc UTEK 3.80%
Symyx Technologies SMMX 3.78%
Amcol Intl ACO 3.76%
Harris & Harris Group TINY 3.74%
Novavax Inc NVAX 3.69%
Jmar Technologies JMAR 3.68%
Pharmacopeia Inc ACCL 3.68%
Westaim Corp WEDX 3.67%
Mts Systems MTSC 3.66%
Flamel Technologies Ads FLML 3.63%
Nanophase Technologies NANX 3.58%
Nanogen Inc NGEN 3.51%
Biosante Pharmaceuticals BPA 3.50%
Immunicon Corp IMMC 3.43%
Lumera Corp LMRA 3.42%
Skyepharma Plc Ads SKYE 3.35%
Altair Nanotechnologies ALTI 3.22%
Kopin Corp KOPN 3.08%


http://www.amex.com/?href=/othProd/prodInf/OpPiIndComp.jsp?P…

[bubu]

Zur Eröffnung in USA rechne ich persönlich mit einem kleinen Gap. Frage mich aber, ob das interessant sein würde, jetzt noch vorab in D ein paar Stücke zu ergattern.

Langfristige Tendenz?????
Wünsche mir natürlich Kurse jenseits der 2 USD

Gruß
bubu

[nort.]

[posting]19.562.976 von bubu am 06.01.06 10:56:58[/posting]kann mir gut vorstellen, dass wir uns in den nächsten Wochen zwischen 3-4 $ einpendeln...

[nort.]

Chicken industry plans to test every flock for bird flu
By LIBBY QUAID / The Associated Press

WASHINGTON — Seeking to reassure people that chicken is safe to eat, companies that raise chickens said Thursday they will test every flock for bird flu before the birds are slaughtered.

Companies that account for more than 90 percent of the nearly 10 billion chickens produced in 2005 in the U.S. have signed up for the testing program and said it expects more to follow, according to the National Chicken Council, a trade group that represents producers.

“We just want to assure people of the safety of the food supply,” council spokesman Richard Lobb said.

Consumption of chicken in the U.S. has held steady despite worries about a bird flu strain that has infected millions of birds throughout Asia and parts of Europe and has killed 74 people.

The average person in the U.S. ate 85 pounds of chicken last year, compared with 84 pounds in 2004, according to the Agriculture Department.

Chicken prices at the grocery store have dropped in recent months, mostly because production is up and exports are down, said David Harvey, a poultry analyst for the department’s Economic Research Service.

The council did not say what companies are participating, although Lobb said, “Practically all the big ones are in it.” Tyson Foods Inc. has more than one-quarter of the market, followed by Pilgrim’s Pride Corp., Gold Kist Inc. and Perdue Farms Inc.

Tyson has been testing for bird flu and expanded efforts last fall, spokesman Gary Mickelson said. The company now tests all of its flocks and conducts 15,000 tests each week, he said. Pilgrim’s Pride said Thursday it was joining in the testing program.

Lobb said many companies already are testing ahead of the program’s start on Jan. 16. The program is voluntary. Companies will cover the costs; the council said it does not have cost estimates.

Georgia-based Fieldale Farms will spend “couple hundred thousand dollars a year,” on testing, executive vice president Tom Hensley said.

“It’s a big number to a little chicken company in Georgia, but it’s worth every cent,” Hensley said. Fieldale started the tests last month.

The plan is for 11 birds to be tested from each chicken flock, or farm. The council said the average flock has 55,000 to 60,000 chickens and that there are an estimated 150,000 flocks produced year. That would mean more than 1.6 million chickens would be tested.

Blood test samples from 11 birds would provide a confidence level of 95 percent of detecting an infection in a flock where 25 percent of birds are infected, said a government expert, Andrew R. Rhorer. He heads the department’s National Poultry Improvement Plan, which focuses on disease prevention.

[bubu]

Ich habe mir in D heute noch ein zusätzliches Päckchen gekauft. Falls es, wie ich vermute, in USA zur Eröffnung zu einem GAP kommt, werden diese Stücke gleich versilbert.

D aktuell:
1,38 x 1,42 (FRA)
1,40 x 1,43 (STU)

Gruß
bubu

[nort.]

CombiMatrix` Announces First CombiCore(TM) Access Program with the University of Colorado; University of Colorado to Obtain Widespread Access to CombiMatrix Microarray Technology
Business Wire - January 06, 2006 07:00

NEWPORT BEACH, Calif., Jan 06, 2006 (BUSINESS WIRE) -- Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group has signed a non-exclusive agreement with The University of Colorado Health Sciences Center under the Company`s CombiCore(TM) access program. Under this agreement all University of Colorado researchers can purchase, through their microarray core facility, CombiMatrix` CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the University of Colorado Health Science Center Microarray Core Facility (UCHSC).

"Our Core lab is dedicated to providing high-quality microarray laboratory instruction, service, and consultation to the research and clinical community affiliated with UCHSC and other research institutions throughout the nation. This program provides us an opportunity to support our customers with more microarray choices for their specific needs," stated Dr. Bifeng Gao, the UCHSC Core Facility Manager.

"The University of Colorado is one of the nation`s largest academic consumers of microarrays," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "Now researchers can purchase our products through the UCHSC Core Facility, in addition to array processing services which include sample processing and data analysis. This agreement provides researchers with unique access to our products by enabling one of the world`s most experienced Microarray Core Facilities providing complete array services and application training."

"CombiMatrix` CombiCore program is a special program designed to meet the unique needs of academic organizations, with core microarray facilities, that want broad access to CombiMatrix`s DNA microarray technology," said Dr. Amit Kumar President and CEO of CombiMatrix. "This program is designed to leverage the infrastructure that already exists at each university to market, sell and deliver products. We hope to add additional university core laboratories to our CombiCore program."

The University of Colorado at Denver and Health Sciences Center is one of three campuses in the University of Colorado system. Located in Denver and Aurora, Colo., the center includes schools of medicine, nursing, pharmacy, and dentistry, a graduate school and a teaching hospital. For more information, visit the Web site at http://microarray.uchsc.edu/.

[nort.]

[posting]19.566.047 von bubu am 06.01.06 13:00:33[/posting]mit einer GAP rechne ich ebenfalls. Aber gleich schmeißen?

[bubu]

habe heute nochmals 5k zu 1,41 nachgefasst, mehr als ich haben möchte. Wenn ein GAP kommt (denke da an ca. 1,80 USD) dann sind die wieder weg. Der Rest bleibt im Depot, wobei ich davon ebenfalls bei ca. 2 USD mich von einem Teil trennen würde.

Gruß
bubu

[bubu]

oops,
meinte GAP im Bereich 1,80 - max. 2,00 USD, eher 1,90

[gehtsjetztendlich]

bin wieder raus zu 1,40€
Gier frißt Hirn....
Werd GBMX aber im Auge behalten

[bubu]

@gehtsjetztendlich

.. der Anstieg kam gestern in der letzten Stunde.
Mag sein, daß du recht hast, aber ich rechne zur Eröffnung erst einmal noch mit Folgekäufen.

Gruß
bubu

[gehtsjetztendlich]

vorbörslich 10c im Minus - aber mit geringsten Umsätzen
Wie schon gesagt: 15% Gewinn in 24h muss reichen!
Allen Investierten ein glückliches Händchen...

[nort.]

wonach sieht das aus?

[nort.]

CBMX Präsentation

http://www.combimatrix.com/cbmxpresentation_files/v3_documen…

[nort.]

presentation (discussed bird flu array)

http://wsw.com/webcast/rrshq7/cbmx/

[nort.]

Interview mit Amit Kumar CEO CBMX:

http://www.devicelink.com/ivdt/archive/04/05/009.html

[weisserwal]

Weitere Kinder an Vogelgrippe erkrankt

Istanbul (dpa) - Bei zwei weiteren Kindern, die in der Türkei mit Verdacht auf Vogelgrippe behandelt werden, ist das lebensgefährliche Virus H5N1 festgestellt worden. Sie seien fünf und acht Jahre alt und stammten aus zwei verschiedenen Familien, berichtete der türkische Nachrichtensender NTV am Sonntag.
Vogelgrippe in der Türkei
Türkische Veterinäre sammeln wegen der Vogelgrippe vorsorglich Hühner ein und töten sie.
© dpa
Vergrößern (Symbol)

Insgesamt würden in der Universitätsklinik in der osttürkischen Stadt Van zurzeit 35 Patienten behandelt. In der Klinik waren in den vergangenen Tagen bereits drei von vier Geschwistern einer anderen Familie gestorben. Sie stammten aus der Kleinstadt Dogubeyazit an der Grenze zum Iran.

Neue Verdachtsfälle wurden auch aus anderen Städten des Landes gemeldet. So wurden in Istanbul 12 Menschen unter Beobachtung gestellt, die Hühner aus dem Osten des Landes gegessen haben sollen. Bei einer siebenköpfigen Familie aus der nordosttürkischen Provinz Igdir, die ebenfalls in Istanbul untersucht wurden war, habe sich der Verdacht hingegen als unbegründet erwiesen, berichtete NTV.

[nort.]

Hat CBMX nicht gute Connections nach Japan?

Poultry workers `may have bird flu`
From correspondents in Tokyo
08jan06
ABOUT 40 poultry farm workers in northern Japan are suspected of having been infected with a mild form of bird flu, an official and a media report said today.

Officials at the National Institute of Infectious Diseases have been testing the blood samples of the workers in Ibaraki Prefecture (state) since the first outbreak of bird flu there in June.

Some of them have tested positive for antibodies to H5N2 - a milder strain of bird flu than the deadly H5N1 - in preliminary tests.

The presence of antibodies means the people were once exposed, according to Hiroshi Takimoto, an official of the Health Ministry.

[whyso]

Hier i.m.h.o. das beste Posting was ich bis jetzt bei Yahoo im CBMX Forum lesen dürfte bisher als absolut dingfeste Argument für CBMX`s Technologie und erfolgreiche überleben im Markt

Here it tells
by: smitty_webern 01/08/06 08:38 am Msg: 23386 of 23392

"She had similar symptoms and the clinical course of her illness was the same," Cheng said. "So it would be very probable that she died of H5N1, but right now we don`t have the laboratory test to prove that."

Das sagt wirklich alles aus
Whyso

[nort.]

jetzt ist es in der Hauptstadt der Türkei...

http://de.today.reuters.com/news/newsArticle.aspx?type=world…

[nort.]

Acacia Research Announces Plan for CombiMatrix to Become Independent Public Company
Monday January 9, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 9, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that its Board of Directors has approved a plan for its wholly-owned subsidiary, CombiMatrix Corporation, to become an independent public company. Acacia expects to complete the transaction in the second quarter of 2006 subject to receiving a satisfactory tax opinion from legal counsel and completing the required filings with the Securities and Exchange Commission. If the conditions are met, Acacia will redeem all of the issued and outstanding shares of Acacia Research-CombiMatrix common stock (CBMX) for all of the common stock of CombiMatrix Corporation, which will register its stock under the Securities Act of 1934 and plans to list its shares for trading on Nasdaq.

ADVERTISEMENT
"The Board of Directors decision enables CombiMatrix Corporation to become an independent public company. This will benefit both companies by eliminating the risk factors associated with the current capital structure," commented Paul Ryan, Chairman and CEO of Acacia. "The separation of the two companies should enable each company to optimize its own identity and business strategy, making an investment in the companies more attractive to investors," concluded Mr. Ryan.

Dr. Amit Kumar, President and CEO of CombiMatrix, said, "As an independent public company, CombiMatrix Corporation should have better visibility in the health care market and enable the public markets to better value the company."

[nort.]

CombiMatrix`s Bird Flu (Influenza A Research Microarray) chip was featured on local ABC affiliate KOMO 4 on October 28, 2005.

http://www.combimatrix.com/news_komo102805.htm

[nort.]

Partner von CBMX:

"
Here`s the link. Oppenheimer bought 6mm shares of NVAX, owning 12% total shares outstanding. I feel sorry for all the shorts and the dumbass who said he shorted at 4.20.

I wonder what Oppenheimer`s cost basis is.

http://sec.gov/Archives/edgar/data/728889/000072888906000010…

"

[whyso]

Das CBMX Chart entdeckt sich selbst

Die endgültigen Turnaround ist jetzt nicht mehr weit



Die Frage bleibt, wie lange braucht NVAX um CBMX komplett zu übernehmen, insbesondere jetzt wo sie demnächst als "stand alone player" auf dem Markt erscheinen werden????

Fragen über Fragen!

Long & Strong,
Whyso

[gehtsjetztendlich]

habe kleinere Position in ACTG aufgebaut....

[nort.]

[posting]19.630.554 von gehtsjetztendlich am 10.01.06 08:30:28[/posting]

[whyso]

[posting]19.633.856 von nort. am 10.01.06 11:56:15[/posting]Yepp-habe ich genausowenig verstanden wie du

[gehtsjetztendlich]

ACTG = Acacia Research Corporation NQ: ACTG
CBMX = Acacia Research Corporation NQ: CBMX

alles klar?

[nort.]

[posting]19.639.505 von gehtsjetztendlich am 10.01.06 17:34:41[/posting]ACTG = Acacia Technology Corporation NQ: ACTG
CBMX = Acacia Research Corporation NQ: CBMX

[whyso]

[posting]19.639.505 von gehtsjetztendlich am 10.01.06 17:34:41[/posting]Danke für die Aufklärung!

vielleicht hätte folgendes besser gepasst:
ACTG = Acacia Research Corporation NQ: RYAN
CBMX = Acacia Research Corporation NQ: KUMAR

und übrigens beide werden (gott sei dank) nicht mehr lange in einen Topf geschmissen...ich denke Bald gibt es Inder unter sich mit ein SINGH & KUMAR Paarung

Die einen stellen der "strain" fest, die anderen heilen entsprechend nach Möglichkeit!

CBMX bleibt für mein dafür halten die logische Wahl gegen ACTG,
But as the old saying goes, "Doctors differ, patients die"!!!
Whyso

[gehtsjetztendlich]

um den Sack zuzumachen: 0,5k NVAX zu 3,64€ geordert
und immer schön llllllllllocker bleiben

[nort.]

Denkt ihr was ich denke?

Homepage:

We are currently actively pursuing strategic alliances with distributors and customers.

http://www.cmdiagnostics.com/

CMDiagnostics is a fully owned subsidiary of CombiMatrix Corporation, a biotechnology company headquartered near Seattle, Washington, USA. Utilizing CombiMatrix’s patented electrochemical manufacturing process, CMDx is developing gene expression profiling products for use in clinical diagnostic applications.


The first cancer diagnostic products, based on Combimatrix`s CustomArray(TM) technology, will be available via CMDX`s Clinical Diagnostic Services Laboratory scheduled to open in mid 2006. Presently CMDx, has a research and development complex in Orange County, Ca. We are currently actively pursuing strategic alliance discussions with potential distributors and customers.

[nort.]

wenn das stimmt, dann kann man das Potential erahhhhnen...

Avian Flu News Tracker
January 10, 2006
1:15 p.m.: Bulgaria reported that a dozen hens died in a village in the southern part of the country near the borders with Turkey and Greece. Veterinary officials played down the possibility of bird flu as the cause, but sent samples for testing anyway. Results are expected within 10 days.

[nort.]

Mysteriöse H5N1-Fälle beunruhigen Experten

http://www.spiegel.de/wissenschaft/mensch/0,1518,394633,00.h…

Früherkennung!

[whyso]

Hi Nort,

mir ging was durch den Kopf bzgl CBMX & NVAX gestern Abend spät...könntest du es dir vorstellen das die geplante 100 Mio Shelf ausschließlich/oder überwiegend/ (für die CBMX übernahme von NVAX bereits reserviert sind ) aber natürlich erst dann wenn sie wieder "frei" sind ...

Das wurde das auch in etwa erklären wieso NVAX diese jetzt bekundet (Dez) aber das ganze zu einen späteren nicht genannten Zeitpunkt durchführen möchte>>>>
"Commenting on this new shelf registration statement, Gary C. Evans, Chairman of the Board, stated, "While Novavax currently has no current plans to access either the public or private equity markets, we believe it is prudent to be prepared for any future financial requirements that may be necessary as we continue to execute our business plan."

Was meinst du-wird auf Gegenseitigkeit die passende Zeitpunkt -und auch Börsenkurs-von beide players momentan abgewartet?

Bin echt gespannt wie es weiter geht mit beiden-hier ist was im Busch!
Whyso

[nort.]

whyso, das habe ich doch im yahoo schon geschrieben. Check NVAX Forum von diesem WE

Bin absolut Deiner Meinung, dass bei CBMX was im Busch ist. Der Kurs wird extrem gedrückt. Siehe Boards in US. Da wird es schon seit langer Zeit vermutet. Trotz der bird flu, besseren Erträge und Technologie News...

Könnte mir vorstellen, dass NVAX sich hier rund um die Vogelgrippe aufstellt. NVAX == die Impfcompany. Eine Neuerfindung der Firma!

Erkennen CBMX & NVAX und CMDX (rechtzeitiges Erkennen von Mutationen)
Erfinden NVAX (Impfstoff und Mutationsanpassungen)
Produktion NVAX & ???

Das ist DER Grund für mich bei CBMX dabei zu sein...


http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[nort.]

CBMX Aktien möglichst spät am Handelstag kaufen Da wird der Kurs am stärksten gedrückt.

[nort.]

Innovation Award Finalists for 2006

http://labautomation.org/LA/LA06/innovationFinalists.php

CBMX ist mit dabei

[nort.]

Patriot Act der USA mal gechekt?

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[nort.]

Es wird immer extremer...

" I would call this the smoking gun," said Dr. Gregory Poland, a Mayo Clinic flu specialist. " All of us have been concerned and have guessed that the data we have so far has been the tip of the iceberg."

http://news.yahoo.com/s/ap/bird_flu_study;_ylt=Ak1Rj_oEdC4VJ…

[nort.]

[posting]19.655.032 von whyso am 11.01.06 13:19:58[/posting]kennst Du die Cashbestände? Angeblich sollen die über 20 Mio$ haben. Bei einer MK von 60mio$

Da kann ja NVAX gleich noch eine kaufen...

[nort.]

Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has entered into a non-exclusive distribution agreement with Cold Spring Biotech to distribute CombiMatrix products and services in mainland China, Taiwan, and Hong Kong. Under the terms of the agreement, Cold Spring Biotech will market and sell CustomArrays(TM) and CatalogArrays(TM), including the recently introduced Influenza A Research Microarray.
ADVERTISEMENT


Cold Spring Biotech has three offices in Taiwan (Taipei, Taichung, and Tainan) and five offices in Mainland China (Beijing, Shanghai, Kwang Chou, Chendu, and Wuhan). With this distributed network and appropriate contacts, Cold Spring Biotech will market CombiMatrix products in rapidly growing markets and is positioned to provide CombiMatrix`s Influenza A Research Microarrays for testing of Influenza H5N1.

[nort.]

SEATTLE, Jan 12, 2006 /PRNewswire via COMTEX/ -- The Washington Biotechnology & Biomedical Association (WBBA), in collaboration with BC Biotech, BC MedTech, BioAlberta, Idaho Bioscience Association, Montana BioScience Alliance and the Oregon Bioscience Association, announced that 60 Pacific Northwest life science companies have been selected to present at Invest Northwest 2006.

Invest Northwest 2006, to be held March 21 and 22 in Seattle, is a forum for venture capitalists, analysts, investment bankers, institutional investors, pension fund managers, and pharmaceutical and biotech corporate partners to meet CEOs and senior executives from selected life science companies based in the Pacific Northwest. The following companies will present at Invest Northwest. Public companies are indicated by ticker symbol.

[nort.]

World Bank approves funds

http://news.yahoo.com/s/nm/20060112/ts_nm/birdflu_dc_26;_ylt…

[nort.]

Bird flu pandemic fears fuel diagnostic development
http://www.devicelink.com/ivdt/archive/06/01/011.html

[bubu]

@nort.de und @ALL

wäre es nicht sinnvoll, sich beim Posten auf einen der beiden Threads zu konzentrieren?
Macht doch keinen richtigen Spass, bei beiden Threads quasi immer identische Beiträge zu lesen.

Alternativ könnte man die Threads ja auch splitten. Einen zum quatschen und einen für Facts

Gruß
bubu

[whyso]

[posting]19.687.530 von bubu am 13.01.06 07:53:18[/posting]Guten Morgen Bubu

da gebe ich dir grundsätzlich Recht-(bin auch gegen überflüssiger Speicherplatzverschwendung in der heutiger Zeit )-das einzigste Problem was ich sehe ist das im anderen Thread das Begriff CBMX fehlt, und so wenn ein User gezielt auf der suche nach Combimatrix begibt(demnächst wichtiger als je für den "stand alone Unternehmen" )findet man unter den anderen Threads Begrifflichkeit leider keinen Eintrag.

Ich denke CBMX steht vor ein ganz gewaltigen Rebound, der China News von gestern "verpuffte im Marktverlauf", als ob die Instis mehr Zeit haben wollten dementspreschend auf die News reagieren zu können...bis ende Januar sollten wir die erste positiven Zückungen gen norden erlebt haben. Die Presse wird jetzt schon etwas hellhörig

http://www.devicelink.com/ivdt/archive/06/01/011.html

Und kaum zu glauben nach der gestrige News, daß man hier in BRD bereit war sich von seine anteile zu trennen zum mickrigen Kurs von 1,35€???

Mein persönliche Kursziel liegt im Bereich zwischen 7,50-10 USD bis zum Jahresende
(Komplette Übernahmegebote natürlich außenvorgelassen )

Good Trades mit CBMX,
Whyso

P.S. Nort dein #93 ist absolut richtig, good bizz einer Firma kaufen zu können mit ein starken Pipeline & Produkt, der sich selbst erstmal -(20 Mio Cash)- sehr gut tragen kann...

[nort.]

Hallo bubu,

ich würde gerne diesen Thread als Faktenthread belassen und den anderen eher zum "chatten" nehmen. Finde ich sehr positiv, wenn der Zug anfängt zu rollen, dass man alle Infos auf einen Schlag bekommt. Nur meine Meinung...


nort

[whyso]

Mit beide Firmen im Blickfang



Cold Spring Biotech has three offices in Taiwan (Taipei, Taichung, and Tainan) and five offices in Mainland China (Beijing, Shanghai, Kwang Chou, Chendu, and Wuhan). With this distributed network and appropriate contacts, Cold Spring Biotech will market CombiMatrix products in rapidly growing markets and is positioned to provide CombiMatrix`s Influenza A Research Microarrays for testing of Influenza H5N1.

"We are pleased to add CombiMatrix`s CustomArray platform to our portfolio," said Dr. Pasteur K. Tai, President of Cold Spring Biotech Corp. "For our customers, we provide a total solution, including instruments and consumables. We anticipate continued growth of our business as our portfolio expands, and specifically with the introduction of CombiMatrix products in the markets we serve. We also are now able to provide the most comprehensive influenza testing product that is commercially available, to the geographic region of the world where influenza concerns are the greatest."
http://biz.yahoo.com/bw/060112/20060112005138.html?.v=1

Dieser Nachricht sollten wir "NOCH" erleben in der Kursentwicklung demnächst-und manche haben jetzt schon aufgegeben???

Long & Strong 2006,
Whyso

[bubu]

[posting]19.690.464 von whyso am 13.01.06 10:41:40[/posting]@whyso und @nort.

dann macht doch den anderen Thread komplett dicht, indem ihr dort einfach nicht mehr postet.
So wird sich das Augenmerk automatisch auf diesen Thread konzentrieren..

BTW: bzgl. Speicherplatzverschwendung. Das Thema interessiert mich überhaupt nicht, vielmehr den Zwang, beide Threads bei neuen Beiträgen anklicken zu müssen um dann die identischen Beiträge zu lesen.


Und jetzt noch eine Frage @ALL,

was macht Acacia und was macht eigentlich Combimatrix und wie verläuft die Trennung?



Gruß
bubu

[whyso]

Was für ein Überschrift

Türke an mutiertem Vogelgrippe-Virus gestorben

http://onnachrichten.t-online.de/c/66/65/87/6665870.html

[nort.]

Hallo zusammen,

wollte Euch mal fragen, ob Ihr diesen Thread bei WO unter CBMX seht. Ich ebenfalls nicht. Somit wahrscheinlich auch andere User nicht. Um Redundanzen zu vermeiden, könnte man den Thread dann tatsächlich dort einbinden und primär nutzen.

nort

[nort.]

CombiMatrix Awarded Additional $2.4 Million from the US Department of Defense
Tuesday January 17, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 17, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that the 2006 Defense Appropriations Bill, recently signed by President Bush, includes an allocation of $2.4 million to fund efforts by CombiMatrix to develop further its microarray technologies for the detection of biological and chemical threat agents. Since March 2004, CombiMatrix has been awarded a $5.9 million contract, a $2.1 million contract that is currently in process, and today`s announced allocation of $2.4 million for its detection technologies.

ADVERTISEMENT
Under previously funded programs with the US government agencies including the Department of Defense, CombiMatrix demonstrated that its microarray could be multiplexed for the simultaneous detection of toxins, viruses, and bacteria using immunoassay and genomic analysis. Unique to this platform is "on chip" electrochemical detection, which eliminates the need for a large, complex and expensive optical system.

"This funding will allow us to continue our efforts to create a reliable and cost effective system for identifying both chemical and biological threat agents," stated Dr. David Danley, Director of Homeland Security and Defense Programs at CombiMatrix. "We anticipate that our success to date and future success on this program will enable us to continue working with the US government to meet its military, defense and anti-terrorist needs."

"We are pleased to be receiving additional funding for our defense oriented work. Though this development work is aimed at military, defense and anti-terrorist applications, much of the effort enables products for civilian applications. For example, our soon to be introduced electrochemical microarray reader was developed substantially with government funding," said Dr. Amit Kumar, President and CEO of CombiMatrix. "In addition to the above referenced awards, we currently have a contract from the U.S. Air Force for a new microarray that expands our Influenza A array to include other life-threatening upper respiratory infections such as SARS, viral and bacterial pneumonia and others. As we go forward, we will continue to monitor the needs of the US government and corresponding funding or procurement opportunities, and will pursue them ourselves or with partners."

[whyso]

Nun auch in Frankreich angekommen:
http://www.mdr.de/nachrichten/meldungen/2427363.html

[nort.]

[posting]19.825.944 von whyso am 22.01.06 15:18:07[/posting]" Die Frau war zu einem Familienbesuch in die türkische Region Tarsus gereist. Die Gegend gilt nicht als Vogelgrippegebiet. Die Patientin habe angegeben, tote Vögel gesehen, aber nicht angefasst zu haben, hieß es."

http://www.rundschau-online.de/html/artikel/1137918127152.sh…

[nort.]

The University of California Davis Joins CombiMatrix` CombiCore(TM) Access Program
Tuesday January 24, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 24, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has signed a non-exclusive agreement with The University of California Davis under the Company`s CombiCore(TM) access program. Under this agreement all University of California Davis researchers can purchase, through the UC Davis Genome Center, CombiMatrix` CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the UC Davis Genome Center.

ADVERTISEMENT
"UC Davis is one of the nation`s top public research universities having over 1,000 research labs focused on Plant Genetics, Human and Veterinary Medicine," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "Through the UC Davis Genome Center, researchers can purchase our products for usage in their lab, or utilize the Genome Center`s expertise in array processing services."

"The CombiCore access program was just initiated this quarter, and we have signed on two Universities, including UC Davis, that are considered leaders in genomic research," said Dr. Amit Kumar, President and CEO of CombiMatrix Corporation. "We hope to continue the momentum we have developed with these early partners."

http://biz.yahoo.com/bw/060124/20060124005275.html?.v=1

[nort.]

CombiMatrix Expands Relationship with INBIO
Thursday January 26, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 26, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that the CombiMatrix group has expanded its relationship with its existing partner, INBIO, for the Asia Pacific region. Major components of the expanded relationship include the transfer of day-to-day operational responsibility and majority ownership of CombiMatrix Corporation`s wholly owned subsidiary, CombiMatrix K.K. (the "KK") to INBIO along with an expanded distribution agreement that encompasses Japan.

ADVERTISEMENT
INBIO has obtained 67% of the voting interests in the KK and will expand its distribution agreements with the CombiMatrix group. INBIO will assume all operational and financial responsibilities of the KK including its liabilities. The CombiMatrix group will manage new business and strategic relationships and opportunities from its US headquarters in Mukilteo, Washington. The KK and INBIO will focus exclusively on sales of the CombiMatrix group`s products and services.

"As we continue to focus on the US market with our direct sales efforts we are pleased that our Australian partner INBIO has agreed to take on majority ownership of the KK, including financial and operational responsibilities. The experience of INBIO executives in the Japanese markets as well as their proximity will enable more efficient management of our now jointly owned Japanese subsidiary," said Dr. Amit Kumar, President and CEO of CombiMatrix.

"We are pleased with the opportunity to expand our geographic reach through this closer relationship with the CombiMatrix group and CombiMatrix K.K. We are confident that with the CombiMatrix group`s expanded suite of products and services that this will be a very beneficial relationship for all parties," said Mr. Mark Humble, President of INBIO.


http://biz.yahoo.com/bw/060126/20060126005190.html?.v=1

[nort.]

2 ways Take-Over Bids are calculated
by: misc_info_04 01/27/06 10:05 pm
Msg: 24559 of 24559

Key Statistics CBMX

VALUATION MEASURES
Market Cap (intraday): 57.32M
Enterprise Value (27-Jan-06)3: 34.57M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-06) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 12.07
Price/Book (mrq): 1.26
Enterprise Value/Revenue (ttm)3: 7.04
Enterprise Value/EBITDA (ttm)3: -2.573


Balance Sheet
Total Cash (mrq): 24.70M
Total Cash Per Share (mrq): 0.633
Total Debt (mrq): 0
Total Debt/Equity (mrq): 0
Current Ratio (mrq): 9.482
Book Value Per Share (mrq): 1.203


Cash Flow Statement
Operating Cash Flow (ttm): -12.88M
Levered Free Cash Flow (ttm): -9.08M


http://finance.yahoo.com/q/ks?s=CBMX


The key to Whitmanesque stock-picking:
Buy companies that are cheap and safe, and hold onto them.

(pg 1, Intro)


Graham used a company`s price/book ratio to determine whether
its stock was cheap. He wouldn`t buy a company unless
its stock was trading for less than 1.2 times book value per share.

---------------
CBMX: Price/Book (mrq): 1.26

1.26 * 1.2 = 1.512

$1.47 < $1.512

(Friday Close is less than this criteria;
So Graham would say CBMX is cheap, and a good take-over target.)
---------------

Whitman takes a different approach. He focuses on a company`s
takeover value, or how much he thinks a buyer would pay to buy
the whole company. Whitman doesn`t like to use book value
because he says it overlooks too many intangibles.

Whitman combs through a company`s financial statements
to figure out what he thinks the business is worth. He then looks
to see whether the company’s balance sheet has remained strong
in spite of setbacks in the business. He will generally pay
no more than 50% of what he thinks a buyer would pay
to acquire the whole firm. Whitman`s criteria for a safe stock
could be represented in this way:

Safe = little debt + great assets + low overhead

---------------
??? = 0 + 24.70M + (-12.88M)

11.82M

Market Cap: 57.32M
Enterprise Value: 34.57M
---------------


According to Whitman, a stock is safe if it meets three criteria:

1. The company has very little debt on its books.

2. The company has high-quality assets.

3. The company doesn`t require a huge overhead to generate cash.

---------------
1)
CBMX: Total Debt (mrq): 0

2)
CBMX: Total Cash (mrq): 24.70M

3)
CBMX: Operating Cash Flow (ttm): -12.88M
CBMX: Levered Free Cash Flow (ttm): -9.08M

---------------


http://news.morningstar.com/classroom2/course.asp?docId=3296…

[nort.]

[nort.]

Vogelgrippe, die Zugvögel kommen wieder zurück...

Erste Fälle von Vogelgrippe in Saudi-Arabien
29. Jan 13:02

http://www.netzeitung.de/vermischtes/vogelgrippe/379785.html

Gefährlicher Vogelgrippe-Typ in Nordzypern bestätigt
http://news.orf.at/index.html?url=http%3A//news.orf.at/ticke…

[nort.]

HERE WE GO:

Spanish Health Minister Elena Salgado, who was also at Davos, said any mass outbreak of bird flu in humans risked submerging health authorities.She called for more provision of instant diagnostic kits. "You cannot wait 24 or 48 hours taking the samples to laboratories outside the country."


http://www.turkishpress.com/news.asp?id=105655

[whyso]

Das Chart wird nicht mehr lange Bestand haben

Warum?....

Key Statistics CBMX
VALUATION MEASURES
Market Cap (intraday): 57.32M
Enterprise Value (27-Jan-06)3: 34.57M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-06) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 12.07
Price/Book (mrq): 1.26
Enterprise Value/Revenue (ttm)3: 7.04
Enterprise Value/EBITDA (ttm)3: -2.573


Balance Sheet
Total Cash (mrq): 24.70M
Total Cash Per Share (mrq): 0.633
Total Debt (mrq): 0
Total Debt/Equity (mrq): 0
Current Ratio (mrq): 9.482
Book Value Per Share (mrq): 1.203


Cash Flow Statement
Operating Cash Flow (ttm): -12.88M
Levered Free Cash Flow (ttm): -9.08M
http://finance.yahoo.com/q/ks?s=CBMX

Der kommende Rebound wir "Hart & Heftig" ausfallen!
Viele Grüße,
Whyso

[whyso]

Der short Interest Verlauf im "Fall CMBX" ist auch nicht ohne:
http://www.nasdaq.com/asp/quotes_full.asp?mode=&kind=shortin…
Lass sie nur laufen, dann sind wir schnell wieder bei 5 Dollar plus in kürzeste Zeit

Achte auf der Tageschart bis mitte Februar-die shorties haben nur wenig CBMX Munition noch im keller


Good trades & steady hands,
Whyso

[whyso]

Ein letzte link für nächste Woche mit "Live Ask" (nur wenn ihr wollt & falls ihr es auch brauchen könnt )
http://www.askresearch.com/asklive_dl.asp

Tschau a tutti,
Whyso

[nort.]

http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic…





23% Institutionelle heute???

[whyso]

Weiß jemanden wenn der Splitt von Acacia vollzogen sein wird?

Spätestens dann werden wir richtige "Druck im Karton" zu spüren bekommen!

Ich habe jedenfalls weiterhin Zeit,
Viele Grüße & steady hands -(es sollte sich auszahlen),
Whyso

[whyso]

Das Chart ist LÄNGST nicht fertig (Bilden wir ein sauberen "W"?), der rebound wird ganz heftig ausfallen ...wenn es endlich eintrifft...ich denke wir sind nicht mehr weit von der Gegenwelle entfernt (ohne jegliche gegenwehr im Chart)

Die anfänge von dieser kommende "Wiederstand" haben wir heute abend während der letzte Handelsstrunde kurz mal sichten dürfen, das wird zum Dauerzustand demnächst!!!

GN8 Y`all,
Whyso

[bubu]

Heute geht es moderat aufwärts.

Kurs aktuell USD 1,54. TT gestern 1,43

Was noch fehlt ist das Volumen!

Gruß
bubu

[whyso]

http://www.tradingday.com/is/gnta.html

@bubu, ich tippe auf leicht ansteigende Volumina ab mitte Februar, ohne der bisherige -Gegenwehr - wird CBMX 200% -300% sehr schnell in die höhe eilen!

Ich halte meinen "Short-Trap"CBMX`s weiterhin fest gebettet im Depot, wenn das Sentiment bzw. Volumina wieder stimmen wird & man ist als "stand alone player" unterwegs, halten wir ein 10$ plus stock im händen

Schönes Wochenende!
Whyso

[whyso]

SPIKE.......

[nort.]

Hongkong erklärt Vogelgrippe zur Epidemie

Hongkong. SDA/baz. Die Vogelgrippe ist in Hongkong inzwischen zu einer ständig auftretenden Krankheit geworden, wie der Gesundheitsminister des Gebiets am Freitag erklärte. Da der Virus inzwischen bei verschiedenen Vogelarten, sowohl bei Wildvögeln als auch bei Hühnern vorkomme, müsse sie als endemisch bezeichnet werden, sagte York Chow. Und es sei nicht nur Hongkong, das Virus sei auch im Süden von China vertreten.


http://www.baz.ch/news/index.cfm?ObjectID=2F70D2C7-1422-0CEF…

[whyso]

http://www.shortsqueeze.com/index.php?symbol=cbmx
Knapp 6% held by insiders...und "nur" 3,3% von Institutions >>>>BIS DATO

Nächste Woche gehts erst richtig los mit CBMX!
Good health & good trading,
Whyso

[whyso]

Tag Zusammen!

ich kann es nur unbedingt empfehlen ein Gespräch mit Bret L. Undem (Media Relations CBMX ), 425-493-2293 zu führen.

Hier vier Dinge an den man sich heute schon Festhalten kann:

1. Amit Kumar besitzt über 1,2 Million CBMX Anteile...

2.Piper Jaffray hat 10 Mio USD Aktien von CBMX gekauft in Sept 2005.

3.Molecular Diagnostics wird CBMX `s eigentliche Hauptfeld (schaut Euch das Chart von Mologen hier in Deutschland mal an) bis mitte 2006 werden...
(der Markt beherbergt über 1 Billion USD Potential)

4.In vier bis sechs Wochen wird der 90 Array (5 fach stärker als alles andere Produkte auf dem Markt) zum freien Verkauf anstehen

Der Splitt von Mutter Acacia & Paul Ryan begrußt man herzlichst bei CBMX, das ganze ohne zu zögern!!!

Schönes Wochenende allerseits,
Whyso

[nort.]

Afrika Februar:




Dezember:



http://www.recombinomics.com

[nort.]

Monday, February 13, 2006

Print this version Email to a friend Send a letter Send a letter
line
Fighting the flu
From game theory to flu chips, researchers experiment with new technologies to help thwart upcoming health catastrophes

ADVERTISEMENT

A multipronged defense

Multiple efforts are under way in government, industry and academia to strengthen the nation’s defense against a possible flu pandemic. Information systems are expected to play a role in nearly every facet of that defense, from modeling and preparation to detection and reaction.

Here is an overview of the key initiatives, which this story discusses in detail.

Planning and modeling: Exploring flu scenarios

Planning and modeling systems, most of which can be downloaded for free, let health care providers and public health officials run different scenarios to help anticipate hospital capacity and staffing needs during a pandemic. Such software estimates an outbreak’s effect in terms of the number of deaths, hospitalizations and outpatient visits.

Prediction: Borrowing from financial markets

Prediction initiatives forecast events using commodity-like trading networks. However, instead of investing in pork bellies or orange juice, they invest in the outcomes of events, such as elections. Their success depends on pooling the information of knowledgeable “traders.” Such initiatives could help hospital administrators better prepare for an avian flu pandemic.

Surveillance: Developing tools for detection and situational awareness

Surveillance and detection systems under development by public health agencies and universities will analyze data from hospitals and public health departments, searching for patterns that could signify an outbreak.

Diagnosis: Speeding virus IDs

A semiconductor-based microarray, consisting of a chip that fits on a microscope slide, can detect the specific flu virus infecting an individual. The array is “spotted” with known flu strains then placed in a wash with flu gene fragments from an infected person. RNA fragments from the sample bind to the DNA segments on the microarray, making it possible to identify the specific flu strain and begin the appropriate treatment.

Supply chain management: Tracking vaccines

Supply chain management focuses on delivering the right quantities of vaccines to the right places at the right times. One system developed by the federal government tracks flu vaccine supplies among manufacturers and distributors. It also offers a Web-based interface that lets states view supply information, place orders and monitor order status.
BY John Moore
Published on Feb. 13, 2006

The westward movement of the H5N1 strain of avian flu has put the United States on alert. The virus first surfaced in East Asia, where it has killed millions of birds and more than 70 people since 2003. The disease, however, expanded its global reach late last year, with the discovery of infected birds in Europe. The World Health Organization (WHO) reports that the virus “is not yet spreading efficiently…among humans” but contends the “world is now closer to another influenza pandemic than at any time since 1968.”

The 1968-69 influenza pandemic, dubbed the Hong Kong flu, killed about 1 million people worldwide. WHO, citing a conservative estimate, believes that between 2 million and 7.4 million people would die if avian flu becomes a pandemic.

To blunt the effects of such a scenario, researchers from government, industry and academia are creating information technology-based systems. The projects described here fall into five categories: planning and modeling, prediction, surveillance, diagnosis, and supply chain management.

Planning and modeling systems let health care providers and public health officials run different outbreak scenarios to help anticipate hospital capacity and staffing needs. Prediction initiatives use commodity-like trading networks as a forecasting method. Flu surveillance systems aim to provide early detection and ongoing monitoring. Emerging influenza microarrays incorporate semiconductor technology to speed the identification of virus strains. Supply chain systems, meanwhile, have begun to automate the process of vaccine administration.

The projects catching on now aren’t necessarily new but have recently gained attention because of the H5N1 strain.

Martin Meltzer, senior health economist at the Centers for Disease Control and Prevention’s National Center for Infectious Diseases, said a flu modeling tool CDC launched in 2000 initially generated little interest. “There wasn’t the urgency,” he said. Several years later, the pandemic threat has changed that situation, and people worldwide are downloading the modeling software.

Avian flu has also raised the profile of surveillance systems, some of which were originally conceived to address bioterrorism concerns. In this area, considerable development has already occurred. At least four systems offer early event detection.

“We believe there is a lot of technology there,” said Susan Penfield, a vice president at Booz Allen Hamilton. “The big question is not necessarily the technology but…the sharing of the data and the integration of those systems.”

Preliminary integration work is under way for CDC’s BioSense program and the Defense Department’s Electronic Surveillance System for the Early Notification of Community-Based Epidemics (ESSENCE). Barry Rhodes, co-leader on BioSense at CDC’s National Center for Public Health Informatics, said the program is discussing harmonization with ESSENCE representatives. The objective is to cultivate a common infrastructure for early event detection.

From availability to acceptance
While the refinements continue, health officials can access a number of technology tools today. Delivery methods range from fee-based subscription services to free downloads. But availability doesn’t always translate into adoption. Some observers say they believe flu-fighting tools must blend into a health care organization’s daily routine to find acceptance.

Robert Egge, a project director at the Center for Health Transformation, a group based in Washington, D.C., that seeks to improve the U.S. health care system, questioned the practicality of fielding systems built to deal specifically with a flu pandemic. A complex initiative that medical professionals can only use once every 20 years or so won’t gain many followers, Egge said. “Realistically, you have to build your approach based on systems that will just become part of normal operations,” he said.

That’s the challenge facing public health officials and the researchers working on technology solutions.

Modeling and planning: Exploring flu scenarios
Health officials preparing for the next flu pandemic don’t have a lot of firsthand experience to go on because the most recent outbreak occurred in 1968.

In addition, familiarity with the annual flu cycle might not be much help. Pandemic flu follows a different path than the more commonplace varieties, experts say. For example, the typical flu strain hits the segment of the population aged 65 and older. The three pandemics in the 20th century, however, affected large numbers of people in younger age brackets.

But public health workers and hospital administrators can simulate what they have not experienced. Flu modeling tools aim to offer insight into an infrequently occurring event, and most are free to download.

CDC has built two such software tools, FluAid and FluSurge. FluAid lets users model the impact of a flu pandemic in their area. The software provides estimates of an outbreak’s effect in terms of deaths, hospitalizations and outpatient visits.

The 1968 pandemic is the basis for the modeling tool’s default values, Meltzer said. Because that pandemic was less lethal than the 1918 flu outbreak, estimates based on default assumptions will be conservatively low, he said. But users can change the default numbers to reflect other scenarios.

Planning for a surge in patients
While FluAid paints a pandemic in broad strokes, CDC’s FluSurge provides more details about an outbreak’s effect on hospitals. The tool compares existing hospital capacity with an estimated number of people who would be hospitalized, require intensive care and need ventilator support in the event of a pandemic.

Users can change the model’s underlying assumptions. “If you want to be drastic, you can put in a 1918 scenario,” Meltzer said. “By keeping the model simple, you can go back and forth and change whatever aspect you think is important.”

Hospital administrators can explore different scenarios to determine the number of beds they would need to handle a flu outbreak. The scenarios can also provide insight into staffing. Meltzer said many hospitals already experience nursing shortages, and the modeling tool might indicate the need to consider other staffing sources, such as retired nurses. Such information could prompt health officials to discuss how to create and maintain a list of supplemental staff.

“What the software has done is prodded them to think about things,” Meltzer said. “The software is really meant to generate conversation and not generate an absolute answer.”

Factory floor approach
Flu modeling tools aren’t the only planning resources available, however. Other software efforts help public health officials design vaccination clinics. Researchers at the University of Maryland’s Clark School of Engineering tapped principles of computer integrated manufacturing to create the Clinic Planning Model Generator. The software, designed to help planners ease congestion in clinics, has been available for download since September 2005.

In manufacturing, queuing models streamline the flow of parts in a production system. General models can also apply to customer service situations to help minimize the length of time people wait in lines. Vaccination clinics, however, face issues that general-purpose queuing models don’t cover because clinics are likely to deal with family groups, the elderly and people with disabilities.

“Those types of details make the problem more difficult,” said Jeffrey Herrmann, an associate professor at the Clark School’s Department of Mechanical Engineering and Institute for Systems Research. “We had to adapt the model.”

The clinic modeling project originally focused on smallpox. In 2004 researchers conducted a time study of a mass vaccination clinic exercise in Montgomery County, Md. Based on that experience, “we realized we could create models that could be useful for a wide variety of similar events,” Herrmann said.

Prediction: Borrowing from financial markets
Health professionals fight against time more than anything when it comes to containing an outbreak. The need for an early warning system is obvious. The source of inspiration for a couple of flu prediction efforts is less obvious — financial markets. Prediction markets have emerged in recent years to forecast election results. Those markets have now been tapped to predict the arrival of flu.

In a prediction market, people buy and sell futures contracts. But instead of investing in pork bellies or orange juice, they invest in the outcome of events. Iowa Electronic Markets, run by the University of Iowa’s Tippie College of Business, have focused primarily on political events. But in 2004 the business school set up its first flu market. That pilot project set out to predict flu activity in Iowa. Last fall the business school and Iowa’s Carver College of Medicine received a $1.1 million grant to expand the prediction market nationally.

Forrest Nelson, professor of economics at the University of Iowa, said he hopes public health officials will use the market forecast as a warning signal. Hospital administrators who anticipate an outbreak, as opposed to learning about one after the fact, have more time to prepare for an increasing number of flu cases, he said.

“People on the front lines seeing patients, administrators and managers — those are the kinds of people that this kind of market should benefit,” Nelson said.

For now, only Iowa health care workers will be able to get a heads-up from the prediction market. Participation in the 2005-2006 influenza market is limited to invited members of the Iowa health care community. The selected traders can purchase contracts corresponding to the level of flu activity in the state during a given week. The contracts are color-coded. A trader buying a white and yellow contract believes there will be no flu reports or activity. A red contract, in contrast, represents a widespread outbreak. Traders can buy contracts on flu activity as far as six weeks in advance. The higher the price, the stronger the feeling that an outbreak is imminent.

Traders ‘in the know’
The Iowa flu prediction market seeks to forecast outbreaks of the more typical strains of flu, which run their annual courses each winter. But Nelson said Iowa is considering an avian flu market. The key hurdle: finding traders in the know. “We need traders with access to the right kinds of information,” he said.

The Iowa flu market cultivates contacts in emergency rooms and pharmacies within the state. But an avian flu market, Nelson said, would require participants in Asia and traders with specialized profiles, such as microbiologists who examine data worldwide.

“We’ve not yet tapped into the right circles to get access to those traders,” he said. “That has kept us from opening an avian flu market.”

Meanwhile, Trade Exchange Network recently closed one avian flu prediction market and is winding down another. In the first market, traders bought and sold futures contracts on whether avian flu would be confirmed in the United States by the end of 2005. The other market has traders testing hunches regarding a confirmed U.S. outbreak by March 31. The flu market operates on Trade Exchange Network’s Tradesports Web site.

Mike Knesevitch, communications director at Trade Exchange Network, said the flu market is the first health-related trading arena the company has posted. The company now lists more than 2,000 markets, spanning basketball games to New York City snowfall amounts.

The Tradesports bird flu market differs from Iowa’s in that the former is open to anyone, not just people in the health field.

“Their exchange is limited to a fixed number of participants with a limited amount of capital,” Knesevitch said of the Iowa market. “Our markets have no limits, similar [to] the world financial markets, so we believe our data points are more representative of the true market.”

Knesevitch said the company’s markets possess a very high predictive value.

Surveillance: Developing tools for detection and situational awareness
To contain an infectious disease, public health officials need to be on top of an outbreak from its onset. An Imperial College of London study, based on a model of an avian flu outbreak in Thailand, found that the disease remained localized for the first 30 days and spread nationwide in 60 to 90 days, according to the journal Nature. Containment depends on rapid disease identification and response.

Against this backdrop, government and university researchers have assembled a number of early event detection systems, intended to keep public health officials apprised of disease outbreaks. The systems may provide a line of defense against a flu pandemic.

The University of Pittsburgh’s Real-time Outbreak and Disease Surveillance (RODS) system provides one example. The system analyzes data from hospitals and public health departments and searches for patterns that could signify an outbreak.

“The algorithms we created will…see if there’s an anomaly in the trending of the data,” said Steve DeFrancesco, director of IT at the university’s RODS Laboratory. If the software detects a spike in a certain syndrome, RODS dispatches an alert to public health officials.

The lab’s Public Health Data Center hosts the system’s software. Health care facilities link to the center through an interface that automatically transmits data such as emergency room registrations. The software processes the data and generates alerts for distribution via e-mail or pager. Health officials can view data as a map or graph via a secure Web interface.

Customers subscribe to the RODS service for a minimal fee, which is based on population and the geographic area covered, DeFrancesco said. He added that a little more than 250 hospitals connect to the system and actively send data to RODS. Health departments in 11 states also use RODS’ early detection feature.

Human observers
CDC’s BioSense program is another system with an early event detection component. BioSense taps sources such as Department of Veterans Affairs treatment facilities, clinical laboratories and hospitals to keep tabs on health events as they unfold. The system is part of CDC’s Public Health Information Network (PHIN).

Other systems with an early detection thrust include Sandia National Laboratories’ Rapid Syndrome Validation Project and DOD’s ESSENCE. In addition, CDC’s National Electronic Disease Surveillance System (NEDSS), another PHIN element, provides a standard reporting format for disease data. Several states use NEDSS-compliant systems for reporting data to CDC.

But human observers — not automated systems — may play the greatest role in identifying an avian flu outbreak in the United States.

“Most likely, these surveillance systems are not going to be the predictors” of avian flu, said Dan Desmond, president of SIMI Group, a systems integrator and Microsoft partner that specializes in health care solutions. “At this point, people are going to be doing the surveillance.”

But surveillance systems would play a role in an outbreak, even if they aren’t first to identify one. “Monitoring what happens after [detection] is the real issue,” Rhodes said.

To that end, systems such as BioSense can provide situational awareness, he added. Once medical professionals confirm an outbreak, BioSenseRT, the system’s real-time component, could monitor the event as it unfolds. The idea is to use BioSense to shed light on the magnitude of an event, its duration and issues such as efficacy of treatment.

Rhodes said other systems such as ESSENCE and RODS could also address the situational awareness questions, assuming close-to-real-time data collection.

Diagnosis: Speeding virus Ids
To identify specific influenza strains and subtypes, medical examiners need several days to complete their tests.

Semiconductor-based microarrays, or biochips as they are sometimes called, promise to shrink detection time to a matter of hours. CombiMatrix, a biotechnology company based near Seattle, launched a DNA microarray last year for typing flu strains. In addition, the University of Colorado at Boulder has developed a Flu Chip that can determine flu strains from patient samples.

“Traditional testing takes days, because you have to grow a virus to get enough sample,” said Bret Undem, vice president of CombiMatrix. In October 2005, CombiMatrix debuted its Influenza Microarray, which the company said can detect and accurately type flu strains in less than four hours. A test last year at CDC found that the University of Colorado’s Flu Chip can uncover the genetic signatures of flu types and subtypes in about 11 hours.

A microarray consists of a chip that fits on a microscope slide. In the case of Colorado’s Flu Chip, an array robotically spots genetic bits of information that correspond to known flu strains, according to a university project summary.

Lab workers then place the microarray in a wash of flu gene fragments obtained from an infected individual. RNA fragments from the sample bind to the specific DNA segments on the microarray. A fluorescent label is applied to the captured RNA, and the array is then placed into a laser scanner.

The glowing portions of the array create a pattern indicative of a particular virus.

Chips gain acceptance
University of Colorado officials expect laboratories to adopt the Flu Chip within a year. The technology has been under development for two years, with funding from the National Institute of Infectious Diseases.

In CDC’s October 2005 review, the chip was tested for avian flu strain H5NI and two common human flu types, H1N1 and H3N2. The chip was more than 90 percent accurate, the university reported. At press time, CDC was expected to conduct an additional test of the Flu Chip.

Kathy Rowlen, a professor in the university’s chemistry and biochemistry department, said a commercial vendor will eventually manufacture the Flu Chip. “Several companies have expressed interest,” she added.

The CDC and WHO, meanwhile, have samples of CombiMatrix’s Influenza Microarray. “We are talking to other government agencies,” Undem said.The Influenza Microarray can identify H5N1 avian flu and other strains of Influenza A, the company said. It can work with samples from birds, pigs, horses, dogs and humans.Undem said the retail price is $550 for one chip, adding that the company is working on ways to make the chip less expensive.


Remote diagnoses ahead
CombiMatrix and the University of Colorado are seeking to refine their flu chip technology. The portability of flu testing gear is one limitation. The current crop of scanners used to read microarrays is too cumbersome to deploy outside a lab environment.

The ability to move diagnoses to remote areas, rather than confining the job to a centralized lab, would further speed the identification process. Undem said DOD has funded the company’s beta test of a portable field unit. The device will read microarrays electrochemically rather than optically. He said the unit is toaster-sized.

Plans to reduce the size of the Flu Chip are also in the works. Rowlen said InDevR, a company that makes biomedical instruments, is developing the “ancillary technology to enable field application of microarrays.” Rowlen, who is chief scientist at InDevR, added that it will take a couple of years to produce the field-portable version.

Supply chain management: Vaccine manufacturing process makes deliveries tough to predict

To combat an influenza pandemic, vaccines need to be delivered in the right quantities to the right place at the right time. Vaccine supply chain management, however, has not been a high-profile activity, industry observers say. Systems exist that automate elements of vaccine logistics, but no single system covers the supply chain from manufacturer to local health authorities.

“It’s a mistake there’s not more focus on that,” Penfield said.

Several issues complicate the timely delivery of flu vaccine. “On the supply side, manufacturers have opted out of the unpredictable vaccine market, causing a chronic shortage of production capacity,” according to a bulletin from the Massachusetts Institute of Technology’s Center for Transportation and Logistics. In addition, the vaccine manufacturing process makes yields hard to predict, according to MIT’s bulletin.

Another factor is the inflexibility of the supply chain. The retail industry routinely shifts supplies from areas in a surplus situation to areas experiencing shortages, but that approach is not common in health care, the bulletin states. The result is price gouging, a practice that is difficult to prevent because “no entity has an overall picture of product flows and where vaccine excesses and shortages are developing,” the bulletin states.

Vaccine finder system
CDC is putting systems in place to deal with the unpredictability of the flu vaccine market. In 2004 CDC launched its Flu Vaccine Finder System when the contamination of flu vaccine from a European manufacturer led to a shortfall in the United States. The system tracks flu vaccine supplies among manufacturers and distributors.

During the 2004 flu vaccine shortage, the system “matched available vaccine supply and production with population densities for priority groups to determine a monthly appropriation,” according to CDC’s Web site. The system also provides a Web-based interface that lets states view supply information, place orders and monitor order status.

The flu vaccine finder falls under PHIN’s Countermeasure and Response Administration. That system also provides a link to the Strategic National Stockpile, which houses medicine and supplies in secure warehouses nationwide. In the event of a bioterrorism attack or flu outbreak, CDC will deliver stockpiled supplies to affected states within 12 hours.

Federal and state roadblocks
Desmond said CDC has a Web-based application that manages the distribution of supplies to state drop-off centers. But each state must act independently when it comes to distributing vaccines. “There’s no overarching process,” he said.

A 2005 report published by the Trust for America’s Health says a gap in the supply chain exists between the federal distribution system and state and local governments. The report states that “only seven states and two cities have achieved ‘green’ status for the Strategic National Stockpile, which means being recognized by [CDC] as adequately prepared to administer and distribute vaccines and antidotes in the event of an emergency.”

Attempts to improve management of vaccine supplies in the United States could get a boost from international projects. In September 2005, the U.S. Agency for International Development awarded a $77 million contract to a consortium that will develop a supply chain management system to dispense HIV/AIDS-related drugs.

“Some of the lessons learned from this opportunity can be applied in developing a supply chain strategy for delivering drugs not only in the [United States], but globally,” said Penfield, whose company is a member of the USAID supply chain consortium.



About Us | Subscribe | Advertise | Webmaster

GovHealthIT.com is a product of FCW Media Group.

Application Development Trends | Campus Technology | CertCities.com | The Data Warehousing Institute
E-Gov | EduHound | ENTmag.com | Enterprise Systems | Federal Computer Week | Government Health IT
IT Compliance Institute | JavaSPEKTRUM | MCPmag.com | OBJEKTspektrum | Recharger | Redmond magazine
Redmond Channel Partner | SIGS-DATACOM | TCPmag.com | T.H.E. Journal | TechMentor

Copyright 2000-2005 101communications. See our Privacy Policy

Click here


http://www.govhealthit.com/article92290-02-13-06-Print

[whyso]

Nah, ganz nah jetzt ...

http://www.taz.de/pt/2006/02/15/a0130.1/text

[nort.]

[posting]20.208.880 von whyso am 14.02.06 22:20:04[/posting]http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

http://www.n-tv.de/633986.html

[whyso]

Das kann nicht mehr lange dauern Die "Rache" der longies wird m.E. hier gewaltig ausfallen!!!

Ich habe weiterhin Geduld-jetzt handelt es sich nur um Stunden & Tagen, und bestimmt nicht mehr um Wochen & Monate bis der Ausbruch eintrifft...

Steady Hands,
Whyso

[nort.]

Gerade hat eine Landespolitikerin von mecklenburg vorpommern auf N24 (hin und wieder bringen die auch Nachrichten ) Unverständnis geäußert, warum die Tests so lange dauern. Es kann ja nicht so schwer sein CBMX zu entdecken und deren Microarrays zu nutzen, die es in 4 Stunden erledigen!

[whyso]

[posting]20.244.915 von nort. am 16.02.06 21:19:53[/posting]und wann sie soweit sind DANN gibts ein richtigen Kursfeuerwerk bei CBMX

Marktkapital.56,93 Mio. USD bei 39 Mio Stücke>>>Ein MK Witz!....noch

[nort.]

whyso alter Junge,

es scheint sich was zu tun

[whyso]

in der Tat Nort
Lauschen die Amis in unsere Unterhaltung schon wieder hinein ?

[weisserwal]

hey nort,
sag mal,hast du eben gelesen, wie der bekloppte mich im yahoo-board bezeichnet hat..??
ist der irre?

gruss
ww

[nort.]

[posting]20.245.315 von weisserwal am 16.02.06 21:41:27[/posting]ja habe ich, machen wir ihn nieder

[bubu]

was ich hier noch vermisse ist das Volumen.
Aktuell in USA gerade mal rund 115k umgesetzt.
Das schaffen wir ja schon fast in D auch!

Aber dem Chart nach scheint ein Boden auf aktuellem Niveau gefunden.
Ich bin ebenfalls optimistisch. Schön bei diesen engen Werten: es kann jederzeit los gehen. Glaube nicht, daß ich meinen Einsatz hier noch verlieren kann.

Kurs aktuell: USD 1,47

Gruß
bubu

[weisserwal]

nort,
diese dumpfbacke...

klar, da halten wir doch zusammen...

ich glaube auch, langsame geht es los mit unserem baby..

klar niedirger umsatz, aber da will keiner mehr verkaufen...

[bubu]

In D kann man übrigens problemlos sammeln. Insb. FFM ist sehr liquide bei Stückelungen bis 5k!
Der Stuttgarter Makler bietet meist nur 2k und macht dann oftmals noch einen Rückzieher bei Ordereingang.

Gruß
bubu

[whyso]

@bubu,
In D kann man übrigens problemlos sammeln ....noch

[bubu]

@whyso

bei 1,90 (USD) geb ich dir gerne 10k. Hab dann immer noch genug davon

Gruß
bubu

[whyso]

[posting]20.245.994 von bubu am 16.02.06 22:16:21[/posting]Das sagst du heute aber ÜBERMORGEN sieht das evtl gaannzzzz anderes aus im stark steigende Kurs befindlich

[whyso]

Was sehen meine müde Augen dar?



Oh welch ein Wunder, Kumar & Co findet endlich mal Beine im Markt...

Und NVAX mit, ein Schelm wer böses dabei denkt

[nort.]

Sehr guter Beitrag


This Technical Journal puts CBMX in good company;
They see CBMX is in the mix with the "Big Dogs".


http://www.ece.ucsb.edu/courses/ECE594/594F_F05Gossard/More%…

TECHNOLOGY FEATURE DNA MICROARRAYS

NATURE | Vol 437 |20 October 2005


As a general rule of thumb, there are three key things
to look out for when it comes to assessing
DNA microarray platforms:

1) feature density per array,

2) flexibility (how easy it is to change
the array content and design),

3) and sensitivity.

CombiMatrix of Mukilteo, Washington,
an operating group of Acacia Research
Corporation, concentrates on designing and
manufacturing relatively low-density custom microarrays
containing up-to-date content.

Last month the company began offering its
4x2K customized microarrays for US$99,
produced using its semiconductor-based
in situ oligonucleotide synthesis method.

The 4x2K CustomArrays contain four arrays of 2,240
oligonucleotide features per slide with a 44-micro-m feature size.

CombiMatrix plans to offer its first high-density array early in 2006,
which will have 90,000 features and a 25-micro-m feature size.

"We`re custom, quick, flexible and cost-effective,"
says Michael Tognotti, vice-president
of sales and marketing at CombiMatrix.
There are no minimum order requirements for these arrays,
which Tognotti says can be reused up to three times,
further driving down costs for researchers.

Pg (1 of 4)


CombiMatrix is developing an electrochemical detection (ECD)
method to read its semiconductor-based microelectrode arrays,
as an alternative to fluorescence.

The company hopes to develop a smaller, less expensive
detection system that will provide better performance
than fluorescence-based systems —
the only method so far to be commercially successful.

A prototype is in beta testing and a
commercial product is expected next year.

CombiMatrix hopes to corner the molecular diagnostics market
with a handheld version.

...
Other companies are taking a different approach.
CombiMatrix of Mukilteo, Washington, formed a
diagnostic subsidiary, CombiMatrix Molecular
Diagnostics, in May, now led by

Pg (2 of 4)

former senior executives from the diagnostics industry.

"We want to capture revenue not just from the chip
but from the test itself," says Michael Tognotti,
vice-president of sales and marketing at CombiMatrix.

Pg (3 of 4)


Photo: Desktop DNA synthesis from CombiMatrix

For those with deeper pockets, CombiMatrix sells
a CustomArray desktop DNA synthesizer
for the in situ synthesis of oligonucleotides
on microarrays with up to 12,000 features.

Synthesis occurs on a blank CombiMatrix semiconductor chip
using standard phosphoramidite chemistry methods.

Pg (4 of 4)

****

looks real to me:

http://www.combimatrix.com/products_customarray.htm



http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[bubu]

Sollte die Aktie einmal "entdeckt" werden, dann wirds eine Gaudi geben.

Heute bislang in US "nur" 360k Umsatz, Kurs 1,58 +7,5% (11ct)

Sollte mehr Interesse geweckt werden, ist klar, wohin der Kurs gehen dürfte.

Gruß
bubu

[whyso]

Hier ein paar Gründe wieso wir CBMX UNBEDINGT brauchen werden, und das ganze recht schnell wenn möglich

Das H5N1-Virus: Porträt eines Killers

Das Vogelgrippevirus H5N1 ist winzig klein und hat nur acht Gene. Dennoch könnte es sich nach Befürchtungen der Weltgesundheitsorganisation (WHO) zu einer Bedrohung mit weltweit bis zu 150 Millionen Toten auswachsen. Voraussetzung wäre die Kreuzung mit einem menschlichen Grippevirus oder eine eigene genetische Veränderung des Erregers. Ein solcher "Supererreger" wäre dem Immunsystem des Menschen nicht bekannt und könnte sich rasend schnell im Körper verbreiten.
H5N1 Das gefährliche Virus

Warten auf die Mutation

"Die Mutation des Virus ist längst überfällig", sagte Professor Matthias Stoll von der Medizinischen Hochschule Hannover. "Wir warten alle darauf, dass das eintritt." Eine Weiterentwicklung des Erregers sei relativ schnell möglich. Noch gibt es keine Anzeichen für ein solches Virus, das sich leicht von Mensch zu Mensch übertragen lässt. "Bislang ist die Vogelgrippe eine Tierseuche", betonen Forscher wie der Virologe Hans-Dieter Klenk. Er leitet das Institut für Virologie an der Universität Marburg und ist in Deutschland einer der führenden Kenner der Influenzaviren.

H5N1 könnte Pandemie auslösen

Die Virologen unterteilen Influenzaviren in die Typen A, B und C. Nur Typ A, zu dem auch der Vogelgrippe-Erreger H5N1 gehört, kann die gefürchtete Pandemie unter Menschen auslösen. Das Virus ist kugelrund, sein Durchmesser beträgt nur 0,1 tausendstel Millimeter. In seinem Inneren ist nur Platz für ein paar Proteine und die Erbsubstanz. Diese schmale Ausstattung reicht den Partikeln aber, um sich in lebenden Zellen zu vermehren und sie schwer zu schädigen.

Rasend schnelle Vermehrung

Die Viren gelangen zunächst auf die Schleimhäute der oberen Atemwege. Dann kommt das erste Virenprotein zum Zuge: Die Neuraminidase (N) sitzt wie ein Stachel auf der Virenhülle und bahnt dem Virus einen Weg durch den feinen Schleimfilm auf den Zellen. So gelangt das Virus bis zur Oberfläche der Zelle. Diese zieht das Virus nun in ihr Inneres, wo es sich vermehrt. Nach 10 bis 24 Stunden erscheinen auf der Oberfläche der befallenen Zelle neue Viren. Sie lösen sich ab, und der Prozess beginnt in weiteren Zellen von Neuem. Durch diesen Schneeballeffekt vermehrt sich das Virus rasend schnell.

Viren gelangen in die Lunge

Dies alles passiert zunächst in den äußersten Zellschichten zum Beispiel des Rachenraums. Von dort gelangen die Viren über die Luftröhre in die Lunge. "Es geht im schlimmsten Fall Stockwerk für Stockwerk tiefer", sagt Virenforscher Klenk. Ein akutes respiratorisches Distress-Syndrom (ARDS) kann wenig später folgen. Bei dieser akuten Entzündung des Lungengewebes verliert das Organ weitgehend seine Fähigkeit zur Sauerstoffaufnahme.

Neuer Impfstoff für jede Saison

Das größte Problem für die Mediziner ist, dass bei der Vermehrung viele Varianten des Erregers entstehen. Die Schlüsselmoleküle mit den Bezeichnungen H und N sitzen an der Außenseite des Virus und sind ständig den Attacken des menschlichen Immunsystems ausgesetzt. Um den Antikörpern zu entgehen, wandeln sich die Moleküle schnell. Täten sie es nicht, würde das Immunsystem schnell mit ihnen fertig, sie blockieren und damit wirkungslos werden lassen. Durch die schnelle Veränderung der Moleküle muss sich der Körper jedes Jahr mit einem leicht veränderten Virus auseinander setzen, gegen das er nur unzureichend gerüstet ist. So kommt es zu den üblichen Grippeepidemien, und daher muss für jede Grippesaison ein neuer Impfstoff hergestellt werden.


Vögel als Wirte genutzt

Die Buchstaben H und N dienen den Experten auch dazu, die Viren zu benennen. Es gibt 16 verschiedene H-Typen und neun Versionen vom Typ N. Klenk geht davon aus, dass in der Natur Viren mit vielen H-N-Kombinationen vorkommen. Die Wirte sind Vögel. Viele Virenvarianten sind so gut an sie angepasst, dass die Vögel problemlos überleben.

Kreuzung mit menschlichem Virus befürchtet

Voraussetzung für eine Pandemie wäre, dass sich das Vogelgrippevirus in ein menschliches Virus verwandelt. "Dies könnte dann passieren, wenn sich das Vogelgrippevirus mit einem menschlichen Influenzavirus kreuzt. Dafür müsste zunächst eine menschliche Zelle von beiden Viren befallen werden", erläutert Klenk. In diesem Fall würden sich die Erbanlagen beider Viren vermischen, und es könnte ein neues menschliches Virus entstehen, das aber an seiner Oberfläche einen Teil des Vogelgrippevirus besitzt. Ein solches Virus wäre nach den Worten von Klenk dem menschlichen Immunsystem völlig unbekannt. Menschen wären ihm ohne jeden Schutz ausgeliefert.

Gefährlich auch ohne Gen-Austausch

Vogelgrippeviren könnten sich aber auch ohne Gen-Austausch in für Menschen sehr gefährliche Erreger verwandeln. "Das war bei der Pandemie 1918 der Fall. Die Viren von 1957 und 1968 entstanden hingegen durch den Austausch menschlicher und tierischer Virus-Gene."

[whyso]

Die Welt wird kleiner


http://www.recombinomics.com/H5N1_Map_2005_QinghaiL.html" target="_blank" rel="nofollow ugc noopener">

http://www.recombinomics.com/H5N1_Map_2005_QinghaiL.html

[whyso]

"Insiders might sell their shares for many reasons, but they buy for only one: they think the price will rise"
Peter Lynch:

Das wird richtig spannende im Großraum CBMX ab nächsten Dienstag...

[RazorLux]

Von mir aus kanns losgehen

[alpine110]

[whyso]

Effektiven TESTS müssen schnell her (Mikroarray 90???)-warum ? darum z.Bsp

Jede Stunde mehr tote Tiere - verzweifelter Kampf gegen Seuche-

oder diese Headline

-Virus H5N1 hat Frankreich erreicht..

http://onnachrichten.t-online.de/c/70/56/34/7056340.html

Europaweiter Kampf gegen die Vogelgrippe



http://onnachrichten.t-online.de/c/70/63/14/7063146.html

Ab Dienstag (morgen Nachmittag ) sollten wir die ersten Bewegungen bei CBMX & NVAX wieder erleben...

Viele Grüße,
Whyso

[whyso]

Die ersten werden Wach im sachen CBMX in Deutschland...

15:16:52 1,51 1000
15:08:25 1,50 2150
15:03:46 1,48 1000
14:59:23 1,48 6757
14:35:48 1,48 1000
14:35:01 1,45 10000
14:26:14 1,42 680
14:20:36 1,37 3000
14:20:17 1,40 5000
13:46:49 1,46 1000
13:46:41 1,44 5500
13:38:52 1,43 6000
13:23:32 1,42 2000
13:14:10 1,42 4560
13:00:28 1,40 2000
12:50:33 1,39 9500
12:47:17 1,38 1000
12:42:35 1,38 5000
12:23:52 1,38 2500
11:42:40 1,37 2000
11:20:54 1,38 750
11:05:03 1,39 1000
10:38:01 1,36 1000
09:33:51 1,37 2000
09:22:49 1,37 3000
09:12:19 1,36 2600
09:01:09 1,37 3000

Morgen gibts ein fetten "GAP UP" wenn die Amis wieder morgen endlich wieder "handeln" dürfen ....

We are at the start with CBMX-Molecular diagnostics, Microarray & Rebounder 2006!
Whyso

[nort.]

MUTATION

Vogelgrippe-Virus wird widerstandfähiger

Die Weltgesundheitsorganisation hat schlechte Nachrichten: Das Vogelgrippe-Virus ist durch mehrere Mutationen gefährlicher für Hühner und Mäuse geworden - und widerstandfähiger. Auf Rügen wird inzwischen die Ausbreitung der Seuche mit allen Mitteln bekämpft.

Berlin/Brüssel - Untersuchungen hätten gezeigt, dass das Virus zunehmend tödlicher für Hühner und Mäuse werde und nun etwa drei Mal so lang - sechs Tage - bei warmen Temperaturen im Freien überdauern könne, hieß es am Montag auf der Internet-Seite der WHO...

http://www.spiegel.de/wissenschaft/mensch/0,1518,402144,00.h…

[whyso]

[posting]20.296.105 von nort. am 20.02.06 21:11:26[/posting]@Nort, das ganze hört sich an wie ein Geständis

Ich denke wir erleben die "Initialzündung" mit CBMX zurzeit:- gut festhalten wenn sie bekannt geben das der neue Produkt(Microarray 90) auf dem Markt kommt (Brett Undem sagt gepalnt war gegen ende Q1) und dann die suabere Trennung von Acacia....spätestens dann will ich die $6-$8 sehen!!!

Good trades & steady hands Nort,
Whyso

[nort.]

[posting]20.296.894 von whyso am 20.02.06 21:56:56[/posting]das ganze hört sich an wie ein Geständis Vorsichtige Vorbereitung der Bevölkerung?

as der neue Produkt(Microarray 90) auf dem Markt kommt (Brett Undem sagt gepalnt war gegen ende Q1)

Stimmt, Whyso. Bei der derzeitigen Thematik habe ich das ganz vergessen. Ich erinnere mich, Dein Anruf Das sollte zusätzliches - wie Du sagst - Öl ins Feuer gießen. Zusätzlich kommen vor/mit dem Split die Finanzzahlen raus. Hier sollte sich der income-Trend bestätigen.

nort

[alpine110]

is der makler in ffm besoffen...

[whyso]

[posting]20.300.561 von alpine110 am 21.02.06 08:54:08[/posting]@alpine110,
kein Angst, spätestens gegen 15.30 (C.E.T.) wird der Makler in FRA auf einmal "blitzartig" wieder nüchtern sein...
Whyso

[nort.]

schöne Zusammenfassung von misc...

some Revenue numbers
by: misc_info_04 02/21/06 04:55 pm
Msg: 25579 of 25579

CBMX Revenues:
(In thousands)

For the Twelve Months Ended

12/31/2005 | 12/31/2004

Collaboration agreements
$2,266 | $17,302

License fees
$19,574 | $4,284

Government contract
$3,849 | $1,993

Service contracts
$153 | $116

Products
$1,765 | $230

----------- -----------
$27,607 | $23,925
----------- -----------


*******


Product Revenues WAY UP
about 7x over 2004

License fees WAY UP
about 5x over 2004

Government contracts UP
about 2x over 2004

http://biz.yahoo.com/bw/060221/20060221006036.html?.v=1

[nort.]

konferenz:

samples were sent to CBMX!!!!!!
by: interblaze (38/M/Astoria, NY)
Long-Term Sentiment: Strong Buy 02/21/06 05:21 pm
Msg: 25590 of 25590

from the world health organization

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

unbedingt anhören wow

[whyso]

Real numbers AND also 4 Million losses (at least to date )

"The CombiMatrix group recognized revenues of $3,644,000 for the fourth quarter of 2005, comprised of previously deferred collaborative revenue, sales of products and services, and government contract revenue. This reflects an increase of 600% relative to the revenue of the fourth quarter of 2004. Total revenues for 2005 were $8,033,000 and our net loss was $12,401,000," commented Dr. Amit Kumar, President and CEO of CombiMatrix

[gehtsjetztendlich]

hab mich gerade von CBMX getrennt 1k zu 1,53€ / KK 1,22€
Gier frißt Hirn.....

[whyso]

[posting]20.324.356 von gehtsjetztendlich am 22.02.06 13:43:43[/posting]Jedem das seine, aber ich schätze Du bist ein "tick" zu früh gewesen diesesmal, ca 3€ zu früh wenn das alles nicht täuscht
----------------------------
Launches Next Generation of Its Influenza A Surveillance Technology; 4X2K(TM) Format for All Strains of Influenza A, Including the H5N1 Bird Flu

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group has launched its Influenza A detection and genotyping technology on the CustomArray(TM) 4X2K platform. This is another step in CombiMatrix`s expansion of its product line and another step in CombiMatrix`s goal to make Influenza A technology more available and affordable.


CombiMatrix`s 4X2K Influenza A Research Microarray is a member of the CatalogArray(TM) product line and can detect and accurately type flu strains using a protocol that requires less than four hours start to finish, at a cost per test much lower than with the earlier CustomArray12K version. This microarray can identify H5N1 bird flu. Unlike other products on the market, it can provide information on the subtype of H5 influenzas while simultaneously identifying all other strains of Influenza A and providing a rich amount of information on mutations and novel strains of flu not yet seen. It is designed to work on samples from humans as well as from birds, pigs, horses, dogs, and various other animals. Strains of Influenza A include H5N1 bird flu, which so far is resulting in a 50% mortality rate among people who are infected; the 1918 strain, which killed an estimated 50 million people; the 1957 "Asian" flu and the 1968 "Hong Kong" Flu, which both caused pandemics; the 1976 "Swine" flu; and the current dog flu.

This system is available as a tool or as a service from CombiMatrix. This system is also being developed as a field-deployable biodetector, to be available soon. This array can be employed as an adjunct to existing technology, to type difficult or ambiguous samples of flu, or to study genetic drift in a flu virus as it moves through a population. Knowledge of the exact strain, origin of the strain, and probable characteristics of the virus are critical for disease surveillance and limiting the spread of the disease.

The 4X2K Influenza A Research Microarray is priced at $99 per assay. This microarray may be run on animal samples and on human samples for Research Use Only (RUO). It is not at this time a U.S. FDA-approved product, although CombiMatrix does have plans to seek FDA approval for it.

"As concerns about influenza grow, CombiMatrix plans to continue to design its products to address this major public health issue," said Dr. Amit Kumar, President and CEO of CombiMatrix.



ABOUT ACACIA RESEARCH CORPORATION



Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 38 patent portfolios, which include over 140 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.



Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:



This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

http://aktien.onvista.de/news-filter.html?ID_OSI=7803134&ID_…

[whyso]

und was machen die Amis draus????



http://www.marketwatch.com/tools/quotes/quotes.asp?symb=cbmx…


INIT kurse: (für der Realtime Handel falls man Java Ünterstütung hat)
http://data.inetats.com/ds/tools/bookviewer/javabook.jsp?STO…

[whyso]

UNDEM HAT RECHT GEHABT & NICHT GELOGEN:

7:06AM CombiMatrix launches next generation of its Influenza A surveillance technology; 4X2K format for all Strains of influenza A, including H5N1 (CBMX) 1.68 : Co announced today that its CombiMatrix group has launched its Influenza A detection and genotyping technology on the CustomArray 4X2K platform. CombiMatrix`s 4X2K Influenza A Research Microarray is a member of the CatalogArray product line and can detect and accurately type flu strains using a protocol that requires less than four hours start to finish, at a cost per test much lower than with the earlier CustomArray12K version. This microarray can identify H5N1 bird flu.

[gehtsjetztendlich]

[posting]20.325.484 von whyso am 22.02.06 14:44:38[/posting]habe den hype zum Ausstieg genutzt da ich auch in die Mutter ACTG investiert bin.
Macht heute ein neues ATH bei 8,43$ (+6%)
Allen Investierten fette Beute......

[whyso]

[posting]20.327.868 von gehtsjetztendlich am 22.02.06 16:25:58[/posting]...auch nicht schlecht
Viele Erfolg dabei!
Whyso

[whyso]

Sowohl das Produkt und der Kunde stehen bereits stramm

CombiMatrix Launches Next Generation of Its Influenza A Surveillance Technology Wednesday February 22, 7:00 am ET
4X2K(TM) Format for All Strains of Influenza A, Including the H5N1 Bird Flu

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 22, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has launched its Influenza A detection and genotyping technology on the CustomArray(TM) 4X2K platform. This is another step in CombiMatrix`s expansion of its product line and another step in CombiMatrix`s goal to make Influenza A technology more available and affordable.

CombiMatrix`s 4X2K Influenza A Research Microarray is a member of the CatalogArray(TM) product line and can detect and accurately type flu strains using a protocol that requires less than four hours start to finish, at a cost per test much lower than with the earlier CustomArray12K version. This microarray can identify H5N1 bird flu. Unlike other products on the market, it can provide information on the subtype of H5 influenzas while simultaneously identifying all other strains of Influenza A and providing a rich amount of information on mutations and novel strains of flu not yet seen. It is designed to work on samples from humans as well as from birds, pigs, horses, dogs, and various other animals. Strains of Influenza A include H5N1 bird flu, which so far is resulting in a 50% mortality rate among people who are infected; the 1918 strain, which killed an estimated 50 million people; the 1957 "Asian" flu and the 1968 "Hong Kong" Flu, which both caused pandemics; the 1976 "Swine" flu; and the current dog flu.

CombiMatrix Announces Additional Cooperative Research and Development Agreement with the U.S. Air Force

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 23, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today its CombiMatrix group has established a Cooperative Research and Development Agreement (CRDA) with the U.S. Air Force Research Laboratory, Human Effectiveness Directorate, Biosciences and Protection Division, Applied Biotechnology Branch (AFRL/HEPB). The CRDA will focus on "Development of a Biomonitor Device with Biomarker-based Microarrays."


Under the CRDA, AFRL/HEPB and CombiMatrix will develop a personal health monitoring system utilizing CombiMatrix`s CustomArray(TM) technology. The goal of the program is to develop a miniaturized device capable of analyzing multiple biomarkers (either DNA or protein) that would aid the U.S. Department of Defense in its mission to effectively monitor the health status of military service personnel before, during, and after deployment where untoward exposures may impact on their performance or health.

"Collaborating with AFRL/HEPB through this CRDA, provides a means for us to work with investigators who are concerned with Force Health Protection. This program is the result of a Presidential Directive and is focused on monitoring the health of all Service members while they are on active duty," said Dr. David Danley, Director of Homeland Defense for CombiMatrix. "Scientists at AFRL are looking at the relationships of genetics, physiology, and environmental stressors that can reduce human performance or lead to acute or chronic health problems. Our microarray technologies will allow them to take expanded capabilities to the field where adverse events occur and palliative intervention needs to be initiated."

"Our technology continues to gain credibility with our military, as indicated by this new relationship with the U.S. Air Force. This agreement is in addition to our previously announced program with the Air Force Institute of Operational Health," said Dr. Amit Kumar, President and CEO of CombiMatrix. "Going forward we hope to expand and strengthen our relationship with the U.S. Department of Defense, Homeland Security, and other segments of our military

[nort.]

Hi whyso,

poste mal hier, das blöde yahoo board spinnt. Ich denke der Rebound hat angefangen. Es wurde mit dem letzten Tief kein neuer abs. Tiefstand gebildet. Zudem wurde die wichtige 1,71 Marke genommen. Diese hat eine starke resistance gebildet... Nun sollte es erstmal eine Unterstützung geben. Der Weg nach 2+ steht also frei

Die nächsten News werden hier - wie Du sagst - Öl ins Feuer gießen



http://www.stockta.com/cgi-bin/analysis.pl?symb=CBMX&num1=7&…

nort

[nort.]

Auf das Misc posting habe ich schon gewartet:

Leaders in Long-Term Growth Rate (5 yr)

ACACIA RES-COMBIMTRX [CBMX] 166.00%
XENOGEN CORPORATION [XGEN] 45.00%
SYMYX TECHNOLOGIES [SMMX] 30.00%
GEN-PROBE INC [GPRO] 21.50%
ALBANY MOLECULAR R [AMRI] 20.00%
LECG CORPORATION [XPRT] 20.00%
COVANCE INC [CVD] 19.00%
PAREXEL INTL CP [PRXL] 17.00%
SFBC INTL INC [SFCC] 15.50%
PRA INTERNATIONAL [PRAI] 15.50%

http://biz.yahoo.com/ic/ll/768g5r.html

[whyso]

Zwei Fragen;

1.Who is shorting CBMX at ever given opportunity?
2.How long will this last, and why?

-------------------
Added to: CBMX@$1.76-3:38pm,2/23/06
by: randstory (55/M/St. Davids, PA) 02/23/06 04:00 pm
Msg: 70749 of 70749

-Buy limit order @$1.76 completed in CombiMatrix, Inc (Nasdaq:CBMX)-3:38pm, Thursday, 2/23/06
-Cap source for buy: sale of residual shares, or "fragment" position in ORCL- remainder of lot bought @$9.10, on 5/02/02. This ORCL fragment- I`d sold the rest of the lot, and all ORCL shares a while ago- was going nowhere slowly, & in too small a way.
-cash position in account left intact for added purchase of DSTI on retracement.

Rationale: CBMX`s attractive valuation and balance sheet, combined with encouraging news.
Initial position taken at $1.50. Believe news has not been fully reflected in the current price of CBMX. A mid-term (4-6mos) target of $2.25 seems entirely reasonable.
Management may be taking heart from recent price support, and find its confidence again.
CBMX chart is below:
http://stockcharts.com/def/servlet/SC.web?c=CBMX,uu[h,a]dacl… 60][iUb14!Lah12,26,9]&pref=G-r.

[nort.]

WHO updates




http://www.who.int/csr/disease/avian_influenza/country/cases…

[whyso]

Kumar & Singh sprechen am gleichen Tag & Ort (mit & für einander) beim "Millennium Speaker":

SIR HARRY KROTO FRS
Recipient of 1996 Nobel Prize for Chemistry for his pioneering work in the field of Nanosciences

Confirmed Speakers
Mr. Kapil Sibal, Union Minister for Science & Technology
Dr. C.N.R. Rao, Linus Pauling Research Professor & Honorary President, Jawaharlal Nehru Centre for Scientific Research, Bangalore
Dr. M.K. Bhan, Secretary, department of Biotechnology, Govt. of India
Dr. Meyyappan, NASA
Dr. Amit Kumar, MD, Combatrix, USA
Dr. Anita Goel, CEO & MD, Biosym, USA
Mr. Nitin Jain, MD, Nanotex, India
Dr. Hackenberger, President, Specialty Chemicals, BASF, Germany
Dr. Christian Garbe, MD, FIZ Biotechnologie GmbH, Germany
Mr. Kitu Bindra, Buchanan Ingersoll LLP, USA
Mr. Alvin Bojar, Nano Green Sciences, USA
Rahul Patwardhan, CEO and President IndiaCo
Dr. (Ms.) Swati Piramal, Director, Nicholas Piramal Ltd.
Mr. Rahul Singhvi, CEO, Novavax, USA
Dr. Mohan Misra, CEO, ITN Energy Systems, USA
Dr. Bala Padma Kumar, CEO, Nano-conduction, USA
Dr. Nety Krishna, Applied Material, USA
Dr. Hari Dharan, Director, Berkeley Composites Laboratory, University of California
Dr. Ian McNiece, Director, Division of Biomedical Sciences, John Hopkins, Singapore
Dr. Sujeet Kumar, Director (Technology), Nanoexa, USA
Prof. C.S. Prakash, Director of the Center for Plant Biotechnology Research, Tuskegee, USA
Dr. M. Vidyasagar, Executive Vice President, Tata Consultancy Services
Mr. Camillo Holecek, President, ENERGEA (Biofuels)
Mr. Utkarsh Pallinitkar, Country Head – Life Sciences & Biotechnology, Ernst & Young, India
Dr. Lok Man S. Palni, Sr. Scientific Advisor- Biotechnology & Project Director State Biotechnology Programme, Govt. of Uttaranchal


http://www.assocham.org/nanobio/speakers.php?PHPSESSID=af279…

[whyso]

Watch this space


A microarray can analyze the expression levels
of many THOUSANDS OF GENES in a SINGLE ASSAY reaction.

The application of this technology in clinical research
has led to the development of gene expression PROFILES
capable of determining response to therapy,
distinguishing human malignancies,
and predicting survival.


Microarrays offer the opportunity to MAKE DIAGNOSES
BASED on MOLECULAR, rather than morphologic, characteristics
and allows treatment decisions to be BASED ON MOLECULAR characteristics,
rather than on appearance.

This has led to the development of DISEASE DATABASES
and the movement FROM a SUBJECTIVE phenotypic classification
to a UNIFORM MOLECULAR BASED diagnosis.

{BarCode-like Indentifiers}

Microarrrays are a KEY component in the quest for PERSONALIZED MEDICINE.

http://cmdiagnostics.com/gep.shtml

[whyso]

Check it out now



http://www.marketwatch.com/tools/quotes/quotes.asp?symb=cbmx…

[nort.]

Dienstag, 28. Februar 2006
H5N1 breitet sich aus
Erstmals Katze infiziert

Das Vogelgrippevirus H5N1 ist erstmals in Deutschland bei einem Säugetier nachgewiesen worden...

http://www.n-tv.de/639260.html

[nort.]

US struggles to fill gaps in bird flu detection

But many affected countries have no way of detecting bird flu in either chickens or people. U.S. appropriations to the Department of State via USAID and other agencies are helping them build labs and train people to look for signs of H5N1, Gerberding, Hill and others told the hearing.

Congress has approved $3.8 billion of the $7.1 billion
President George W. Bush asked for last year to prepare for a possible pandemic.

NO EARLY WARNING

Late last year U.S. health officials toured bird flu-affected areas. "We visited countries where there is no laboratory so there is definitely no system of early warning in these regions," Gerberding said, adding that her agency and others were trying to "jumpstart" preparations.

http://news.yahoo.com/s/nm/20060302/us_nm/birdflu_usa_dc_1

[nort.]

Wird CBMX mit Sicherheit nicht schaden:

US-Senat stimmt unbefristeter Verlängerung des Patriot Act zu

http://www.heise.de/newsticker/meldung/70339

[whyso]

[posting]20.496.629 von nort. am 03.03.06 21:03:50[/posting]Hi Nort,

wie heisst es so schön bei der Raiffeisenbank Werbung?
"CBMX -und der US SENAT" ...wir machen Ihnen den Weg frei

Schönes Wochenende!
Whyso

[whyso]

Nun stellt Euch dieser Überschrift nur mal vor wenn es mal in der "Washington Post" zum Beispiel gestanden hätte, und es wurde sich hierbei um irgendeine amerikanischer Großstadt handeln-könnt ihr Euch das mal ausrechnen???

Vogelgrippe erreicht deutsche Großstadt!
In den deutschen Vogelgrippegebieten gelten verschärfte Maßnahmen, um eine Ausbreitung der gefährlichen Tierseuche zu verhindern. Erstmals muss mit Mannheim auch eine Großstadt die Schutzvorkehrungen anwenden.

Hunde und Katzen dürfen seit Samstag im Radius von zehn Kilometern um einen Fundort eines infizierten Tieres nicht mehr frei herumlaufen. Betroffen sind die fünf Bundesländer Mecklenburg- Vorpommern, Schleswig-Holstein, Baden-Württemberg, Brandenburg und Bayern.

In Mannheim war am Freitag eine infizierte Wildente gefunden worden. Deshalb tragen jetzt auch Privatfirmen die Müllberge ab, die sich durch den Streik im öffentlichen Dienst angehäuft hatten. So sollen mögliche Gefahrenherde schnell beseitigt werden, sagte Oberbürgermeister Gerhard Widder (SPD). Baden-Württembergs Agrarminister Peter Hauk (CDU) schätzt die Gefahr in Großstädten aber als nicht so groß ein, weil dort nicht so viele Tiere dicht beieinander leben.

Mehr Fälle am Bodensee

Um den Bodensee herum hat sich die Zahl der Vogelgrippefälle auf 14 erhöht, nachdem erstmals am österreichischen Seeufer infizierte Wildvögel gefunden wurden. Vorher waren bereits infizierte Vögel auf der deutschen und der Schweizer Seite des Sees entdeckt worden. In den meisten Fällen steht bislang noch nicht fest, ob es sich um den aggressiven asiatischen Stamm des H5N1-Virus handelt.

In Indonesien ist ein Vierjähriger nach Behördenangaben an dem Virus gestorben. Sollte die Weltgesundheitsorganisation (WHO) diesen Fall bestätigen, handelt es sich um 21. Todesfall durch Vogelgrippe in dem südostasiatischen Land.

In China wächst die Bedrohung

Auch ein Todesfall in China wird wieder mit der Tierseuche in Verbindung gebracht: Ein 32-Jähriger aus Hongkong ist möglicherweise in der südchinesischen Provinz Guangdong an Vogelgrippe gestorben, berichteten Hongkonger Behörden am Samstag.

Der Mann habe sich vermutlich beim Besuch von Märkten in Kanton infiziert. Der Sprecher der Gesundheitsbehörde warnte vor einer wachsenden Bedrohung für die Millionenstadt wegen des regen Grenzverkehrs mit Südchina. In Hongkong waren 1997 die ersten Fälle der Übertragung von Vogelgrippe auf den Menschen entdeckt worden. Seitdem sind dort Geflügelhandel und -haltung strikt reguliert.

dpa, 12:17 Uhr
© 2006 Financial Times Deutschland

http://www.ftd.de/politik/international/53551.html

(und in Deutschland ist der FTD schon wer )

[nort.]

ZUSAMMENFASSUNGEN ZU CBMX

http://messages.yahoo.com/bbs?.mm=FN&action=m&board=16029006…

http://messages.yahoo.com/bbs?.mm=FN&action=m&board=16029006…

[whyso]

Zwei Links die Angst machen könnten

http://www.nzz.ch/2006/03/04/vm/newzzEKDSMZQO-12.html

http://archiv.tagesspiegel.de/archiv/05.03.2006/2392805.asp

und wir dürfen nicht vergessen, die Flugsaison (Migration Season) findet erst noch statt
Whyso

[whyso]

Kumar & Ryan bewegen sich endlich..


CombiMatrix to Webcast Presentation at Invest Northwest(TM) 2006 Conference

(Nasdaq:ACTG) announced today that its CombiMatrix group will present at the Invest Northwest(TM) 2006 Conference at the Bell Harbor Conference Center, located in Seattle, Washington. Dr. Amit Kumar, President and CEO of CombiMatrix, will present an overview of the company.

A live transmission of the presentation will take place at 2:20 pm PT on Tuesday, March 21, 2006. An archived webcast will be available for 30 days. To access the live webcast or archived presentation, please go to
www.combimatrix.com/news_events.htm.

Invest Northwest(TM) is a forum for institutional investors, pension fund managers, analysts, investment bankers, venture capitalists, angel investors and pharmaceutical and biotech corporate partners to meet with executives from public and private life sciences companies based in Washington, Oregon, Montana, British Columbia and Alberta. Sixty-five Pacific Northwest bioscience companies have been selected to present. The event also provides networking opportunities for leaders in the life science industry and financial community.
----------------------------------------------
Acacia Technologies CEO Scheduled to Appear on CNBC
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 4, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that the company`s Chairman and CEO, Paul Ryan, is scheduled to be a featured guest on CNBC`s "Squawk Box" on Monday, March 6, at 7:00 AM EST.

A replay of the broadcast will be archived on the Acacia Technologies website www.acaciatechnologies.com.

Mr. Ryan`s recent appearance on CNBC`s "Street Signs" with Ron Insana on February 24, 2006 is currently archived at www.acaciatechnologies.com.

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 40 patent portfolios, which include over 150 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology

KW10 dürfte recht Spannend werden,
Whyso

[nort.]

Sonntag, 5. März 2006
"Das ist nur ehrlich"
USA erwarten Vogelgrippe

Auch die USA bereiten sich auf einen möglichen Ausbruch der Vogelgrippe vor. Es werde nicht möglich sein, einen Sicherheitsring um das Land zu legen, sagte US-Landwirtschaftsminister Mike Johanns am Samstag. "Ich glaube, dass es nur ehrlich ist, davon auszugehen, dass wir uns mit der Vogelgrippe auseinander setzen müssen."

Dabei sei ein Auftreten der Seuche sowohl in Zuchtbeständen als auch bei Wildvögeln wahrscheinlich. Die USA hätten bereits Pläne ausgearbeitet, wie bei einen Ausbruch der Krankheit vorgegangen werden solle. Der Verzehr von Geflügelfleisch sei aber weiter unbedenklich, wenn das Fleisch ordnungsgemäß zubereitet werde. "Das Erhitzen des Geflügels tötet das Virus. So einfach ist das", sagte Johanns.

US-Gesundheitsminister Michael Leavitt hatte am Mittwoch erklärt, es sei nur noch eine Frage der Zeit, bis die Vogelgrippe auch die USA erreicht habe. Das Virus ist bereits in zahlreichen Ländern nachgewiesen worden, darunter auch in Deutschland.

http://www.n-tv.de/640842.html

[whyso]

Watch this space

Abstract:
Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group has begun work on a one year, $2.1 million contract with the US Department of Defense (DoD). Funding for this contract, which focuses on the use of CombiMatrix` array technology for military and antiterrorist applications, was previously announced as part of the DoD budget.:
http://home.businesswire.com/portal/site/google/index.jsp?nd…

BUT THIS ONE ALSO:


CombiMatrix Launches ElectraSense(TM) Influenza Surveillance System Monday March 6, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 6, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has launched the ElectraSense(TM) Influenza Typing System based on CombiMatrix`s propriety electrochemical detection technology and its Influenza A Typing Microarray.


CombiMatrix is prepared to make this system available to domestic and international government agencies that are engaged in monitoring influenza and planning for a potential pandemic. Using this system, government agencies can verify, before disseminating potentially alarming information to the public, whether samples contain a highly pathogenic substrain of H5N1 or one of the several non-lethal substrains of H5N1. The system is designed for research use, surveillance and monitoring applications, use for animal studies, and other applications not requiring FDA registration. CombiMatrix will seek FDA approval for this product.

The ElectraSense platform is a simple, compact, and rugged system for microarray analysis. This portable system eliminates the bulk, complexity, delicate lasers, and fluorescent dyes common with existing technologies.

The CombiMatrix Influenza A Typing Microarray can identify all strains of Influenza A, including the pathogenic H5N1 strain that has a roughly 50% mortality. Recent studies by CombiMatrix and others indicate that there are multiple sub-strains of H5N1. Some of these are highly pathogenic, some less so, and each may exhibit different responses to drugs such as Tamiflu®. CombiMatrix`s system can differentiate highly pathogenic from less-lethal flu strains and identify strains that may be resistant to therapy, by tracking mutations and recombination events in the genetic makeup of the virus. The system functions even as new mutations appear in influenza strains, maximizing the chance that, as new strains emerge, they can always be detected. In addition, this system can detect mixed or multiple infections of influenza of a single bird or human.

"ElectraSense is an inexpensive yet powerful system for detection and analysis of genomic and proteomic materials on CombiMatrix`s CustomArray(TM). We believe the simplicity of the ElectraSense reader and the power of our Influenza microarray make this system well suited for monitoring influenza outbreaks in the field," said Dr. Amit Kumar, President and CEO of CombiMatrix. "The capabilities of this system are expandable to other pathogens, and we expect to broaden the applications of this product."

Tamiflu is a registered trademark of Hoffmann-La Roche, Inc.(Sag bloß, wirklich ...

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology

Just one question -ready for take off????
Whyso

[whyso]

Watch the "up-coming" musik (LIVE)

http://data.inetats.com/ds/tools/bookviewer/javabook.jsp?STO…

[whyso]

REALTIME US>>>>(1,10 Hrs before open)>>>2.03 0.11 (5.73%)

[whyso]

I see a "W"

[nort.]

[posting]20.534.741 von whyso am 06.03.06 14:31:27[/posting]bleibt nicht mehr lang bei einem einfachen W

[whyso]

Only a matter of time für CBMX
Whyso

[nort.]

[posting]20.603.250 von whyso am 09.03.06 19:22:16[/posting]Wenn der weiße Fleck da, mit den hysterischen Bewohnern einmal erfasst ist, gibt es kein Halten mehr.

Weißt Du noch was im letzten CC bezüglich Tests in US von der WHO gesagt wurde?

[nort.]

With avian flu spreading, U.S. to expand its testing
-----------------------------------------------
The U.S. government, bracing for the possibility that migrating birds
could carry a deadly strain of bird flu to North America, plans to
test nearly 8 times as many wild birds this year [2006] as have been
tested in the past decade. Starting in April 2006, samples from 75 000 to 100 000 birds will be tested for the virus, mainly in Alaska,
as part of a joint effort of the departments of Agriculture and
Interior, along with state Fish & Wildlife agencies. That`s a jump
from the 12 000 birds tested since 1996, the USDA`s Angela Harless
says. [Related item: Graphic - Migratory path of birds:
<http://www.usatoday.com/news/health/bird_flu_06/flash.htm>…

...
Tests also will be made on birds killed by hunters in Alaska this spring 2006, and in Oregon, Washington and California during the fall, Throckmorton says.
...



http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[whyso]

Hi Nort, da sagst du was, BEIM -(fast sicheren)- ANKUNFT wird die reinste Panik ausbrechen, -Geld wird bald fließen-
da habe ich so`n Art Vorahnung ...

[whyso]

Gut Ding will halt weile haben...



http://biz.yahoo.com/bw/060314/20060314005238.html?.v=1


...aber dann lohnt es sich auch

Festhalten & weglegen,
Whyso

[nort.]

[posting]20.684.584 von whyso am 14.03.06 21:19:18[/posting]dann machen wir doch mal die 10% voll für heute

[whyso]

[posting]20.684.796 von nort. am 14.03.06 21:29:24[/posting]Naja, mir wäre nochmals 7,2% morgen wieder... und das ganze dann auch forgestetzt am Donnerstag & Freitag

Nort, wir stehen hier am Anfang-ich freue mich auf den Splitt

[e.1]

na dann kann es ja doch nicht sooooo falsch gewesen sein, ein paar nvax in cbmx umzuschichten.
ich hoffe , wir können uns auf weitere steigende kurse freuen.

[whyso]

HOLD ONTO YOUR SEATS.... Die 2Dollar marke lässt wieder Grüßen



CombiMatrix Granted Key Nanotechnology Patent
Patent Enables Unique Proteomics Technology and Products


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 16, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group was granted a key patent in Europe (EP1185363B1), titled "Self-Assembling Arrays" by the European Patent Office. This European Patent was registered throughout the European Union in Germany, France, Spain, Great Britain, and Italy, and the opposition period has passed. A corresponding U.S. patent is pending in the U.S. Patent and Trademark Office and is moving through the process.
ADVERTISEMENT


The European patent claims both self-assembled arrays and a method for making self-assembled arrays on electrode arrays with self-assembled antibodies. This microarray configuration is especially useful for arraying proteins specifically antibodies. The technology enables products such as multiplexed immunoassays, monitoring of biowarfare and terrorist agents, and general protein analysis tools.

"CombiMatrix`s intellectual property strategy is designed to provide freedom to operate for CombiMatrix products as well as to establish strong barriers to protect the unique aspects and commercial advantages of our electrochemical synthesis and detection technologies," said Dr. Jeff Oster, Senior Vice President, Legal at CombiMatrix. "In this case, we decided to wait the nine months after publication of the grant to let the opposition period expire before announcing."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 41 patent portfolios, which include over 150 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 19

http://biz.yahoo.com/bw/060316/20060316005227.html?.v=1

[nort.]

Donnerstag, 16. März 2006
Neueste Vogelgrippeforschung
H5N1 Spanischer Grippe ähnlich

Nach Angaben von US-Forschern ähneln Vogelgrippeviren inzwischen den Grippeerregern von Menschen stärker als bislang angenommen. Daher könnten schon wenige weitere Veränderungen der Eiweiße auf der Oberfläche der Vogelgrippeviren reichen, um sie hochgefährlich für Menschen zu machen. Die Eiweiße des Virus H5N1 ähneln demnach denen der Erreger der Spanischen Grippe von 1918. Mit dem 1997 bei Enten isolierten ursprünglichen Vogelgrippevirus gebe es dagegen weniger Gemeinsamkeiten. Das berichtet die Gruppe um James Stevens vom Scripps Research Institute in La Jolla (US-Staat Kalifornien) im Fachjournal "Science" (10.1126/science.1124513).

Die Gruppe um Stevens analysierte die Struktur des Eiweißstoffes Hämagglutinin an der Oberfläche der Viren. Das mit der Abkürzung "H" bezeichnete Molekül ermöglicht dem Erreger das Eindringen in die Wirtszellen. Dazu hakt es sich an Andockproteinen (Rezeptoren) dieser Zellen fest. Vogelgrippeviren docken dabei an anderen Rezeptoren an als die Erreger der Grippe des Menschen. Dies ist der Grund dafür, dass H5N1-Viren derzeit nur selten Menschen befallen - bislang infizierte der Erreger rund 180 Menschen, etwa 100 von ihnen starben.

Wissenschaftler befürchten, dass das Virus mutieren und eine weltweite Grippewelle mit Millionen Toten verursachen könnte - der Spanischen Grippe von 1918 fielen je nach Angaben 20 bis 50 Millionen Menschen zum Opfer. Ein solches für den Menschen gefährliche Virus könnte entstehen, wenn sich ein Grippekranker zusätzlich mit H5N1 infiziert und sich eine neue Kombination aus beiden Erregern bildet. Eine andere Möglichkeit ist, dass das Hämagglutinin so mutiert, dass es künftig auch leicht an menschlichen Grippe-Rezeptoren andockt.

Die Forscher verglichen das Hämagglutinin von Viren aus einer Blutprobe eines 2004 an der Vogelgrippe gestorbenen vietnamesischen Jungen mit dem anderer Grippeerreger. Das Hämagglutinin des Erregers aus der Blutprobe war dem menschlicher Grippeviren ähnlicher als dem der ursprünglichen Vogelgrippeviren von 1997. Welche weiteren Mutationen noch folgen müssten, damit das Virus komplett auf den Menschen "umschwenkt", könne man nicht vorhersagen, heißt es in dem Aufsatz.



http://www.n-tv.de/645268.html

[whyso]

@Nort, kennst`d den hier aus Bayern

Top News
Weiterer Fall in Bayern

LZ|NET/dpa. In Bayern gibt es einen weiteren Fall von Vogelgrippe. Das Friedrich-Löffler-Institut auf der Ostseeinsel Riems bestätigte den ersten Fall einer mit H5N1-Erreger infizierten Wildente in der Region Rosenheim.

Das Tier wurde am 7. März tot am Innufer im Gemeindebereich Kiefersfelden aufgefunden. Derzeit ist nach Angaben des Landratsamts Rosenheim noch unklar, ob es sich um die hoch pathogene Form des Virus handelt. Rund um den Fundort wurde eine Schutzzone errichtet.

Schweden hat erstmals das Auftreten des Vogelgrippevirus H5N1 gemeldet. Wie das staatliche Veterinäramt in Stockholm mitteilte, hätten Analysen im EU-Speziallabor im britischen Weybridge erste eigene Testergebnisse bestätigt. Die untersuchten Wildenten waren vor gut zwei Wochen in der Umgebung des Atomkraftwerkes Oskarshamn an der schwedischen Ostseeküste gefunden worden.

Forschungsprogramm soll anlaufen

Bundeslandwirtschaftsminister Horst Seehofer (CSU) will unterdessen das geplante deutsche Forschungsprogramm im Kampf gegen die Vogelgrippe zügig auf den Weg bringen.

«Wir werden das nächste Woche im Bundeskabinett behandeln», sagte Seehofer der Hörfunkagentur dpa/Rufa. Er hoffe, dass «in überschaubarer Zeit» ein moderner Impfstoff für Geflügel die Stallpflicht und eine Keulung der Tiere überflüssig machen werde. Bei den bislang üblichen Impfstoffen lassen sich infizierte Tiere nicht von geimpften unterscheiden. Damit kann sich das Virus unter einer Impfdecke ausbreiten.
(und genau dort kommt CBMX wie eingeladen zum Einsatz )

Das Friedrich-Loeffler-Institut (FLI) für Tiergesundheit geht von mehreren Jahren aus, um einen so genannten Marker-Impfstoff zu entwickeln. «Wir sind weit davon entfernt, (diesen) Impfstoff massenhaft und kostengünstig herstellen zu können», sagte FLI- Präsident Thomas Mettenleiter der «Süddeutschen Zeitung".

16. März 2006

[whyso]

POSTING und zugleich KURSZIEL ...200

[nort.]

Ein paar Infos über CBMX:

Thread: Acacia Research-(CBMX)-die CombiIMatrix- Vogelgrippe Play & rebounder 2006 ???

[whyso]

DAS CBMX & NVAX POWERHOUSE wächst zusammen ....
--------------------------
CombiMatrix and Novavax collaborate
by: misc_info_06 03/17/06 11:09 am
Msg: 27031 of 27113

Pharmaceutical Business Review:

CombiMatrix and Novavax collaborate on vaccine production

10th November 2005

CombiMatrix, part of Acacia Research, is collaborating
with specialist biopharmaceutical company Novavax
on the development of a technique to
improve synthetic vaccine production,
possibly aiding the rapid production of a bird flu treatment.


Traditional flu-vaccine development involves the process
of viral amplification in chicken eggs,

followed by a LENGTHY process of inactivation,
sterilization, and packaging. This method IS
very time consuming and does NOT allow rapid response
to quickly evolving threats.

In the case of H5N1 bird flu,
the THREAT IS THAT THE STRAIN NOW PRESENT WILL MUTATE
or recombine to form a new strain that will be easily transmissible
among humans and have high mortality rates.

If such a new strain appears, traditional flu-vaccine
development and production will likely be TOO SLOW
to ramp up to cover the world`s need.


COMBIMATRIX IS DEVELOPING A TECHNIQUE designed to
IMPROVE THE PROCESS OF SYNTHETIC VACCINE PRODUCTION
BY TRACKING THE GENETIC FIDELITY of the genes
encoding the vaccine in the fermentation process.

such a method would be a SIGNIFICANT ADVANCE
FOR LARGE-SCALE SYNTHETIC PRODUCTION PROCESSES and

could help speed FDA regulatory processes.
The method is designed to be both inexpensive and fast.

CombiMatrix and Novavax are now collaborating
to test efficacy of the method on Novavax`s VLP process
for producing H5N1 bird-flu vaccine.


"CombiMatrix`s belief is that, for a variety of reasons,
THE WORLD NEEDS the ability to DESIGN NEW VACCINES
and to produce them much MORE RAPIDLY than it can today,"
said Dr Amit Kumar, president and CEO of CombiMatrix.

"Reasons include the possibility of rapidly evolving
natural threats such as bird flu and SARS
as well as increased terrorist activity throughout the world."

*****

http://www.pharmaceutical-business-review.com/article_news.a…

as far as I know this is all that has been disclosed
about the agreement. Although, during last CC Kumar discussed
the agreement, plus his personal history with NVAX CEO:

====================
Human & Birds samples from North America
were recently sent to CBMX for analysis by WHO;
CBMX H5N1 Findings on those samples have
already been sent back to WHO,
including level of pathegenity of strains.

These WHO Samples Results are to be published soon
====

Currently engaged in collaborative work
with NVAX, regarding Influenzia Drift Monitoring.

CEO`s of CBMX & NVAX are "personal friends"
and have worked together on Research projects
in the past, at MIT & Havard.

Vaccines are subjected to genetic drift,
which can render the vaccines under development ineffective.

CBMX Arrays are Very effective for monitoring such genetic drift.

CBMX & NVAX are Researching how to measure and control
genetic drift during vaccine development.
This collaborative Program will continue to expand
as NVAX vaccine development efforts
continue to grow.
====================

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065… 00656&action=m&mid=25639

perhaps will will find out more about NVAX & CBMX Plans
after there meeting in an India Biotech Summit at the end of March?

http://www.combimatrix.com/news_events.htm
-----------------------
CombiMatrix and Novavax collaborate (2)
by: misc_info_06 03/17/06 11:16 am
Msg: 27034 of 27114

*****
Pharmaceutical Business Review:

Novavax enters flu vaccine research collaboration
16th February 2006

This preclinical data will supplement recent data published in collaboration
with the Centers for Disease Control and Prevention showing Novavax
influenza VLP vaccines can elicit a protective immune response.

http://www.pharmaceutical-business-review.com/article_news.a…
*****

perhaps NAVX needs CBMX to SPEED UP the Gov`t Approval Process
afterall?

A mutating Virus in the Vaccine process
or in the Population at large could put
a serious "crimp" in Vaccine Production "turn-around" plans
*****

What is "Genetic Fidelity"?

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065…
*****

CDC`s BioSense Surveillance System,

CBMX Govt in-roads, Flu Chip Sales:

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065…
*****

CBMX`s Long-Term Potential of bringing many
OTHER VACCINES development programs into the 21st Century

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065…

FAZIT: Ein 20$ Stock, den wir gestern für mickrigen 2,10$ erweren dürften

Ja nee, ist klar...STRONGEST BUY -(MIT NVAX als Partner)-am Markt überhaupt.

Schönes Wochenende ihr lieben,
Whyso

[whyso]

Egyptian Woman dies of Bird Flu?
http://abcnews.go.com/Health/wireStory?id=1740830

[whyso]

Guten morgen zusammen

Hier the "smart money chart" from last week


Augen auf beim Autokauf,
Whyso

[whyso]

What must be done before a
by: berhardwaldmann
Long-Term Sentiment: Buy 03/19/06 01:19 pm
Msg: 27178 of 27181

takeover at $25 is more likely than not ? The following conditions must be met :

1. Split of CBMX away from Acacia Research
2. 90k launched
3. CLIA Certification for CMDX
4. Furuno next generation BTS launched
5. Leuchemix Phase I Trials started
6. Bird Flu arrived in several States in the US

You know what ? All this conditions will be met within the next 90 days.
I have no doubt at all that CBMX is a takeover target and already on the radar screen of 5-10 very large life science companies.

Not having this stock in the portfolio is a big mistake.
Being short this stock is plain stupid.

[whyso]

http://www.marketwatch.com/tools/quotes/quotes.asp?symb=cbmx…

[whyso]

Watch this space

Diagnostic Devices Break Out

Researchers believe 2006 will be a big year, with the number of microarray-based diagnostic devices increasing from just one to several.

Patrick McGee, Senior Editor

Diagnosing disease is an imperfect science in many ways. For example, most tumor classifications are done based on visual characteristics and then confirmed using immunohistochemical tests, but despite these steps, many cases are still difficult to diagnose. When it comes to treating cancer and other diseases and conditions, the
click the image to enlarge

The AmpliChip CYP450 Test predicts phenotype, a factor which influences the concentration of drug in a patient’s blood and allows clinicians to determine therapeutic strategies and optimal dosing for patients. (Source: Roche Diagnostics Corp.)
efficacy and toxicity of drugs vary greatly from person to person, and genetics can account for 20% to 95% of the variability in drug disposition and effects. Microarray-based diagnostic tests are an emerging solution to this quandary because they have the potential to detect diseases and predict the desired and undesired effects of drugs developed to treat them.

In January 2005, the AmpliChip CYP450 Test became the first microarray for in vitro diagnostic use approved by the US Food and Drug Administration (FDA). The AmpliChip, which is manufactured by Roche Diagnostics Corp., Indianapolis, detects variations in CYP2D6 and CYP2C19, two cytochrome P450 genes that play a key role in the metabolism of many drugs, so it can be used to ensure that drugs are used in an optimal manner and to prevent harmful drug interactions. But it is unlikely that the AmpliChip will be the only microarray-based diagnostic for long, researchers in the field say.

"Everyone can see the writing on the wall, that the microarrays are going to be a very, very powerful tool both in the diagnosis and management of disease and on the prognostic side," says David Baunoch, PhD, president and cheif operating officer of CombiMatrix Molecular Diagnostics Inc. (CMD), Irvine, Calif. CMD, a subsidiary of CombiMatrix Corp., Newport Beach, Calif., develops microarray-based diagnostics. "We`re going to see a whole wave of microarray applications that are going to move into the clinical lab in the next decade. The first will be focused on unresolved diagnostic challenges, but I think ultimately what you`re going to see is a wave of tests that are going to revolutionize how we manage patient care on a daily basis." Baunoch adds that diagnostic lymphoma arrays, which are being developed by CMD and several other companies, will likely be the first microarray product approved since the AmpliChip.

Unlimited applications
Walter Koch, PhD, head of research at Roche Molecular Diagnostics, also sees a promising future for microarray-based diagnostics. "We believe that microarrays will be another tool in the toolbox for physicians in the laboratories for molecular diagnostic purposes in the years ahead. The number of applications are basically unlimited in terms of what you can dream up," says Koch. "I believe the initial wave will primarily be in oncology. It just seems to be the disease area where we have a greater in-depth understanding of the genes that are involved that lead to the disease and that also define differential or subclasses of disease which dictate differential treatment regimes. I think there will be more of these. I don`t know that it`s going to be a huge number very quickly. I think it`s going to be incremental."

Glenda Anderson, CEO of PathWork Informatics Inc., San Jose, Calif., says 2006 will be a breakout year for microarray-based diagnostics, and she sees a number of factors behind the development of these new products. One is "significant" improvements in reproducibility for microarrays, reagents, and kits. "They are now demonstrating the kind of performance you`d expect from a clinical product. Three years ago it wasn`t as clear that you could say that. That`s probably the overarching
Last January, the AmpliChip CYP450 Test became the first microarray for in vitro diagnostic use approved by the FDA. It detects variations in CYP2D6 and CYP2C19, two cytochrome P450 genes that play a key role in the metabolism of many drugs. (Source: Roche Diagnostics Corp.)
trend, improved reproducibility," she says. Another factor is the improved performance of scanners and some other ancillary instruments required for diagnostics. Also, because the human genome is more fully characterized, the choice of oligonucleotides or probes bound to arrays are more specific, so there is less cross-hybridization.

Another key factor, Anderson says, is that the technology offered by Affymetrix, Santa Clara, Calif., has stabilized. This is key, because many microarray-based diagnostic platforms are based on their technology. The company has a program called Powered by Affymetrix which enables companies to license their GeneChip technology, the first microarray instrumentation system for molecular diagnostics laboratories. This allows the partner companies to develop microarray products for applications in diagnostics, forensics, animal testing, and more.

One partner is Roche, whose AmpliChip is used on the GeneChip Microarray Instrumentation System. One advantage of the GeneChip platform is a scalability that allows it to be used for investigating specific genetic targets or an entire genome of human, plant, animal, or microbial systems. PathWork Informatics is another program partner, as is BioMérieux, Marcy l`Etoile, France; Vita Genomics, Taipei, Taiwan; and Veridex LLC, a Johnson & Johnson company, Warren, N.J.

Incorporating microarrays
Under their partnership with Affymetrix, PathWork Informatics can incorporate Affymetrix microarrays into the diagnostic PathWork Oncology Suites they are developing. Anderson says PathWork has two in vitro diagnostic kits in development and both comprise proprietary software and a companion microarray that allow a collection of tests to be done on one microarray. When approved, the suites will be sold to clinical laboratories which can use them to process a biopsy specimen and assess multiple parameters.

The first suite will identify a tissue of origin and compare the gene-expression signature and gene-expression data for a specimen against 15 alternative candidate tissues of origin. "In this way, we take a single specimen and answer many questions. Is this specimen similar to a prostate cancer, is it similar to breast cancer, is it similar to a melanoma, is it similar to a lymphoma?" Anderson says. "The second product in development is expected to answer a more clinically diverse mix of questions: How
The CombiMatrix Custom 4x2K Array is predominantly developed for diagnostic applications and allows for the simultaneous analysis of 2000 unique markers for four independent patient samples. (Source: CombiMatrix Molecular Diagnostics Inc.)
aggressive is this tumor, is it resistant to several of the commonly used therapeutics?"

Under the partnership, PathWork will design the products, Affymetrix will manufacture the microarrays, and PathWork will then sell the diagnostic suites. The PathChips, as they are called, will be gene expression mRNA-based tests, as opposed to the AmpliChip, which is a DNA-based test. "The AmpliChip is looking at polymorphism in the nuclear DNA; we`re looking at variations in expression. In fact, we expect to be the first gene expression-based test to find our way into, and with luck, out the other side of the FDA," Anderson says. While PathWork is a small, early-stage company, they have already formed collaborations with many cancer centers across the country, something that accelerated their path to development, she adds.

Roche is working on two near-term cancer applications based on the Affymetrix platform. One is a p53 tumor suppressor re-sequencing array. It uses an approach similar to the AmpliChip, but it is much denser, using more than 220,000 oligonucleotides to determine the sequence of the p53 tumor suppressor gene, which is mutated in over half of all cancers. The second will use gene expression profiling to classify some 20 different types of leukemia and related diseases like myelodysplastic syndrome. The diagnostic will target a subset of a few thousand genes which optimally distinguish and discriminate between different classes of leukemia, Koch says.

Home brew
One company that is not partnering with Affymetrix is CMD, which is instead taking a "home brew" approach to diagnostics. Home brew tests are brought to market by reference laboratories and medical centers and are configured using analyte-specific reagents (ASRs). While the components that comprise home brew tests are regulated by the FDA, especially regarding features such as quality control and labeling of reagents, the agency does not regulate how the tests are put together.

But that could be changing, Anderson says. "If you look at the regulatory landscape today, the FDA is taking a much more active role in restricting access to the market as a home brew, not only for the microarray platforms, but we`re seeing the same in RT-PCR-based tests as well. So even those who have taken an alternative technology platform and offered it up as a home brew using CLIA [Clinical Laboratory Improvement Amendments] as their regulatory framework are finding that the FDA has something to say about it. . . . In summary, what we expect to see is a more consistent position on the FDA`s part in terms of regulating molecular diagnostics independent of the platform."

Baunoch says CMD is focusing on several areas with unresolved diagnostic challenges for its home brew tests. The first is melanoma, specifically a test that could distinguish between a benign dysplastic nevis (a mole) and melanoma. "It`s really the most miscalled of all diagnoses in the pathology world. It`s very difficult. Even the very best dermatopathologists have difficulty in calling these cases. What we were looking for was a test that would allow us to take these moles and determine which ones were actually melanomas so that patients could be treated in the appropriate fashion." Baunoch adds that this is a potentially large market because the number of melanoma cases in the United States has climbed from approximately 40,000 annually just seven years ago to over 60,000 annually today, with 8,000 melanoma-related deaths yearly.

CMD is collaborating with Scott Binder, MD, to develop a gene-based test for the diagnosis of malignant melanoma using routinely prepared formalin-fixed paraffin-embedded material. Binder is in the department of pathology and laboratory medicine at the David Geffen School of Medicine at the University of California, Los Angeles. In addition to collaborating on this project, Binder and his colleagues will provide clinically validated patient samples for the development and validation phase of the project. The test will serve as an adjunct to traditional morphologic and immunohistochemical methods and should be available by the end of the year.

CMD is also developing array-based methods that would enable the development of a molecular classification system for tumors. Today, most tumor classification is done based on visual characteristics. A piece of the tumor is taken, stained with dyes, and examined under a microscope, and then confirmatory immunohistochemical tests are conducted. "Rather than diagnosing it under a microscope we could basically take a very small portion of that tumor, apply it to an array, and diagnose it." CMD first introduced the idea for such a microarray three years ago, and there are now seven or eight companies doing similar work, Baunoch says. He adds that CMD plans to have its tumor classification system on the market early in 2007.

http://www.dddmag.com/showpr.aspx?PUBCODE=016&ACCT=160000010…

[whyso]

Tagesverlauf von CBMX gestern an der Nasdaq...



After Hours weitere 4.25% Ansteig, der session wurde "angehalten" bei $2.70...die magische 3$ Grenze rüft

Keep the faith, and the shares,
Whyso

[whyso]

Der springende Satz:

"Acacia will redeem all Acacia Research-CombiMatrix common stock for all the common stock of CombiMatrix Corporation, which will register its stock and plans to list its shares for trading on Nasdaq. Acacia expects the transaction to complete in the second quarter of 2006 subject to conditions. The deal is expected to benefit both companies by eliminating the risk factors associated with the current capital structure, Acacia said"

Nach der kommende Indien "Besuch" wird es schnell nach oben gehen mit der Combimatrix-verschiedende Regierungen sind auch noch mit im Spiel

Schönes Wochenende ihr lieben,
Whyso

[whyso]

Alles unter die 8$ Grenze ist wirklich "leichte Beute" für die Investoren die ein Value Investment für 2007 tätigen wollen....

Augen auf beim Aktienkauf!

Schönes WE Y'all,
Whyso

[nort.]

Barchart steht auf vollem grün. Grüner geht es nicht mehr

http://quotes.barchart.com/texpert.asp?sym=cbmx

[whyso]

Antwort auf Beitrag Nr.: 20.941.360 von nort. am 24.03.06 17:51:50

Guten morgen Nort, guten morgen all

leckere Charts gibt es reichlich im Bezug auf die CBMX z.Zt, diese "Bäumschen" hier zum Beispiel...



oder schau die grüne "Schnitt-Marke" im unteren Chartbereich hier an:
http://stockcharts.com/gallery/?cbmx

Genauso fing es damals bei NVAX auch an
Ich verkaufe jedenfalls kein Stk.davon!

Schönes Wochenende,
Whyso

[whyso]

Antwort auf Beitrag Nr.: 20.945.569 von whyso am 25.03.06 06:51:06

Ach ja, ich vergaß folgendes...

Schaut Euch der IR Name hinter die letzten 2 "ad hocs" von Acacia mittlerweile an, nicht mehr der hier:

Acacia Research Corporation
Bret L. Undem (Media Relations), 425-493-2293
Fax: [phone]

sondern jetzt der ehemalige Ehemann von Frau Hunter & "Whiskystimme Sänger":

Acacia Research Corporation
Rob Stewart (Investor Relations), 949-480-8300
Fax: [phone]

Naja, Rob & Rod Stewart ist fast das selber ...oder?

Die Trennung wird langsam aber sicher vollzogen!
Ich freue mich sehr,
Whyso

[whyso]

Watch this space während KW's 13-14

http://stockcharts.com/h-sc/ui

http://stockcharts.com/h-sc/ui?c=cbmx,uu[r,a]waclyiay[df][pb…

[nort.]

Antwort auf Beitrag Nr.: 20.945.569 von whyso am 25.03.06 06:51:06

Hallo whyso,

ist ein seeehr interessantes Bäumchen

nort

[whyso]

Tja Nort





NVAX lässt grüssen!
Whyso

[whyso]

Lesen & kräftigst rechnen dabei

“Acacia Technologies’ revenues for the fourth quarter of 2005 increased to $8,246,000 compared to $779,000 in the year ago period. Revenues for the year ended December 31, 2005 increased to $19,574,000 compared to $4,284,000 for the year ended December 31, 2004,”

http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx…
---------------------------------
"The separation of the two companies should enable
each company to optimize ITS OWN IDENTITY AND BUSINESS STRATEGY,

making an investment in THE COMPANIES MORE ATTRACTIVE TO INVESTORS," concluded Mr. Ryan.

Dr. Amit Kumar, President and CEO of CombiMatrix, said,
"As an INDEPENDENT public company, CombiMatrix Corporation
should HAVE BETTER VISIBILITY IN THE HEALTH CARE MARKET
and enable the public MARKETS TO BETTER VALUE THE COMPANY."


Acacia expects to complete the transaction in the second quarter of 2006
http://biz.yahoo.com/bw/060109/20060109005233.html?.v=1" target="_blank" rel="nofollow ugc noopener">http://biz.yahoo.com/bw/060109/20060109005233.html?.v=1

*****
let me see ....Qtr2 begins in 1 WEEK !!!
Let the spin off begin!
------------------------
DIE AKTUELLE ZAHLEN & AUSBLICK ...

The CombiMatrix group recognized
revenues of $3,644,000 for the fourth quarter of 2005,

comprised of

previously deferred collaborative revenue,
sales of products and services, and
government contract revenue.

This reflects an increase of 600% relative to
the revenue of the fourth quarter of 2004.

Total revenues for 2005 were $8,033,000
and our net loss was $12,401,000,"

commented Dr. Amit Kumar, President and CEO of CombiMatrix.


"As we continue to commercialize our products
we are positioning ourselves well for success
in all of our initiatives, including

product sales,
government contracting,
drug development and
our molecular diagnostics initiative,"

concluded Dr. Kumar.

*****

For the Three Months Ended December 31, 2005 and 2004

Revenues for the fourth quarter of 2005 were
$3,644,000 versus
$522,000 in the comparable 2004 period.


Fourth quarter 2005 revenues were comprised of

$2,266,000 in previously deferred
collaboration agreement revenues recognized as a result of
the CombiMatrix group's completion of its research and development
agreement with Toppan Printing Co., Ltd,

$864,000 in government contact revenues and

$514,000 in CustomArray TM product, equipment and service revenues.

Fourth quarter 2004 revenues were comprised of $390,000 of government contract revenues and $132,000 of CustomArray TM product and service revenues.
Government contract revenues relate to the CombiMatrix group's
development of biological threat detection technology under its
$5.9 million Department of Defense cost plus fixed fee contract,
which was completed in December 2005.
-----------
The fourth quarter 2005 division net loss was $1,785,000 versus
$4,118,000 in the comparable 2004 period.

The fourth quarter 2005 results also included non-cash patent amortization and depreciation charges totaling
$553,000 as compared to $534,000 in the comparable 2004 period.

The fourth quarter 2005 results included a non-cash charge of
$565,000, primarily related to the write off of goodwill related to CombiMatrix K.K.

Fourth quarter 2005 government contract costs totaled $863,000 versus $369,000 in the comparable 2004 period.

The increase was due to increased costs recognized in connection with the CombiMatrix group's commitments under its biological threat detection contract with the Department of Defense, which was completed in December 2005.

Fourth quarter 2005 internal research and development expenses were
$1,701,000 versus
$1,362,000 in the comparable 2004 period.

During the fourth quarter of 2005 and 2004,
the CombiMatrix group continued internal research and development efforts to improve and expand the CombiMatrix group's technology and product offerings.

The increase in internal research and development expenses
was due primarily to the impact of the CombiMatrix group's
wholly owned subsidiary, CombiMatrix Molecular Diagnostics,

which was formed and began research and development activities
in the second quarter of 2005.

Fourth quarter 2005 marketing, general and administrative expenses
decreased to
$2,582,000 versus
$2,597,000 in the comparable 2004 period,

due primarily to a reduction in sales staff headcount in the fourth quarter of 2005

and a reduction in general and administrative expenses,
including a decrease in Sarbanes-Oxley compliance costs

I rest my case-CBMX STRONG(EST) BUY 2006!
Gruß-Whyso

[nort.]

Presence of live avian flu chain worrying: scientists
Wednesday March 29 2006 00:00 IST

IANS

BHOPAL: India may seem to have contained the spread of the bird flu, but scientists testing for the H5N1 virus say the presence of a live chain of the disease is worrying.

Researchers at the High Security Animal Disease Laboratory here say that many of the samples are unfit for testing as proper procedures were not followed for their collection and preservation.

"Most bird flu samples reaching us remain unfit for testing," H.K. Pradhan, head laboratory, told IANS. Several thousand samples, packed in iceboxes, arrive in the lab from various places.

"Many of the samples come in such a poor condition that it is not possible for the virus to be alive," he lamented.

The four samples that tested positive last week, he said, were from scattered domesticated population. "Though the samples showed the presence of the H5 virus, their N1 status could not been tested.

"But it is quite certain that they would have tested positive for N1 as well which means the virus is still in the environment and a direct link exists, as H5N1 cannot transmit without a live carrier," Pradhan said.

Culling and cordoning of affected zones - predominantly in Maharashtra - were done quickly enough to check the spread of the disease, he said. But the existence of a live bird chain is worrying.

"This live chain has to be broken as the disease is transmitted from bird to bird and not through air," he asserted.

"It is not possible to get a clear picture of the spread of the disease because proper procedures while collecting and preserving samples for testing are not followed.

"Many of the samples reaching us are in such a state that it becomes impossible to get a positive result even if they are infected."

Narrating the example of a sample that was so bad that scientists had to dump it in the incinerator without even opening it, Pradhan said: "A sample has to reach us when the virus is alive in the medium - dead chicken, blood, egg, tissue, or faecal matter - by maintaining a cold chain and sticking to the time of collection and packaging norms".

As for the culling procedure, Pradhan said, it is better to burn the carcasses.

"Buried animals can be dug out by dogs or jackals if the hole is not deep enough or they have not been treated properly with lime and chemicals," he said.

The lab is at present running out of time and space. While it can handle a maximum of about 2,000 blood samples and 100 tissue and faecal samples a week, it has been receiving 4,000 samples every week over the past month.

Six out of the eight rooms in the laboratory are now engaged in H5N1 work, distributed across a dozen scientists.

The pressure is forcing Pradhan and his colleagues to pick and choose samples.

"There is pressure," Pradhan admits, adding: "The top priority is for samples from sites with mortality."

[whyso]

Bei CBMX wird kräftig gesammelt, schaut Euch die buy & sales von gestern an

http://host.businessweek.com/businessweek/Historical_Quotes.…

Achte insbesondere auf die Zeit um die 14:31/14:32 >>>>12:55 vormittags war auch schon sehr "auffällig"

Hold tight:- alles unter die 5$ Marke ist & bleibt der Einsatz Wert!

Viele Grüße & good UP-trades,
Whyso

[whyso]

Meine Meinung
-------------------
Re: CNBC . What you must know.
by: bloodfromastein (40/M)
Long-Term Sentiment: Strong Buy 03/29/06 01:08 am
Msg: 29083 of 29083

I d'ont agree with you at all!!!

EVERY PLATFORM that introduces and talks about this still "communal company" and its excellent new emerging technologies, is an integral part of the communal advertising for both "stand alone players" later on in the day.

By the way, I also believe Dr.Kumar will have much more to say -(and not limited)- when he is running the CBMX show solely on his own terms, and not having to air Paul Ryans approved point of view...

Time will tell.

[nort.]

http://www.nasdaq.com/aspxcontent/NewsStory.aspx?cpath=20060…

UPDATE: Avian Flu Expected In U.S. This Spring; Stocks Ignited

By Ciara Linnane

NEW YORK (Dow Jones) -- U.S. government officials monitoring the spread of avian influenza are expecting the first case to reach Alaska in about three weeks and to hit the West Coast by autumn, Prudential Equity Group said Wednesday.

The H5 pathogen has been confirmed in 51 or more countries, according to the Paris-based World Organization for Animal Health, causing the culling of millions of birds across Asia, Europe and, more recently, the Middle East.

The first cases in the U.S. won't necessarily make humans ill -- only the bird version of the disease is expected here, at least initially, said Kim Monk, a Prudential senior health-care-policy analyst.

"The virus might only spread bird to bird or, rarely, bird to human, and it may or may not ever mutate into a human-to-human virus," said Monk. "So for now, the only real threat is to the poultry industry."

More than 100 people have died since the H5 virus first occurred in Asia in 2003, most of them after direct contact with infected birds.

But scientists are worried the pathogen could mutate and become transmissible between humans, potentially creating a pandemic to rival the outbreak of Spanish Flu in 1918. That virus killed about 50 million people.

The Bush administration, like other governments, is bracing for a potential pandemic. It is seeking up to $7 billion to fund programs to develop and stock supplies of vaccines.

Among the companies most likely to benefit from the effort are Roche, the biggest manufacturer of Tamiflu; GlaxoSmithKline (GSK) , which makes the antiviral Relenza; and makers of cell-based vaccines such as Chrion (CHIR) , Solvay and Sanofi-Aventis (SNY) .

3M (MMM) could gain attention if there's increased demand for protective paper masks, the analyst said.

Trend Macroanalytics, a research firm serving institutional investors, has taken its analysis a step further and created an "avian-flu index" comprising 17 stocks in the health-care sector that can be expected to see a surge in demand for their products should the flu become a threat to humans.

The index includes stocks like Embrex (EMBX) , a leader in "in ovo" technology for the poultry industry; Hemispherx (HEB) , whose interferon inducer Ampligen is considered a strong candidate as a flu treatment, and BioCryst (BCRX) and Generex (GNBT) , which are both producing antivirals.

Donald Luskin, chief investment officer at Trend Macro, said the index has gained 105% since its inception last Aug. 31 and is up 40.5% so far in 2006.

Luskin said he considers the chance of mutation and a pandemic small.

"The reason why investors should buy these stocks, though, is because it is the vaccines, therapeutics and diagnostics of the companies in this sector that are making sure the pandemic doesn't happen," he said.

"Lots of money will be spent by governments -- spent with these companies -- to be sure to prevent the worst case."

He likened the bird-flu situation to Y2K, when companies spent billions of dollars upgrading technology to ensure computers could cope with the switch to the new millennium. "The worst case didn't happen because people were warned," he recalled.

Among the companies outside the health-care sector that might attract a sales spurt from avian flu is Pall (PLL) , which makes filtration systems that can also be used in vaccine production as well as breathing ventilators that can be used to discourage the spread of viruses such as SARS and certain flu strains.


http://www.healthday.com/view.cfm?id=531827

Bird-Flu Pandemic Would Likely Start in California
And it would sweep across the U.S. in less than a month, study predicts

By Ed Edelson
HealthDay Reporter

THURSDAY, March 30 (HealthDay News) -- If a bird-flu pandemic does hit the United States, it may well start in California and spread across the country in just two to four weeks.

And the best way to slow its spread would be to have workers stay at home.

That's the scenario drawn from results of a computer model created by researchers at the U.S. National Institutes of Health's Fogarty International Center. And while the results of that computer model should be interpreted with caution, it is based on data from ordinary flu epidemics for the last three decades, said study author Dr. Mark A. Miller, associate director for research at the center.

"The unique feature of this model is that it challenges conventional wisdom, which says that flu is spread by children bringing it back to the household," Miller said. "That may be true at the household level, but regionally it is spread by adults."

That's why measures to keep people at home could slow the spread of infection, Miller said. Another finding in the study is that states with large populations, such as California, are more likely to reach epidemic levels of the flu at the same time than less-populous states, where transmission tends to be more erratic, he said.

So California, the most populous state, would be the most logical place for a pandemic to start, Miller said. Another factor pointing toward California is that bird -- also called avian -- flu is expected to arrive from Asia, he said.

As for the speed of spread, the estimate is based on ordinary epidemics. "What we see is that epidemics with more pathogenic viruses spread more quickly, two to four weeks versus five to seven weeks for less pathogenic viruses nationwide," Miller said.

The findings appear in the March 31 issue of the journal Science.

The Fogarty researchers used epidemiological data on seasonal flu epidemics that have occurred yearly in the United States since 1972. They connected that information with data from the Census Bureau and the federal Department of Transportation, looking at variations in yearly epidemics from state to state and links with local flows of people to workplaces.

Bird flu is pathogenic, but it does not yet spread easily from person to person; close exposure to an infected bird is needed to cause a human infection. The danger will come when, and if, a mutation makes human-to-human transmission easy.

Since 2003, the H5N1 bird flu virus has been detected in 45 countries in Africa, Asia, and Europe. More than 100 people have died after coming into contact with infected poultry.

The model developed by the Fogarty researchers can go just so far in predicting what might happen if such a mutation occurs, Miller said. This model notably doesn't include previous pandemics, just ordinary epidemics, and a pandemic might have different characteristics, he said.

Still, the model can help plan for ordinary, predictable epidemics by showing how they start and spread, Miller said. It's also not the first of its kind, he said: "We did a similar model to explain the spread of measles."

[whyso]

$4 and beyond: volume
by: clearcoated 04/01/06 02:09 pm
Msg: 29680 of 29698

Something significant is happening to CBMX right now. Volume tells what's coming ahead. It shows what big money is doing, and this interest moves the stock's price. Volume preceeds large movements in stocks.

http://tinyurl.com/g9w6l

This simple daily chart (link above) shows the dramatic increase in volume. The verticle lines correspond to PRs 1/04 thru 3/31. I was curious to see any relationship between PR and volume. The PRs are listed below. (Helpful for new investors) I need to split it into 2 posts.

(feel free to re-post and get the word out to any other retail investors or boards who may be interested. We are still largely undiscovered... I believe much like NVAX at end of last September/early October.)

3/31
CombiMatrix Molecular Diagnostics Receives CLIA Certification
http://biz.yahoo.com/bw/060331/20060331005119.html?.v=1
"Now that we have met those standards we are cleared to begin offering high quality clinical testing services at our state-of-the-art laboratory in Irvine, California."
(blockbuster news that isn't recognized yet = $)

3/16
CombiMatrix Granted Key Nanotechnology Patent
http://biz.yahoo.com/bw/060316/20060316005227.html?.v=1
"The technology enables products such as multiplexed immunoassays, monitoring of biowarfare and terrorist agents, and general protein analysis tools."

3/14
Renowned Microarray and Genomics Expert, Dr. Mansoor Mohammed, Joins CombiMatrix Molecular Diagnostics
http://biz.yahoo.com/bw/060314/20060314005238.html?.v=1
"Dr. Mohammed later directed the Advanced Technologies and Genomics program at Quest Diagnostics Incorporated, North America's largest commercial clinical laboratory. He is an internationally renowned scientist, speaker, and author and holds multiple patents in the fields of clinical genomics and microarray technology."

3/13
CombiMatrix Molecular Diagnostics and Array Genomics Collaborate to Expand Diagnostic Microarray Technology Internationally
http://biz.yahoo.com/bw/060313/20060313005303.html?.v=1
"It is anticipated that the arrays will begin generating revenue for both companies within the next several weeks."
(can't hardly wait for these PRs to start rolling in = $)

3/07
CombiMatrix President and CEO Dr. Amit Kumar Invited to Speak at the International Knowledge Millennium Summit in India
http://biz.yahoo.com/bw/060307/20060307005332.html?.v=1

3/06
CombiMatrix Launches ElectraSense(TM) Influenza Surveillance System
http://biz.yahoo.com/bw/060306/20060306005341.html?.v=1
"CombiMatrix is prepared to make this system available to domestic and international government agencies that are engaged in monitoring influenza and planning for a potential pandemic."

3/02
CombiMatrix to Webcast Presentation at Invest Northwest(TM) 2006 Conference
http://biz.yahoo.com/bw/060302/20060302005159.html?.v=1

$4 and beyond: volume - pt 2
by: clearcoated 04/01/06 02:13 pm
Msg: 29681 of 29698

pt 2 (the rest of PR links... quick reference and review)

http://tinyurl.com/g9w6l

2/23
CombiMatrix Announces Additional Cooperative Research and Development Agreement with the U.S. Air Force
http://biz.yahoo.com/bw/060223/20060223005269.html?.v=1
"Our technology continues to gain credibility with our military, as indicated by this new relationship with the U.S. Air Force."

2/22
CombiMatrix Launches Next Generation of Its Influenza A Surveillance Technology
http://biz.yahoo.com/bw/060222/20060222005305.html?.v=1
"This microarray can identify H5N1 bird flu. Unlike other products on the market, it can provide information on the subtype of H5 influenzas while simultaneously identifying all other strains of Influenza A and providing a rich amount of information on mutations and novel strains of flu not yet seen. It is designed to work on samples from humans as well as from birds, pigs, horses, dogs, and various other animals."

2/13
CombiMatrix Begins Work on $2.1 Million Department of Defense Contract
http://biz.yahoo.com/bw/060213/20060213005296.html?.v=1
"Funding from the U.S. DoD enables us to continue developing products for military applications, and the funded R&D is also useful for the development of products we plan to launch in the civilian marketplace,"

1/26
CombiMatrix Expands Relationship with INBIO
http://biz.yahoo.com/bw/060126/20060126005190.html?.v=1

1/24
The University of California Davis Joins CombiMatrix' CombiCore(TM) Access Program
http://biz.yahoo.com/bw/060124/20060124005275.html?.v=1

1/23
CombiMatrix to Webcast Presentation at the Brean Murray Carret & Co. Small Cap Institutional Investor Conference
http://biz.yahoo.com/bw/060123/20060123005205.html?.v=1

1/17
CombiMatrix Awarded Additional $2.4 Million from the US Department of Defense
http://biz.yahoo.com/bw/060117/20060117005100.html?.v=1
"As we go forward, we will continue to monitor the needs of the US government and corresponding funding or procurement opportunities, and will pursue them ourselves or with partners."

1/12
CombiMatrix Enters into Distribution Agreement for China and Taiwan with Cold Spring Biotech
http://biz.yahoo.com/bw/060112/20060112005138.html?.v=1

1/06
CombiMatrix' Announces First CombiCore(TM) Access Program with the University of Colorado
http://biz.yahoo.com/bw/060106/20060106005165.html?.v=1

1/04
CombiMatrix Expands Catalog Microarray Product Line By Launching microRNA arrays
http://biz.yahoo.com/bw/060104/20060104005399.html?.v=1
"CombiMatrix's portfolio of miRNAs includes arrays that can be used in studies for human, dog, rat, mouse, and other plants and animals. This portfolio will grow throughout 2006,"

[whyso]

A little tidbit
by: oldiron42
Long-Term Sentiment: Strong Buy 04/01/06 06:51 pm
Msg: 29694 of 29698

For those that may not be aware best I can tell from looking at CBMX from a purely T/A point of view. Money flow into Combimatrix has remained at extremely high levels for the past several months and a longer term look at these indicators shows that money flow has consistently stair - stepped higher. This suggests that regardless of the price action over the past couple of years, the smart money has not only remained in the stock, but that there has been quiet accumulation occurring by astute investors. I hope this helps to reassure some you



Wir stehen hier am Anfang von der "eigentliche Entwicklung",
GN8
Whyso

[whyso]

Digitalised DNA -(Dr Andy o' Shea)-...für das ganze Amerikanische VOLK

http://www.combimatrix.com/docs/710KiroSpotlight_032906.mp3

Wir stehen hier am Anfang!
Whyso

[e.1]

weiß jemand etwas über den anstehenden split.
im moment zerreisst es ja die bios regelrecht. cbmx hält sich noch recht gut. ich kann nur hoffen, daß wir schnellstens wieder zu einer erholung finden.

gruß
e.1

[bubu]

So nun bin ich auch wieder dabei!

US-Schlußkurs: USD 6,20
Deutschland (FRA): EUR 4,80

Danke!

Gruß
bubu

[bubu]

Bei einem USD-Stand von 1,23 kostet die NVAX in D rechnerisch 5,05 EUR.
Gehandelt wird sie aktuell mit 4,89 (4,86 x 4,96). Da ist die Angst in D noch größer als in USA nach dem dortigen 22% Rückschlag.

Mal sehn, wo wir um 15:30 stehen werden.

Gruß
bubu

[bubu]

Antwort auf Beitrag Nr.: 21.080.291 von bubu am 05.04.06 09:41:37

#226, #227

Oooops, sorry falscher Thread!

Bezog sich auf NVAX

Gruß
bubu

[whyso]

Hier ein paar "Links" mit den man rechnen kann...

http://www.fda.gov/OHRMS/DOCKETS/98fr/E6-5203.htm

http://www.pandemicflu.gov/

Deaths to date:

Azerbaijan 0 0 0 0 0 0 8 5 8 5
Cambodia 0 0 0 0 4 4 2 2 6 6
China 0 0 0 0 8 5 8 6 16 11
Egypt 0 0 0 0 0 0 4 2 4 2
Indonesia 0 0 0 0 17 11 14 12 31 23
Iraq 0 0 0 0 0 0 2 2 2 2
Thailand 0 0 17 12 5 2 0 0 22 14
Turkey 0 0 0 0 0 0 12 4 12 4
Viet Nam 3 3 29 20 61 19 0 0 93 42
Total 3 3 46 32 95 41 50 33 194 109

Total number of cases includes number of deaths.
WHO reports only laboratory-confirmed cases.

Kennt ihr den hier noch????
http://biz.yahoo.com/bw/060314/20060314005238.html?.v=1
Der Name wird man öfters hören nach der bald kommende Split von Acacia

The spinoff is expected to be completed in the second quarter. CombiMatrix tracking shares will then convert to shares in the new company, which will be listed on the Nasdaq.

The other division, Acacia Technologies, buys and sells licenses to patented technologies.

Separating two such different units allows each one to raise money in ways appropriate to its business, said Jarrad Harford, a finance professor at the University of Washington.

CombiMatrix had almost $25 million in cash and accumulated losses of $122.8 million. Shares of its tracking stock gained 9 cents, or 5.7 percent, to close at $1.67 Monday.


CBMX bleibt m.E. ein absoluten Strong Buy für den Zeitraum 2006-2008!
Whyso

[whyso]

Hier der springende Satz im Bezug auf CBMX's erratische trading an der Nasdaq bis dato

CombiMatrix already trades on Nasdaq, but only as a tracking stock, in which shares represent a part of the parent company's business.

http://archives.seattletimes.nwsource.com/cgi-bin/texis.cgi/…

Molecular Diagnostics wird sich zum Spitzenmarkt von übermorgen entwickeln:

"With the abundance of stellar scientists and research and clinical activities in and around the MaRS Discovery District and the fact that our Chief Scientific Officer and Vice President, Dr. Mansoor Mohammed, is a Canadian citizen, it was an easy and obvious choice for our expansion into the Canadian arena," said Dr. Amit Kumar, CEO of CombiMatrix. "Moving forward we anticipate establishing strong relationships with Canadian customers, partners and the government."


http://www.finanznachrichten.de/nachrichten-2006-04/artikel-…

Ich verkaufe jedenfalls kein Stück unter 12$,

Good trades mit CBMX,
Whyso

[nort.]

http://www.genengnews.com/news/bnitem.aspx?name=632307

CombiMatrix Molecular Diagnostics Launches and Ships First Microarray Diagnostic Product Ahead of Schedule
4/21/2006 6:00:00 AM EST

BIOWIRE

Acacia Research Corporation (NASDAQ:CBMX) (NASDAQ:ACTG) announced today its CombiMatrix group's subsidiary CombiMatrix Molecular Diagnostics (CMDX) has begun shipment of its first diagnostic microarray product.

"This product, developed in conjunction with Array Genomics of France, has been designed to detect genomic copy number variations associated with constitutional chromosome imbalances as well as with those associated with over 40 defined genetic diseases and syndromes, such as DiGeorge and William's syndromes," said Dr. Mansoor Mohammed, CSO and Vice President of CMDX. "The more we learn about the heterogeneity with which specific genetic syndromes can be manifested, the more we begin to appreciate the need for array CGH in aiding more accurate differential diagnoses."

Roughly two thirds of patients, mostly children, who exhibit genetic developmental disorders are currently undiagnosed due to the lack of technology for such diagnosis. This inability to diagnose the underlying cause of the disorder makes it difficult to provide appropriate medication or useful genetic counseling. Our array, which can be used for pre- and post-natal analysis, will provide much greater genetic information for diagnosing and treating these disorders, than is available through conventional cytogenetic testing. This array is the first of several arrays in our pipeline that will help to enable the era of personalized medicine based on a genetic analysis of individual patients.

"We are pleased to have launched our first product ahead of schedule," stated Matt Watson, CEO of CMDX. "We began shipping this product to Europe this week. We will require FDA approval before we can sell the arrays for diagnostic applications in the U.S. This regulatory hurdle will not prevent us from selling the arrays domestically for research purposes, however. Also, now that we have achieved our CLIA certification, we will soon begin offering genetic testing services in our clinical laboratory. This quarter our clinical services will be based on this CGH array, and in the late third quarter of this year we will begin providing melanoma (skin cancer) diagnosis and typing services to our customers."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (NASDAQ:ACTG) and Acacia Research-CombiMatrix (NASDAQ:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[nort.]

http://www.ece.ucsb.edu/courses/ECE594/594F_F05Gossard/More%…


durchlesen

[nort.]

H5N1 Pandemic Level 4 Declared by Research Team Citing 23 Clusters and Case Histories





Using the World Health Organizations own guidelines for determining pandemic level status, an independent research team has gathered enough factual H5N1 data to substantiate the need to declare a "Pandemic Level 4" response to Avian Flu. The Information that supports this claim is derived from scientific and medical papers, laboratory reports, government, geneticist, virologist and other experts around the world.

(PRWEB) April 23, 2006 -- Using the World Health Organizations own guidelines for determining pandemic level status, an independent research team has gathered enough factual H5N1 data to substantiate the need to declare a "Pandemic Level 4" response to Avian Flu. The Information that supports this claim is derived from scientific and medical papers, laboratory reports, government, geneticist, virologist and other experts around the world. The combined effort focused on a three year period from 2003 to the 2006, listing 23 documented clusters of H2H. The report is based on millions of Internet searches and thousands of hours verifying data.

"Clusters of H5N1 infections," says one research member "They may indicate human to human transmission of H5N1 influenza or alternatively indicate common exposure to the virus from an environmental source, presumably avian. A cluster here is defined as two or more individuals: 1. Who are in close physical contact, 2. Who become very sick with a respiratory disease, and 3. at least one of whom is a confirmed H5N1 influenza case.

[whyso]

Tommorows Global Player zu gestrige preisen



Das Chart spricht bände wenn man die folgende Zeilen vearbeitet kann:

"CombiMatrix's goal is to aggressively expand its marketing and sales through partnerships and distribution deals," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We already have distribution deals in place with INBIO and have been extremely pleased with their progress and expertise. CombiMatrix Europe expands this relationship to Europe, where CombiMatrix and INBIO see considerable opportunity and expansion."

"We are delighted to launch CombiMatrix Europe GmbH and anticipate a rapid uptake of CustomArray products within Europe. Importantly, our European customers will benefit significantly via the improved access to this unique microarray technology. The timing is perfect given recent and imminent advances in the capability of the CustomArray platform," said Mark Humble, CEO of INBIO.


http://biz.yahoo.com/bw/060426/20060426005218.html?.v=1

Hier Ensteht ein richtig kaufenswerte Story bzw. Firma!
Whyso

[whyso]

China calling: http://www.finanznachrichten.de/nachrichten-2006-04/artikel-…

[whyso]

Nis auf die 15 Tages Trend, alles weiterhin im Butter!

Moving Average Indicators
15 Day Trend (n)
45 Day Trend (p)
100 Day Trend (p)

Long & Strong,
Whyso

[whyso]

Ohne Worte....



und der globalen Diagnostic Markt lässt demnächst kräftigst grüßen!

Good trades mit CBMX,
Whyso

[nort.]

http://www.chron.com/disp/story.mpl/ap/world/3845300.html

May 6, 2006, 10:58AM
Nations Urged on Bird Flu Response Time

By MARGIE MASON AP Medical Writer
© 2006 The Associated Press

DANANG, Vietnam — Only half of the human bird flu cases detected by countries are being reported to the World Health Organization within two weeks _ a response time that must be improved to head off a potential flu pandemic, a senior WHO official said Saturday.

Dr. Shigeru Omi, the WHO's regional director for the Western Pacific, said it's estimated that two to three weeks is all countries would have to stamp out or at least slow a pandemic flu strain after it began spreading. He said the first move would be to identify cluster cases and report them to WHO. International teams would then be deployed to investigate the site, the area would be quarantined and antiviral treatment would be given.

"All the steps have to be done within two to three weeks. As of now ... even reporting the first step, it takes sometimes more than two weeks for half of the cases," Omi said at the end of an Asia-Pacific meeting on bird flu in central Vietnam. "There's a lot of challenges."

Omi said political commitment is now strong at national levels across the region, but weaknesses still exist in getting the message all the way down to villages. He said the level of public awareness must increase so that ordinary people will understand what to do if they see a number of people or poultry coming down sick at once.

Omi attended a meeting with agriculture and health ministers representing the 21-member Asia-Pacific Economic Cooperation. On Friday, they endorsed a plan aimed at stamping out bird flu and preparing for a potential flu pandemic.

Meanwhile, other delegates donned masks, goggles and biohazard suits Saturday morning as they toured a chicken farm in central Vietnam for a firsthand look at how hygiene is maintained.

"These countries have been dealing with avian influenza for several years and have clearly advanced thinking on it, so that's why I wanted to be here this morning to look at the activities that were successful here in Vietnam," said John Lange, the U.S. special representative for avian influenza. "They've been dealing with it and we're just expecting it."

Experts fear the H5N1 bird flu virus, which began ravaging Asian poultry stocks in late 2003, could mutate and potentially spark a global pandemic. The virus has killed at least 114 people worldwide, but most human cases have been linked to contact with infected birds.

The farm in Hoa Quy village in the coastal town of Danang had about 7,000 chickens, all of which had been vaccinated. Laying hens were kept in cages in an enclosed coop sprayed with disinfectant.

Much of the poultry in Vietnam and throughout Asia, however, is produced on a much smaller scale, with many households raising a handful of chickens in backyards. Such farming practices are much harder to control and make it easier for the H5N1 virus to spread.

A regional action plan adopted Friday calls for the restructuring of some backyard farming practices into larger, more controlled operations.

Officials said Australia will coordinate a regional practice exercise on June 7-8, with help from Singapore, to see how well countries respond and cooperate during a mock pandemic scenario.

[nort.]

% Shares Owned: 10.6 # New Buyers: 9
# Institutions: 25 # Closed Positions: 6
Total Shares Held: 4,122,563 # Buyers: 15
3 Mo. Net Change: 1,134,710 # Sellers: 8
Price Range Quarter: $1.67 - $2.90 # Net Buyers: 7

http://today.reuters.com/stocks/InstHolders.aspx?ticker=CBMX

[whyso]

Leute die Party darf beginnen...

jetzt bin ich wirklich gespannt auf das Interview (und die Auswirkungen) mit Doc Kumar auf der "Squak Box" heut Abend

"The US government continues to be justifiably concerned about the entrance of highly pathogenic avian influenza into North America, and CombiMatrix continues to demonstrate the power of its technology in this realm," stated Dr. Amit Kumar, President and CEO of CombiMatrix. "This collaboration with EAI gets our technology into the field and into the hands of people and groups standing watch on US soil. This program is in addition to our participation in the US Government\'s National Early Detection System."

"We are pleased that the Institute for Defense and Homeland Security has agreed to fund this combined effort with CombiMatrix," said Dr. Joe Dudley, Chief Scientist at EAI. "We believe that the CombiMatrix system is a powerful, versatile, and portable system for influenza monitoring. We believe that this approach, combined with EAI\'s mobile-laboratory products and expertise, will provide a very powerful tool for monitoring and preparedness in the event of a pandemic."


Watch this space:


Good trades but steady hands mit CBMX,
Whyso

P.S. heute hätte man CBMX für schlappe 1,67€ haben können-nur so, um den weiteren Verlauf "etwa" festzuhalten )))))

[whyso]

Leute, Pre market stateside....
Pre-Market (RT-ECN): 2.58 0.42 (19.44%)

[whyso]

CBMX Lesenswertes...

Why Brean Murray thinks CBMX=12 PT 1
by: barbing1965 05/22/06 01:25 pm
Msg: 35406 of 35432

CombiMatrix group:

* In January 2006, the CombiMatrix group launched a series of catalog microarrays specifically designed for microRNA analysis. MicroRNAs ("miRNAs") are small, RNA molecules encoded in the genomes of plants and animals. These highly conserved, approximately 21-mer RNAs regulate the expression of genes and are believed to be critical to controlling physiology in areas that include neural development, viral disease, and cancer. Each miRNA is thought to regulate multiple genes, and since hundreds of miRNA genes are predicted to be present in higher eukaryotes the potential regulatory circuitry afforded by miRNAs is enormous. There is evidence that miRNAs may act as key regulators of processes as diverse as early development, cell proliferation and cell death, apoptosis and fat metabolism, and cell differentiation.
* In January 2006, the CombiMatrix group signed a non-exclusive agreement with The University of Colorado Health Sciences Center under the Company's CombiCore(TM) access program. Under this agreement all University of Colorado researchers can purchase, through their microarray core facility, CombiMatrix' CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the University of Colorado Health Science Center Microarray Core Facility.
* In January 2006, the CombiMatrix group entered into a non-exclusive distribution agreement with Cold Spring Biotech to distribute CombiMatrix products and services in mainland China, Taiwan, and Hong Kong. Under the terms of the agreement, Cold Spring Biotech will market and sell CustomArrays(TM) and CatalogArrays(TM), including the recently introduced Influenza A Research Microarray.
* In January 2006, the CombiMatrix group signed a non-exclusive agreement with The University of California Davis under the Company's CombiCore(TM) access program. Under this agreement all University of California Davis researchers can purchase, through the UC Davis Genome Center, CombiMatrix' CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the UC Davis Genome Center.
* In January 2006, the CombiMatrix group expanded its relationship with its existing partner, INBIO, for the Asia Pacific region. Major components of the expanded relationship include the transfer of day-to-day operational responsibility and majority ownership of CombiMatrix Corporation's wholly owned subsidiary, CombiMatrix K.K. (the "KK") to INBIO along with an expanded distribution agreement that encompasses Japan. INBIO obtained 67% of the voting interests in the KK and expanded its distribution agreements with the CombiMatrix group. INBIO assumed all operational and financial responsibilities of the KK including its liabilities.
* In January 2006, the CombiMatrix group announced that the 2006 U.S. Defense Appropriations Bill signed by President Bush included an allocation of $2.4 million to fund efforts by the CombiMatrix group to further develop its microarray technologies for the detection of biological and chemical threat agents.
* In February 2006, the CombiMatrix group began work on its one-year, $2.1 million contract with the US Department of Defense ("DoD"). Funding for this contract, which focuses on the use of CombiMatrix' array technology for military and antiterrorist applications, was previously announced as part of the DoD budget. CombiMatrix's development program with the DoD is focused on the integration of CombiMatrix's biotechnology with microelectronics and microfluidics and the development of an automated system with maximum flexibility and sensitivity for biothreat agents with reduced size and cost.

[whyso]

This was a HUGE STEP on the way zu unsere "Unabhängigkeit"

http://biz.yahoo.com/bw/060517/20060517005144.html?.v=1

SAIC ist/war & bleibt der US Regierung sehr nah,
Whyso

[whyso]

Nice afterhours action (wie bei NVAX)

ACACIA RES-COMBIMTRX (RT-ECN)
Symbol: CBMX
Last Trade: 2.19 5:11PM ET
After Hours Change: 0.19 (9.50%)
Today's Change: 0.16 (7.88%)
Bid: 2.13
Ask: 2.24

[nort.]

Avian influenza – situation in Indonesia – update 14

23 May 2006

The Ministry of Health in Indonesia has confirmed an additional case of human infection with the H5N1 avian influenza virus. The case occurred in a 32-year-old man. He developed symptoms on 15 May and died on 22 May.

The case is part of a family cluster in the Kubu Sembelang village, Karo District, of North Sumatra. The man is the seventh member of an extended family to become infected with the H5N1 virus and the sixth to die. An additional person, who was the first member of the family to fall ill, died of respiratory disease on 4 May. No specimens were taken prior to her burial and the cause of her death cannot be determined. However, as her clinical course was compatible with H5N1 infection, epidemiologists at the outbreak site include this woman as the initial case in the cluster.

The newly confirmed case is a brother of the initial case. Specimens were taken on 21 May and flown the same day to Jakarta. Tests run overnight confirmed his infection. His 10-year-old son died of H5N1 infection on 13 May. The father was closely involved in caring for his son, and this contact is considered a possible source of infection.

Although the investigation is continuing, preliminary findings indicate that three of the confirmed cases spent the night of 29 April in a small room together with the initial case at a time when she was symptomatic and coughing frequently. These cases include the woman’s two sons and a second brother, aged 25 years, who is the sole surviving case among infected members of this family. Other infected family members lived in adjacent homes.

All confirmed cases in the cluster can be directly linked to close and prolonged exposure to a patient during a phase of severe illness. Although human-to-human transmission cannot be ruled out, the search for a possible alternative source of exposure is continuing.

Both the Ministry of Health and WHO are concerned about the situation in Kubu Sembelang and have intensified investigation and response activities. Priority is now being given to the search for additional cases of influenza-like illness in other family members, close contacts, and the general community. To date, the investigation has found no evidence of spread within the general community and no evidence that efficient human-to-human transmission has occurred.

Analysis of viruses

Full genetic sequencing of two viruses isolated from cases in this cluster has been completed by WHO H5 reference laboratories in Hong Kong and the USA. Sequencing of all eight gene segments found no evidence of genetic reassortment with human or pig influenza viruses and no evidence of significant mutations. The viruses showed no mutations associated with resistance to the neuraminidase inhibitors, including oseltamivir (Tamiflu).

The human viruses from this cluster are genetically similar to viruses isolated from poultry in North Sumatra during a previous outbreak.

[nort.]

Vogelgrippe: Tausende in Bukarest unter Quarantäne
Maßnahme gilt für bis zu drei Wochen

Nach der Bestätigung eines Vogelgrippe-Falles sind mehr als 13.000 Bewohner der rumänischen Hauptstadt Bukarest unter Quarantäne gestellt worden. Die Maßnahme gelte für einen Zeitraum von ein bis drei Wochen, sagte der Bürgermeister des südlich gelegenen vierten Bezirks, Adrian Inimaroiu. Alle Geschäfte und Behörden in dem Viertel blieben in dieser Zeit geschlossen. Etwa 2500 Vögel in der Gegend würden so schnell wie möglich getötet.

Polizisten und Soldaten sperrten die Zugangsstraßen ab. Das rumänische Landwirtschaftsministerium hatte zuvor bestätigt, dass in der Region das Virus in mehreren toten Hühnern gefunden worden sei. Am Sonntagabend war bereits eine Gegend in den nördlichen Vorstädten von Bukarest unter Quarantäne gestellt worden. In den vergangenen zehn Tagen waren laut Landwirtschaftsministerium 38 Vogelgrippe-Fälle in Rumänien festgestellt worden. In 26 weiteren Fällen ist das Virus noch nicht offiziell bestätigt.


http://www.mittelbayerische.de/SID_2e0c1c48ab2ded70267a7c08f…

[e.1]

ist im pre market schon bei 2,20$

wunderbar

[whyso]

A "testing devise" wird bald zum "Pflicht-Geräte" werden, wenn das so weiter geht

http://www.thejakartapost.com/detaillgen.asp?fileid=20060528…

[nort.]

Renowned Genomics Expert, Stephen W. Scherer, Joins CombiMatrix Molecular Diagnostics' Science Advisory Board

http://biz.yahoo.com/bw/060531/20060531005254.html?.v=2

Dr. Stephen W. Scherer
by: misc_info_06 06/01/06 01:09 pm
Msg: 36158 of 36165

Understanding the composition of the human genome for studies of genetic disease.

Recent work characterizes structural variation in the human genome,
and examines the role genetics has in autism.

Long-standing endeavors include the study of human chromosome 7
as a model of the chromosomal basis of disease, and

building genomics infrastructure to facilitate biomedical research.

http://www.tcag.ca/scherer/


Awards

2005/2006 GlaxoSmithKline Endowed Chair in Human Genetics and Genomics (to be awarded spring of 2006)
2005 10th Anniversary Distinguished Achievement Award in Health Sciences, Canada's Top 40 Under 40
2004 Steacie Prize Award in the Natural Sciences
2003-2008 Canadian Institutes of Health Research (CIHR) Investigator Award
2002-2007 Howard Hughes Medical Institute International Scholar Award
2002 Genetics Society of Canada Young Scientist Award
2002 The Canadian Institute for Advanced Research (CIAR) Young Explorer's Prize
2001 International Year of the Volunteer Recipient, The Hospital for Sick Children Foundation
2001 Burroughs-Wellcome Visiting Professorship in the Basic Sciences (Visiting Professor to Memorial University, St. John's Newfoundland)
2001 Honorary Degree from the University of Windsor for contributions to genetics, genomics and public education
2000 Canada's Top 40 Under 40 AwardTM for Contributions to Society
1999-2002 Premier's Research Excellence Award

... many more

http://www.tcag.ca/scherer/awards.html


first microarrays for mental abnormalities, now an "autism expert"

kind of looks like CMD is targeting a market.

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[nort.]

so ab jetzt wird es wieder spannend...

[whyso]

Hang on to your hats, Very good news for CBMX



Alpha Innotech and CombiMatrix Diagnostics Combine Products in a Marketing Agreement

SAN LEANDRO, Calif.--(BUSINESS WIRE)--June 15, 2006--Alpha Innotech Corp. (OTCBB:APNO - News), a leading provider of bioanalytical systems for drug discovery and life science research, today announced a marketing agreement with CombiMatrix Molecular Diagnostics (CMDX) to mutually promote and distribute an integrated analysis solution for Comparative Genomic Hybridization. The agreement is centered on the synergies between Alpha Innotech's AlphaScan® laser scanner and CMDX's Comparative Genomic Hybridization (CGH) arrays for neonatal screening and biomarker discovery. As part of the deal, CombiMatrix Molecular Diagnostics will integrate Alpha Innotech's AlphaScan® scanner into its CGH platform. Financial terms were not disclosed.

Sia Ghazvini, Vice President of Business Development at Alpha Innotech, said "We are pleased to be working with CombiMatrix Molecular Diagnostics to provide this integrated solution for customers performing CGH analysis. We believe customers will appreciate a turnkey solution that combines DNA content, a reader, analysis software, and a validated laboratory protocol into a single integrated package. We intend to continue partnering with leading application developers like CMDX to provide best-of-class, application-focused integrated solutions for their customers."

"Our customers are looking for a single integrated platform that will enable them to quickly set up a CGH laboratory and begin running experiments," said Matt Watson, CEO of CMDX. "Alpha Innotech's AlphaScan® scanner represents a key component of that platform and we are excited to be able to offer it as part of our turnkey solution."

http://biz.yahoo.com/bw/060615/20060615005770.html?.v=1

[whyso]

Antwort auf Beitrag Nr.: 22.138.413 von whyso am 15.06.06 23:44:26

What does Alpha Innotech do exactly & who do they serve????

About Alpha Innotech Corporation

Founded in 1992 and with over 8,000 systems sold worldwide, Alpha Innotech is a leading developer, manufacturer and marketer of digital imaging and analysis systems for the life science research and drug discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide.

More information about Alpha Innotech can be found at the Company's website www.alphainnotech.com .

Das gibt ein Fest(und das beste ist, wir sind alle frühzeitig eingeladen)
Whyso

[e.1]

da findet ja fast gar kein umsatz statt. auf was wird da gewartet. immer noch der splitt?

macht mich schon etwas nervös.

trotzdem schöne grüße
e.1

[schappi64]

ich war der meinung das hir keiner mehr drin ist in diesen thread.

[nort.]

Vogelgrippe: Erste Ansteckung unter Menschen erwiesen
zurück
Der gefährliche Vogelgrippe-Erreger H5N1 ist während der Übertragung innerhalb einer indonesischen Familie mutiert. Das ergab eine Untersuchung der Weltgesundheitsorganisation (WHO).

http://www.orf.at/?href=http%3A%2F%2Fwww.orf.at%2Fticker%2F2…

[e.1]

hallo nort,
hast du eine ahnung weshalb der kurs so vor sich hin dümpelt.
wann ist denn der split?
ich war schon drauf und dran in nvax umzuschichten.

gruß e.1

[nort.]

Antwort auf Beitrag Nr.: 22.251.844 von e.1 am 23.06.06 19:31:46

keine Ahnung wundert mich auch. Deshalb fülle ich derzeit meine verkauften Bestände wieder auf. Der nächste Peak kommt bestimmt...

[e.1]

na hoffentlich, zum schluß gibt sie nochmal etwas ab.

na dann, trotzdem eine gute nacht


gruß e.1

[nort.]

Kleine yahoo Zusammenfassung:

Re: Mutual Funds Ownership

06/05/06 2.45%
06/20/06 5.02%

An increase of 2.57% in mutual funds ownership since June 5, 2006. Other figures (institutional & 5% insider ownership) have not changed.

hxxp://moneycentral.msn.com/investor/invsub/ownership/ownership.asp?Symbol=CBMX

Und ein Klasse Beitrag von Blood

1.We have 50 Million financing guarenteed (in a negative loan climate for Biotechs)

2. we have a ready to go "global product" (produced, tried and tested, ready to be shipped)

3. we have a global remarketing partner with established sales and revenue streams worldwide.

4.We have government contractual backing and closing orders.

5.We have only 39 million shares in circulation to date, and a total MK 66,68 Mio. USD

6. we will have a long desired "stand alone" status by the end of coming September

7.We have the dreaded "Bird Flu" standing at americas backdoor in canada

8.We have an ongoing migratory problem

9.We have the four hour strain determination product(90 K Array) that EVERYONE will be cringing for the nearer the threat comes

10. We have the cure for the issue within the co-oeration with our partner NVAX???

We will see- Long & strong 06-07!
Blood

[whyso]

Antwort auf Beitrag Nr.: 22.253.727 von nort. am 23.06.06 22:31:14

@Nort, die Firma dankt

CBMX sollte sehr bald "brandaktuelle" auf dem US Analysten Radar stehen, wenn der folgende Schlagzeile sich bewahrheiten sollte

http://biz.yahoo.com/ap/060622/ahead_of_the_bell_bird_flu.ht…

Bis spätestens September(Herbst Rally) sollte der "splitt" von Acacia komplett vollzogen sein...ich glaube das wir dann sehr viel Spaß mit CBMX wieder haben werden für mindestens 10 monate am stück-ich bin bereit!!!

Bis die tage & schönes Wochenende,
Whyso

[nort.]

CombiMatrix Molecular Diagnostics to Offer First Commercial Genetic Test from Its CLIA Certified Laboratory

http://biz.yahoo.com/bw/060626/20060626005280.html?.v=1

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--June 26, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics (CMDX) is planning to commercially launch its first molecular diagnostic service offering in August, 2006. This first product offering, which is already being sold in Europe through CMDX' distributor Array Genomics, is in the final phases of internal human/clinical validation prior to U.S. launch. This service utilizes CMDX' Constitutional Genetic Array Test (CGAT), which can genetically identify over 50 common genetic disorders in one test.

Also pünktlich zur nächsten Grippeseason sind die schlagkräftig aufgestellt. Sommerschwäche nutzen und das Winterdepot ausbauen...

nort

[e.1]

hat jemand einen plan, wie weit sie charttechnisch noch runtergehenkann?

wäre sehr nett

gruß e.1

[nort.]

Antwort auf Beitrag Nr.: 22.286.362 von e.1 am 26.06.06 20:39:25

sind derzeit an einer spannenden Marke, hält die, sollte der Aufstieg erfolgen, bricht die, gehen wir nochmal in einem Rutsch runter. Ich habe jetzt gekauft und bei einem Rutsch werde ich nochmals shoppen gehen

[nort.]

Antwort auf Beitrag Nr.: 22.286.460 von nort. am 26.06.06 20:45:45

das untere Bollinger wird derzeit schön bestätigt. Ist ein Kaufsignal. Zudem ist die Aktie bei niedrigem Volumen Überverkauft!

[e.1]

vielen dank nort, für deine mühe.

ich war schon etwas unsicher, da ich um die 1,60 nochmal nachgekauft hatte.
ich hoffe natürlich nicht, daß sie nochmal runtergeht.

schönen abend noch

gruß
e.1

[nort.]

DOW nach FED bei +1,7% und CBMX bei 12 %. Oberes Bollinger wird durchschnitten, here we GOGOGOGO

[e.1]

doch immer wieder schön, wenn sich eine intuition bestätigt. ich bin keine charttechnikerin, finde es aber klasse, wie du das hinbekommst.
klasse arbeit. genauso an whyso.

ich wünsche allen einen schönen abend und natürlich steigende kurse.

gruß e.1

[nort.]

Antwort auf Beitrag Nr.: 22.350.703 von e.1 am 29.06.06 21:52:39

danke e1, bisschen Glück braucht man aber auch

[e.1]

ja das gehört immer dazu. ich hof´fe, dass es nicht schon wieder des guten zu viel war. muß meinen durchschnittskurs noch erreichen.

gruß e.1

[nort.]

CombiMatrix to Present at the Asian-European Conference on Avian Influenza 2006

http://www.genengnews.com/news/bnitem.aspx?name=2970308

Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group will present an overview of its Influenza Array and Electrochemical Influenza Surveillance Technology at the Asian-European Conference on Avian Influenza 2006 to be held on June 29-30, 2006 at the Pasteur Institute, Paris, France.


anscheind ist die recht gut angekommen

[whyso]

Wir stehen hier am Anfang...
---------------------
U.S. Department of Agriculture
Pandemic Planning Report
__________
From Secretary Mike Johanns
June 29, 2006

http://www.usda.gov/documents/PandemicPlanningReport180.pdf

USDA is establishing offices and personnel in
China, Laos, Cambodia, Thailand, and Indonesia,
which will be dedicated exclusively to avian influenza activities
and wherever possible, colocated with the U.S. Department
of Health and Human Services’ Centers for Disease Control
and Prevention offices;


DOMESTIC EFFORTS

USDA has worked to further strengthen safeguards in place
to protect against the introduction of HPAI H5N1 into the United States.

USDA maintains trade restrictions on the importation of poultry
and poultry products from regions currently affected by HPAI H5N1
in commercial or traditionally raised flocks.

Increased surveillance between both wild and commercial bird populations
serves as an early warning system and will help Federal and State officials
rapidly detect and prevent spread of the disease in the United States.

In the event of a detection of HPAI,
APHIS personnel are the primary Federal responders
along with State counterparts. APHIS and State animal health officials
are working cooperatively with the poultry industry to conduct surveillance
at breeding flocks, slaughter plants, live-bird markets, livestock auctions,
and poultry dealers.


Preparedness and Communication

In addition to actions USDA is taking to protect the United States
from an introduction of HPAI H5N1, USDA is preparing for the possibility
that highly pathogenic avian influenza could reach our country.

Of the supplemental funds, the Department has allocated approximately
$25 million to enhance domestic preparedness and communication.
In coordination with other Federal agencies, USDA protects the United States
against the intentional or unintentional introduction of
foreign animal diseases [FAD] or natural disasters affecting
animal health, public health, and the food system.

Current NVS efforts have been focused on
preparing for a potential detection of HPAI H5N1.


Surveillance and Detection

One of the pillars of the National Strategy
is an aggressive surveillance and detection program.

USDA has allocated about $47 million for this effort,
of which approximately $28 million is for domestic poultry surveillance
and $19 million is for wildlife surveillance.


Domestic Poultry Surveillance

There are four areas of concentration among domestic poultry:
live bird marketing system,
upland game,
commercial/backyard surveillance outside of the live bird marketing system, and
assistance to the broiler industry for expansion of AI surveillance
in commercial operations through the National Poultry Improvement Plan (NPIP).


Wildlife Surveillance and Diagnostics

[ the Animal and Plant Health Inspection Service (APHIS) will work closely
with the Food Safety and Inspection Service (FSIS),
Agricultural Marketing Service (AMS),
the United States Trade Representative, and the Department ]


APHIS leads an interagency effort to detect HPAI H5N1 in wild birds.
The initiative is divided into two phases.

The initial phase addresses early detection activities in Alaska,
particularly in coastal areas that have the most potential
for contact among Asian and North American birds.

The second phase addresses subsequent HPAI H5N1 detection activities
in four major North American flyways. Over 30 cooperative agreements with
State Wildlife Agencies are in process.

[whyso]

USDA RELEASES 180-DAY REPORT ON AVIAN INFLUENZA EFFORTS
AND SUPPLEMENTAL SPENDING

WASHINGTON, June 29, 2006 - The U.S. Department of Agriculture today released
its 180-day report on avian influenza (AI) efforts and the use
of $91 million appropriated in the Emergency Supplemental Appropriation
to Address Pandemic Influenza six months ago. The report details USDA's efforts
both internationally and domestically to combat highly pathogenic H5N1 avian influenza (HPAI H5N1).

"We're working with federal and state government partners,
as well as industry to prepare the public for the possibility
of a highly pathogenic avian influenza detection in the United States,"
said Agriculture Deputy Secretary Chuck Conner.

[nort.]

Avian influenza – epidemiology of human H5N1 cases reported to WHO

30 June 2006

This week’s issue of the Weekly Epidemiological Record, published online by WHO, sets out results from the first analysis of epidemiological data on all 205 laboratory-confirmed H5N1 cases officially reported to WHO by onset date from December 2003 to 30 April 2006.

Data used in the analysis were collected for surveillance purposes. Quality, reliability and format were not consistent across data from different countries. Despite this limitation, several conclusions could be reached.

* The number of new countries reporting human cases increased from 4 to 9 after October 2005, following the geographical extension of outbreaks among avian populations.
* Half of the cases occurred in people under the age of 20 years; 90% of cases occurred in people under the age of 40 years.
* The overall case-fatality rate was 56%. Case fatality was high in all age groups but was highest in persons aged 10 to 39 years.
* The case-fatality profile by age group differs from that seen in seasonal influenza, where mortality is highest in the elderly.
* The overall case-fatality rate was highest in 2004 (73%), followed by 63% to date in 2006, and 43% in 2005.
* Assessment of mortality rates and the time intervals between symptom onset and hospitalization and between symptom onset and death suggests that the illness pattern has not changed substantially during the three years.
* Cases have occurred all year round. However, the incidence of human cases peaked, in each of the three years in which cases have occurred, during the period roughly corresponding to winter and spring in the northern hemisphere. If this pattern continues, an upsurge in cases could be anticipated starting in late 2006 or early 2007.

A more standardized collection of epidemiological data by countries and timely sharing of these data are needed to improve monitoring of the situation, risk assessment, and the management of H5N1 patients.


http://www.who.int/csr/don/2006_06_30/en/index.html

[nort.]

WHO Warns Against Bird Flu Mutation

June 30, 2006 1:52 p.m. EST

Nji Che - All Headline News Staff Writer

Geneva, Switzerland (AHN) - The World Health Organization (WHO) on Friday warned against the risk of bird flu mutation into a form that could easily be transmitted from human-to-human. The UN health agency added that there could be more cases of human infection by the end of the year.

According to a report that analyzed 200 known bird flu cases, there have been three phases of human infection since the first one was reported in 2003. All the phases were witnessed during spring and winter in the northern hemisphere.

The document says, "If this pattern continues, an upsurge in cases could be anticipated starting in late 2006 or early 2007."

It adds that, "Moreover, the widespread distribution of the H5N1 virus in poultry and the continued exposure of humans suggest that the risk of virus evolving into a more transmissible agent in humans remains high."

The WHO says the analysis of the bird flu infection pattern is similar to that witnessed in the 1918-1919 Spanish flu outbreak. The epidemic claimed more than 40 million lives across the globe.


http://www.birdflubreakingnews.com/templates/birdflu/window.…

[nort.]

7 Jul 2006 10:50 GMT DJ EU: Human Risk From Bird Flu Low But Pandemic Will Happen

Copyright © 2006, Dow Jones Newswires

BRUSSELS (AP)--European Union experts said Friday an influenza pandemic that could kill millions remains inevitable, although the immediate threat to human health from bird flu in Europe remains low.

"It's when and not if," said Robert Madelin, director general of the E.U.'s health and consumer protection department. Influenza pandemics are rare, but recurrent events.

Madelin cited scientists' predictions suggesting a flu pandemic could kill between 2 million and 7 million people worldwide, 10 times the death rate from regular flu. However, he warned forecasting was very difficult and current predictions could be "wildly wrong." There is no way of predicting how deadly an influenza pandemic might be, and any guesses at a future death toll are speculative at best.

The head of the E.U.'s center for disease control said efforts to contain outbreaks of the avian influenza H5N1 strain among domestic poultry in Europe had been successful.

"H5N1 is a very low risk to public health in the European Union," said Zsuzsanna Jakab.

She added the threat of more outbreaks among European birds remained, and warned continued cases of humans contracting the disease from infected birds in Asia increased the risk that the virus could mutate into a strain that might pass more easily from person to person.

"It may be a low level threat but it is one which we must take very seriously," Jakab told a news conference. "As long as the virus is endemic in Asia and parts of Africa it is quite likely that it will recur in Europe."

The E.U. said all 25 of its member nations had now drawn up national preparedness plans to deal with a pandemic. Among other measures, the bloc has invested EUR200 million in helping countries in Asia, Africa and other high risk areas monitor and control the disease, and was spending EUR20 million on research on vaccines.

However, Madelin said E.U. nations should also improve plans for dealing with the social and economic impact of a pandemic which he said could put up to half of the work force on sick leave, severely curtail consumer spending, and add a huge burden to medical services by putting up to 5 million extra people into European hospital beds.

(END) Dow Jones Newswires

July 07, 2006 06:50 ET (10:50 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc.

[e.1]

da kann man nur hoffen, dass das hier bald vorbei ist.
heute haben wir ja nochmal die volle breitseite bekommen.

augen zu und durch?

gruß e.1

[puddy66]

wann steigt diese drecks aktie mal wieder!!

[nort.]

Antwort auf Beitrag Nr.: 22.686.998 von puddy66 am 18.07.06 09:51:51

interessanter Beitrag, puddy...

Okay, mal sehen was am Donnerstag so kommt. Hoffendlich der Spin!!!

Acacia Research to Release Second Quarter Financial Results and Host Conference Call
Monday July 17, 6:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--July 17, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today it will release its first quarter financial results on Thursday, July 20, 2006. Results will be released at the close of trading on the NASDAQ national market.

ADVERTISEMENT
click here
A conference call is scheduled for the same day.

The Acacia Technologies Group presentation and Q&A will start at 1:15 p.m. Pacific Time (4:15 p.m. Eastern).

The CombiMatrix Group presentation and Q&A session will start at 2:00 p.m. Pacific Time (5:00 p.m. Eastern).

To listen to the presentation by phone, dial [phone] for domestic callers and [phone] for international callers, both of whom will need to provide the operator with the confirmation code 8240145. A replay of the audio presentation will be available for 30 days at [phone] for domestic callers and [phone] for international callers, both of whom will need to enter the code 8240145 when prompted.

[DagobertDuck57]

Guckst Du hier
http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic…

[whyso]

Watch this space

http://biz.yahoo.com/bw/060717/20060717005231.html?.v=1

CBMX ist m.E. am ende von sein "Down-Zyklus" jetzt angekommen:



Ich freue mich jetzt schon auf dem Herbst!

Viele Steigende Grüße,
Whyso

[whyso]

Im minuten Takt:



Das dürfte Spannend bleiben bis ende August, gegen ende kommenden November möchte ich die 5$ Grenze allerdings von weit darüber betrachten dürfen

Keep the faith (and the shares)
Whyso

[whyso]

For the Three Months Ended June 30, 2006 and 2005

Revenues for the second quarter of 2006 were $1,792,000 versus $1,857,000 in the comparable 2005 period. Second quarter 2006 revenues were comprised of $574,000 in government contact revenues and $1,218,000 in CustomArray(TM) product, equipment and service revenues, including $71,000 of array revenue from our diagnostics subsidiary, CombiMatrix Molecular Diagnostics. Second quarter 2005 revenues were comprised of $1,281,000 of government contract revenues and $576,000 of CustomArray(TM) product and service revenues.

The second quarter 2006 division net loss was $3,442,000 versus $3,657,000 in the comparable 2005 period. The second quarter 2006 results included non-cash stock compensation, patent amortization and depreciation charges totaling $971,000 versus $541,000 in the comparable 2005 period. The increase in non-cash charges primarily reflects the adoption of SFAS No. 123®, effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their consolidated financial statements, as discussed earlier. Second quarter non-cash stock compensation charges included in research and development expense and marketing, general and administrative expense totaled $193,000 and $280,000, respectively. The second quarter 2006 results also included a non-cash gain of $1,490,000 related to the adjustment of the CombiMatrix group's long-term warrant liability to fair value as of June 30, 2006.

Second quarter 2006 government contract costs totaled $542,000 versus $1,209,000 in the comparable 2005 period. The decrease was due to an anomalously high level of activity under our biological threat detection contract with the Department of Defense during the second quarter of 2005. Second quarter 2006 internal research and development expenses were $2,182,000 (including non-cash stock compensation charges of $193,000) versus $1,415,000 in the comparable 2005 period. During the second quarter of 2006 and 2005, the CombiMatrix group continued internal research and development efforts to improve and expand the CombiMatrix group's technology and product offerings. The increase in internal research and development expenses was due primarily to the impact of the CombiMatrix group's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, which was formed and began research and development activities in the second quarter of 2005.

Second quarter 2006 marketing, general and administrative expenses increased to $3,229,000 (including non-cash stock compensation charges of $280,000) from $2,517,000 in the comparable 2005 period. Excluding the impact of the adoption of SFAS No. 123®, the increase was due primarily to an increase in general and administrative expenses incurred by CombiMatrix Molecular Diagnostics and an increase in other general and administrative expenses related to ongoing operations.

Financial Condition

Total assets for the CombiMatrix group were $41,396,000 as of June 30, 2006 compared to $52,541,000 as of December 31, 2005. Cash and cash equivalents and short-term investments totaled $9,976,000 as of June 30, 2006 compared to $20,213,000 as of December 31, 2005.

Kumar ist bzgl. der "Shortbarkeit" der Cornell shares von Acacia im call angesprochen worden, er hat diese Möglichkeit eindeutig verneint!!!!

In June 2006, Acacia Research Corporation executed a standby equity distribution agreement for up to $50 million in common stock equity financing from Cornell Capital Partners, LP ("Cornell") for the CombiMatrix group. Subject to the terms and conditions of the agreement between Acacia Research Corporation and Cornell, over the next 24 months, Acacia may sell up to 13,368,674 registered shares of its AR-CombiMatrix common stock at its discretion to Cornell less a 2.5% discount from the market price and associated fees ranging from 4-5%. The shares of common stock are being offered pursuant to an effective registration statement filed with the SEC on April 25, 2006. A fee was paid to Cornell in the amount of $550,000, upon closing of the agreement.



Ich denke das Cornell sein Investment bald richtig im Schütz nehmen wird, und bei CBMX entsprechend kräftigst zukaufen(investieren) wird zum tiefspreisen....es handelt sich meineserachtens hier mehr um Wochen, als Monate bis sie dieses tun, ich persönlich erwarte immer noch kursen um die 3$-4,2$ plus bis Weihnachten.

Just my personal opinion & sicherlich kein Kaufempfehlung (Kurs heute genau 1€ bei -9,09% in Frankfurt)

Tja, mal sehen sagt der blinde!

Viele Grüße,
Whyso

[puddy66]

ich persönlich erwarte immer noch kursen um die 3$-4,2$ plus bis Weihnachten.


das wird wohl wenn weihnachten und ostern an einem tag fällt!

[nort.]

Der Markt ist da... Es ist nur eine Frage der Zeit...


China und Bulgarien melden neue Fälle

In Westchina verendeten in der Region Xinjiang über 3000 Hühner an dem auch für Menschen gefährlichen H5N1-Virus. In Bulgarien gab es den landesweit ersten Ausbruch bei Nutzgeflügel.

Über die neuerlichen Vogelgrippe-Fälle in China berichtete die amtliche Nachrichtenagentur Xinhua. Mehr als 356.900 weitere Tiere seien vorsorglich getötet worden. Menschen hätten sich nicht infiziert. Der Ausbruch sei unter Kontrolle, hieß es unter Berufung auf das Landwirtschaftsministerium weiter. Weltweit starben seit 2003 mindestens 133 Menschen an der Vogelgrippe.

Nach dem ersten Ausbruch der Vogelgrippe bei Nutzgeflügel in Bulgarien ist gestern landesweit der Handel mit lebendigen Vögeln auf freien Märkten verboten worden.

[whyso]

Antwort auf Beitrag Nr.: 22.889.750 von puddy66 am 22.07.06 15:18:11

Jedem das Seine

Was bringt es wenn man an der Börse als "Schönwetter Aktionär" agiert ich habe jedenfalls nie sehr viel davon gehalten, und freue mich auf das kommende "Mischfest Weihoster" mit CBMX im Depot.

Mein due diligence ist längst geleistet, jetzt muss NUR der Kurs die entsprechende Kursentwicklung hinlegen, es kann auch dauern aber GEDULD bis ende 2007 habe ich direkt mit im Gepäck

Herzliche Sonntagsgrüße,
Whyso

[nort.]

Vogelgrippe-Virus verändert sich bei Übertragung zwischen Menschen
Untersuchungen einer infizierten indonesischen Großfamilie zeigen Mutationen des Virus
London/Wien - Nach der Erkrankung von acht Angehörigen einer indonesischen Familie an H5N1 im Mai dieses Jahres - sieben der Betroffenen starben - haben wissenschaftliche Studien gezeigt, dass die Vogelgrippe-Viren selbst schon bei Übertragung von einem Menschen auf den nächsten Mutationen im Erbgut aufweisen. Das könnte die Entstehung eines Pandemie-Virus voran treiben.

http://derstandard.at/?url=/?id=2525394

[doktor7]

Antwort auf Beitrag Nr.: 22.959.560 von whyso am 23.07.06 09:40:00

Hi whyso

sag mal..

Die Wahrscheinlichkeit einer neuen Epedemie ist ja eine Sache,
die Markt-Chancen des Test´s eine andere.

Ist der Test eigentlich preislich konkurrenzfähig?
Wie schnell und zu welchen Kosten kann er "aktualisiert" werden?
(habe CBMX in letzter Zeit nicht mehr so verfolgt...)

Ein Einstieg bei Biota (Relenza) böte sich momentan eigentlich
auch wieder an. Sind ja ebenfalls ganz schön "zurückgekommen".

gruß........d7

[DagobertDuck57]

I am delighted that Dr. Gunn has joined our company," said Dr. Mansoor Mohammed, President and Chief Operating Officer of CombiMatrix Molecular Diagnostics

Ich bin auch entzückt
Gute Kaufgelegenheit!!!!!

[whyso]

Antwort auf Beitrag Nr.: 23.012.410 von doktor7 am 24.07.06 17:57:31

Gruß dich Doc

deiner Frage habe ich zur Kenntnis genommen, habe allerdings kein Zeit jetzt ich melde mich hierzu per BM, hoffentlich am späteren Nachmittag ...dieses nur zum neuen gemeinsamen zu Vermarktung freigegebene Produkt mit Furono vorab:

Features on the new QuadroCAS Synthesizer include:

The QuadroCAS Synthesizer, along with the CombiMatrix CustomArray Synthesizer(TM), are the only commercially available DNA microarray synthesizer instruments in the marketplace, providing high quality in situ fabricated arrays on demand.
The QuadroCAS Synthesizer fabricates up to 4 high quality in situ arrays simultaneously with the same or unique probe designs in 24 hours or less, depending on the array format of the experiments run.
The QuadroCAS Synthesizer allows the flexibility to design each probe sequence to the exact specification of the user for any organism and allows customers complete control over inventory for on-demand in situ microarrays.
The QuadroCAS Synthesizer has a compact footprint and incorporates all reagents and hardware into a stand-alone instrument.
The QuadroCAS Synthesizer will be certified by TUV to be compliant to EU directive IEC61010-1 73/23/EEC and 89/336/EEC with the latest amendments 92/31/EEC and 93/68/EEC.


Alle Euro & US Parameter sind bereits erfüllt worden, CBMX braucht hierfür -(ALS EINZIGE ANBIETER VON ARRAYS ÜBERHAUPT AM MARKT)- keiner FDA Zulassung für den Verkauf von deren neuen Produktaria

Das kann recht schnell gehen nach der split von Acacia!

Viele Grüße sendet dir,
Whyso

[doktor7]

Antwort auf Beitrag Nr.: 23.034.805 von whyso am 25.07.06 10:08:27

Hi whyso,

hört sich ja fast eilig an.....

wann und wie wird denn gesplittet?

übrigens:

DNA-Synthesizer gibt es ja mittlerweile gebraucht schon für wenige Tausend-Dollar.
Natürlich keine MicroArray-Tech.
Aber ist ein hartumkämpfter Markt. Da dürfte es nicht leicht zu
ermitteln sein, wie geldwert der technologische Vorsprung von CBMX
gegenüber Konkurrenten wie Quiagen oder Appl.Biosystems ist.

Gibt´s da schon Einschätzungen oder gar harte Fakten?

gruss......d7

[doktor7]

upps.....natürlich Qiagen

[whyso]

Hi Doc,

Witzig, da spricht man von Teufel(FDA) und plötzlich liegt deren Einladung vor

http://www.otcbb.com/asp/quote_module.asp?qm_page=89317&qm_s…

[whyso]

Der hier natürlich(sorry):
http://www1.investorvillage.com/smbd.asp?mb=521&pt=qn

[e.1]

Antwort auf Beitrag Nr.: 23.039.550 von whyso am 25.07.06 14:59:34

dann hoffe ich, dass es dem kurs mal auf die sprünge hilft. wäre echt nett.

gruß e.1

[nort.]

Acacia's CombiMatrix unit to meet with FDA

LOS ANGELES, July 25 (Reuters) - Acacia Research Corp. (ACRI.O: Quote, Profile, Research) on Tuesday said that federal regulators have invited its CombiMatrix unit to present its plans to market its Constitutional Genetic Array Test in September.

The CombiMatrix group is developing technology to quickly produce semiconductor-based tools that can be used to identify and determine the roles of genes, gene mutations and proteins.

The group is expected to meet with the Office of In Vitro Diagnostic Device Evaluation and Safety of the U.S. Food and Drug Administration "in the near future," the company said.

http://today.reuters.com/stocks/QuoteCompanyNewsArticle.aspx…

[doktor7]

Antwort auf Beitrag Nr.: 23.034.805 von whyso am 25.07.06 10:08:27

Hi,

ursprünglich hieß es doch:

...Alle Euro & US Parameter sind bereits erfüllt worden, CBMX braucht hierfür -(ALS EINZIGE ANBIETER VON ARRAYS ÜBERHAUPT AM MARKT)- keiner FDA Zulassung für den Verkauf von deren neuen Produktaria...

Da bist Du und vielleicht auch manch Anderer ja wohl davon ausgegangen
dass das Kind schon "geschaukelt" ist.

Nunmehr heißt es u.a. in der MW-Meldung:

...The letter invites the company to meet with the OIVD to discuss CombiMatrix Molecular Diagnostics' (CMDX) plans to market its Constitutional Genetic Array Test (CGAT) in September...

Ist das nun eine neue Entwicklung, oder nicht?

Dass eine Firma daraufhin verbreitet, sie "freuen sich" auf die
Gespräche, ist eh üblich. Eine gewisse Gefahr stellen solche Gespräche
allerdings immer dar.

Könnte ja auch ein Grund für die Tiefstkurse sein.

Ansonsten verstehe ich das nicht, bei CBMX sah es doch seit
Jahren nicht so vielversprechend aus....hmmm

Wie war das nun mit dem Split? Hab bis jetzt nichts gesehen dazu.

gruß...d7

[whyso]

Antwort auf Beitrag Nr.: 23.060.630 von doktor7 am 26.07.06 11:18:52

@Doc,

völlig richtig was du schreibst-ABER-bisher hat CBMX die märkte außerhalb Amerika anvisiert z.Bsp die mit Furono wie hier unten umschrieben, hier hat der FDA kein mitspracherecht, die Zulassung ist durch
--------------------------------
CombiMatrix and Furuno Launch DNA Microarray Synthesizer
Thursday July 13, 6:00 am ET
New CE Marked Instrument Incorporates Reagents and Arrays in a Single Stand-Alone Unit

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--July 13, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that its CombiMatrix group, working in partnership with Furuno Electric Co., Ltd. of Japan, has launched its new QuadroCAS(TM) CustomArray(TM) Synthesizer. Jointly designed and developed by the two companies, this new instrument integrates CombiMatrix's proprietary electrochemical in situ oligonucleotide synthesis technology into a compact, stand-alone design.

Manufactured by Furuno at their instrument production facility in Japan, the QuadroCAS Synthesizer combines convenient and reliable reagent handling hardware with state of the art Furuno instrument control and signal processing electronics to deliver a full-featured, small footprint instrument for CustomArray production applications. Designed and tested to meet appropriate safety certification standardsthe QuadroCAS Synthesizer will bear the CE ("European Conformity") and TUV markings (i.e., tested by TUV to meet the minimum requirements of prescribed product safety standards) and is suitable for worldwide distribution. Using this instrument, researchers around the world will be able to rapidly produce custom DNA microarrays to their exact specifications with complete control over the content.

Hidetoshi Tanigaki, Managing Director and General Manager of Furuno, said, "We are excited about the launch of the new QuadroCAS DNA Microarray Synthesizer. This instrument represents an important new product line for the life-science business group at Furuno."

"The QuadroCAS Synthesizer expands our synthesis product line," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "We look forward to offering our customers this dynamic enabling instrument."

The QuadroCAS Synthesizer fabricates CombiMatrix CustomArray microarrays that contain thousands of microelectrodes that are individually addressable using embedded logic circuitry on the microarray. Placed in one of four specially designed fluidic chambers, the system software digitally directs the molecular assembly of oligonucleotides for each separate array. During this process thousands of different oligonucleotide probes can be synthesized simultaneously on four different individual arrays.
----------------------------------
Hiernach wär der Amerikanische Markt ein zusätzliche "bon-bon" für die Furuno & CBMX global kooperation on top going forward!!!!!

Die 90k Kauf kurz vor Handelschluß an der Nasdaq gestern, sprach (für mein dafürhalten) ein relativ eindeutige sprache

21:59:42 1,2700 335
21:59:39 1,2500 500
21:59:39 1,2600 500
21:59:37 1,2000 90000

Der split von Acacia soll zu ende August/Anfang September vollzogen sein, dann sollten wir viel mehr Ad-hocs im bereich der Molecular diagnostics zu hören bekommen...

Nun ja wie immer, only time will tell,
Whyso

[doktor7]

Antwort auf Beitrag Nr.: 23.061.652 von whyso am 26.07.06 12:17:32

Danke für die Infos

Gibt´s schon einen "Stichtag" für den Split
und wie wird gesplittet?

auf der Furuno-HP habe ich noch folgende Passage
entdeckt:

"...Unlike the conventional DNA Microarray synthesizers that create a large amount of identical DNA sequences, oligonucleotide probes are synthesized directly on the chip with this new synthesizer. This cuts down the up front costs of buying hundreds of different oligonucleotides, hence helping greatly the research institutes, for they require only a small amount of different samples...."

...leuchtet schon mal ein .....und weiter:

"...The BTS instrument will synthesize DNA microarrays at core facilities, phamaceutical/biotech research sites and academic microarray centers. The synthesized CustomArray microarrays will be used for gene expression applications in life science research. FURUNO is planning to launch the products in a year time, and anticipating the annual sales of ¥ 2 billions once the products are put in circulation..."

wobei die Frage ist, welchen Zeitpunkt Furuno mit "in a year time" meint?

gruß.........d7

[doktor7]

Haaaloooo,

keiner mehr da?

Gibt´s schon einen "Stichtag" für den Split
und wie wird gesplittet??

gruss....d7

[doktor7]

letzte Meldung....

http://today.reuters.com/stocks/QuoteCompanyNewsArticle.aspx…

aber.... Psssssst

[zillus]

Antwort auf Beitrag Nr.: 23.159.625 von doktor7 am 28.07.06 22:14:45

so, die 1,30 Dollar sind zurückerobert ! - wer jetzt noch dabei ist
wird nicht bei 1,50 verkaufen !!! meiner Meinung nach dürfte in Kürze die Party steigen !---Die letzten Tage waren eine schweißtreibende Angelegenheit-----ich denke es kann jetzt schnell gehen ! Gruß an alle investierten !

[buyer10]

Antwort auf Beitrag Nr.: 23.293.878 von zillus am 03.08.06 09:01:29

Die $1,30 sind leider wieder gefallen.
Jetzt sich von dem Papier trennen tut zwar weh, aber evtl. doch die bessere Lösung?
Bei uns gibt es ja aktuell wieder die Vogelgrippe- Diskussion. Allerdings interessiert das in Ami-Land keine S..!
Von der derzeitigen Erholung am Aktienmarkt, können wir nicht profitieren.
Wie seht Ihr die Lage bei CBMX?- Bitte Info
Schöne Grüsse an alle Investierten

[DagobertDuck57]

Wieder mehr Vogelgrippe-Fälle in Asien

(www.emfis.com) 03.08.06
Bangkok
In den Ländern Thailand, Indonesien und Vietnam sind in der vergangenen Woche wieder vermehrt neue Vogelgrippe-Verdachtsfälle aufgetreten. So ist in Thailand ein Mann ins Krankenhaus eingeliefert worden, der vom H5N1-Virus befallen sein könnte. Wie ein Sprecher des Gesundheitsministeriums mitteilte, habe ein erster Test diesen Verdacht erhärtet; weitere Resultate müssten nun abgewartet werden. Es würde sich dort damit um die zweite Vogelgrippe-Erkrankung innerhalb von 8 Tagen handeln. Daneben ist gestern ein achtjähriges Mädchen verstorben, das ebenfalls von dem Virus befallen gewesen sein könnte.

In Südvietnam wiederum würden derzeit drei Erwachsene und drei Kinder weiteren Tests unterzogen. Daneben sei eine 61jährige Frau bereits infiziert, ein weiterer Mann sei mit hohem Fieber und schweren Lungenschäden in ein Krankenhaus in der Nähe der kambodschanischen Grenze eingeliefert worden. In Indonesien, wo es im Mai sechs Todesfälle gegeben hatte, befinden sich derzeit drei Kinder aus einem Nachbarsbezirk unter Quarantäne

Bisher sind weltweit 232 Fälle von Vogelgrippe-Erkrankungen in zehn Ländern aktenkundig geworden. 134 der Infizierten sind an der Krankheit verstorben.

[e.1]

hallo,

kann jemand sagen, wie es charttechnisch aussíeht. ich habe immer noch die hoffnung, dass wir die 3$ sehen können.

gruß e.1

[whyso]

Hallo e.1.

hier ist ein sehr gute Nachricht für die zukünftige Chartentwicklung

The Australian Genome Research Facility Joins CombiMatrix CombiCore(TM) Access Program

PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 6:00 AM ET Aug 7, 2006

NEWPORT BEACH, Calif., Aug 07, 2006 (BUSINESS WIRE) -- Acacia Research Corporation (CBMX : acacia resh corp combimtrx com
News , chart, profile, more
Last: 0.000.000.00%

7:30am 08/08/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
CBMX0.00, 0.00, 0.0%) (ACTG : acacia resh corp acacia tch com
News , chart, profile, more
Last: 11.00-0.02-0.18%

ACTG11.00, -0.02, -0.2%) announced today that its CombiMatrix group has signed a non-exclusive agreement with the Australian Genome Research Facility (AGRF) under the company's CombiCore(TM) access program. Under the terms of the agreement, all AGRF researchers can purchase CombiMatrix CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the AGRF.
"We see the CombiMatrix platform as a robust, flexible, and cost-effective complement to our existing portfolio of microarray services," said Kirby Siemering, Business Development Manager for AGRF. "We are delighted to be working with CombiMatrix to help meet the custom arraying needs of the Australasian research community."
"AGRF is Australia's largest contract genomics research and services organization serving in excess of 2,000 researchers," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "Researchers throughout Australia and New Zealand can now send their biological samples to AGRF, a certified CombiCore, for array and data processing."
ABOUT AGRF Ltd
AGRF Ltd was established in 1997 with the mission of providing high quality genomic services to the academic and industry research sectors. With facilities in Brisbane, Melbourne, and Adelaide, AGRF is Australia's largest contract genomics research and services organization. The company places a high value on quality and maintains accreditation to the internationally recognized ISO 17025:2005 quality standard.
AGRF provides services covering large-scale DNA sequencing, genotyping, gene expression, methylation, nucleic acid extraction, plant growth/stress and associated bioinformatics. The company provides services to organizations spanning the entire biological and biotechnological research spectrum including biomedicine, plant and animal science, microbiology, evolutionary biology and biodiversity.
Information about AGRF Limited is available at www.agrf.org.au.
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 46 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.
Acacia Research-Acacia Technologies (ACTG : acacia resh corp acacia tch com
News , chart, profile, more
Last: 11.00-0.02-0.18%

7:30am 08/08/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
ACTG11.00, -0.02, -0.2%) and Acacia Research-CombiMatrix (CBMX : acacia resh corp combimtrx com
News , chart, profile, more
Last: 0.000.000.00%

7:30am 08/08/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
CBMX0.00, 0.00, 0.0%) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
SOURCE: Acacia Research Corporation
Acacia Research Corporation Bret L. Undem (Media Relations), 425-493-2293 Fax: [phone] Copyright Business Wire 2006 ********************************************************************** As of Thursday, 08-03-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 07-17-2006 for ACTG @ $12.28. For more information on Comtex SmarTrend® Alert, contact your market data provider or go to CSTADirect.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright © 2004-2006 Comtex News Network, Inc. All rights reserved.
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7BECD…

[whyso]

Die Abeles connection wirkt jetzt schon...

[e.1]

hallo whyso,
danke für deine info.
anscheinend wird wirklich der split abgeartet, sonst müßte es doch verstärkter nach oben gehen, oder sehe ich das falsch?

Gruß
e.1

[doktor7]

Antwort auf Beitrag Nr.: 23.353.574 von whyso am 08.08.06 14:00:11

Hast BM

[buyer10]

Antwort auf Beitrag Nr.: 23.366.246 von doktor7 am 09.08.06 11:57:09

Die Kursentwicklung ist einfach nur noch zum
Biotechs stehen momentan nicht gerade im Focus, aber was hier abgeht ist einfach nur noch was für echte Masochisten!
Ca. 65% Kursverlust vom Jahreshoch!!!!!!!!!!!!!!
Wie gesagt - momentan einfach nur zum

[zillus]

Antwort auf Beitrag Nr.: 23.396.151 von buyer10 am 11.08.06 10:27:34

was sollen diejenigen sagen, die schon seit ein paar Jahren dabei sind ?--also ich finde auch, daß es Nervenkrieg ist !--aber ich werde auch das Gefühl nicht los, daß hier Leute am Werk sind, die uns "raushaben wollen"----Gewonnen hat hier kaum jemand etwas, aber falls doch eines Tages die Post hier abgeht, dann wollen hier alle Ihr Geld zurückhaben und zahlen dann vielleicht auch 5 Dollar und mehr pro Stück !--ganz zu schweigen von den ganzen Neulingen, die auch Ihren Teil abbekommen möchten ! Gruß an Alle-Zillus !

[whyso]

Forbes Artikel über CBMX von gestern...

"Another key player in the biothreat detection space is Combimatrix (nyse: CBMX - news - people ). Its versatile microarray assay contains over 12,000 electrodes available for individual assay. If a chemical or biological agent binds to the electrode, it triggers a signal. By knowing which electrodes were triggered, it is possible to determine what agent is present. Combimatrix is under a $2.1 million contract with the Department of Defense on this project. Combimatrix also announced a cooperative agreement with the U.S. Air Force for the development of a biomonitor device with biomarker-based microarrays. This technology would allow the monitoring of the health status of military personal in real time"


Wenn dieses alles eintreffen sollte werden wir feststellen müssen das wir ein hoch explosiven Stoff im Depot verwalten im Form von CBMX, der ein Gesamt MK von 44,59 USD vorzuweisen hat z.Zt.

Der kurs ist momentan "schmerzhaft", die Aktie & Marktumfeld (Molecular Diagnostics) halte ich weiterhin für extreme Spannend,

Steigende Grüße,
Whyso

P.S. Doc, wie versprochen...BM

[nort.]

H5N1 ist wieder im Anflug

http://www.stern.de/wissenschaft/medizin/:Vogelgrippe-Im-Her…

[nort.]

H5N1 ist wieder im Anflug

http://www.stern.de/wissenschaft/medizin/:Vogelgrippe-Im-Her…

[nort.]

CBMX auf Bloomberg

http://www.bloomberg.com/apps/news?pid=20601070&sid=as9dQ6i_…

[whyso]

Hi Nort-die "auswirkungen" der letzte presse release von CBMX müssen erst noch zur Geltung kommen, ich denke der Herbst wird alle Kursverluste (und mehr dazu) wieder bringen

CombiMatrix Updates Influenza Array with New Flu Sequences from the Centers for Disease Control
Thursday August 24, 6:00 am ET
The US Centers for Disease Control and Prevention Has Released Sequences from Influenza Strains Including Those from the Recent Human Deaths in Indonesia


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Aug. 24, 2006--Acacia Research Corporation announced today that its CombiMatrix group (Nasdaq:CBMX - News; Nasdaq:ACTG - News) is making available an updated version of its Influenza A Array. Incorporated into version 3.0 are the new sequences that have been released by the US Centers for Disease Control and Prevention (CDC), which include the strains from the recent infections and deaths in Indonesia.

http://biz.yahoo.com/bw/060824/20060824005192.html?.v=1

Naja, manchmal sollte man den Kursentwicklung eine Aktie völlig außenvorlassen-dieses gilt bei CBMX seit ca. 8-10 Wochen, ich denke "der neue Era" bricht auch dort baldigst wieder an...

Steigende Grüße & ein schönes Wochenende,
Whyso

[e.1]

hallo whyso,
schön zu sehen, wie positiv du zu cbmx und nvax stehst.
auch ich hoffe, das der kurs bald in andere bereiche aufbrechen wird. vielleicht kaufe, ich doch noch ein wenig nach.

einige versuche hat cbmx ja schon unternommen.
was ist eigentlich mit dem splitt? der müßte doch eigentlich bald kommen. gibt es da schon einen verbindlichen termin?

gruß
e.1

[wiwifant]

CombiMatrix Molecular Diagnostics Announces Commercial Launch of Its First Genetic Test from Its CLIA Certified Laboratory

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Sept. 5, 2006--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics (CMDX) has commercially launched its first molecular diagnostic service. Physicians are now able to prescribe this test for their patients.

This first offering utilizes CMDX' Constitutional Genetic Array Test (CGAT), which can genetically identify over 50 common genetic disorders in one test. This array is already being sold in Europe, and is now being offered as a service in the US, after internal clinical validation. CMDX will be featuring this test through a number of sales and marketing efforts during the upcoming Annual Meeting of the American Society of Human Genetics, in New Orleans on October 9-13, 2006.

Over two thirds of young children with developmental disorders are either undiagnosed or mis-diagnosed through conventional techniques, making it difficult to provide appropriate treatment or counseling. CMDX' CGAT array is designed to provide a cost and time effective approach to accurately identify the specific genomic abnormality that is the cause of the clinical disorder.

"With this launch, our CLIA laboratory is open for business. This is a major technical and scientific milestone for CMDX," stated Matt Watson, CEO of CMDX. "During the next quarter we anticipate launching our Melanoma (skin cancer) product, and several other products are in various stages of development. We will provide more detailed information on our next product launch and pipeline shortly."

Dr. Amit Kumar, President and CEO of CombiMatrix, and Chairman of CMDX, stated, "Our goal for CMDX is to launch new array services in rapid succession. We hope to have, on the market, the broadest portfolio of array based molecular diagnostic products and services, of any microarray company, within the next two or three quarters. We have invested in and developed our technology platforms specifically to enable this rapid 'turnkey' type capability."

[whyso]

Danke dafür

und sehe da der FDA ist plötzlich nicht mehr anwesend

http://www.quote.com/qc/stocks/quotes.aspx?symbols=NASDAQ:CB…

Das könnte die Initialzündung sein für ein starken Herbsthandel mit CBMX,

Good trades & etwas mehr Geduld ihr lieben,
Whyso

[e.1]

hallo leute,

dieses hin und her zerrt allmählich ein meinen nerven. vorgestern der schöne hype brachte etwas optimismus hinein, und gestern schon wieder alles aufgezehrt.
kann jemand genaueres zum splitt sagen. termin etc.
wäre sehr nett.

sonnige grüße
e.1

[Namaycush]

Antwort auf Beitrag Nr.: 23.817.947 von e.1 am 08.09.06 08:36:51

Hallo e.1
lass dich nicht stressen - du bist ja auch, so wie ich, seit längerem engagiert und hast die gesamte Talfahrt mitgemacht. Der momentane Zeitpunkt ist sicher nicht optimal für einen Ausstieg (meine persönliche Ansicht!) Dafür stehen verschiedene Sachen an welche den Kurs in Kürze positiv bewegen können. Split, Geld von Goverment, Vogelgrippe durch vogelzum mehr im Fokus im Herbst etc.

Zum Termin des Splits weiss ich nur was in dem Yahoo Board gepostet wurde - zuerst hiess es im August nun soll es September werden. Ich rechne einfach mit dem Split noch in diesen Jahr.

herzlich Namaycush

[e.1]

hallo namaycush,
vielen dank für deine antwort. ja zum aussteigen ist wirklich nicht der rechte zeitpunkt. ich hoffe schon auf einen wirklich exzellenten anstieg. nur dieses hin und her zerrt nun mal schon etwas an den nerven.
danke für dein feedback.

liebe grüße e.1

[nort.]

[DagobertDuck57]

News
http://biz.yahoo.com/bw/060919/20060919005222.html?.v=1

[whyso]

Yepp Dagobert... that one caught my eye as well


"The addition of CombiMatrix CustomArray and CatalogArray products to our offering enables us to provide an alternative platform for gene expression and genotyping services to those researchers that would like to perform novel experiments," said Divyen Patel, CEO and founder of Genome Explorations. "CombiMatrix offers the best option for researchers that require low-priced unique-content microarrays. The agreement also allows us to provide our current service clients an extremely accurate validation tool."

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B432…

Stay tuned...

[whyso]

Genome hat auch sein "footprint" in Europa bereits hinterlassen:

http://www.genome-explorations.com/news_going_global.html
Naja, we will see

Viele grüße an die geduldigen,
Whyso

[nort.]

Finanzinvestor Kleiner Perkins erhöht Einsatz für grüne Technologien und Gesundheit


KPCB hat zudem einen 200 Millionen Dollar umfassenden Pandemie-Vorbereitungsfonds lanciert. Mittlerweile werden bereits drei Projekte zur Bekämpfung von weltweiten ansteckenden Krankheiten unterstützt. Dies sind Biocryst (BCRX), Novavax (NVAX) und eine Schnelldiagnose-Technologie. KPCB-Partner Brook Byers dazu: Die Welt ist erbärmlich schlecht auf eine weltweite Pandemie vorbereitet. Im nächsten Jahr werden wir vier weitere Durchbrüche zur Erkennung einer globalen Pandemie, für Diagnose, Antivirusmittel und Impfstoffe finanzieren. Wir arbeiten eng mit den Gesundheits- und Regierungsbehörden in den USA und in Asien zusammen. Ausserdem drängen wir darauf, dass diese Innovationen weltweit zugänglich gemacht werden, und zwar in den Entwicklungsländern entweder zum Selbstkostenpreis oder unter Lizenz und in der entwickelten Welt zu normalen kommerziellen Bedingungen."


...

http://www.wirtschaftsblatt.at/cgi-bin/page.pl?id=511126&tid…

[nort.]

Kampf gegen Tierseuchen in China soll verstärkt werden

Angesichts der weiter kritischen Lage in Bezug auf Tierseuchen in China hat Agrarminister Du Qinglin für den Herbst verstärkte Anstrengungen zur Vorbeugung und Kontrolle von Tierepidemien einschließlich der Vogelgrippe gefordert.

In einer Erklärung rief Du am Donnerstag in Beijing die Veterinärbehörden auf, umfassende Impfaktionen bei Tieren durchzuführen. Zudem drängte er auf eine verstärkte Überwachung der Immunität von Tieren. An die zuständigen Behörden in den Grenzgebieten appellierte der chinesische Agrarminister, Tierepidemien im Ausland mit großer Aufmerksamkeit zu verfolgen und Maßnahmen gegen ein Übergreifen von Tierepidemien aus dem Ausland nach China zu ergreifen.

(China.org.cn, 22. September 2006)

[e.1]

es wird langsam zeit, dass es sich in die positive richtung bewegt.
der split lässt auch auf sich warten.

ich hoffe, dass es bald losgeht, hier ist wirklich geduld gefragt.

gruß
e.1

[e.1]

wie weit geht es denn noch abwärts

[DagobertDuck57]

Antwort auf Beitrag Nr.: 24.188.939 von e.1 am 25.09.06 17:18:14

Wenn es noch weiter fällt, dann machen die anstelle des Splits noch einen Reverse-Split daraus
Dann hamse wieder viel spielraum nach unten

[e.1]

so langsam bekomme ich echt etwas panik. ds geht ja immer weiter bergab anstatt bergauf. da hatte ich mir etwas anderes vorgestellt.

hoffe, dass sich das bald ändern wird.

gruß e.1

[buyer10]

Antwort auf Beitrag Nr.: 24.285.885 von e.1 am 29.09.06 18:27:00

Hi e.1

mir ist auch zum

Zur Zeit läuft es mit den Biotechs generell nicht gut.

Aber schön langsam glaub ich bei CBMX aufs falsche Pferd gesetzt zu haben.

Macht mir meine schönen Gewinne im Depot total zunichte

Wir sind jetzt ungefähr 70% vom Jahreshoch entfernt!!!:mad

Ich glaub rein von der Charttechnik her, kann man keine Beurteilung geben.

Was wir brauchen wären mal interessante Meldungen ect.!!

Vielleicht......schon bald?


Schöne Grüsse
buyer10

[chrisslyzorri]

Hallo zusammen,
bin nun schon einige Zeit in cbmx investiert.....
doch was da in letzter Zeit abgeht,geht schon etwas an die Nerven.
Üerlege mir langsam ob ich nicht doch noch das sinkende Schiff ver-lassen soll...oder was spricht dagegen....


chrissly

[chrisslyzorri]

b wie Überlege vergessen na ja...
Was haben die eigentlich noch Geld in der Kasse.....
Habe irgendwo was von 55.Mios gelesen stimmt das....
Wann soll eigentlich das erste Geld in die Kasse kommen...


chrissly

[doktor7]

Antwort auf Beitrag Nr.: 24.409.344 von chrisslyzorri am 04.10.06 22:13:48

also laut yahoo 9.98M. Kommt schon eher hin.

http://finance.yahoo.com/q/ks?s=CBMX

[chrisslyzorri]

Hallo zusammen,
langsam nervt das ganze....brauche mal ein paar aufmunternde
Worte
Jetz mal im ernst wie gehts weiter was meint ihr.
Laut Chart schauts nicht so toll aus ...das Geld reicht auch
nicht mehr lange...Wann oder durch was sollte demnächt Geld in die Kasse kommen.

chrissly

[WARREN.]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[wiwifant]

CombiMatrix Receives Additional $2 Mln For Monitoring Influenza And To Detect Biological Threat Agents - Update



(RTTNews) - Early Monday, Acasia Research Corp., (ACTG) revealed that its division CombiMatrix group (CBMX), a developer of technologies in areas of drug development, has been awarded two new allocations of $1 million each in the 2007 Defense Appropriations Bill, which was recently signed into law by President George Bush. The company noted that this funding would support the company's effort to continue the development and deployment of its microarray technologies for the detection of biological-threat agents and infectious pathogens such as the highly pathogenic Eurasian Influenza A Virus H5N1.

CombiMatrix have recently demonstrated that the DNA-array technology would enable the company to modify the analytical capability as the virus continues to mutate. The company noted that the system has recently been used in a number of government-funded studies to monitor birds entering North America. The company said that the studies were conducted in collaboration with several government agencies as well as with industrial partners. The company added that with the additional funding, it expects to continue improving the capability of the system, which includes cost reduction and integration.

CombiMatrix noted that since March 2004, it has been awarded funding of about $15 million from the US Government, including the recent appropriations. Out of the $15 million in commitments, CombiMatrix has drawn down about $8 Million. CombiMatrix also stated that it has other collaborative efforts and requests into various government agencies that might result in additional contracts.

According to the company, the funding would support the development of products such as CombiMatrix's portable ElectraSense Reader and arrays for the detection of biological-warfare agents, infectious diseases such as influenza, and upper-respiratory infections, as well as the development of microfluidics and hand held detection systems.

David Danley, director of Homeland Defense of CombiMatrix Corp. in a statement said that with the additional capital, the goal would be to develop an integrated system that could be used in a laboratory as well as military and civilian environments where early detection can reduce the spread of the disease or the impact of a biothreat attack.

CBMX closed Friday's regular trading session at $0.96, up $0.04, on a volume of 258,200 shares.

[e.1]

ne, ne, ne, das kann doch alles nicht sein. wann gehts wieder aufwärts. das ist ja wirklich grausam.
weiß jemand was , weshalb dieses minus?

gruß
e.1

[zillus]

Antwort auf Beitrag Nr.: 24.582.700 von e.1 am 12.10.06 16:55:37

So ein Scheiß, ----<so jetzt kann es nach oben gehen ! habe am Freitag alles verkauft---und das war viel !

[DagobertDuck57]

FDA Provides Positive Opinion on the Regulatory Status of CombiMatrix's First Array-Based Molecular Diagnostic
Wednesday October 18, 5:59 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has received a letter from the Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) of the US Food and Drug Administration (FDA). The text of the letter is given below. The letter states that the FDA is not defining CombiMatrix's first commercial microarray-based molecular-diagnostic service, the Constitutional Genetic Array Test (CGAT), as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA). Thus the test does not require regulation covered in the FDA's Draft Guidance document issued on September 5, 2006.
ADVERTISEMENT


In July of 2006, the OIVD requested a meeting with CombiMatrix to discuss the regulatory status of the CGAT, which was to be launched in the third quarter 2006. Additionally, on September 5, 2006, the OIVD published a Draft Guidance document titled "In Vitro Diagnostics Multivariate Index Assays." These guidelines were specifically designed to consider the regulatory status of products and services in the emerging field of molecular diagnostics and personalized medicine. On September 14, 2006, executives of CombiMatrix and its clinical laboratory, CombiMatrix Molecular Diagnostics (CMD), met with the FDA to discuss the CGAT. The FDA has now informed CMD that it agrees that the CGAT is not an IVDMIA. Thus CMD will continue to offer the CGAT as a service to patients and clinicians.

The CGAT is CombiMatrix's first commercially launched array-based molecular diagnostic test, offered as a service through its CLIA-certified clinical laboratory, CMD. This test, launched in early September, is designed to identify common genetic disorders that result in developmental anomalies. Though this test has only recently been introduced, CMD has already performed roughly 50 clinical assays. The patients were all children or infants with undiagnosed or mis-diagnosed genetic abnormalities that were not readily apparent through conventional diagnostic procedures.

Though the current opinion provided by the FDA only applies to the CGAT, CombiMatrix's diagnostic strategy is to develop a series of array-based molecular diagnostic services as laboratory-developed tests, offered to patients and physicians through CMD. Eventually, the company may seek regulatory approval for certain tests so they may be sold to other labs as In Vitro Diagnostic products. Currently, CMD believes that it is the only laboratory that has the platform technologies enabling it to produce both Oligonucleotide Arrays and Bacterial Artificial Chromosome Arrays. By having access to both array platforms, CMD has the ability to develop tests that analyze chromosome-level defects, gene-expression patterns, and single-nucleotide polymorphisms.

"We are pleased to learn that FDA agrees that our microarray-based CGAT does not fall into a category known as an IVDMIA, and thus to know that this test does not require regulation covered in the IVDMIA Draft Guidance," said Dr. Amit Kumar, President and CEO of CombiMatrix and Chairman of CombiMatrix Molecular Diagnostics. "This test marks the beginning of our entrance into the molecular-diagnostics and personalized-medicine markets."

Matt Watson, CEO of CombiMatrix Molecular Diagnostics, stated, "Our goal is to make CMD the leading array-based molecular-diagnostics laboratory in the world. This opinion by the FDA is a significant milestone in that effort."

Text of the FDA letter:

"Dear Mr. Watson:

"We would like to thank you for meeting with us on September 14,
2006, to discuss your microarray based Consitutional Genetic Array
Test (CGAT). We believe that scientific advances in this area have the
potential to significantly impact the field of molecular diagnostic
testing, and we are very interested in following developments in
technologies for chromosomal copy number determination.

"In your letter dated September 18, 2006, you have expressed the
opinion that the CGAT is not an In Vitro Diagnostic Multivariate
Index Assay (IVDMIA). We agree with your assessment. We do not believe
that your device, as described, meets the definition of an IVDMIA as
defined in the Draft Guidance document on IVDMIAs.

"No further information is needed at this time. If you have
additional questions, please feel free to contact me at 240-276-0450.

"Sincerely yours,

"Steven I. Gutman, M.D., M.B.A.
Director
Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health"

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce CUSTOMARRAYS(TM), which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 51 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



Contact:
Acacia Research Corporation
Dr. Amit Kumar, 425-493-2200
Fax: [phone]

--------------------------------------------------------------------------------
Source: Acacia Research Corporation

[GoofMan]

Antwort auf Beitrag Nr.: 24.698.874 von DagobertDuck57 am 18.10.06 12:35:56

Klingt gut, dann hoffen wir mal das auch der Kurs wieder reagiert. In letzter Zeit war die Entwicklung der Aktie ja doch sehr enttäuschend. Seit heute bin ich auch wieder an Bord.

[whyso]

@e.1. BM wie versprochen ...

[radic]

und nun

[whyso]

Antwort auf Beitrag Nr.: 24.815.195 von radic am 24.10.06 11:34:23

Nicht zu Danken...

[radic]

Antwort auf Beitrag Nr.: 24.815.429 von whyso am 24.10.06 11:45:51

scusa für verspätete sichtung,




wird wohl noch ne hängepartie, aber das kann ja einen drillianer nicht erschüttern, das sitzen wir ab

[nort.]

[Aptamilla]

Antwort auf Beitrag Nr.: 24.826.121 von nort. am 24.10.06 18:13:54

Wo ist das Auffangbecken?Das ist Sturzflug ohne Schleudersitz!

[whyso]

so, oder so ähnlich habe ich heute Abend Kumar gemailt(siehe unten) :O
------------------------------

-----Ursprüngliche Nachricht-----
Von:
Gesendet: Dienstag, 24. Oktober 2006 21:12
An: '[e-mail]'
Betreff: CBMX Stock Performance (24.10.06)
Wichtigkeit: Hoch

Dear Amit,

this is not a stock performance anymore, it’s just the usual shareholders “daily massacre” at the hands of your Combimatrix:



Please look carefully at what your last six months of mismanagement has done for the shareholder value in this stock issue!

Is this your idea of “public relations” for Combimatrix, or are you just content to let this car run against a new wall of short sellers day for day until there are simply no survivors left???

This performance is nothing short of a disgrace, the Dow has seen 12,000 points recently, and we see the accurate reflection of your leadership in Combimatrix reflected in the chart above.

Do you feel this is a job well done?

You sir, have many questions still left to answer, especially to people who placed their hard earned money in your hands IN TRUST. I hope my children will be able to forgive me in time for not recognising the perils of investing in a company which has been practically led to ruin by you, without reason, and indeed without rhyme. Good products, but no sales. A bad workman blames his tools, or in your case the small cap market as a whole.

I am very disappointed and ashamed of myself, I hope you are too!
---------------------------------

Er hat in einen längeren Telefongespräch dieser Woche viel gutes versprochen-hier die wesentlche punkte daraus (ich gebe es nur wieder, und kann die Wahrheitsgehalt die aussagen nicht weiter kommentieren)

Nachricht von whyso am 18.10.2006 22:37 ------

Hi E.1, hi Radic,

ich habe heute Abend vieles erfahren, ich muss das ganze etwas zu recht legen & n'bissl sachen lassen(wir sprachen glatte 35 minuten miteinander) Fünf Produkte sind in die Pipeline z.Zt, wir haben ein Europaischen Partner in Frankreich, "ArrayGenomics" die jetzt schon Produkt bezieht zum wholsesale Preisen von CBMX, und diese dann weiter verkauft als reseller fungieren...diese Produkt kommt demnächst auch auf dem Amerikanischen Markt zum vorschein. Array Genomics hat Produkt für 235.000$ bereits bezogen, der MD dort ist der ehemalige CEO von Abbot technologies...das lässt mein Anlegerherz etwas höher schlagen!!!

Es gibt ein interessierte Großinvestor der sich einen Einstieg in CBMX zurzeit in Erwägung zieht (insbesondere bei diese niedrige Sharepreis Gestaltung)-talks sind hierbei angeblich weit fortgeschritten.

Beim upcoming Konferenzcall & Quartalsbereicht, wird Kumar ein sehr interessanter Gesichte zu erzählen haben: ein kleines 4 jährige mädchen die bereits von ihr eigene Facharzt als totkrank an Leukamie leidened diagnostiert wurde, hat durch ein CBMX array test ein GANZ ANDERE ERGEBNIS binnen 48 std erhalten, und jetzt mittels eine entsprechende Diat-Umstellung bis ins höhen Alter sich beste Gesundheit erfreun soll/wird...die Eltern von dieses Kind sind natülich komplett erleichtert & wollen die CBMX story laut und breit erzählen, ich glaube das wird sehr gut rüberkommen in good old Amerika.

Geld ist vorhanden bis mitte nächstes Jahr, keine weiter pipes sind bis dahin geplant -(weder mit Cornell noch mit jemand anderes)-auch keine reverse splitt bis dahin.

Die Trennung von Acacia bedarf ein Gehnehmigung von der IRS, und dieses soll bis ende Novemeber (Steuerrechtlichte Auslegung???) vorliegen...hier war er recht wage, und wollte sich absolut nicht festlegen wieso das ganze solange andauert.

Er sagte der Markt hat bis heute gar nicht geglaubt das Combimatrix überhaupt in die lage sei ein Produkt raus zu bringen, und so kommt der wacklige Börsen-Bewertung momentan zur stande im fallende shareprice reflektiert....er sieht drei von die Fünf kommende Produkte als zugelassen an & im Markt erhältlich bevor Weihnachten. Der US Leukamie test wird offizielle bis ende der 2nd Quartal 07 im Umlauf gebracht!

Er denkt mit der heutigen FDA ZUlassung das Geld & Vertrauen in der Wert wieder zurückfliessen wird-langsam aber dafür sicher!

Thats it for now-jeder muss es natürlich selber wissen wie er/sie weiterhandelt.

Viele Grüße & wer schreibfehler findet darf sie ruhig behalten-(ich lese das ganze hier nicht einmal wieder durch-"gespostet wie geschrieben")

Bis die Tage & good trades wünscht Euch,
Whyso

[weisserwal]

bin jetzt mal rein in die aktie...
vielleicht klappt ja jetzt mal ein durchschlagender return..

[zelltim]

Antwort auf Beitrag Nr.: 24.845.913 von weisserwal am 25.10.06 15:49:25

Meine Herren bin schon lange nicht mehr in Combi Investiert / zurzeit zum Glück in Ambri Ltd. denn da ging es sogar ohne News Bergauf /echt toll was !!Ich überlege mir aber wieder bei 164630 einzusteigen denn die Aktien ist meines erachtens völlig ohne Grund in den Keller geschickt worden !!!Ist klar fehlendes Intresse !!Bloß der Grund es findet sich einfach kein Boden hier bei dem Wert um einsteigen zu können !!

Wenn der gefunden ist gehe ich wieder binne!!

[radic]

Antwort auf Beitrag Nr.: 24.834.246 von whyso am 24.10.06 22:51:48

er sollte mal mit dem MArkt sprechen,

wieder und weitere 10% abgekackt, als ob die Pleite sicher droht

[wiwifant]

so Leute, die Q3 Zahlen sind da.einzig positives was herauslesbar wäre. Die Umsätze aus eigenen Produkten und Serviceleistungen steigen.
Cash reicht noch für eventuell ein Jahr, falls Verbrennungsrate nicht signivikant steigt und wir notieren unter EK.
Hat von euch jemand CC verfolg? Falls dort keine ermutigenden Erkenntnisse hervorgingen, sehe ich nur wenig Erholungschancen, da viele Chartisten das Teil nichtmal mit der Kneifzange anfassen werden.
Aus Risikomanagentüberlegungen stehe ich nach -50% nun auch vor einer Rauswurfentscheidung - nur der Bauch sagt nööö!



Web NASDAQ.com






Oct 26, 2006

US Market Closed NASDAQ 2379.1 22.51 0.96% | DJIA 12163.66 28.98 0.24% | S&P 1389.08 6.86 0.5%

Home › Quotes+ › Company News






Company News

FlashQuotes InfoQuotes Summary Quote Charts Revenue / EPS Summary Company Financials - View Competitors - Short Interest Company News Analyst Info Stock Report Real-Time SEC Filings - Holdings/Insider Summary - Institutional Holdings - Insider Form 4 - Insider Form 144 Equity Options Extended Trading Company Research - StockConsultant - Guru Analysis Annual Report CREENUANTEVASYMCSSTICBMXCHKPFEHWLMGR









CBMX
Acacia Research Corporation NASDAQ-GM




Back to Headlines | Previous Story | Next Story

StockConsultant
Enter Symbol




Acacia Research Reports Third Quarter Financial Results



NEWPORT BEACH, Calif.--(BUSINESS WIRE)--

Acacia Research Corporation (Nasdaq:ACTG) (Nasdaq:CBMX) today reported results for the three months ended September 30, 2006. Acacia Research Corporation comprises two operating groups, the Acacia Technologies group and the CombiMatrix group.

"Acacia Technologies' revenues for the third quarter increased to $8,424,000 compared to $6,783,000 in the year ago period. Trailing 12-month revenues increased to $35,758,000 compared to $12,107,000 as of the end of the third quarter of 2005. Acacia Technologies reported a GAAP net loss of $1,049,000 or $0.04 per share, including non-cash patent amortization and non-cash stock compensation charges totaling $2,307,000. Cash and short-term investments increased by $5,256,000 from the previous quarter to $45,971,000. We continue to expect significant growth in 2006 annual revenues compared to 2005," commented Acacia Chairman and CEO, Paul Ryan.

"New licensing agreements in the third quarter included licenses of our Resource Scheduling technology to GE Healthcare and 3M, our Multi-Dimensional Bar Code technology to Allstate, Emdeon (formerly WebMD), and Texas Instruments, our Audio/Video Enhancement & Synchronization and Image Resolution technology to Sanyo, and our Interstitial Internet Advertising technology to Datalex."

"We continue to build our leadership position in technology licensing. Our licensing success is increasing opportunities for partnering with owners of patented technologies. We acquired control of 4 new patent portfolios in the third quarter and now control 52 patent portfolios," concluded Mr. Ryan.

"The CombiMatrix group recognized revenues of $1,844,000 for the third quarter of 2006. This represented total revenue growth of 26% over the year ago quarter and revenue growth of 3% over the second quarter of 2006," commented Amit Kumar, CEO and President of CombiMatrix Corporation.

"Third quarter revenues for our subsidiary, CombiMatrix Molecular Diagnostics, more than doubled from the previous quarter to $153,000. With the launch in September of our first array based diagnostic service, we are executing our plan to become the premier array based diagnostic service laboratory," concluded Dr. Kumar.

Acacia Research Corporation Consolidated Financial Results

For the Three Months Ended September 30, 2006 and 2005

Consolidated revenues for the third quarter of 2006 were $10,268,000 versus $8,246,000 in the comparable 2005 period. Third quarter 2006 revenues recognized by the Acacia Technologies group were $8,424,000 versus $6,783,000 in the comparable 2005 period. Third quarter 2006 revenues recognized by the CombiMatrix group were $1,844,000 versus $1,463,000 in the comparable 2005 period.

The third quarter 2006 consolidated net loss was $5,376,000 versus $5,441,000 in the comparable 2005 period. The third quarter 2006 net loss was comprised of a net loss for the Acacia Technologies group of $1,049,000 versus $1,558,000 in the comparable 2005 period, and a net loss for the CombiMatrix group of $4,327,000 versus $3,883,000 in the comparable 2005 period.

The third quarter 2006 consolidated results included non-cash patent amortization, stock compensation and depreciation charges totaling $3,405,000 versus $1,990,000 in the comparable 2005 period. The increase in non-cash charges primarily reflects Acacia Research Corporation's adoption of SFAS No. 123 (revised 2004), "Share-Based Payments," ("SFAS No. 123R"), effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their consolidated financial statements. Consolidated stock compensation expense for the third quarter of 2006 totaled $1,573,000 ($311,000 included in research and development expense and $1,262,000 included in marketing, general and administrative expense).

Third quarter 2006 consolidated results also included a non-cash gain of $913,000 versus $163,000 in the comparable 2005 period, related to the adjustment of the CombiMatrix group's long-term warrant liability to fair value as of September 30, 2006.

Third quarter 2006 government contract costs totaled $684,000 versus $920,000 in the comparable 2005 period. The decrease was due to a higher level of activity under the CombiMatrix group's biological threat detection contract with the Department of Defense during the third quarter of 2005. Third quarter 2006 internal research and development expenses were $2,819,000 (including non-cash stock compensation charges of $311,000) versus $1,527,000 in the comparable 2005 period. The increase in internal research and development expenses was due to increased activity in the area of high-density array development as well as to the impact of the CombiMatrix group's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, which was formed and began research and development activities in the second quarter of 2005.

Marketing, general and administrative expenses for the third quarter of 2006, including non-cash stock compensation charges, were $6,315,000 versus $4,918,000 in the comparable 2005 period. Third quarter 2006 marketing, general and administrative expense included $1,262,000 in non-cash stock compensation expense versus $88,000 in the comparable 2005 period. Excluding the impact of the adoption of SFAS No. 123R, the net increase was due primarily to the addition of licensing, business development and engineering personnel for the Acacia Technologies group, an increase in the Acacia Technologies group's patent-related research and consulting expenses for new and ongoing licensing programs, and an increase in corporate, general and administrative costs related to the Acacia Technologies group's ongoing operations. The change also reflects a decrease in CombiMatrix group sales and marketing expenses as well as a reduction in general and administrative expenses as a result of the deconsolidation of CombiMatrix KK in January 2006.

Acacia Technologies group operating expenses for the third quarter of 2006 and 2005 included inventor royalties expenses of $1,837,000 and $2,105,000, respectively, and contingent legal fees expenses of $786,000 and $1,834,000, respectively. The majority of the Acacia Technologies group's patent portfolios are subject to patent and patent rights agreements with inventors containing provisions granting to the original patent owner the right to receive inventor royalties based on future net revenues, as defined in the respective agreements, and may also be subject to contingent legal fee arrangements with external law firms engaged on a contingent fee basis. The economic terms of the inventor and contingent arrangements, if any, vary across the Acacia Technologies group's 52 patent portfolios. As such, inventor royalties and contingent legal fees expenses fluctuate period to period based on the amount of revenues recognized each period and the mix of specific patent portfolios generating revenues each period.

The Acacia Technologies group's third quarter 2006 patent-related legal expenses were $2,354,000 versus $1,076,000 in the comparable 2005 period. Patent-related legal expenses fluctuate from period to period based on patent enforcement and prosecution activity associated with ongoing licensing and enforcement programs and the timing of the commencement of new licensing and enforcement programs in each period. Patent-related legal expenses include case related costs billed by outside counsel for economic analyses and damages assessments, expert witnesses and other consultants, case related audio/video presentations for the court, and other litigation support and administrative costs. We expect patent-related legal expenses to continue to fluctuate quarter to quarter based on the factors summarized above, in connection with the Acacia Technologies group's current and future patent commercialization and enforcement programs.

Financial Condition

Total consolidated assets were $107,995,000 as of September 30, 2006 compared to $121,434,000 as of December 31, 2005. Cash and cash equivalents and short-term investments on a consolidated basis totaled $54,302,000 as of September 30, 2006 compared to $59,173,000 as of December 31, 2005.

Acacia Technologies Group Financial Results

(A Division of Acacia Research Corporation)

For the Three Months Ended September 30, 2006 and 2005

Third quarter 2006 license fee revenues recognized by the Acacia Technologies group were $8,424,000 versus $6,783,000 in the comparable 2005 period. Third quarter 2006 revenues included license fees from 10 new licensing agreements covering 7 of our technology licensing programs. Third quarter 2006 license fee revenues included fees from the licensing of our DMT(R) technology, Audio/Video Enhancement and Synchronization technology, Image Resolution Enhancement technology, Interstitial Internet Advertising technology, Laptop Connectivity technology, Multi-Dimensional Bar Code technology, and Resource Scheduling technology. To date, the Acacia Technologies group has generated revenues from 18 of its technology licensing programs.

The Acacia Technologies group reported a third quarter 2006 division net loss of $1,049,000 versus $1,558,000 in the comparable 2005 period. Included in third quarter 2006 divisional results are non-cash stock compensation charges and non-cash patent amortization charges totaling $2,307,000 versus $1,457,000 in the comparable 2005 period. Third quarter 2006 non-cash stock compensation charges were $985,000 versus $123,000 in the comparable 2005 period. The increase reflects the adoption of SFAS No. 123R, effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their financial statements, as described earlier.

Third quarter 2006 marketing, general and administrative expenses increased to $3,562,000 (including non-cash stock compensation charges of $985,000 related to the adoption of SFAS No. 123R, as described earlier) from $2,113,000 (including non-cash stock compensation charges of $123,000) in the comparable 2005 period. Excluding the impact of the adoption of SFAS No. 123R, the net increase was due primarily to the addition of licensing, business development and engineering personnel, an increase in the Acacia Technologies group's patent-related research and consulting expenses related to new and ongoing licensing programs, and an increase in corporate, general and administrative costs related to the Acacia Technologies group's ongoing operations.

Acacia Technologies group operating expenses for the third quarter of 2006 and 2005 included inventor royalties expenses of $1,837,000 and $2,105,000, respectively, and contingent legal fees expenses of $786,000 and $1,834,000, respectively. The majority of the Acacia Technologies group's patent portfolios are subject to patent and patent rights agreements with inventors containing provisions granting to the original patent owner the right to receive inventor royalties based on future net revenues, as defined in the respective agreements, and may also be subject to contingent legal fee arrangements with external law firms engaged on a contingent fee basis. The economic terms of the inventor and contingent arrangements, if any, vary across the Acacia Technologies group's 52 patent portfolios. As such, inventor royalties and contingent legal fees expenses fluctuate period to period based on the amount of revenues recognized each period and the mix of specific patent portfolios generating revenues each period.

Third quarter 2006 patent-related legal expenses were $2,354,000 versus $1,076,000 in the comparable 2005 period. Patent-related legal expenses included patent-related prosecution and enforcement costs, incurred by outside patent attorneys engaged on an hourly basis and the out-of-pocket expenses incurred by law firms engaged on a contingent fee basis. Patent-related legal expenses fluctuate from period to period based on patent enforcement and prosecution activity associated with ongoing licensing and enforcement programs and the timing of the commencement of new licensing and enforcement programs in each period. Patent-related legal expenses include case related costs billed by outside counsel for economic analyses and damages assessments, expert witnesses and other consultants, case related audio/video presentations for the court, and other litigation support and administrative costs. We expect patent-related legal expenses to continue to fluctuate quarter to quarter based on the factors summarized above, in connection with the Acacia Technologies group's current and future patent commercialization and enforcement programs.

Financial Condition

Total assets for the Acacia Technologies group were $68,995,000 as of September 30, 2006 compared to $68,893,000 as of December 31, 2005. Cash and cash equivalents and short-term investments totaled $45,971,000 as of September 30, 2006 compared to $38,960,000 as of December 31, 2005.

CombiMatrix Group Financial Results

(A Division of Acacia Research Corporation)

For the Three Months Ended September 30, 2006 and 2005

Revenues for the third quarter of 2006 were $1,844,000 versus $1,463,000 in the comparable 2005 period. Third quarter 2006 revenues were comprised of $725,000 in government contact revenues and $1,119,000 in CustomArray(TM) product, equipment and service revenues, including $153,000 of array revenue from our diagnostics subsidiary, CombiMatrix Molecular Diagnostics. Third quarter 2005 revenues were comprised of $973,000 of government contract revenues and $490,000 of CustomArray(TM) product and service revenues.

The third quarter 2006 division net loss was $4,327,000 versus $3,883,000 in the comparable 2005 period. The third quarter 2006 results included non-cash stock compensation, patent amortization and depreciation charges totaling $1,079,000 versus $516,000 in the comparable 2005 period. The increase in non-cash charges primarily reflects the adoption of SFAS No. 123R, effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their consolidated financial statements, as discussed earlier. Third quarter non-cash stock compensation charges included in research and development expense and marketing, general and administrative expense totaled $311,000 and $277,000, respectively. The third quarter 2006 results also included a non-cash gain of $913,000 related to the adjustment of the CombiMatrix group's long-term warrant liability to fair value as of September 30, 2006, compared to $163,000 for the comparable 2005 period.

Third quarter 2006 government contract costs totaled $684,000 versus $920,000 in the comparable 2005 period. The decrease was due to a higher level of activity under our biological threat detection contract with the Department of Defense during the third quarter of 2005. Third quarter 2006 internal research and development expenses were $2,819,000 (including non-cash stock compensation charges of $311,000) versus $1,527,000 in the comparable 2005 period. The increase in internal research and development expenses was due to increased activity in the area of high-density array development as well as to the impact of the CombiMatrix group's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, which was formed and began research and development activities in the second quarter of 2005.

Third quarter 2006 marketing, general and administrative expenses decreased to $2,753,000 (including non-cash stock compensation charges of $277,000) from $2,805,000 in the comparable 2005 period. Excluding the impact of the adoption of SFAS No. 123R, the decrease was due primarily to a decrease in sales and marketing expenses as well as a decrease related to the deconsolidation of the CombiMatrix KK, which occurred during the first quarter of 2006.

Financial Condition

Total assets for the CombiMatrix group were $39,000,000 as of September 30, 2006 compared to $52,541,000 as of December 31, 2005. Cash and cash equivalents and short-term investments totaled $8,331,000 as of September 30, 2006 compared to $20,213,000 as of December 31, 2005.

In June 2006, Acacia Research Corporation executed a standby equity distribution agreement for up to $50 million in common stock equity financing from Cornell Capital Partners, LP ("Cornell") for the CombiMatrix group. Subject to the terms and conditions of the agreement between Acacia Research Corporation and Cornell, over the next 24 months, Acacia may sell up to 13,024,924 registered shares of its AR-CombiMatrix common stock at its discretion to Cornell less a 2.5% discount from the market price and associated fees ranging from 4-5%. The shares of common stock are being offered pursuant to an effective registration statement filed with the SEC on April 25, 2006. A fee was paid to Cornell in the amount of $550,000, upon closing of the agreement. During the third quarter of 2006, Acacia Research Corporation received $2,207,000 in net proceeds from the sale of 2,019,646 shares of AR-CombiMatrix common stock to Cornell. The net proceeds and applicable fees and expenses were allocated to the CombiMatrix group.

Due to the recent decline in the market value of AR-CombiMatrix stock, which began trading below $1.00 per share in late September 2006, and due to the limitation of the number of shares of AR-CombiMatrix stock available on the SEDA, the CombiMatrix group will likely be required to seek other sources of financing including the issuance of securities in order to maintain its operations for the next twelve months. However, such additional financing options may not be available at times and at terms acceptable to the CombiMatrix group, in which case it may be necessary to reduce its operating costs including research projects and personnel, which could jeopardize the future strategic initiatives and business plans of the CombiMatrix group.

Business Highlights and Recent Developments

Business highlights of the third quarter and recent developments include:


Acacia Technologies group:

-- Certain of the Acacia Technologies group's wholly owned
subsidiaries entered into license agreements with companies
covering patents that apply to our Audio/Video Enhancement and
Synchronization, and Image Resolution Enhancement technologies
as follows:

-- New Medium Technologies, LLC, IP Innovation, LLC and AV
Technologies, LLC entered into a license and settlement
agreement with Sanyo Electric Co., Ltd. The agreement with
Sanyo Electric resolves a patent infringement lawsuit
which was pending in the United States District Court for
the Northern District of Illinois Eastern Division.

-- In October 2006, IP Innovation, LLC entered into a
settlement and license agreement with Funai Electric Co.,
Ltd.

The Audio/Video Enhancement and Synchronization technologies
generally relate to the use of a noise reduction filtering
system for digital video compression, and for video and audio
signals received by digital radios and video displays. Other
aspects of the technologies apply to the synchronization of
audio/video signals. The Image Resolution Enhancement
technology generally relates to the modification of a video or
printed display to improve the perceived image quality beyond
the basic pixel resolution of the display.

-- InternetAd Systems, LLC, a wholly owned subsidiary that is
part of the Acacia Technologies group, entered into a license
agreement with Datalex (Ireland) Ltd., covering a patent that
applies to interstitial Internet advertising. Datalex is a
leading provider of e-Business solutions for the global travel
industry and is a publicly-traded company on the Irish stock
exchange.
The interstitial Internet advertising technology generally
relates to the display of certain advertising, informational,
and branding messages that appear between or outside the web
pages when the user is conducting a search.

-- VData, LLC, a wholly owned subsidiary that is part of the

Acacia Technologies group, entered into license agreements

with the following companies covering a portfolio of patents

that apply to certain multi-dimensional bar codes:

-- Allstate Insurance Company. The agreement settles a
lawsuit that was filed in the District of Minnesota
concerning Allstate Insurance Company and American
Heritage Life Insurance Company.

-- Emdeon Corporation (formerly WebMD)

-- Texas Instruments, Incorporated

-- In October 2006, entered into a license agreement with
Dell Inc.

The multi-dimensional bar code technology generally relates to
encoding and reading a data matrix consisting of an array of
data cells with a border. The data matrix can contain a
variety, amount, and depth of information that would not fit
onto an ordinary bar code. This patented technology can have
many applications in the manufacturing, distribution,
accounting, and security industries such as tracking the
movement of products, collection of data, improved production
capabilities, and anti-counterfeiting.

-- Resource Scheduling Corporation, a wholly owned subsidiary
that is part of the Acacia Technologies group, entered into
license agreements with the following companies, covering a
patent that applies to systems for scheduling and managing
resources.
-- General Electric Company, acting through its GE Healthcare
business

-- 3M Company

-- Infor Global Solutions

The Resource Scheduling technology generally relates to
methods and software application tools for scheduling and
managing resources used in manufacturing facilities, hospital
facilities, fleet delivery organizations, and other
resource-dependent markets. These resource scheduling tools
are often integrated as part of an Enterprise Resource
Planning (ERP) solution used to manage a company's complete
operations.

-- Acacia Patent Acquisition Corporation, a wholly owned

subsidiary that is part of the Acacia Technologies group,

continued its patent and patent rights acquisition activities

as follows:

-- In August 2006, acquired rights to a patent relating to
systems used in the remote control and monitoring of fluid
flow, both gas and liquid. This technology can be used in
heating/ventilation/air conditioning (HVAC), plumbing and
other industrial, commercial and residential fluid flow
systems.

-- In September 2006, acquired rights to a patent relating to
web personalization. One use of the patented technology is
in making personalized recommendations to consumers for
ecommerce purchases. The patent generally relates to
technology for learning user preferences and automatically
personalizing a user's online experience. The technology
is applicable to web sites that use categories plus
attributes to identify items, and where individual
attributes apply to multiple categories.

-- In September 2006, acquired rights to patents relating to
vehicle magnetic braking and induction motors. These
patents generally relate to technology for smooth,
reliable braking and acceleration of vehicles on parallel
rails.

-- In September 2006, acquired rights to a patent portfolio
relating to imaging technology that aids medical personnel
in the examination of patients. This technology can be
used in stabilizing medical images for interventional
procedures such as cardiac catheters and stents, and for
diagnostic procedures such as visualization of arterial
lesions.

-- In October 2006, acquired rights to patents relating to
wireless traffic information technology from TrafficGauge,
Inc., www.trafficgauge.com. This patented technology
generally relates to transmitting, receiving and
displaying traffic information on portable handheld and
mobile displays. It covers a variety of wireless
distribution methods, such as FM radio and satellite, as
well as the devices used to display the traffic maps. This
technology enables users to identify traffic congestion
and can be used with in-vehicle navigation displays and
portable handheld units such as cell phones and PDA's.

-- In July 2006, the Acacia Technologies group expanded its

business development and engineering teams with the addition

of three new vice presidents.

-- Joseph Lee, Vice President, Business Development. Mr. Lee
joins Acacia from Conexant Systems where he was Chief
Intellectual Property Counsel. Prior to Conexant, Mr. Lee
was Division IP Counsel for Gateway, Inc.'s Enterprise
Division, and IP Counsel for Callaway Golf Company. He
also practiced law at the IP law firm of Lyon & Lyon. Mr.
Lee is a registered patent attorney and holds a B.S.
degree in Electrical Engineering from the University of
Southern California, and J.D. degree from the University
of California Berkeley Boalt Hall School of Law.

-- Jacob Hawley, Vice President, Engineering. Mr. Hawley
joins Acacia from Microsoft Corporation where he held the
position of Architect. Prior to Microsoft he was CEO of
TKO Software, Inc.; Vice President of Engineering at ASML,
a leader in the manufacture of advanced technology for the
semiconductor industry; Vice President of Engineering of
Embedded Solutions; and Director of Engineering at
Creative Labs.

-- Marc Booth, Vice President, Engineering. Mr. Booth joins
Acacia from Nicholas Laboratories, a privately held
technology company owned by ex-Broadcom CEO, Dr. Henry
Nicholas, III, where he was the Director of Systems
Engineering. Previously Mr. Booth was Vice President of
Engineering of In The Air Net; Senior Director Engineering
of Powerwave Technologies; Vice President of Engineering
and CTO of Comarco Wireless Technologies; and Vice
President of Engineering, Sony Corporation. Mr. Booth
holds a B.S. Physics, from the University of CaliforniaRiverside and a MSEE degree from the University of
Southern California.

-- Since the last report to stockholders on July 20, 2006,
companies that are part of the Acacia Technologies group
dismissed lawsuits against three companies in connection with
our User Activated Internet Advertising and Multi-Dimensional
Barcode technologies. In addition, we became involved in
lawsuits with 17 companies in connection with our Audio/Video
Enhancement and Synchronization, High Resolution Optics, User
Activated Internet Advertising, Micromesh, Multi-Dimension Bar
Code, Product Activation, Peer to Peer Communications and
Credit Card Fraud Control technologies. We currently have 33
ongoing lawsuits involving 107 companies.

CombiMatrix group:

-- On July 13, 2006, the CombiMatrix group, working in
partnership with Furuno Electric Co., Ltd. of Japan, announced
the launch of its new QuadroCAS(TM) CustomArray(TM)
Synthesizer. Jointly designed and developed by the two
companies, this new instrument integrates CombiMatrix's
proprietary electrochemical in situ oligonucleotide synthesis
technology into a compact, stand-alone design. Manufactured by
Furuno at their instrument production facility in Japan, the
QuadroCAS Synthesizer combines convenient and reliable reagent
handling hardware with state of the art Furuno instrument
control and signal processing electronics to deliver a
full-featured, small footprint instrument for CustomArray
production applications. Designed and tested to meet
appropriate safety certification standards, the QuadroCAS
Synthesizer will bear the CE ("European Conformity") and TUV
markings (i.e., tested by TUV to meet the minimum requirements
of prescribed product safety standards) and is suitable for
worldwide distribution. Using this instrument, researchers
around the world will be able to rapidly produce custom DNA
microarrays to their exact specifications with complete
control over the content.

-- On July 24, 2006, the CombiMatrix group announced that Dr.
Shelly Gunn, M.D., Ph.D. had joined CombiMatrix Molecular
Diagnostics (CMDX) as its Medical Director. Dr. Gunn earned
her B.A. and Masters degrees from Trinity University, and a
Ph.D. in genetics from the University of Texas Health Science
Center at San Antonio (UTHSCSA) Graduate School of Biomedical
Sciences. Her doctoral work focused on the detection of
cryptic chromosomal abnormalities in pediatric patients with
normal cytogenetics and central nervous system dysmyelination.
She has published papers and abstracts related to array-based
comparative genomic hybridization (array CGH) and has been a
featured speaker at various scientific meetings and symposia.
Her current translational research interest is the development
of array CGH-based clinical assays for scanning tumor genomes
in hematological malignancies.

-- On July 25, 2006, the CombiMatrix group announced that it had
received a letter from the Office of In Vitro Diagnostic
Device Evaluation and Safety (OIVD) of the US Food and Drug
Administration (FDA). The letter invited the company to meet
with the OIVD to discuss CMDX's plans to market its
Constitutional Genetic Array Test (CGAT).The company met with
OIVD on September 14, 2006. On October 16, 2006 we received a
letter from OIVD indicating that the CGAT test need not be
regulated as an In Vitro Diagnostic Multivariate Index Assay,
under its recently published guidelines.

-- On July 28, 2006, the CombiMatrix group announced that John H.
Abeles, M.D. had joined the Scientific Advisory Board of
CombiMatrix Corporation. Dr. Abeles practiced medicine in
London, before joining the Pharmaceutical Industry as a Senior
Medical Executive, with Pfizer, Inc., Sterling Drug, and
Revlon Health Care. From 1975 until1980, he was a healthcare
analyst with Kidder Peabody and later formed MedVest Inc., a
healthcare consulting firm. Since 1992, Dr. Abeles has been a
Founder and investor in several investment funds for both
venture capital and public equities, whose investments were
centered around healthcare and medical equipment companies. He
also presently serves as a Managing Member of a New York based
investment fund focused on healthcare investments.

-- On August 2, 2006, the CombiMatrix group announced that it had
updated the Species-Specific miRNA product line to version 8.1
of the miRBase Sequence Database published by the Sanger
Institute. The Species-Specific miRNA line includes human,
mouse, rat, arabidopsis, c. elegans, fruit fly, and maize
microarrays. CombiMatrix's miRNAarrays start at $99 per
microarray and are re-usable multiple times.

-- On August 7, 2006, the CombiMatrix group announced that it had
signed a non-exclusive agreement with the Australian Genome
Research Facility (AGRF) under the company's CombiCore(TM)
access program. Under the terms of the agreement, all AGRF
researchers can purchase CombiMatrix CustomArrays(TM) and
CatalogArrays(TM), including arrayprocessing services
performed at the AGRF.

-- On August 14, 2006, the CombiMatrix group announced that it
had begun work on a two-year, $1.9 million contract with the
Army Research Office. Funding from this contract focuses on
the integration of the CombiMatrix group's microarray and
lab-on-a-chip technology for military and homeland security
applications.

-- On August 24, 2006, the CombiMatrix group announced that it
was making available an updated version of its Influenza A
Array. Incorporated into version 3.0 are the new sequences
that have been released by the US Centers for Disease Control
and Prevention (CDC), which include the strains from the
recent infections and deaths inIndonesia.

-- On September 5, 2006, the CombiMatrix group announced that its
subsidiary, CMDX had commercially launched its first molecular
diagnostic service. Physicians are now able to prescribe this
test for their patients. This first offering utilizes CMDX's
Constitutional Genetic Array Test, which can genetically
identify over 50 commongenetic disorders in one test. This
array is already being sold in Europe, and is now being
offered as a service in the US, after internal clinical
validation.

-- On September 19, 2006, the CombiMatrix group announced that it
had signed a non-exclusive agreement with Genome Explorations
of Memphis, Tennessee, under the company's CombiCore(TM)
access program. Under the terms of the agreement, Genome
Explorations is certified as an authorized service provider
for CombiMatrix CustomArray(TM) and CatalogArray(TM) products.
Customers of Genome Explorations can now purchase CombiMatrix
CustomArray and CatalogArray products through Genome
Explorations for services to be rendered by Genome
Explorations.

-- On October 9, 2006, the CombiMatrix group announced that the
2007 Defense Appropriations Bill signed into law by President
Bush includes two new allocations of $1.0M each for the
CombiMatrix group. This funding will support efforts by
CombiMatrix to continue the development and deployment of its
microarray technologies for the detection of biological-threat
agents and infectious pathogens such as the highly pathogenic
Eurasian Influenza A Virus (H5N1).

A conference call is scheduled for today. The Acacia Technologies Group presentation and Q&A will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern). The CombiMatrix Group presentation and Q&A session will start at 2:15 p.m. Pacific Time (5:15 p.m. Eastern).

To listen to the presentation by phone, dial [phone] for domestic callers and [phone] for international callers, both of whom will need to provide the operator with the confirmation code 4409291. A replay of the audio presentation will be available for 30 days at [phone] for domestic callers and [phone] for international callers, both of whom will need to enter the code 4409291 when prompted.

The call is being webcast by CCBN and can be accessed at Acacia's website at www.acaciaresearch.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 52 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

ACACIA RESEARCH CORPORATION
SUMMARY FINANCIAL INFORMATION
(In thousands, except share and per share information)
(Unaudited)

CONSOLIDATED BALANCE SHEET INFORMATION

September 30, December 31,
2006 2005
------------- ------------

Total Assets $107,995 $121,434
============= ============
Total Liabilities $11,037 $14,090
============= ============
Minority Interests $- $447
============= ============
Total Stockholders' Equity $96,958 $106,897
============= ============

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three For the Nine
Months Ended Months Ended
----------------------- -----------------------
September September September September
30, 30, 30, 30,
2006 2005 2006 2005
----------- ----------- ----------- -----------
Revenues:
License fees $8,424 $6,783 $27,512 $11,328
Government contract 725 973 1,563 2,985
Products 968 453 3,050 1,298
Service contracts 151 37 268 106
----------- ----------- ----------- -----------

Total revenues 10,268 8,246 32,393 15,717
----------- ----------- ----------- -----------

Operating expenses:
Cost of government
contract revenues 684 920 1,476 2,820
Cost of product
sales 412 282 973 635
Research and
development
expenses (including
non-cash stock
compensation
expense of $311 and
$797 for the three
and nine months
ended September 30,
2006) 2,819 1,527 7,380 4,082
Marketing, general
and administrative
expenses (including
non-cash stock
compensation
expense of $1,262
and $3,881 for the
three and nine
months ended
September 30, 2006
and $88 and ($23)
for the three and
nine months ended
September 30, 2005) 6,315 4,918 20,086 12,957
Legal expenses -
patents 2,354 1,076 3,803 2,173
Inventor royalties
and contingent
legal fees expense
- patents 2,623 3,939 12,741 5,706
Inventor royalties -
V-chip - 225 - 225
Amortization of
patents 1,596 1,607 4,813 4,407
Write-off of patent-
related intangible
asset - - 297 -
Legal settlement
credits - (211) - (406)
Loss from equity
investments 253 100 786 202
----------- ----------- ----------- -----------

Total operating
expenses 17,056 14,383 52,355 32,801
----------- ----------- ----------- -----------

Operating loss (6,788) (6,137) (19,962) (17,084)
----------- ----------- ----------- -----------

Total other income
(expense) 1,414 597 2,151 1,253
----------- ----------- ----------- -----------

Loss from continuing
operations before
income taxes and
minority interests (5,374) (5,540) (17,811) (15,831)

(Provision) benefit
for income taxes (2) 98 (6) 232
----------- ----------- ----------- -----------

Loss from continuing
operations before
minority interests (5,376) (5,442) (17,817) (15,599)

Minority interests - 1 - 1
----------- ----------- ----------- -----------

Loss from continuing
operations (5,376) (5,441) (17,817) (15,598)

Discontinued
operations:

Estimated loss on
disposal of
discontinued
operations - - - (210)
----------- ----------- ----------- -----------

Net loss $(5,376) $(5,441) $(17,817) $(15,808)
----------- ----------- ----------- -----------

Earnings (loss) per
common share:
Attributable to the
Acacia Technologies
group:
Net loss $(1,049) $(1,558) $(2,359) $(5,192)
Basic and diluted
loss per share (0.04) (0.06) (0.09) (0.20)

Attributable to the
CombiMatrix group:
Net loss $(4,327) $(3,883) $(15,458) $(10,616)
Basic and diluted
loss per share (0.11) (0.12) (0.39) (0.33)

Weighted average
shares:
Acacia Research -
Acacia Technologies
stock:
Basic and diluted 27,567,848 27,302,693 27,492,410 26,387,562
=========== =========== =========== ===========
Acacia Research -
CombiMatrix stock:
Basic and diluted 40,209,640 33,239,726 39,411,421 31,887,872
=========== =========== =========== ===========

ACACIA TECHNOLOGIES GROUP
(A Division of Acacia Research Corporation)
SUMMARY FINANCIAL INFORMATION
(In thousands)
(Unaudited)

GROUP BALANCE SHEET INFORMATION

September 30, December 31,
2006 2005
------------- ------------

Total Assets $68,995 $68,893
============= ============
Total Liabilities $6,257 $6,647
============= ============
Minority Interests $- $443
============= ============
Total Stockholders' Equity $62,738 $61,803
============= ============

GROUP STATEMENTS OF OPERATIONS

For the Three For the Nine
Months Ended Months Ended
------------------- --------------------
September September September September
30, 30, 30, 30,
2006 2005 2006 2005
--------- --------- --------- ----------

Revenues:
License fees $8,424 $6,783 $27,512 $11,328
Other revenue - - - -
--------- --------- --------- ----------

Total revenues 8,424 6,783 27,512 11,328
--------- --------- --------- ----------

Operating expenses:
Marketing, general and
administrative expenses
(including non-cash stock
compensation expense of
$985 and $2,922 for the
three and nine months
ended September 30, 2006
and $123 for the three and
nine months ending
September 30, 2005) 3,562 2,113 10,142 5,482
Legal expenses - patents 2,354 1,076 3,803 2,173
Inventor royalties and
contingent legal fees
expense - patents 2,623 3,939 12,741 5,706
Inventor royalties - V-chip - 225 - 225
Amortization of patents 1,322 1,334 3,991 3,586
Write-off of patent-related
intangible asset - - 297 -
--------- --------- --------- ----------

Total operating expenses 9,861 8,687 30,974 17,172
--------- --------- --------- ----------

Operating loss (1,437) (1,904) (3,462) (5,844)
--------- --------- --------- ----------

Total other income 390 312 1,143 762
--------- --------- --------- ----------

Income (loss) from continuing
operations before income
taxes and minority interests (1,047) (1,592) (2,319) (5,082)

(Provision) benefit for
income taxes (2) 33 (40) 99
--------- --------- --------- ----------


Loss from continuing
operations before minority
interests (1,049) (1,559) (2,359) (4,983)

Minority interests - 1 - 1
--------- --------- --------- ----------

Loss from continuing
operations (1,049) (1,558) (2,359) (4,982)

Discontinued operations:
Estimated loss on disposal
of discontinued operations - - - (210)
--------- --------- --------- ----------

Division net loss $(1,049) $(1,558) $(2,359) $(5,192)
========= ========= ========= ==========

COMBIMATRIX GROUP
(A Division of Acacia Research Corporation)
SUMMARY FINANCIAL INFORMATION
(In thousands)
(Unaudited)

GROUP BALANCE SHEET INFORMATION

September 30, December 31,
2006 2005
------------- ------------

Total Assets $39,000 $52,541
============= ============
Total Liabilities $4,780 $7,443
============= ============
Minority Interests $- $4
============= ============
Total Stockholders' Equity $34,220 $45,094
============= ============

GROUP STATEMENTS OF OPERATIONS

For the Three For the Nine
Months Ended Months Ended
------------------- -------------------
September September September September
30, 30, 30, 30,
2006 2005 2006 2005
--------- --------- --------- ---------

Revenues:
Government contract $725 $973 $1,563 $2,985
Products 968 453 3,050 1,298
Service contracts 151 37 268 106
--------- --------- --------- ---------

Total revenues 1,844 1,463 4,881 4,389
--------- --------- --------- ---------

Operating expenses:
Cost of government contract
revenues 684 920 1,476 2,820
Cost of product sales 412 282 973 635
Research and development
expenses (including non-
cash stock compensation
expense of $311 and $797
for the three and nine
months ended September 30,
2006) 2,819 1,527 7,380 4,082
Marketing, general and
administrative expenses
(including non-cash stock
compensation expense of
$277 and $959 for the three
and nine months ended
September 30, 2006 and
($35) and ($146) for the
three and nine months ended
September 30, 2005) 2,753 2,805 9,944 7,475
Amortization of patents 274 273 822 821
Legal settlement credits - (211) - (406)
Loss from equity investments 253 100 786 202
--------- --------- --------- ---------

Total operating expenses 7,195 5,696 21,381 15,629
--------- --------- --------- ---------

Operating loss (5,351) (4,233) (16,500) (11,240)
--------- --------- --------- ---------

Other income (expense):
Interest and investment
income 111 122 429 328
Loss on sale of interest in
subsidiary - - (84) -
Warrant gains (charges) 913 163 663 163
--------- --------- --------- ---------

Total other income
(expense) 1,024 285 1,008 491
--------- --------- --------- ---------

Loss from operations before
income taxes (4,327) (3,948) (15,492) (10,749)

Benefit for income taxes - 65 34 133
--------- --------- --------- ---------

Division net loss $(4,327) $(3,883) $(15,458) $(10,616)
========= ========= ========= =========

Source: Acacia Research Corporation















NASDAQ Toolbar | © Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search

[DagobertDuck57]

Schaut euch mal die heutige News an
http://www.combimatrix.com/pr/111006.pdf

[radic]

Antwort auf Beitrag Nr.: 25.264.787 von DagobertDuck57 am 10.11.06 18:06:10

danke

[radic]

und tatsächlich

sie reagiert

[whyso]

Antwort auf Beitrag Nr.: 25.358.634 von radic am 13.11.06 14:22:00

Phase 1- von insgesamt 5...

[buyer10]

Antwort auf Beitrag Nr.: 25.362.033 von whyso am 13.11.06 17:01:19

Hallo whyso,

Phase 1- von insgesamt 5...

.....kapier ich nicht. War das ein Witz oder was meinst Du damit?

Ich bin von meinen 2 Biotech- Knallern stark enttäuscht worden. Bis jetzt waren es eher Knallfrösche!!

Die eine ist eben CBMX, die 2.=Genta, wobei ich bei letzterem doch noch Hoffnung habe, dank Infos von Welke.

CBMX hatte ich schon so gut wie abgeschrieben.
Was macht Dich so zuversichtlich?

Bitte Info - Danke

Schöne Grüsse
buyer10

[whyso]

Antwort auf Beitrag Nr.: 25.364.275 von buyer10 am 13.11.06 18:22:35

Hi Buyer10...sehe der Boardmail unten von 18.10. nach ein Gespräch mit Kumar stateside:

Nachricht von whyso am 18.10.2006 22:37 ------

Hi E.1, hi Radic,

ich habe heute Abend vieles erfahren, ich muss das ganze etwas zu recht legen & n\'bissl sachen lassen(wir sprachen glatte 35 minuten miteinander) Fünf Produkte sind in die Pipeline z.Zt, wir haben ein Europaischen Partner in Frankreich, "ArrayGenomics" die jetzt schon Produkt bezieht zum wholsesale Preisen von CBMX, und diese dann weiter verkauft als reseller fungieren...diese Produkt kommt demnächst auch auf dem Amerikanischen Markt zum vorschein. Array Genomics hat Produkt für 235.000$ bereits bezogen, der MD dort ist der ehemalige CEO von Abbot technologies...das lässt mein Anlegerherz etwas höher schlagen!!!

Es gibt ein interessierte Großinvestor der sich einen Einstieg in CBMX zurzeit in Erwägung zieht (insbesondere bei diese niedrige Sharepreis Gestaltung)-talks sind hierbei angeblich weit fortgeschritten.

Beim upcoming Konferenzcall & Quartalsbereicht, wird Kumar ein sehr interessanter Gesichte zu erzählen haben: ein kleines 4 jährige mädchen die bereits von ihr eigene Facharzt als totkrank an Leukamie leidened diagnostiert wurde, hat durch ein CBMX array test ein GANZ ANDERE ERGEBNIS binnen 48 std erhalten, und jetzt mittels eine entsprechende Diat-Umstellung bis ins höhen Alter sich beste Gesundheit erfreun soll/wird...die Eltern von dieses Kind sind natülich komplett erleichtert & wollen die CBMX story laut und breit erzählen, ich glaube das wird sehr gut rüberkommen in good old Amerika.

Geld ist vorhanden bis mitte nächstes Jahr, keine weiter pipes sind bis dahin geplant -(weder mit Cornell noch mit jemand anderes)-auch keine reverse splitt bis dahin.

Die Trennung von Acacia bedarf ein Gehnehmigung von der IRS, und dieses soll bis ende Novemeber (Steuerrechtlichte Auslegung???) vorliegen...hier war er recht wage, und wollte sich absolut nicht festlegen wieso das ganze solange andauert.

Er sagte der Markt hat bis heute gar nicht geglaubt das Combimatrix überhaupt in die lage sei ein Produkt raus zu bringen, und so kommt der wacklige Börsen-Bewertung momentan zur stande im fallende shareprice reflektiert....er sieht drei von die Fünf kommende Produkte als zugelassen an & im Markt erhältlich bevor Weihnachten. Der US Leukamie test wird offizielle bis ende der 2nd Quartal 07 im Umlauf gebracht!

Er denkt mit der heutigen FDA ZUlassung das Geld & Vertrauen in der Wert wieder zurückfliessen wird-langsam aber dafür sicher!

Thats it for now-jeder muss es natürlich selber wissen wie er/sie weiterhandelt.

Viele Grüße & wer schreibfehler findet darf sie ruhig behalten-(ich lese das ganze hier nicht einmal wieder durch-"gespostet wie geschrieben")

Bis die Tage & good trades wünscht Euch,
Whyso

[nort.]

Sie wacht auf

This exciting new test represents a breakthrough in the field of dermatology," said Dr. Scott Binder, M.D., Professor of Clinical Pathology and Dermatology, Chief of Dermatopathology, and Senior Vice Chairman at the David Geffen School of Medicine at UCLA. "As a dermatopathologist I am often called upon to make very difficult decisions regarding whether or not a patient has malignant melanoma, particularly after traditional laboratory methods have failed to provide a clear diagnosis. This test from CombiMatrix Molecular Diagnostics provides me with a powerful new tool to help resolve many of these tough cases."

"Melanoma is the fastest growing cancer in the United States, and like most cancers early identification and detection is an important factor in survival. We are encouraged that this new test is now available to physicians and patients in our battle against this often fatal disease," said Karen Graham, the Founder and Chairperson of the William S. Graham Foundation for Melanoma Research. "I founded the William S. Graham Foundation in honor of my son, Billy, who died as a result of the mis-diagnosis of melanoma. Had this test been available then, the outcome might have been different."

"We are very excited about the release of this powerful new diagnostic service," said Matt Watson, CEO of CombiMatrix Molecular Diagnostics. "This is the second microarray service that we have launched in as many calendar quarters, and it is only the first in a broad menu of array-based cancer tests that we hope to release in the near future."

[RazorLux]

Hallo Heute werden die 1 Dollar Marke wieder testen. Hoffentlich schliessen wir in den USA drüber

[schappi64]

wir stehen kurz davor.hoffendlich gehts auch drüber.

[RazorLux]

Antwort auf Beitrag Nr.: 25.464.911 von schappi64 am 16.11.06 18:44:54

11/16/2006 04:04 PM
Last:0.910Change:-0.05
Change:-5.21%
High:0.99
Low:0.9
Volume:371,801

Naja, für heute hat es nicht gereicht . Hoffentlich geht die Talfahrt jetzt nicht weiter

[whyso]

Kumar handelt wieder


http://pro.edgar-online.com/Profile.aspx?ticker=cbmx

und hier mit 30K Accacia shares:
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3…

Naja, jetzt läuft wieder "irgendwas" anscheint-Paul Ryan hat am 14.Nov gehandelt!

Schönes WE,
Whyso

[RazorLux]

Antwort auf Beitrag Nr.: 25.502.652 von whyso am 18.11.06 11:06:38

Hy whyso. Hoffe doch sehr, dass wir die 1-Dollar-Marke nächste Woche hinter uns lassen
Bis dahin,
schönes Wochenende

[zelltim]

Antwort auf Beitrag Nr.: 25.502.652 von whyso am 18.11.06 11:06:38

Tm Bioscience reports positive results confirming utility of respiratory viral panel to detect and discriminate Influenza A-H5 (bird flu) in patient samples

TSX: TMC

TORONTO, Nov. 23 /CNW/ - Tm Bioscience Corporation (TSX: TMC), a leader
in the commercial genetic testing market, today announced results from
clinical testing relating to high discriminating ability of the ID-Tag(TM) RVP
with regards to the highly pathogenic H5 subtype of the influenza A virus.
This virus is the focus of the current pandemic threat being monitored through
the World Health Organization.
The primary aim of the European arm of the multi-national clinical study
sponsored by Tm was to collect data on viruses that are underrepresented in
the general population, including the H5 subtype of Influenza A. This was
achieved by including archived samples in the study, which had an overall
recruitment of more than 1000 unique patient specimens. Results have confirmed
the ability of the ID-Tag(TM) RVP to detect the bird flu virus in all positive
clinical samples tested (0% false negative rate for H5). Additionally, the
majority of patient samples tested by the ID-Tag(TM) RVP across both the
European and North American arms of the clinical trial were probed for
Influenza A-H5. There were no false positive results observed in any of these
samples.
"This seminal study definitively establishes the ID-Tag(TM) RVP as a
rule-in / rule-out test in the area of respiratory virus testing," said Dr.
Richard Janeczko, Chief Scientific Officer of Tm Bioscience. "In addition, our
collaboration with one of the world\'s leading centres for research on avian
influenza has confirmed that this test can accurately detect the H5 subtype of
Influenza A in samples originally collected from patients infected with
mutated strains that were responsible for human outbreaks in Vietnam, Hong
Kong and Indonesia."
"The productive collaborations that we\'ve had with world renowned
virology laboratories have helped Tm establish a strong footprint in the area
of infectious disease testing, which represents the majority of the market for
molecular diagnostics. These laboratories are also part of the integrated
network of health care professionals that are crucial in managing epidemics
like the recent SARS crisis experienced in many countries," said Mr. Greg
Hines, President and CEO of Tm Bioscience. "Our investment in this clinical
trial program and related regulatory submissions for the ID-Tag(TM) RVP
product has set the stage for this test to become a worldwide standard."
The ID-Tag(TM) RVP is a proprietary test that, in a single patient
sample, simultaneously probes up to 20 distinct viral sequences that represent
more than 95 percent of all circulating respiratory viruses. Viruses targeted
by the ID-Tag(TM) RVP include those that are important for patient management
in addition to those monitored by public health authorities and pandemic
surveillance programs, such as SARS and influenza A-H5 (the subtype associated
with avian influenza - "bird flu").
The ID-Tag(TM) RVP has been designed in such a way to enable, through a
single test on a patient sample, discrimination of the H5 subtype of influenza
A from the subtypes generally seen in the human population (H1, and H3). It
also discriminates influenza A from a panel of respiratory viruses, including
those with similar clinical presentations. The fact that the ID-Tag(TM) RVP
can provide a definitive result in six hours will allow public health
authorities to rapidly implement infection control measures in the event of a
highly contagious agent being identified.

The Tm Bioscience ID-Tag(TM) Respiratory Viral Panel (RVP) - Differential
Diagnosis Made Easy
The ID-Tag(TM) RVP from Tm Bioscience is a reliable and cost-effective
test designed to play a key role in patient management, infection control and
in countering the pandemic threat of respiratory diseases, all with results in
less than six hours.
In addition to CE marking in Europe, the Company is focused on gaining
regulatory clearance from the FDA for the ID-Tag(TM) RVP as an in vitro device
(IVD) in the United States and is also working towards Health Canada approval.
The CE marked IVD product probes for 20 viral sequences and Tm is seeking a
license for an equivalent IVD product in Canada. In the United States, the IVD
application is for a product which excludes the SARS sequence.
In January 2006, Tm Bioscience made the ID-Tag(TM) RVP commercially
available as an IUO (Investigational Use Only) device. Most recently, the
Company has signed distribution agreements for ID-Tag(TM) RVP in the
Netherlands, Scandinavia, Greece and Turkey. Tm anticipates securing
additional distribution agreements for the product with the goal of making the
test available globally.
For more information, visit the newly launched ID-Tag(TM) website,
www.idtag.tmbioscience.com.

About Tm Bioscience - Putting the Human Genome to Work(TM)
Tm Bioscience (TSX: TMC) is a Toronto-based diagnostics company
developing a suite of DNA-based tests for genetic disorders, drug metabolism
(pharmacogenetics) and infectious diseases.
Tm Bioscience has developed and commercialized Analyte Specific
Reagents(*) and a series of Tag-It(TM)(xx) tests for a variety of genetic
disorders. These tests are based on Tm Bioscience\'s proprietary Tag-It(TM)
Universal Array platform, which utilizes a proprietary universal tag system
that allows for easy optimization, product development and expansion.
Tm Bioscience\'s Cystic Fibrosis (CF) test is the first multiplexed human
disease genotyping test to be cleared by the FDA as an in vitro device (IVD)
for diagnostic use in the U.S. It has also received CE mark certification and
Health Canada clearance, allowing the test to be marketed for diagnostic
purposes in the European Union and Canada. In addition, the Company is
developing a companion test for the blood-thinning drug warfarin and a test
for patients under treatment for sepsis.
For more information, visit http://www.tmbioscience.com.

(*) Analyte Specific Reagent. Analytical and performance characteristics
are not established.
(xx) For Investigational Use Only. The performance characteristics of
these products have not been established.

Forward-Looking Statements
This press release contains information that is forward-looking
information within the meaning of applicable securities laws. In some cases,
forward-looking information can be identified by the use of terms such as
"may", "will", "should", "expect", "plan", "anticipate", "believe", "intend",
"estimate", "predict", "potential", "continue" or the negative of theses terms
or other similar expressions concerning matters that are not historical facts.
In particular, statements about the timing of the anticipated launch of
ID-Tag(TM) RVP, its expected role as a cornerstone diagnostic product and as a
tool to manage pandemic threats and the expected regulatory status for
ID-Tag(TM) RVP in the United States and Canada, are or involve forward-looking
information.
Forward-looking information is based on certain factors and assumptions.
In particular, in making the statements in this press release, the Company has
assumed that the ID-Tag(TM) RVP will receive U.S. FDA approval in 2006 or
early 2007, that the Company will be able to develop and manufacture
sufficient quantities of its ID-Tag(TM) RVP and that market penetration of
ID-Tag(TM) RVP will be such that it will serve a key role in the management
and treatment of patients infected by respiratory viruses. While the Company
considers these assumptions to be reasonable based on information currently
available to it, they may prove to be incorrect.
Forward-looking information, by its nature necessarily involves risks and
uncertainties including, without limitation, the difficulty of predicting
regulatory approvals, the timing and conditions precedent to obtaining any
regulatory approval, market acceptance and demand for new products, the
availability of appropriate genetic content and other materials required for
the Company\'s products, the Company\'s ability to manufacture its products on a
large scale, the protection of intellectual property connected with genetic
content, the impact of competitive products, currency fluctuations, risks
associated with the Company\'s manufacturing facility and any other similar or
related risks and uncertainties. Additional risks and uncertainties affecting
the Company can be found in the Company\'s 2005 Annual Report, available on
SEDAR at www.sedar.com. If any of these risks or uncertainties were to
materialize, or if the factors and assumptions underlying the forward-looking
information were to prove incorrect, actual results could vary materially from
those that are expressed or implied by the forward-looking information
contained herein. The Company disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, Future events or otherwise.

%SEDAR: 00005375E

[nort.]

hmmm, scheint so, dass es wieder losgeht...

Südkorea bestätigt Ausbruch der Vogelgrippe

http://www.donaukurier.de/nachrichten/wissenschaft/art201,15…

[nort.]

hier sollte was zu holen sein...

[nort.]

Neu eingekauft seit 30.9.06:

CREDIT SUISSE 9/30/2006 737,112 737,112 New $691


OPPENHEIMER & CO INC 9/30/2006 204,000 204,000 New $191

[radic]

danke für infos

[DagobertDuck57]

Uiijuiiijuiiiiiiii, das Sorgenkind lebt noch

[lake]

Acacia Technologies Licenses Multi-Dimensional Bar Code Technology to Unilever

NEWPORT BEACH, Calif., Dec 26, 2006 (BUSINESS WIRE) --
Acacia Research Corporation (Nasdaq:ACTG) (Nasdaq:CBMX) announced today that VData, LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has entered into a license with Unilever covering a portfolio of patents that apply to certain multi-dimensional bar codes. The portfolio of patents is owned by VCode Holdings, Inc., a wholly-owned subsidiary of Veritec, Inc. (OTC:VRTC), from whom VData, LLC has been granted the exclusive right and power to license and enforce the patent portfolios.

The multi-dimensional bar code technology generally relates to the generation of, encoding, capturing the image of and decoding a data matrix consisting of an array of data cells with a border. The data matrix can contain a variety, amount, and depth of information that would not fit onto an ordinary bar code. This patented technology has many applications such as tracking the movement of products or verification of the unique identity of persons.

Viel Erfolg im neuen Jahr wünscht allen

lake

[nort.]

[sensolight]

hallo,

weiß jemand hierzu Genaueres?

---------------------------------------------------------------

WASHINGTON, Dec 26 (Reuters) - CombiMatrix Corp., a wholly owned subsidiary of Acacia Research Corp. (ACTG.O: Quote, Profile , Research), on Tuesday filed with the U.S. Securities and Exchange Commission plans to split itself from the parent company.

CombiMatrix, according to a filing with the U.S. Securities and Exchange Commission, said it will apply to list its common stock on the American Stock Exchange under the symbol "CBMX."

The Mukilteo, Washington-based life sciences company said no stockholder approval is required.

Acacia Research, based in Newport Beach, California, is primarily made up of wholly owned subsidiaries and limited liability companies.

----------------------------------------------------------------

.........senso

[nort.]

Antwort auf Beitrag Nr.: 26.551.939 von sensolight am 29.12.06 17:02:38

CombiMatrix wants to split from parent company
Puget Sound Business Journal (Seattle) - 10:50 AM PST Wednesday

Biotechnology company CombiMatrix plans to split off from its parent company, Acacia Research Corp. of Newport Beach, Calif., according to a Dec. 26 filing with the U.S. Securities and Exchange Commission.

Mukilteo-based CombiMatrix, which makes semiconductor-based microarrays to identify genes and proteins, is currently a subsidiary of Acacia (NASDAQ: ACTG).

CombiMatrix shares are now traded on the NASDAQ as a separate class of Acacia stock called AR-CombiMatrix. Under the split-off plan, each share of AR-CombiMatrix will be redeemed for one share of the new stand-alone company, according to the SEC filing.

CombiMatrix Corp. will apply to list its common stock on the American Stock Exchange under the symbol "CBMX," according to the filing.

CombiMatrix reported losses of nearly $15.5 million on revenue of $4.9 million for the nine months ended Sept. 30, 2006.


http://www.bizjournals.com/seattle/stories/2006/12/25/daily1…

[sensolight]

Antwort auf Beitrag Nr.: 26.597.704 von nort. am 31.12.06 08:07:18

Also 1:1 Aktientausch, wenn ich das richtig sehe.
Weiß jemand mehr zu den Hintergründen?
-------
senso

[nort.]

Antwort auf Beitrag Nr.: 26.634.721 von sensolight am 02.01.07 11:51:25

Seit einem Jahr gibt es das Ziel, dass Combimatrix sich von der Accacia trennt und eigenständig notiert wird. Dass es jetzt so weit ist, ist absolut als positiv zu sehen. Das ursprüngliche Ziel war Q3/06 für diesen Schritt.

[sensolight]

Antwort auf Beitrag Nr.: 26.634.790 von nort. am 02.01.07 11:56:20

ja, aber warum? und zu welchen Kosten?
Eine eigenständige Aktie ist es ja schon lange. Wobei
"die anderen Acacia" sich ja wesentlich besser entwickeln!
Ich hatte schon einmal überlegt, ob CBMX dafür da ist, Verluste
aufzusaugen, damit "die andere Acacia" sauber gehalten werden kann.

------
senso

[nort.]

Antwort auf Beitrag Nr.: 26.638.373 von sensolight am 02.01.07 16:23:54

Die andere Acacia ist Ryan's Baby. Schon deshalb ist eine selbständige CBMX vom Vorteil

[buyer10]

Antwort auf Beitrag Nr.: 26.638.411 von nort. am 02.01.07 16:26:17

Die andere Acacia ist Ryan\'s Baby. Schon deshalb ist eine selbständige CBMX vom Vorteil

Hi nort.,

also diesen Satz verstehe ich wirklich nicht. Was meinst Du damit?

Außerdem sehe ich es genauso wie sensolight:
was soll das bringen?

Mir kommt es auch so vor, daß in CMBX der Schrott hineinkommt.

Siehe Chart, das sagt mir alles!

[nort.]

Antwort auf Beitrag Nr.: 26.655.329 von buyer10 am 03.01.07 14:56:51

Siehe Chart, das sagt mir alles!

Eben. Mit ACTG zusammen hat es nicht funktioniert. CBMX war ein Stiefkind und Kumar konnte nicht so aggieren, wie er wollte. Es kann nicht mehr schlechter laufen....

[nort.]

Antwort auf Beitrag Nr.: 26.656.022 von nort. am 03.01.07 15:29:50

sehen anscheinend auch andere so

https://isht.comdirect.de/charts/big.chart?hist=10d&type=can…

[nort.]

Antwort auf Beitrag Nr.: 26.657.393 von nort. am 03.01.07 16:25:01

http://finance.yahoo.com/q?s=CBMX

+10%

[buyer10]

Antwort auf Beitrag Nr.: 26.657.467 von nort. am 03.01.07 16:28:08

Folgende Antwort bezieht sich auf Beitrag Nr.: 26656022 von nort. am 03.01.07 15:29:50
--------------------------------------------------------------------------------
sehen anscheinend auch andere so


Tja, das kommt ja wie auf Kommando!

Hast Du Dich mit der Aktie intensiver beschäftigt?

Wo siehst Du die kurz- bis mittelfristigen Kurse bei CMBX?

Sollte man auf diesem Niveau nachlegen?


Schöne Grüsse

buyer

[nort.]

Antwort auf Beitrag Nr.: 26.658.204 von buyer10 am 03.01.07 16:59:24

Charttechnisch ist es im Moment interessant. Habe allerdings mein Limit erreicht. Vor einem Jahr habe ich gute Gewinne eingefahren, als die Aktie um die 2,5$ stand. Ich denke hier wird es durchaus noch interessant...

[nort.]

Antwort auf Beitrag Nr.: 26.659.048 von nort. am 03.01.07 17:32:24

Boden wurde bestätigt, jetzt sehen wir mal wie weit es nach oben geht...

[derwolf1]

Purchase Acacia Research - CombiMatrix Warrants (right to buy) 2006-12-08 2006-12-13 2011-12-13 2006-12-12
14:11:32 ACACIA RESEARCH CORP ACTG KUMAR AMIT Pres/CEO of CombiMatrix Corp.
Director 300,000 $0.87 300,000

[nort.]

Nach Grippewelle Tamiflu®-Welle?

Umweltschützer befürchten, dass nach einer Grippewelle die Gewässer mit hohen Konzentrationen von Oseltamivir (Tamiflu®) belastet werden, was die Resistenzbildung von H5N1 bei Vögeln begünstigen könnte. Einer ersten Grippewelle könnte dann eine zweite mit resistenten H5N1-Viren folgen.

Hintergrund für dieses Szenario sind Berechnungen, die vom Centre for Ecology & Hydrology in Oxford erstellt wurden. Ausgehend davon, dass im Falle einer Grippeepidemie die großen Mengen an eingelagertem Oseltamivir auch verbraucht werden, werden vor allem in den Gewässern in der Umgebung von Großstädten hohe Oseltamivir-Carboxylat-Konzentrationen erwartet. Oseltamivir wird in Form seines aktiven Metaboliten Oseltamivir-Carboxylat zu 70% über die Nieren ausgeschieden. Die in den Gewässern erreichten Konzentrationen sollen den Hochrechnungen zufolge ausreichen, um bei den Vögeln, die dieses Wasser trinken, virustatisch zu wirken. Die Herstellerfirma Roche scheint die Befürchtungen der Umweltforscher nicht zu teilen. Sie geht davon aus, dass Oseltamivir-Carboxylat sehr schnell zerfällt und die für eine Wirkung notwendigen Konzentrationen nicht erreicht werden.

Quelle: Singer, A. C. et al: Environmental Health Perspectives. 115, 102 - 106 (2007


Verdacht auf Vogelgrippe in Japan

Die japanische Regierung will wegen eines Falls von möglicher Vogelgrippe Geflügelfarmen im ganzen Land untersuchen lassen. Anlass ist der Tod von rund 750 Hühnern auf einer Geflügelfarm mit rund 12.000 Tieren in der südlichen Provinz Miyazaki.

Das Agrarministerium vermutet den Ausbruch von Vogelgrippe und richtete heute einen Einsatzstab ein. Weder bei den Angestellten der betroffenen Geflügelfarm noch bei ihren Familien sind laut Medien bisher gesundheitliche Probleme aufgetreten.

Zweiter tödlicher Vogelgrippefall in Indonesien
In Indonesien ist bereits der zweite Patient in diesem Jahr an Vogelgrippe gestorben. Eine 37-jährige Hühnerhändlerin, die am 30. Dezember ein infiziertes Huhn gekocht und gegessen hatte, starb nach Angaben der Gesundheitsbehörden heute in einem Krankenhaus in Jakarta.

Am Mittwoch war ein 14-jähriger Junge aus einem Dorf in Westjava an Vogelgrippe gestorben. Mit 59 Todesfällen ist Indonesien das weltweit am schwersten betroffene Land.

[lake]

05:12 13.01.2007, aktualisiert um 13:06
Vogelgrippe-Todesfälle in Indonesien - Verdacht in Japan bestätigt


In Indonesien sind in diesem Jahr bereits vier Menschen an der Vogelgrippe gestorben. Eine 27-Jährige sei am späten Freitagabend, eine 22-Jährige am heutigen Samstag an dem gefährlichen Virus gestorben, teilten die Behörden mit. Anzeige
Anzeige[sda] - Beide Frauen waren zuvor in einem Spital in Jakarta behandelt worden. "Sie sind an Vogelgrippe gestorben", sagte ein Vertreter des Informationszentrums für Vogelgrippe im indonesischen Gesundheitsministerium.

Zuvor war bereits eine 37 Jahre alte Hühnerhändlerin gestorben. Am Mittwoch war ein 14-jähriger Junge aus einem Dorf in Westjava an dem Virus gestorben. Damit ist Indonesien mit 61 von weltweit 150 Todesfällen das am stärksten betroffene Land.

Unterdessen hat Japan einen neuen Fall von Vogelgrippe gemeldet. Nach dem Tod einer grossen Zahl von Hühnern auf einer Geflügelfarm mit 12 000 Tieren in der südlichen Provinz Miyazaki habe sich der Verdacht auf Vogelgrippe bei Untersuchungen des nationalen Instituts für Tiergesundheit bestätigt, wie japanische Medien berichteten.

Nach Angaben der Provinzregierung handelt es sich um den Virus-Typ H5. Sie hatte zuvor für den bestätigten Fall von Vogelgrippe angekündigt, rund 10 000 der übrigen Tiere auf der Farm töten zu lassen. Es ist der fünfte Fall von Vogelgrippe in Japan.

Zuletzt hatte es in Japan Anfang vergangenen Jahres einen Fall von Vogelgrippe gegeben, wobei es sich dabei um den schwächeren Virustyp H5N2 handelte, wie Medien unter Berufung auf das Agrarministerium berichteten.

Todesopfer unter Menschen in Folge von Vogelgrippe gab es in Japan bislang nicht. Nach dem jüngsten Fall hatte die Regierung in Tokio eine landesweite Überprüfung von Geflügelfarmen angeordnet.

Gruss lake

[derwolf1]

Habe im Yahoo Board gelesen das diese Woche evtl.
CBMX delisted wird.

Weiß jemand was darüber....

[buyer10]

Antwort auf Beitrag Nr.: 27.103.614 von derwolf1 am 22.01.07 08:47:59

Habe im Yahoo Board gelesen das diese Woche evtl.
CBMX delisted wird.

Weiß jemand was darüber....



Würde mich nicht wundern bei dieser D.....Aktie!!

Hab mir hier die Finger so richtig verbrannt.(sowie bei Genta)

Mit den Biotechs läuft zur Zeit gar nicht rund.

Siehe z.B. YM Bio (heute - 54%) und bei Hana gehts schon seit Wochen nur nach Süden.

Mal schaun wie' s so weitergeht - kann ja (hoffentlich) nur besser werden.

Also von einer Kursrakete habe ich mir mehr erwartet und werde auch so schnell keine mehr anfassen

Hat jemand neue Infos über Cmbx?

Wenn ja - bitte Info

Schöne Grüss

buyer10

[lake]

Vogelgrippe kommt immer näher. Wer kann als erster ein wirksames Mittel anbieten??

Neuer Vogelgrippe-Ausbruch in Grossbritannien


In Grossbritannien ist erneut die Vogelgrippe ausgebrochen. Der Erreger der H5-Untergruppe sei auf einer Geflügelfarm im Osten Englands gefunden worden, erklärten die britischen Behörden. Anzeige
Anzeige[sda] - Erste Tests hätten Vogelgrippe als Ursache für den Tod von Tieren des Geflügelhofs bestätigt. Derzeit werde geprüft, ob es sich um die aggressive Virus-Variante H5N1 handle. Die Behörde ordnete Massnahmen an, um den Geflügelbestand zu isolieren. Gemäss der Presseagentur Press Association könnten bereits rund 1000 Truthähne der Farm der Seuche erlegen sein.

Im März vergangenen Jahres war bei einem toten Wildschwan in Schottland der auch für Menschen gefährlich H5N1-Erreger diagnostiziert worden. An H5N1 sind seit 2003 mindestens 164 Menschen gestorben, die meisten von ihnen in Asien.

200 Millionen Vögel verendeten an der aggressiven Form der Vogelgrippe oder wurden vorsorglich getötet. In der Europäischen Union wurde der erste H5N1-Fall in diesem Jahr vor eineinhalb Wochen bei Gänsen in Ungarn nachgewiesen.

Gruss lake

[DagobertDuck57]

Antwort auf Beitrag Nr.: 27.103.614 von derwolf1 am 22.01.07 08:47:59

Oder vielleicht kommt auch ein Reverse-Split
Ist jedenfalls nicht normal, was die abziehn

[DagobertDuck57]

Antwort auf Beitrag Nr.: 27.393.880 von DagobertDuck57 am 03.02.07 15:13:07

Geht mal zu investorshub
http://www.investorshub.com/boards/read_msg.asp?message_id=1…
Ist meiner Meinung nach informativer als dieses Yahoogeschwätz ala Bfire und Konsorten.

[nort.]

[DagobertDuck57]

Der letzte macht dann (heute noch) das GAP zu

http://finance.yahoo.com/q/bc?s=CBMX&t=5d

[nort.]

Antwort auf Beitrag Nr.: 27.726.498 von DagobertDuck57 am 15.02.07 17:01:56

run away GAP?

[e.1]

weiß jemand was?
gibt es bestimme nachrichten oder hat es mit der vogelgrippe anst zu tun.
aber bei dem anstieg müßte doch ein gewichtiger grund vorliegen.

würde mich freuen, wenn jemand was dazu schreiben könnte.

gruß e.1

[zillus]

Antwort auf Beitrag Nr.: 27.726.959 von e.1 am 15.02.07 17:24:23

also --was soll denn das ??? entweder wollte einer unbedingt rAUS ODER REIN--WAS MEINT Ihr ?

[GerdKill]

schaut euch mal die Umsätze an der NQ in den ersten 5Minuten an!
Da ist doch was im Busch...
Gruss

[GCEnte]

Hm, weiß jemand, was hier los ist?
Habe die Dinger schon seit einem Jahr und würde mich ja durchaus freuen, wenn statt 50% vielleicht nur noch 30% dastünden - auch wenn ich schon mal 50% Pkus hatte....

[powerchord]

Antwort auf Beitrag Nr.: 27.733.080 von GCEnte am 15.02.07 22:07:28

habe solcher art kursbewegungen schon öfters unmittelbar vor übernahmen beobachten können. mal sehen ob wir heute in form einer news aus dem hause cbmx aufgeklärt werden. unabhängig davon ist der derzeitige kurs eine eklatante unterbewertung. den dollar sollten wir die nächsten wochen so oder so überwinden können.

keep your shares

[nort.]

Someone opened the trading day with a block trade of 1.5 million at $1.85. No way that's a trading manipulation or momentum play for a day. Some one took a big position in CBMX today. We will have good, confirming news.

[zillus]

Antwort auf Beitrag Nr.: 27.737.002 von powerchord am 16.02.07 07:24:04

Ja, aber warum schmiert der Kurs danach so dermaßen wieder ab ?

[nort.]

Antwort auf Beitrag Nr.: 27.737.367 von nort. am 16.02.07 07:42:40

Im AH ging es weiter so...

http://dynamic.nasdaq.com/dynamic/afterhourma.stm

[radic]

supermerkwürdig,

irrer Sprung und dann wieder runter und trotzdem noch hoch. Andererseits auch kein Wunder, hab ich doch letzte Woche die Hälfte gegeben.

Ob ich die mir jetzt nochmal ein paar zurückhol? Damned

Richtig ist: entweder will einer raus und investiert dafür oder..

Ev. kommt ja auch der Split oder.. oder.. die Chanchen kennen wir ja, ciao, we'll see

[GerdKill]

Antwort auf Beitrag Nr.: 27.738.396 von radic am 16.02.07 08:37:30

Moin radic -
bist Du der von QSC?
Wenn ja, beste Grüsse eines Ex-QSClers!
Gerd

[sensolight]

Sieht ja lustig aus... weiß wohl im Moment auch keiner
so recht, wie er hier in D. taxen soll...

Von 0,53 bis 0,89 alles dabei....die 0,66 im FHM Ask
sind schon fast ein Schnäppchen.....hmmm

Aber null Infos.(?)

[sensolight]

und 0,62 gehen übern Tisch....mann was´n Blindflug.

[GerdKill]

http://biz.yahoo.com/bw/070216/20070216005110.html?.v=1

Acacia Research to Release Fourth Quarter Financial Results and Host Conference Call
Friday February 16, 6:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today it will release its fourth quarter financial results on Wednesday, February 21, 2007. Results will be released at the close of trading on the NASDAQ national market.
ADVERTISEMENT


A conference call is scheduled for the same day.

The Acacia Technologies Group presentation and Q&A will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern).

The CombiMatrix Group presentation and Q&A session will start at 2:15 p.m. Pacific Time (5:15 p.m. Eastern).

To listen to the presentation by phone, dial [phone] for domestic callers and [phone] for international callers, both of whom will need to provide the operator with the confirmation code 5946001. A replay of the audio presentation will be available for 30 days at [phone] for domestic callers and [phone] for international callers, both of whom will need to enter the code 5946001 when prompted.

The call is being webcast by CCBN and can be accessed at Acacia's website at www.acaciaresearch.com.

[whyso]

Bookmark... http://finance.yahoo.com/q?s=cbmx
Schönes WE,
Whyso

[GerdKill]

heute wieder 150k an der NQ zum Handelsstart aus dem ask gerissen.
Das waren doch keine Zocker?!

[nort.]

Die Aktie ist der absolute Hammer. Da kann kommen was will, das Ding liegt wie Blei am Boden



Dieser Chart kommt in meine best of...

[powerchord]

Antwort auf Beitrag Nr.: 27.756.563 von nort. am 16.02.07 19:00:54

die anzeichen verdichten sich daß der split eventuell schon nächste woche verkündet wird. die CBMX group müsste dann ja neu bewertet und an der AMEX gelistet werden. das interessanteste dabei wird der erste kurs sein unter dem man CBMX kaufen kann. vermute der wird um einiges höher sein als der jetzige. würde die dubiosen aufkäufe erklären. mein bauchgefühl sagt mir jetz nur nicht rausdrängen lassen denn im ersten quartal 2007 sollte sich einiges heir bewegen. mein persönliches kursziel für heuer liegt auf jeden fall über 3USD. wer das für überhöht ansieht sollte sich mal ansehen wo die aktie herkommt und welch zahlungskräftige fixkunden im hintergrund schon vorhanden sin (stichwort us regierung, NASA). dies soll keine aufforderung zum kauf sein sondert spiegelt nur die bescheidene meinung eines wachsamen börsioaners wider

good trades and steady hands an alle

[nort.]

Antwort auf Beitrag Nr.: 27.756.926 von powerchord am 16.02.07 19:09:27

3$ überhöht? Nein das sicherlich nicht. Nur langweilt mich die Geschichte mit dem Split langsam schon. Seit über einem Jahr läuft das Gefassel mit dem Split und Kumar ist nicht in der Lage hier endlich mal den Deckel draufzumachen. Für mich ist das, was die letzten 12 Monate ablief eine einzige Manipulation.

Was die Aktie für Potential hat, hat man am gestrigen Beispiel gesehen. Nov 05 hatten wir schon mal 80% Anstieg an einem Tag. Das Ergebnis war das gleich wie heute.... Pustekuchen.

Kann zwar noch behaupten einer der wenigen zu sein, der auch realisierte Gewinne mit CBMX eingefahren hat. Nur leider dann auf die Unterstützungslinie verlassen und wieder hinzugekauft...

Vielleicht hat ja Kosto am Ende doch Recht - "An der Börse gibt es Schmerzensgeld. Erst kommen die Schmerzen und dann das Geld..."

Wird Zeit, dass die Geschichte hier endlich den planmäßigen Lauf annimmt....

[hedger_de]

NEWS-NEWS-NEWS vom 17.02.2007

KAUFEMPFEHLUNG VON US-BÖRSENBRIEF /

BUY AT 0,86 USD / Sell: at 1,20+ USD
(Short & LONG Term hold)

..."stock volume is nearing 3 million shares and our analysts are recommending a strong buy. this could be a prime long term penny play to have in your portfolio, so don`t miss out!"

(DIES STELLT KEINE KAUFEMPFEHLUNG MEINERSEITS DAR)

grüße timo...

[DagobertDuck57]

Antwort auf Beitrag Nr.: 27.792.646 von hedger_de am 18.02.07 11:45:32

Oooh Nachtigal, ick hör dir Trapsen

[zelltim]

Antwort auf Beitrag Nr.: 27.800.904 von DagobertDuck57 am 18.02.07 17:23:55

Ich weiß nicht ob hier schonmal davon was gepostet wurde !!

Combimatrix wird als Übernahmekandidat gehandelt !!
Möglich Käufer Affymatrix und den Zweiten habe ich nicht mehr im Kopf fängt aber auch mit A an !!Quelle Biotechreport !!

Deutsche Sprache schwere Sprache /Ich hoffe ihr habt mich schon verstanden !

[sensolight]

Vielleicht hatte auch irgendjemand lediglich diese Meldung falsch verstanden...

...oder hat doch noch auf einen außergerichtlichen Vergleich
mit Texas Intstruments im Anschluß gesetzt.

http://www.marketwatch.com/news/story/t-shares-rise-after-fa…


TXN30.99, +0.21, +0.7% ) shares gained Wednesday after the company received a favorable summary judgement in a patent infringement dispute with Acacia Research Corp.'s CBMX . T-I shares rose 78 cents, or 2.6%, to $31.05 in afternoon action on volume of 10.3 million. Before the opening bell, the company said a District Court in California dismissed the case, ruling that T-I didn't infringe on any claim and that each claim of the Microprocessor Enhancement patent was invalid. The court also ordered Microprocessor Enhancement to pay T-I's costs related to the suit.

[whyso]

The CombiMatrix Group presentation and Q&A session will start at 2:15 p.m. Pacific Time (5:15 p.m. Eastern).

http://biz.yahoo.com/bw/070216/20070216005110.html?.v=1

Morgen wissen wir sicher mehr...

[GerdKill]

Antwort auf Beitrag Nr.: 27.865.212 von whyso am 20.02.07 23:59:26

Press Release Source: Acacia Research Corporation


Acacia Research Reports Fourth Quarter and Year End Financial Results
Wednesday February 21, 4:00 pm ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) today reported results for the three months and year ended December 31, 2006. Acacia Research Corporation comprises two operating groups, the Acacia Technologies group and the CombiMatrix group.
ADVERTISEMENT


"Acacia Technologies revenues for the year ended December 31, 2006 were $34,825,000 compared to $19,574,000 for the year ended December 31, 2005. Acacia Technologies reported a GAAP net loss of $5,496,000 or $0.20 per share, including non-cash patent amortization and non-cash stock compensation charges totaling $9,259,000. Cash and short-term investments were $44,998,000 compared to $38,960,000 at the end of the prior year. In 2006, Acacia Technologies began generating revenues from 7 new licensing programs and has now generated revenues from 22 licensing programs. We acquired control of 20 patent portfolios for future licensing and now control 60 patent portfolios," commented Acacia Research Corporation Chairman and CEO, Paul Ryan.

"Revenues for the fourth quarter of 2006 were $7,313,000 compared to $8,246,000 in the year ago period. We acquired control of 7 new patent portfolios in the fourth quarter. For the fourth quarter, Acacia Technologies reported a GAAP net loss of $3,137,000 or $0.11 per share, including non-cash patent amortization and non-cash stock compensation charges totaling $2,346,000."

"In 2007, Acacia Technologies expects continued growth in revenues, new licensing programs, and new patent portfolios for future licensing, as we build our leadership position in patent licensing. Our licensing success during the past year is increasing opportunities for partnering with owners of patented technologies for future licensing programs," concluded Mr. Ryan.

"The CombiMatrix group recognized revenues of $859,000 for the fourth quarter of 2006. This represented a revenue decline of 76% over the year ago quarter as well as a revenue decline of 53% over the third quarter of 2006. This was primarily due to the one-time recognition of $2,266,000 of previously deferred revenues, which were recognized during the fourth quarter of 2005 from the completion of our collaboration and development agreement with Toppan Printing, Ltd.," commented Dr. Amit Kumar, CEO and President of CombiMatrix Corporation.

"Additionally, our revenue decline reflects the transition from selling products into the R&D market to a major focus on the molecular diagnostics market. With the launch of our array-based diagnostic services last year, our near-term pipeline, the positive response from the US FDA (announced last October), recent strategic and operational changes, coupled with our recent financing, we feel we are positioned well to succeed in the lucrative diagnostics market. We will continue to service our customers and distributors, but we have made operational changes to eliminate substantial costs of marketing into the R&D market. These changes were made in the fourth quarter of 2006 and early this year, and the results will be evident in our financial results during 2007," concluded Dr. Kumar.

Acacia Research Corporation Consolidated Financial Results

For the Three Months Ended December 31, 2006 and 2005

Consolidated revenues for the fourth quarter of 2006 were $8,172,000 versus $11,890,000 in the comparable 2005 period. Fourth quarter 2006 revenues recognized by the Acacia Technologies group were $7,313,000 versus $8,246,000 in the comparable 2005 period. Fourth quarter 2006 revenues recognized by the CombiMatrix group were $859,000 versus $3,644,000 in the comparable 2005 period.

Acacia Research Corporation reported a fourth quarter 2006 consolidated GAAP net loss of $7,639,000 versus $2,868,000 in the comparable 2005 period. The fourth quarter 2006 net loss was comprised of a net loss for the Acacia Technologies group of $3,137,000 versus $1,083,000 in the comparable 2005 period, and a net loss for the CombiMatrix group of $4,502,000 versus $1,785,000 in the comparable 2005 period.

The fourth quarter 2006 consolidated results included non-cash patent amortization, stock compensation and depreciation charges totaling $3,489,000 versus $2,125,000 in the comparable 2005 period. The increase in non-cash charges primarily reflects Acacia Research Corporation's adoption of SFAS No. 123 (revised 2004), "Share-Based Payments," ("SFAS No. 123R"), effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their consolidated financial statements. Consolidated stock compensation expense for the fourth quarter of 2006 totaled $1,625,000, compared to $220,000 in the comparable 2005 period.

Fourth quarter 2006 consolidated results also included a non-cash gain of $1,091,000 versus $649,000 in the comparable 2005 period, related to the adjustment of the CombiMatrix group's long-term warrant liability to fair value as of December 31, 2006.

Fourth quarter 2006 government contract costs totaled $483,000 versus $863,000 in the comparable 2005 period. Fourth quarter 2006 internal research and development expenses were $2,105,000 (including non-cash stock compensation charges of $300,000) versus $1,701,000 in the comparable 2005 period. Refer to "CombiMatrix Group Financial Results" below for additional information.

Consolidated marketing, general and administrative expenses for the fourth quarter of 2006, including non-cash stock compensation charges, were $7,130,000 versus $5,099,000 in the comparable 2005 period. Fourth quarter 2006 marketing, general and administrative expense included $1,325,000 in non-cash stock compensation expense versus $220,000 in the comparable 2005 period. Excluding the impact of the adoption of SFAS No. 123R, the net increase was due primarily to the addition of licensing, business development and engineering personnel for the Acacia Technologies group, an increase in the Acacia Technologies group's patent-related research and consulting expenses for new and ongoing licensing programs, an increase in accounting and legal professional fees related to the split-off of CombiMatrix Corporation from Acacia Research Corporation (the "split-off transaction") and an increase in corporate, general and administrative costs related to the continued growth of Acacia Technologies group's ongoing operations. The change also reflects an increase in general and administrative expenses incurred by the CombiMatrix group in connection with the ongoing operations of CombiMatrix Molecular Diagnostics, as well as increased accounting and legal expenses incurred in connection with the split-off transaction.

Acacia Technologies group operating expenses for the fourth quarter of 2006 and 2005 included inventor royalties expenses of $2,496,000 and $2,590,000, respectively, and contingent legal fees expenses of $1,922,000 and $2,810,000, respectively. Refer to "Acacia Technologies Group Financial Results" below for additional information.

The Acacia Technologies group's fourth quarter 2006 patent-related legal expenses were $977,000 versus $295,000 in the comparable 2005 period. Refer to "Acacia Technologies Group Financial Results" below for additional information.

For the Year Ended December 31, 2006 and 2005

Consolidated revenues for the year ended December 31, 2006 were $40,565,000 versus $27,607,000 in 2005. Acacia Technologies group revenues recognized in 2006 totaled $34,825,000 versus $19,574,000 in 2005. CombiMatrix group revenues recognized in 2006 totaled $5,740,000 versus $8,033,000 in 2005.

For the year ended December 31, 2006, Acacia Research Corporation reported a consolidated GAAP net loss of $25,456,000 versus $18,676,000 in 2005. The 2006 net loss was comprised of a net loss for the Acacia Technologies group of $5,496,000 versus $6,275,000 in 2005, and a net loss for the CombiMatrix group of $19,960,000 versus $12,401,000 in 2005.

The 2006 consolidated results included non-cash patent amortization, stock compensation and depreciation charges totaling $13,719,000 versus $7,361,000 in 2005.

The 2006 consolidated results also included a non-cash gain of $1,754,000, versus $812,000 in 2005, related to the adjustment of the CombiMatrix group's long-term warrant liability to fair value as of December 31, 2006.

Government contract costs for 2006 totaled $1,959,000 versus $3,683,000 in 2005. Internal research and development expenses for 2006 were $9,485,000 (including non-cash stock compensation charges of $1,097,000) versus $5,783,000 in 2005. Refer to "CombiMatrix Group Financial Results" below for additional information.

Consolidated marketing, general and administrative expenses for 2006, including non-cash stock compensation charges, were $26,963,000 versus $17,926,000 in 2005. Marketing, general and administrative expense in 2006 included $5,206,000 in non-cash stock compensation expense versus $197,000 in 2005. Excluding the impact of the adoption of SFAS No. 123R, the net increase was due primarily to the addition of licensing, business development and engineering personnel for the Acacia Technologies group, an increase in the Acacia Technologies group's patent-related research and consulting expenses for new and ongoing licensing programs, an increase in professional fees related to the split-off transaction and an increase in corporate, general and administrative costs related to the continued growth of Acacia Technologies group's ongoing operations. The change also reflects an increase in general and administrative expenses incurred by the CombiMatrix group in connection with the ongoing operations of CombiMatrix Molecular Diagnostics, as well as increased accounting and legal expenses incurred in connection with the split-off transaction.

Acacia Technologies group operating expenses for 2006 and 2005 included inventor royalties expenses of $9,614,000 and $5,504,000, respectively, and contingent legal fees expenses of $7,545,000 and $5,602,000, respectively. Refer to "Acacia Technologies Group Financial Results" below for additional information.

The Acacia Technologies group's 2006 patent-related legal expenses were $4,780,000 versus $2,468,000 in 2005. Refer to "Acacia Technologies Group Financial Results" below for additional information.

Financial Condition

Total consolidated assets were $109,604,000 as of December 31, 2006 compared to $121,434,000 as of December 31, 2005. Cash and cash equivalents and short-term investments on a consolidated basis totaled $59,340,000 as of December 31, 2006 compared to $59,173,000 as of December 31, 2005.

Acacia Technologies Group Financial Results

(A Division of Acacia Research Corporation)

For the Three Months Ended December 31, 2006 and 2005

Fourth quarter 2006 license fee revenues recognized by the Acacia Technologies group were $7,313,000 versus $8,246,000 in the comparable 2005 period. Fourth quarter 2006 revenues included license fees from 13 new licensing agreements covering 6 of our technology licensing programs, including initial license fee revenues for our Audio Communications Fraud Detection technology licensing program. Fourth quarter 2006 license fee revenues also included fees from the licensing of our DMT® technology, Audio/Video Enhancement and Synchronization technology, Image Resolution Enhancement technology, Interstitial Internet Advertising technology, and Multi-Dimensional Bar Code technology. To date, the Acacia Technologies group has generated revenues from 22 of its technology licensing programs.

Trailing twelve-month revenues for the Acacia Technologies group were $34.8 million as of December 31, 2006, as compared to $35.8 million at September 30, 2006, $34.1 million as of June 30, 2006, $22.4 million as of March 31, 2006, and $19.6 million as of December 31, 2005.

The Acacia Technologies group reported a fourth quarter 2006 division net loss of $3,137,000 versus $1,083,000 in the comparable 2005 period. Included in fourth quarter 2006 divisional results are non-cash stock compensation charges and non-cash patent amortization charges totaling $2,346,000 versus $1,569,000 in the comparable 2005 period. Fourth quarter 2006 non-cash stock compensation charges were $1,024,000 versus $233,000 in the comparable 2005 period. The increase in non-cash charges reflects the adoption of SFAS No. 123R, effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their financial statements, as described earlier.

Fourth quarter 2006 marketing, general and administrative expenses increased to $4,114,000 (including non-cash stock compensation charges of $1,024,000 related to the adoption of SFAS No. 123R, as described earlier) from $2,617,000 (including non-cash stock compensation charges of $233,000) in the comparable 2005 period. Excluding the impact of non-cash stock compensation, the net increase was due primarily to the addition of licensing, business development and engineering personnel, an increase in patent-related research and consulting expenses for new and ongoing licensing programs, an increase in accounting and legal expenses related to the split-off transaction and an increase in corporate, general and administrative costs related to the continued growth of Acacia Technologies group's ongoing operations.

Acacia Technologies group operating expenses for the fourth quarter of 2006 and 2005 included inventor royalties expenses of $2,496,000 and $2,590,000, respectively, and contingent legal fees expenses of $1,922,000 and $2,810,000, respectively. The majority of the Acacia Technologies group's patent portfolios are subject to patent and patent rights agreements with inventors containing provisions granting to the original patent owner the right to receive inventor royalties based on future net revenues, as defined in the respective agreements, and may also be subject to contingent legal fee arrangements with external law firms engaged on a contingent fee basis. The economic terms of the inventor and contingent arrangements, if any, vary across the Acacia Technologies group's patent portfolios. As such, inventor royalties and contingent legal fees expenses fluctuate period to period based on the amount of revenues recognized each period and the mix of specific patent portfolios generating revenues each period.

Fourth quarter 2006 patent-related legal expenses were $977,000 versus $295,000 in the comparable 2005 period. Patent-related legal expenses include patent-related prosecution and enforcement costs incurred by outside patent attorneys engaged on an hourly basis and the out-of-pocket expenses incurred by law firms engaged on a contingent fee basis. Patent-related legal expenses fluctuate from period to period based on patent enforcement and prosecution activity associated with ongoing licensing and enforcement programs and the timing of the commencement of new licensing and enforcement programs in each period. Patent-related legal expenses include case related costs billed by outside counsel for economic analyses and damages assessments, expert witnesses and other consultants, case related audio/video presentations for the court, and other litigation support and administrative costs. We expect patent-related legal expenses to continue to fluctuate quarter to quarter based on the factors summarized above in connection with the Acacia Technologies group's current and future patent commercialization and enforcement programs.

For the Year Ended December 31, 2006 and 2005

License fee revenues recognized by the Acacia Technologies group in 2006 totaled $34,825,000 versus $19,574,000 in 2005. License fee revenues in 2006 included fees from the licensing of our DMT® technology, Audio/Video Enhancement and Synchronization technology, Image Resolution Enhancement technology, Credit Card Fraud Control technology, Interstitial Internet Advertising technology, Laptop Connectivity technology, Multi-Dimensional Bar Code technology, Product Activation technology, Dynamic Manufacturing Modeling technology, Enhanced Internet Navigation technology, Interactive Data Sharing technology, Audio Communications Fraud Detection technology and Resource Scheduling technology.

The Acacia Technologies group's 2006 division net loss was $5,496,000 versus $6,275,000 in 2005. Included in the 2006 divisional results are non-cash stock compensation charges and non-cash patent amortization charges totaling $9,259,000 versus $5,278,000 in 2005. Non-cash stock compensation charges in 2006 totaled $3,946,000 versus $356,000 in 2005. The increase in non-cash stock compensation charges reflects the impact of the adoption of SFAS No. 123R, effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their financial statements, as described earlier.

Marketing, general and administrative expenses for 2006 increased to $14,256,000 (including non-cash stock compensation charges of $3,946,000) from $8,099,000 (including non-cash stock compensation charges of $356,000) in the comparable 2005 period. Excluding the impact of non-cash stock compensation, the net increase was due primarily to the addition of licensing, business development and engineering personnel for the Acacia Technologies group, an increase in the Acacia Technologies group's patent-related research and consulting expenses for new and ongoing licensing programs, an increase in accounting and legal fees related to the split-off transaction and an increase in corporate, general and administrative costs related to the continued growth of Acacia Technologies group's ongoing operations.

Acacia Technologies group operating expenses for 2006 and 2005 included inventor royalties expenses of $9,614,000 and $5,504,000, respectively, and contingent legal fees expenses of $7,545,000 and $5,602,000 respectively. The majority of the Acacia Technologies group's patent portfolios are subject to patent and patent rights agreements with inventors containing provisions granting to the original patent owner the right to receive inventor royalties based on future net revenues, as defined in the respective agreements, and may also be subject to contingent legal fee arrangements with external law firms engaged on a contingent fee basis. The economic terms of the inventor and contingent arrangements, if any, vary across the Acacia Technologies group's patent portfolios. As such, inventor royalties and contingent legal fees expenses fluctuate period to period based on the amount of revenues recognized each period and the mix of specific patent portfolios generating revenues each period.

Patent-related legal expenses for 2006 were $4,780,000 versus $2,468,000 in 2005. Patent-related legal expenses include patent-related prosecution and enforcement costs incurred by outside patent attorneys engaged on an hourly basis and the out-of-pocket expenses incurred by law firms engaged on a contingent fee basis. Patent-related legal expenses fluctuate from period to period based on patent enforcement and prosecution activity associated with ongoing licensing and enforcement programs and the timing of the commencement of new licensing and enforcement programs in each period. Patent-related legal expenses include case related costs billed by outside counsel for economic analyses and damages assessments, expert witnesses and other consultants, case related audio/video presentations for the court, and other litigation support and administrative costs. We expect patent-related legal expenses to continue to fluctuate quarter to quarter based on the factors summarized above in connection with the Acacia Technologies group's current and future patent commercialization and enforcement programs.

Financial Condition

Total assets for the Acacia Technologies group were $65,770,000 as of December 31, 2006 compared to $68,893,000 as of December 31, 2005. Cash and cash equivalents and short-term investments totaled $44,998,000 as of December 31, 2006 compared to $38,960,000 as of December 31, 2005.

CombiMatrix Group Financial Results

(A Division of Acacia Research Corporation)

For the Three Months Ended December 31, 2006 and 2005

Revenues for the fourth quarter of 2006 were $859,000 versus $3,644,000 in the comparable 2005 period. Fourth quarter 2006 revenues were comprised of $511,000 in government contact revenues and $348,000 in CustomArray(TM) product, equipment and service revenues. Fourth quarter 2005 revenues were comprised of $864,000 of government contract revenues, $514,000 of CustomArray(TM) product and service revenues, and $2,266,000 in one-time collaboration revenues from completion of our development and collaboration agreement with Toppan Printing, Ltd. during the fourth quarter of 2005.

The fourth quarter 2006 division net loss was $4,502,000 versus $1,785,000 in the comparable 2005 period. The fourth quarter 2006 results included non-cash stock compensation, patent amortization and depreciation charges totaling $1,119,000 versus $540,000 in the comparable 2005 period. The increase in non-cash charges primarily reflects the adoption of SFAS No. 123R, effective January 1, 2006, which requires public companies to measure all employee stock-based compensation awards using a fair-value method and record such expense in their consolidated financial statements, as discussed earlier. Fourth quarter non-cash stock compensation charges included in research and development expense and marketing, general and administrative expense totaled $300,000 and $301,000, respectively. The fourth quarter 2006 results also included a non-cash gain of $1,091,000 related to the adjustment of the CombiMatrix group's long-term warrant liability to fair value as of December 31, 2006, compared to $649,000 for the comparable 2005 period.

Fourth quarter 2006 government contract costs totaled $483,000 versus $863,000 in the comparable 2005 period. The decrease was due to a lower level of activity under our biological threat detection contract with the Department of Defense during the fourth quarter of 2006 compared to 2005. Fourth quarter 2006 internal research and development expenses were $2,105,000 (including non-cash stock compensation charges of $300,000) versus $1,701,000 in the comparable 2005 period. The increase in internal research and development expenses was due to increased activity in the area of high-density array development as well as to the impact of the CombiMatrix group's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, which was formed and began research and development activities in the second quarter of 2005.

Fourth quarter 2006 marketing, general and administrative expenses increased to $3,016,000 (including non-cash stock compensation charges of $301,000) from $2,482,000 in the comparable 2005 period. Excluding the impact of non-cash stock compensation, the increase was due primarily to an increase in general and administrative expenses incurred by the CombiMatrix group in connection with the ongoing operations of CombiMatrix Molecular Diagnostics, as well as increased accounting and legal expenses incurred in connection with the split-off transaction.

For the Year Ended December 31, 2006 and 2005

Revenues for 2006 were $5,740,000 versus $8,033,000 in 2005. Revenues for 2006 were comprised of $2,074,000 in government contact revenues and $3,666,000 in CustomArray(TM) product, equipment and service revenues, including $221,000 of array revenue from our diagnostics subsidiary, CombiMatrix Molecular Diagnostics. Revenues for 2005 were comprised of $3,849,000 of government contract revenues, $1,918,000 of CustomArray(TM) product and service revenues and $2,266,000 in one-time collaboration revenues from completion of our development and collaboration agreement with Toppan Printing, Ltd. during the fourth quarter of 2005.

The 2006 division net loss was $19,960,000 versus $12,401,000 in 2005. The 2006 results included non-cash stock compensation, patent amortization and depreciation charges totaling $4,382,000 versus $2,024,000 in 2005. The increase in non-cash charges primarily reflects the adoption of SFAS No. 123R, effective January 1, 2006, as discussed earlier. Annual non-cash stock compensation charges included in research and development expense and marketing, general and administrative expense totaled $1,097,000 and $1,260,000, respectively. The 2006 results also included a non-cash gain of $1,754,000 related to the adjustment of the CombiMatrix group's long-term warrant liability to fair value as of December 31, 2006, compared to $812,000 for the comparable 2005 period.

Government contract costs for 2006 totaled $1,959,000 versus $3,683,000 in 2005. The decrease was due to lower levels of activity under our biological threat detection contracts with the Department of Defense in 2006 compared to 2005. Internal research and development expenses for 2006 were $9,485,000 (including non-cash stock compensation charges of $1,097,000) versus $5,783,000 in 2005. The increase in internal research and development expenses was due to increased activity in the area of high-density array and synthesizer development as well as to the impact of the CombiMatrix group's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, which was formed and began research and development activities in the second quarter of 2005.

Marketing, general and administrative expenses for 2006 increased to $12,707,000 (including non-cash stock compensation charges of $1,260,000) from $9,827,000 in 2005. Excluding the impact of non-cash stock compensation, the increase was due primarily to an increase in general and administrative expenses incurred by the CombiMatrix group in connection with the ongoing operations of CombiMatrix Molecular Diagnostics, as well as increased accounting and legal expenses incurred in connection with the split-off transaction.

Financial Condition

Total assets for the CombiMatrix group were $44,214,000 as of December 31, 2006 compared to $52,541,000 as of December 31, 2005.

In December 2006, Acacia Research Corporation completed a registered direct offering raising gross proceeds of $9,964,000 through the issuance of 9,768,313 units. Each unit consists of one share of AR-CombiMatrix common stock and 1.2 five-year common stock warrants, for a total of 9,768,313 shares and warrants to purchase 11,721,975 shares of AR-CombiMatrix common stock, respectively, issued to investors. Each warrant entitles the holder to purchase a share of AR-CombiMatrix stock at a price of $0.87 per share. Acacia Research Corporation issued an additional 488,416 warrants of AR-CombiMatrix stock with an exercise price of $1.09 per share to the placement agent. Net proceeds raised from the private equity financing of $9,266,000 were attributed to the CombiMatrix group. In addition, the standby equity distribution agreement with Cornell Capital Partners, LP ("Cornell") was canceled in December 2006.

Cash and cash equivalents and short-term investments totaled $14,342,000 as of December 31, 2006 compared to $20,213,000 as of December 31, 2005. Due to the CombiMatrix group's lower cash and short-term investment balances as of December 31, 2006, coupled with the CombiMatrix group's expected use of cash from operations during 2007, there is substantial doubt regarding CombiMatrix group's ability to continue as a going concern. Management plans to obtain additional equity financing to obtain the cash necessary to continue to fund operations and execute its business objectives. However, there is no assurance that CombiMatrix group will be successful in obtaining additional equity financing, or will be able to obtain such financing on acceptable terms.

Business Highlights and Recent Developments

Business highlights of the fourth quarter and recent developments include:

Acacia Technologies group:

-- IP Innovation, LLC, a wholly owned subsidiary that is a part of the
Acacia Technologies group, entered into license agreements with
Funai Electric Co., Ltd., and Dell Inc., covering patents that
apply to our Image Resolution Enhancement technologies.
The Agreement with Dell Inc. resolves litigation that was pending
in the District Court for the Northern District of Illinois with
respect to certain Dell products. The Image Resolution Enhancement
Technology generally relates to the modification of a video or
printed display to improve the perceived image quality beyond the
basic pixel resolution of the display.

-- IP Innovation, LLC entered into a license and settlement agreement
with L.G. Electronics, Inc. covering patents that apply to
Audio/Video Enhancement and Synchronization, and Image Resolution
Enhancement technologies. The agreement with L.G. Electronics
resolves a patent infringement lawsuit which was pending in the
United States District Court for the Northern District of Illinois.
The Audio/Video Enhancement and Synchronization technologies
generally relate to the use of a noise reduction filtering system
for digital video compression, and for video and audio signals
received by digital radios and video displays. Other aspects of the
technologies apply to the synchronization of audio/video signals.

-- InternetAd Systems, LLC, a wholly owned subsidiary that is part of
the Acacia Technologies group, entered into license agreements with
OpenTable, Inc. (provides restaurants with a realtime online
electronic reservation system) and Best Western International,
Inc., covering a patent that applies to interstitial Internet
advertising. The agreement with Best Western International, Inc.
resolves a patent infringement lawsuit that was pending in the
District Court for the Northern District of Texas. The interstitial
Internet advertising technology generally relates to the display of
certain advertising, informational, and branding messages that
appear between or outside the web pages when the user is conducting
a search.

-- VData, LLC, a wholly owned subsidiary that is part of the Acacia
Technologies group, entered into license agreements with the
following companies covering a portfolio of patents that apply to
certain multi-dimensional bar codes:

-- Wyeth
-- Unilever
-- Capital One
-- LG Electronics, Inc.

-- Credit Card Fraud Control Corporation, a wholly owned subsidiary of
the Acacia Technologies group, entered into a non-exclusive license
covering a patent that applies to fraud protection technology with
Center.com, Inc., dba Astrocenter.com. The patented technology
generally relates to methods for determining and preventing fraud
when using telephonic, computer network or other communication
services to complete a sale. The claims cover methods for
preventing fraud during the purchase of services for entertainment
or technical support. These methods help protect vendors from
credit card charge-backs and help protect consumers whose credit
card numbers may have been stolen.

-- Acacia Patent Acquisition Corporation, a wholly owned subsidiary
that is part of the Acacia Technologies group, continued its patent
and patent rights acquisition activities as follows:

-- In October 2006, acquired a patent relating to automated
notification of tax return status. This patented technology
generally relates to a system for monitoring the status of a
client's tax return and automatically notifying the client of a
change in status. This system can be used by a tax preparation
service to monitor the electronic filing of their client's
income tax returns.

-- In October 2006, acquired rights to patents relating to wireless
traffic information technology from TrafficGauge, Inc.,
www.trafficgauge.com. This patented technology generally relates
to transmitting, receiving and displaying traffic information on
portable handheld and mobile displays. It covers a variety of
wireless distribution methods, such as FM radio and satellite,
as well as the devices used to display the traffic maps. This
technology enables users to identify traffic congestion and can
be used with in-vehicle navigation displays and portable
handheld units such as cell phones and PDA's.

-- In November 2006, acquired rights to a patent relating to
aligned wafer bonding technology. This patented technology
generally relates to the precision alignment and bonding of
micromechanical, electrical and optical structures. This
technology can be used for the bonding of surface features in
the fabrication of Micro Electromechanical Systems (MEMS) and
semiconductor devices, including high end microprocessors.

-- In November 2006, acquired rights to patents relating to
location based services (LBS) technology. This patented
technology generally relates to locating mobile units, such as
cell phones and embedded vehicle radios, within a cellular
network and using the position information to provide services
to the mobile user. It covers various means of accurately
locating a mobile unit, including GPS and cell site
triangulation. This technology is applicable to wireless
emergency services (E911), vehicle tracking, vehicle assistance
services and many other services that rely on knowing the
location of a mobile user.

-- In November 2006, acquired rights to patents relating to
document generation technology. This patented technology
generally relates to storing data in databases such that it
could be used to quickly populate multiple document templates.
This technology can be used in medical applications such as
Electronic Medical Records (EMR) and Electronic Health Records
(EHR), as well as document generation applications in the
financial, legal, and insurance industries.

-- In December 2006, acquired rights to a patent relating to
electronic address list management. This patented technology can
allow a user to manage an address list on a computer and
transfer the list to an electronic device such as a cell phone.

-- In December 2006, acquired rights to a patent relating to
systems used to monitor patient statistics and lab data for
critical events. This patented technology detects patient
statistics or lab results, such as vital signs or blood tests,
which are outside a specified range and then automatically pages
the appropriate medical personnel with a critical event message.

-- In November 2006, Matthew Vella joined the Acacia Technologies
group, as Vice President, Licensing. Mr. Vella was most recently
Senior Intellectual Property Counsel with ATI Technologies. He
previously held positions with Nortel Networks, Inc. as Lead Patent
Licensing Counsel and with Nortel Networks Corporation as Corporate
Counsel. Mr. Vella is a registered patent attorney who holds a B.S.
degree in Electrical Engineering from the Carleton University, and
a J. D. degree from University of Toronto Law School.

-- Since the last report to stockholders on October 26, 2006,
companies that are part of the Acacia Technologies group dismissed
5 lawsuits in their entirety involving 7 parties, in connection
with our Broadcast Data Retrieval, Product Activation, and Image
Resolution Enhancement technologies. We also dismissed 5 parties
from ongoing litigation in connection with our Audio/Video
Enhancement, User Activated Internet Advertising, Portable Devices
with links and Credit Card Fraud Protection technologies. As
previously announced, our Credit Card Fraud Protection patent
emerged from re-reexamination from the USPTO with all of its claims
in tact, and we are again vigorously pursuing our licensing and
enforcement campaign for that technology. In addition, we became
involved in 5 new lawsuits with 22 companies in connection with our
Information Monitoring, Portable Devices with links, Telematics,
High Quality Image Processing, and Broadcast Data Retrieval
technologies. We currently have 33 ongoing lawsuits involving 118
companies.

CombiMatrix group:

-- On September 5, 2006, the CombiMatrix group announced that its
subsidiary, CMDX, had commercially launched its fist molecular
diagnostic service. Physicians are now able to prescribe this test
for their patients. The first offering utilizes CMDX's
Constitutional Genetic Array Test, which can genetically identify
over 50 common genetic disorders in one test.

-- On October 9, 2006, the CombiMatrix group announced that the 2007
Defense Appropriations Bill signed into law by President Bush
includes two new allocations of $1.0M each for the CombiMatrix
group. This funding will support efforts by CombiMatrix to continue
the development and deployment of its microarray technologies for
the detection of biological-threat agents and infectious pathogens
such as the highly pathogenic Eurasian Influenza A Virus (H5N1).

-- On October 18, 2006 the CombiMatrix group received a letter from
the Office of In Vitro Diagnostic Device Evaluation and Safety
(OIVD) indicating that CMDX's plans to market its Constitutional
Genetic Array Test need not be regulated as an In Vitro Diagnostic
Multivariate Index Assay, under the OIVD's recently published
guidelines.

-- On November 10, 2006, the CombiMatrix group announced that its
diagnostics subsidiary, CMDX, had launched a new test that
discriminates malignant melanoma from benign moles. This test,
which is based on the company's CustomArray platform, is a new
molecular diagnostics tool that enables pathologists to resolve
difficult-to-diagnose cases through an objective genetic analysis.

A conference call is scheduled for today. The Acacia Technologies Group presentation and Q&A will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern). The CombiMatrix Group presentation and Q&A session will start at 2:15 p.m. Pacific Time (5:15 p.m. Eastern).

To listen to the presentation by phone, dial 800-289-0569 for domestic callers and 913-981-5542 for international callers, both of whom will need to provide the operator with the confirmation code 5946001. A replay of the audio presentation will be available for 30 days at 888-203-1112 for domestic callers and 719-457-0820 for international callers, both of whom will need to enter the code 5946001 when prompted.

The call is being webcast by CCBN and can be accessed at Acacia's website at www.acaciaresearch.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 60 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

ACACIA RESEARCH CORPORATION
SUMMARY FINANCIAL INFORMATION
(In thousands, except share and per share information)
(Unaudited)

CONSOLIDATED BALANCE SHEET INFORMATION

December 31, December 31,
2006 2005
-------------- -------------

Total Assets $109,604 $121,434
============== =============
Total Liabilities $15,295 $14,090
============== =============
Minority Interests $- $447
============== =============
Total Stockholders' Equity $94,309 $106,897
============== =============

CONSOLIDATED STATEMENTS OF OPERATIONS



For the Three For the Years
Months Ended Ended
----------------------- -----------------------
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
2006 2005 2006 2005
----------- ----------- ----------- -----------

Revenues:
Collaboration
agreements $- $2,266 $- $2,266
License fees 7,313 8,246 34,825 19,574
Government contract 511 864 2,074 3,849
Products 228 467 3,278 1,765
Service contracts 120 47 388 153
----------- ----------- ----------- -----------
Total revenues 8,172 11,890 40,565 27,607
----------- ----------- ----------- -----------

Operating expenses:
Cost of government
contract revenues 483 863 1,959 3,683
Cost of product sales 285 185 1,258 820
Research and
development expenses
(including non-cash
stock compensation
expense of $300 and
$1,097 for the three
and twelve months
ended December 31,
2006 and $0 for the
three and twelve
months ended
December 31, 2005) 2,105 1,701 9,485 5,783
Marketing, general
and administrative
expenses (including
non-cash stock
compensation expense
of $1,325 and $5,206
for the three and
twelve months ended
December 31, 2006
and $220 and $197
for the three and
twelve months ended
December 31, 2005) 7,130 5,099 26,963 17,926
Legal expenses -
patents 977 295 4,780 2,468
Inventor royalties
and contingent legal
fees expense -
patents 4,418 5,400 17,159 11,106
Inventor royalties -
V-chip - - - 225
Goodwill impairment
charge - 565 - 565
Write-off of patent-
related intangible
asset - - 297 -
Amortization of
patents and
royalties 1,729 1,697 6,795 6,234
Legal settlement
charges (credits) - - - (406)
Loss from equity
investment 250 150 1,036 352
----------- ----------- ----------- -----------

Total operating
expenses 17,377 15,955 69,732 48,756
----------- ----------- ----------- -----------
Operating loss (9,205) (4,065) (29,167) (21,149)

Total other income 1,566 1,153 3,717 2,406
----------- ----------- ----------- -----------

Loss from continuing
operations before
income taxes and
minority interests (7,639) (2,912) (25,450) (18,743)

(Provision) benefit
for income taxes - 70 (6) 302
----------- ----------- ----------- -----------
Loss from continuing
operations before
minority interests (7,639) (2,842) (25,456) (18,441)

Minority interests - 1 - 2
----------- ----------- ----------- -----------
Loss from continuing
operations (7,639) (2,841) (25,456) (18,439)
----------- ----------- ----------- -----------

Discontinued
operations:
Estimated loss on
disposal of
discontinued
operations - (27) - (237)
----------- ----------- ----------- -----------
- -
Net loss $(7,639) $(2,868) $(25,456) $(18,676)
=========== =========== =========== ===========

Earnings (loss) per
common share:
Attributable to the
Acacia Technologies
group:
Loss from continuing
operations $(3,137) $(1,056) $(5,496) $(6,038)
Basic and diluted loss
per share (0.11) (0.04) (0.20) (0.23)
Loss from discontinued
operations $- $(27) $- $(237)
Basic and diluted loss
per share - - - (0.01)
Net loss $(3,137) $(1,083) $(5,496) $(6,275)
Basic and diluted loss
per share (0.11) (0.04) (0.20) (0.24)

Attributable to the
CombiMatrix group:
Net loss $(4,502) $(1,785) $(19,960) $(12,401)
Basic and diluted loss
per share (0.10) (0.05) (0.49) (0.37)

Weighted average
shares:
Acacia Research -
Acacia Technologies
stock:
Basic and diluted 27,708,902 27,352,312 27,547,651 26,630,732
=========== =========== =========== ===========
Acacia Research -
CombiMatrix stock:
Basic and diluted 44,120,736 38,992,402 40,605,038 33,678,603
=========== =========== =========== ===========

ACACIA TECHNOLOGIES GROUP
(A Division of Acacia Research Corporation)
SUMMARY FINANCIAL INFORMATION
(In thousands)
(Unaudited)

GROUP BALANCE SHEET INFORMATION



December 31, December 31,
2006 2005
------------- --------------

Total Assets $65,770 $68,893
============= ==============
Total Liabilities $4,276 $6,647
============= ==============
Minority Interests $- $443
============= ==============
Total Stockholders' Equity $61,494 $61,803
============= ==============

GROUP STATEMENTS OF OPERATIONS



For the Three For the Years
Months Ended Ended
----------------- -----------------
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
2006 2005 2006 2005
-------- -------- -------- --------

Revenues:
License fees $7,313 $8,246 $34,825 $19,574
-------- -------- -------- --------

Total revenues 7,313 8,246 34,825 19,574
-------- -------- -------- --------

Operating expenses:
Marketing, general and
administrative expenses
(including non-cash stock
compensation expense of $1,024
and $3,946 for the three and
twelve months ended December 31,
2006 and $233 and $356 for the
three and twelve months ended
December 31, 2005) 4,114 2,617 14,256 8,099
Legal expenses - patents 977 295 4,780 2,468
Inventor royalties and contingent
legal fees expense - patents 4,418 5,400 17,159 11,106
Inventor royalties - V-chip - - - 225
Write-off of patent-related
intangible asset - - 297 -
Amortization of patents 1,322 1,336 5,313 4,922
-------- -------- -------- --------

Total operating expenses 10,831 9,648 41,805 26,820
-------- -------- -------- --------

Operating loss (3,518) (1,402) (6,980) (7,246)

Total other income 381 309 1,524 1,071
-------- -------- -------- --------

Loss from continuing operations
before income taxes and minority
interests (3,137) (1,093) (5,456) (6,175)

Benefit (provision) for income
taxes - 36 (40) 135
-------- -------- -------- --------

Loss from continuing operations
before minority interests (3,137) (1,057) (5,496) (6,040)

Minority interests - 1 - 2
-------- -------- -------- --------

Loss from continuing operations (3,137) (1,056) (5,496) (6,038)

Discontinued operations:

Estimated loss on disposal of
discontinued operations - (27) - (237)
-------- -------- -------- --------

Division net loss $(3,137) $(1,083) $(5,496) $(6,275)
======== ======== ======== ========

COMBIMATRIX GROUP
(A Division of Acacia Research Corporation)
SUMMARY FINANCIAL INFORMATION
(In thousands)
(Unaudited)

GROUP BALANCE SHEET INFORMATION


December 31, December 31,
2006 2005
-------------- --------------

Total Assets $44,214 $52,541
============== ==============
Total Liabilities $11,399 $7,443
============== ==============
Minority Interests $- $4
============== ==============
Total Stockholders' Equity $32,815 $45,094
============== ==============

GROUP STATEMENTS OF OPERATIONS



For the Three For the Years
Months Ended Ended
----------------- -------------------
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
2006 2005 2006 2005
-------- -------- --------- ---------

Revenues:
Collaboration agreements $- $2,266 $- $2,266
Government contract 511 864 2,074 3,849
Products 228 467 3,278 1,765
Service contracts 120 47 388 153
-------- -------- --------- ---------

Total revenues 859 3,644 5,740 8,033
-------- -------- --------- ---------

Operating expenses:
Cost of government contract
revenues 483 863 1,959 3,683
Cost of product sales 285 185 1,258 820
Research and development
expenses (including non-cash
stock compensation expense of
$300 and $1,097 for the three
and twelve months ended
December 31, 2006 and $0 for
the three and twelve months
ended December 31, 2005) 2,105 1,701 9,485 5,783
Marketing, general and
administrative expenses
(including non-cash stock
compensation expense of $301
and $1,260 for the three and
twelve months ended December
31, 2006 and ($13) and ($159)
for the three and twelve months
ended December 31, 2005) 3,016 2,482 12,707 9,827
Goodwill impairment charge - 565 - 565
Amortization of patents and
royalties 407 361 1,482 1,312
Legal settlement charges
(credits) - - - (406)
Loss from equity investment 250 150 1,036 352
-------- -------- --------- ---------

Total operating expenses 6,546 6,307 27,927 21,936
-------- -------- --------- ---------

Operating loss (5,687) (2,663) (22,187) (13,903)

Total other income 1,185 844 2,193 1,335
-------- -------- --------- ---------

Loss from operations before
income taxes (4,502) (1,819) (19,994) (12,568)

Benefit for income taxes - 34 34 167
-------- -------- --------- ---------

Division net loss $(4,502) $(1,785) $(19,960) $(12,401)
======== ======== ========= =========



Contact:
Acacia Research Corporation
Rob Stewart, 949-480-8300
Investor Relations
fax: [phone]

--------------------------------------------------------------------------------
Source: Acacia Research Corporation

[powerchord]

Antwort auf Beitrag Nr.: 27.887.420 von GerdKill am 21.02.07 22:11:00

weiss jemand etwas zu details aus dem conference call?
wenn ja bitte hier reinstellen

danke

[e.1]

gibt schon wieder ab, was gestern gewonnen wurde.

dachte es ginge jetzt endlich mal wieder aufwärts.

so langsam steigt aber das frustpotential

[DagobertDuck57]

Antwort auf Beitrag Nr.: 27.899.713 von e.1 am 22.02.07 15:44:26

War doch soooo klar, wie das Amen in der Kirche

[ronjanerin]

Wer von Euch kann mir den sagen, was in diesem riesen langen Text alles drin steht?
Auf alle fälle scheint es so als hätte sich jetzt einmal ein Boden gebildet rein Charttechnisch gesehen.
Mit den nicht aufhörenden Vogelgrippefällen müsste dieser Wert doch endlich mal wieder gen Norden steigen oder gibt es Firmen die das selbige Produkt günstiger verkaufen?
Ciao Ronja

[buyer10]

Antwort auf Beitrag Nr.: 27.999.143 von ronjanerin am 27.02.07 11:51:27

Ohne Worte - wer hat hier von einer unterbewerteten Biotech- Perle gesprochen?

Mann, ich habe die Schnauze aber so was von voll mit diesen ach so wundervollen Biotechs. Der Chart sieht nach Insolvenz aus!!!

Wieviele Bereiche werden denn noch ausgegliedert. Mittlerweile gibts schon eine Acacia Automotive. Hier wird doch nur abgezockt!

Aus welchem Grund spaltet man denn sonst so auf?
Das Tafelsilber ist doch schon längst verkauft!


Meine Meinung - tut mir echt leid für die noch investierten, einschließlich mir!!!!

[DagobertDuck57]

CombiMatrix to Webcast Presentation at Invest Northwest 2007 Conference
Thursday March 15, 6:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group will present at the Invest Northwest(TM) 2007 Conference at the Bell Harbor Conference Center, located in Seattle, Washington. Dr. Amit Kumar, President and CEO of CombiMatrix, will present an overview of the company.
ADVERTISEMENT


A live transmission of the presentation will take place at 11:55 a.m. PDT on Tuesday, March 20, 2007. An archived webcast will be available for 30 days. To access the live webcast or archived presentation, please go to www.combimatrix.com/news_events.htm.

Invest Northwest(TM) is a forum for institutional investors, pension fund managers, analysts, investment bankers, venture capitalists, angel investors and pharmaceutical and biotech corporate partners to meet with executives from public and private life sciences companies in Washington, Oregon, Montana, British Columbia and Alberta. Fifty-seven Pacific Northwest bioscience companies have been selected to present. The event also provides networking opportunities for leaders in the life science industry and financial community.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 63 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



Contact:
Acacia Research Corporation
Dr. Amit Kumar, 425-493-2200
Fax: [phone]

--------------------------------------------------------------------------------
Source: Acacia Research Corporation

[GoofMan]

Press Release Source: Acacia Research Corporation

CombiMatrix Awarded New US Air Force Contract to Advance Influenza-Detection System
Friday March 16, 6:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has been awarded a new contract worth $869,000 by the Air Force Research Laboratory to advance its Influenza Genotyping System. The field-deployable system is based upon the company's CustomArray(TM) microarray platform and ElectraSense(TM) detection technologies. The system can provide the user with a compact and rugged analyzer that can identify H5N1 bird flu as well as all human strains of influenza A and various other upper-respiratory pathogens of interest.

Conventional assays can either identify the matrix protein (common to all influenza A strains) or individual variants of the two cataloging proteins, hemagglutinin (H) and neurominidase (N). The CombiMatrix system is the most-comprehensive detection system available. In a single assay, it can identify all of the variants of influenza A, including those that have resulted in millions of deaths in the past, as well as the deadly Eurasian Influenza (H5N1 bird flu). The influenza genotyping assay can be tailored to provide the level of detail that the user needs to understand and predict trends during the worldwide flu season. This system has been used to detect bird flu (H5N1) and various human influenza strains (various serotypes including H1 and H3) in both animal and human samples and currently is used by several government laboratories in their influenza studies.

"Over the last several years, there has been concern about the emergence of the highly pathogenic bird flu strain (H5N1) that could lead to a pandemic," said Dr. Amit Kumar, President and CEO of CombiMatrix. "Identifying and tracking mutations in that strain is important. In addition, the common strains of flu continue to take a great toll in terms of human suffering and death because they are exquisitely adapted to us. Our system can identify H5N1, can determine when any other strain of influenza A is gaining an upper hand in a population, and can identify other infectious diseases that cause flu-like symptoms."

Recently, over 2000 new genetic sequences of influenza have been published (http://www.niaid.nih.gov/dmid/genomes/mscs/influenza.htm). Dr. David Danley, Director of Homeland Security and Defense Programs at CombiMatrix stated, "We are pleased to receive additional support from the Department of Defense to tailor our system towards supporting Force Health Protection. Though there are a number of activities that are funded with this award, one of our first activities will be to update the array to include newly published sequence information on influenza A variants of human concern. This effort demonstrates the power of our technology to rapidly refine our arrays as new information becomes available."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 63 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


Contact:

Acacia Research Corporation
Dr. Amit Kumar, 425-493-2200
Fax: [phone]

Source: Acacia Research Corporation

[nort.]

[DagobertDuck57]

Da falln mir doch beide Eier aus der Hose
Naja, passt ja gut zu Ostern

After Hours Last: $ .22

Time (ET) After Hours
Price After Hours
Share Volume
18:40 $ .58 1,000
18:40 $ .55 1,000
18:40 $ .22 100
18:40 $ .22 2,900
18:40 $ .22 600
18:40 $ .22 457

[chrisslyzorri]

Hallo zusammen,
was meint ihr wie gehts weiter????????
Kommen neue Produkte oder woher bezieht die Fa.Geld.
Nach dem Kurs zu urteilen sind sie bald Pleite.

chrissly

[e.1]

ich weiß auch nicht was da los ist. was mich immer noch festhalt ist der absolute höhenflug vor ein paar wochen. bin mir nicht sicher ob da irgend etwas im busch ist.
allerdings kann diese kursabsackerei ganz schön zermürben.

gruß e.1

[DagobertDuck57]

CombiMatrix Updates Influenza-Detection System and Demonstrates Use
Monday April 23, 5:59 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has updated its Influenza-Detection System, which consists of the CombiMatrix Influenza A Microarray, ElectraSense(TM) reader, and sample-preparation kit. The system is the most-comprehensive commercially available Influenza A detection system available. The new version, v4.1, of the system's content (the probes on the array and the sample preparation) takes into account the more than 2,000 new sequences that have been recently released by the Influenza Genome Sequencing Project.

The sequencing project, funded by the National Institute of Allergy and Infectious Diseases (NIAID), uses samples of human and avian influenza from around the world. A copy of NIAID's release can be obtained at this link: http://www3.niaid.nih.gov/news/newsreleases/2007/flu2000.htm

CombiMatrix's Influenza A Microarrays are being used today in various testing programs in different regions of the world to track influenza and to screen for the highly pathogenic Eurasian avian influenza H5N1 (bird flu). The arrays have been used on animal samples as well as human samples to type influenza. Also, the arrays have recently detected sub-strains or "clades" of influenza A that are not H5N1 yet that have been implicated in human fatalities. CombiMatrix plans to publish data from these studies if government health agencies involved give clearance to do so.

The recently updated system can identify all strains of Influenza A, including bird and human varieties. By tracking changes in genetic makeup of the virus, this array can differentiate highly pathogenic from less-lethal flu strains and can identify strains that may be resistant to drug therapy. This version, which is CombiMatrix's fourth update, highlights the ability of CombiMatrix's technology to continue matching the rapid evolution of this virus and information about it.

In collaboration with additional government agencies, CombiMatrix is beginning a comprehensive study of samples from birds in North America that are known to be infected with influenza. The results will be published in concert with the collaborating agencies. The Influenza Detection System will also be utilized in further studies to be conducted under our recently awarded $869,000 contract from the Air Force Research Laboratory. (See http://www.combimatrix.com/pr/031607.pdf for information about this contract.)

Additionally, this week the US Food and Drug Administration approved the first vaccine for influenza H5N1, developed by the sanofi pasteur division of sanofi-aventis (NYSE:SNY - News). This vaccine is being stockpiled to address a portion of the US population, and reports indicate that the vaccine is expected to be partially effective. Should a pandemic occur, this vaccine and any other therapies or vaccines will likely have limited availability. Also, they will have limited history in human beings. Consequently, our array, which will be able to tell physicians whether patients are infected with pathogenic influenza or the seasonal variety, could be critical in stratifying patients for treatment.

"Again we demonstrate the strength of our technology in taking the most up-to-date genetic information and incorporating it into an array that can be used for research and diagnostics," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We applaud NIAID in its effort to make this information public, and we support its efforts as well as that of the WHO in encouraging other labs around the world to do the same."

"The only way to stay on top of an infectious disease that mutates as rapidly as influenza A is to have an assay that can be changed as rapidly. Recent findings from our arrays have provided new information regarding Influenza A, and appropriate public health agencies are aware of these," stated Dr. David Danley, Director of Homeland Security and Defense Programs at CombiMatrix. "We are currently working with these agencies to analyze this information and develop a prediction of risk that is useful to decision makers."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce tailored-content arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 65 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



Contact:
Acacia Research Corporation
Dr. Amit Kumar, 425-493-2200
Fax: [phone]

--------------------------------------------------------------------------------
Source: Acacia Research Corporation

[DagobertDuck57]

Interessantes über CBMX mit Sandia auf Seite 5
http://www.sandia.gov/LabNews/ln04-13-07/labnews04-13-07.pdf

[nort.]

[Gommez]

[Gommez]

ACACIA RSRCH-COMBIMATRIX (U-CBMX) - News Release
Acacia Technologies Acquires Patent for Text Auto-Completion Technology

2007-05-02 06:00 ET - News Release

Also News Release (U-ACTG) ACADIA RSRCH-ACADIA TECH



NEWPORT BEACH, Calif. -- (Business Wire)

Acacia Research Corporation (Nasdaq:ACTG)(Nasdaq:CBMX) announced today that Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has acquired a patent relating to text auto-completion technology.

"As Acacia's licensing success grows, more companies are selecting us as their partner for the licensing of their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios,” concluded Mr. Ryan.

This patented technology generally relates to systems and software that perform auto-completion of user text entry. This technology may be used in cell phones/PDAs, computers, email clients, web browsers, search engines and other applications where auto-completion makes text entry more efficient.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 67 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.These statements are based upon our current expectations and speak only as of the date hereof.Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions.Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition.We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:

Acacia Research Corporation
Rob Stewart (Investor Relations), 949-480-8300
Fax: [phone]

Source: Acacia Research Corporation

"Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios,” concluded Mr. Ryan.

[lake]

CombiMatrix to Receive $5 Million from Registered Direct Offering

NEWPORT BEACH, Calif., May 07, 2007 (BUSINESS WIRE) --
Acacia Research Corporation (Nasdaq:ACTG)(Nasdaq:CBMX) announced today that is has obtained commitments to purchase $5 million of its Acacia Research-CombiMatrix common stock and warrants in a registered direct offering. Under the terms of the transaction, Acacia will sell approximately 6.8 million units for $0.738 per unit to a select group of investors. Participants in this financing included Dr. Amit Kumar, President and CEO of CombiMatrix, Tom Akin and Dr. John Abeles, all of whom are directors of CombiMatrix Corp. Each unit will consist of one share of Acacia Research-CombiMatrix common stock and a five-year warrant for the purchase of 1.5 shares of stock at an exercise price of $0.55 per share. The closing of the offering is expected to take place on May 7, 2007, subject to the satisfaction of customary closing conditions. All of the shares of Acacia Research-CombiMatrix common stock are being offered by Acacia pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.

"This financing strengthens our balance sheet as we split-off from Acacia, and it provides additional capital to fund our expansion in the molecular diagnostics market," said Dr. Amit Kumar, President and CEO of CombiMatrix Corporation.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state of jurisdiction. The shares of common stock may only be offered by means of a prospectus. Copies of the prospectus supplement and accompanying base prospectus are on file with the Securities and Exchange Commission.

Gruss lake

[chrisslyzorri]

Antwort auf Beitrag Nr.: 29.204.404 von lake am 08.05.07 07:01:35

Hallo zusammen,
wollte einfach mal unsere cbmx wieder aus der Versenkung holen.
Na was meint ihr wie gehts weiter......
Nach den letzten Kursanstiegen dachte ich, jetzt kann es nur noch
nach oben gehen
Gibts eigentlich whyso noch??????Habe schon lange nichts mehr von dir gehört...........

chrissly.

[italy05]

Antwort auf Beitrag Nr.: 29.517.375 von chrisslyzorri am 28.05.07 22:25:01

Der whyso LUSER traut sich nicht mehr

der soll mir mal unter die Finger kommen

scheiss Typ

[ChidGord]

So durch einen scanner bin ich auf die Aktie gestossen. Habe sie seit gestern im depot. Sieht gut aus derzeit. Kurze Konsolidierung Sollte über die 0,81$ steigen und möglichst nicht unterschreiten. Kursziel ergibt sich aus der aktuellen Lage ca 0,95$. Wie gesagt wenn sie die letzten Hochstände wieder überschreiten so ist der Abwärtstrend endgültig durchbrochen. 

[wiwifant]

Die Trennung von ACTG wird endlich vollzogen, allerdings erschließt sich mir die Aufteilung der Aktiva noch nicht. Etwas Aufmerksamkeit sollte diese Aktion trotzdem erzeugen.

SEC Declares CombiMatrix S-1 Registration Statement Effective


Split off of CombiMatrix Corporation to Occur on August 15, 2007


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--

Acacia Research Corporation (Nasdaq:ACTG)(Nasdaq:CBMX) and CombiMatrix Corporation announced today that on June 8, 2007 the U.S. Securities and Exchange Commission declared the effectiveness of CombiMatrix's S-1 registration statement. Following the redemption period required by Acacia's Articles of Incorporation, on August 15, 2007, ("Redemption Date") CombiMatrix Corporation will split off from Acacia Research Corporation through the redemption of all outstanding shares of Acacia Research-CombiMatrix common stock (Nasdaq:CBMX).

On the Redemption Date, every ten (10) shares of Acacia Research-CombiMatrix common stock outstanding on August 15, 2007, will be redeemed for one (1) share of common stock of CombiMatrix Corporation. CombiMatrix Corporation common stock is scheduled to begin trading on the Nasdaq Capital Market at 9:00 a.m. Eastern Time on August 15, 2007, under the symbol CBMXD. Following 20 days of trading, CombiMatrix Corporation common stock will trade under the symbol CBMX. Until August 15, 2007, Acacia Research-CombiMatrix common stock will continue to trade on Nasdaq under the symbol CBMX.

"CombiMatrix will become a separate public company on the date of the split-off. Acacia Research Corporation will continue to trade on the National NASDAQ Market under the ACTG symbol," commented Paul Ryan, Chairman and CEO of Acacia Research.

"The separation of our two companies will enable each to execute its business independently, and we are excited about the future prospects of our company as we re-invent ourselves with a focus on molecular diagnostics and personalized medicine," said Dr. Amit Kumar, President and CEO of CombiMatrix Corporation.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state of jurisdiction. The shares of common stock may only be offered by means of a prospectus. Copies of the prospectus are on file with the Securities and Exchange Commission.

[DagobertDuck57]

CombiMatrix Molecular Diagnostics Launches HemeScan(TM) Ploidy Test for the Management of Acute Lymphoblastic Leukemia
Monday June 25, 6:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has completed the clinical validation and launched the second of its HemeScan(TM) suite of BAC (Bacterial Artificial Chromosome) array CGH (Comparative Genomic Hybridization) based tests. The test is designed to quickly evaluate tumor genomic content (ploidy), a strong predictor of clinical outcome in pediatric and adult acute lymphoblastic leukemia (ALL). This test is now available to the clinical community through both routine clinical sample processing as well as through CMDX's innovative Technical Only Program for reference laboratories. The HemeScan tests are the industry's first clinically validated cancer diagnostics based on BAC array CGH technology.


Several thousand cases of ALL are diagnosed each year in the United States. The majority of cases occur in children and adolescents with an incidence rate in the 1 to 4 year old age group, almost 10 times that of young adults. The overall cure rate for ALL in children has improved dramatically in the past decade due in large measure to the application of improved chemotherapeutic agents combined with risk-adapted therapy based on prognostic factors. However, in adults the importance of tumor genomic content as a prognostic indicator has only recently been shown to be an important predictor of clinical outcome.

Recent studies have shown that patients with hyperdiploid ALL (greater than 50 chromosomes per leukemia cell) have a generally favorable prognosis, particularly those with extra copies of chromosomes 4, 10 and 17. Conversely the finding of a hypodiploid genome (less than 45 chromosomes per leukemia cell) confers a poor prognosis warranting more aggressive therapy choices. In addition to whole chromosome gains and losses, a number of specific recurrent genomic copy number changes involving genes associated with tumorogenesis such as deletion of the CDKN2A tumor suppressor gene on chromosome 9p and complex karyotypes (greater than 5 genomic rearrangements) have prognostic significance in ALL.

HemeScan is designed to quickly give clinicians an overview of genome ploidy and identify the specific chromosomes gained and lost in the ALL tumor genome. At the same time HemeScan identifies the known prognostic genomic imbalances relevant to the clinical course of ALL. When used in conjunction with FISH (Fluorescence in-situ Hybridization) for identification of clinically relevant balanced translocations, HemeScan provides an innovative alternative to time consuming and laborious traditional cytogenetic methods for enumerating chromosomal content of a tumor genome.

"We are very pleased with the performance of our HemeScan array in ALL. It is an important addition to our HemeScan suite of products designed to give hematopathologists the ability to provide clinicians and patients with information about prognosis at the time of their leukemia diagnosis," said Dr. Shelly Gunn, Medical Director of CMDX. "Our HemeScan Ploidy test for ALL, the most common leukemia in children, complements our recently introduced HemeScan Prognostic test for CLL, the most common leukemia in adults. We look forward to adding additional hematology/oncology tests in the near future as we continue to leverage the information gleaned from the complete sequencing of the human genome through our partnership with the world renowned Centre for Applied Genomics in Toronto."

According to Dr. Ryan Robetorye, assistant professor and hematopathologist at the University of Texas Health Science Center in San Antonio, "The HemeScan test is transforming our ability to go beyond the diagnosis of leukemia, and quickly provide clinically relevant prognostic information about the tumor genome to our clinicians. Leukemia cells from patients with the same diagnosis often look virtually the same under the microscope, but response to treatment and ultimately outcome are often dramatically different. Scanning leukemia genomes for ploidy status and prognostically relevant copy number changes give us clues about how the tumor may behave and positively impacts treatment decisions and patient management."

"The release of our second HemeScan product solidifies our role as the leading designer, manufacturer and clinical provider of innovative array based molecular diagnostic tests and places us firmly on track toward our goal of being the premiere center of excellence for cutting edge molecular diagnostics and personalized medicine initiatives," said Dr. Mansoor Mohammed, President and CEO of CMDX.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce tailored-content arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 71 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



Contact:
Acacia Research Corporation
Rob Stewart, Investor Relations, 949-480-8300
Fax: [phone]

--------------------------------------------------------------------------------
Source: Acacia Research Corporation

[gerdass]

Acacia Research Corporation (Nasdaq:ACTG)(Nasdaq:CBMX) announced today that IP Innovation, LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, has entered into a license and settlement agreement with LG Philips LCD Co., Ltd., covering patents that apply to Audio/Video Enhancement and Image Resolution Enhancement technologies. The agreement with LG Philips resolves a patent infringement lawsuit which was pending in the United States District Court for the Northern District of Illinois.



The Audio/Video Enhancement technologies generally relate to the use of a noise reduction filtering system for digital video compression, and for video and audio signals received by digital radios and video displays. The Image Resolution Enhancement technologies generally relate to the modification of a video or printed display to improve the perceived image quality beyond the basic pixel resolution of the display.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 74 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Acacia Research Corporation
Rob Stewart, Investor Relations, 949-480-8300
Fax: [phone]
[e-mail]

[US336]

July 16, 2007 06:00 AM

CombiMatrix Molecular Diagnostics Launches Next Enhanced Version of Its Constitutional Genetic Array Test

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group’s subsidiary, Combimatrix Molecular Diagnostics (CMDX), has completed the clinical validation of and has launched the third version of its Constitutional Array Genetic Test (CA1000). The test utilizes the company’s Bacterial Artificial Chromosome (BAC) array, which includes over 200 new, validated probes obtained through the company’s partnerships with The Center of Applied Genomics (TCAG), in Toronto, Canada and the Erasmus University Medical Center, the Netherlands’ largest academic medical center.

The CA1000 improves upon the previous CA850 by virtue of its increased coverage of genomic loci found in disease “hotspots” further enhancing the test’s ability to detect and characterize common genetic disorders. Moreover, greater background genomic coverage has been added to the CA1000 enabling the broader detection of spurious chromosomal abnormalities. The CA1000 array now has the most comprehensive and robust, clinically validated genomic coverage in the industry. The demonstrated serial development of CMDX’s arrays, enabled by platform flexibility and partnerships with leading academic centers, underscores the unique ability to incorporate the latest genetic information available at a pace that is unrivaled in the industry.

“As clinical diagnostics continue to take advantage of the rapidly increasing knowledge of the molecular basis for diseases, cutting-edge test development must be able to incorporate new information as efficiently as possible. In few other diagnostics specialties is this more evident, however challenging, than in genomics testing,” said Dr. Mercedes Gorre, VP of Scientific Affairs at CMDX. “From the outset, it has been clear to us that this emergent field of clinical diagnostics will require the ability to respond to the evolving body of knowledge of genetic disease associations and so we developed a system of platform flexibility, content procurement, and clinical validation that could accommodate such standards. An added advantage is that this also allows us to seamlessly integrate client suggested content into our development pipeline further enabling the most clinically relevant tests in the market.”

“Combimatrix Molecular Diagnostics has delivered excellent results for us with their 'CA 850' microarray. We are particularly pleased with CMDX’s continued advancement of their microarray products and services, and eagerly anticipate utilizing the new 'CA 1000' with enhanced genomic coverage. Their state-of-the-art microarray products and services deliver cutting edge technologies to our patients,” said Dr. Dianne Abuelo, M.D., Director of the Genetics Division, Department of Pediatrics, Hasbro Children's Hospital, Providence, Rhode Island.

“Our use of the CA 850 microarray through Combimatrix Molecular Diagnostics’ unique and innovative Tech-Only Program provides us with fast, accurate results customized to our needs, and with the shortest turn around time in the industry. We look forward to the progression from the already impressive CA 850 to CMDX’s new CA 1000 microarray for clinical chromosomal analysis. Throughout our experience with CMDX, we have been instantly upgraded to the most advanced version of aCGH technology available. This saltatory technical evolution keeps us in the forefront of patient care in this field. Thanks to CMDX, we are able to consistently offer the very best of aCGH services to our clients,” said Dr. Greg Mengden, Ph.D., Laboratory Director, Southwest Genetics Laboratory.

ABOUT TCAG

The Centre for Applied Genomics (TCAG; www.tcag.ca) is a core infrastructure within the Research Institute at The Hospital for Sick Children, Toronto, Canada, and is a Science and Technology Platform for the Ontario Genomics Institute and Genome Canada. TCAG’s mandate includes the provision of genomics research infrastructure and resources for investigators in the public, private and government/NGO sectors worldwide. Additionally, TCAG provides consultative resources related to genomics project design, data generation and analysis. Dr. Steve Scherer is the Scientific Director of TCAG and is a world-renowned researcher in the areas of genomic variability and the genetics of autism and related neurodevelopmental disorders. For a detailed biography, see www.tcag.ca/scherer/.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 74 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


Contacts
Acacia Research Corporation
Dr. Amit Kumar, 425-493-2200
Fax: [phone]

[Knochenpaule]

Stichtag ist am 15 August

[buyer10]

Antwort auf Beitrag Nr.: 30.798.307 von Knochenpaule am 22.07.07 17:10:04

Stichtag ist am 15 August




WAS soll da passieren????

Bitte um Aufklärung - Danke

[Knochenpaule]

Antwort auf Beitrag Nr.: 30.809.055 von buyer10 am 23.07.07 10:30:54

Siehe posting#441 von wiwifant

[DagobertDuck57]

Antwort auf Beitrag Nr.: 30.809.233 von Knochenpaule am 23.07.07 10:44:16

Geiiiiiiiiiiiiiiil

[wiwifant]

U.S. Department of Defense Awards $2.2 Million to CombiMatrix for Anti-Terrorism and Infectious-Disease Products

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--

Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that the U.S. Department of Defense (DoD) has awarded a one-year, $2.2 million contract to CombiMatrix for further development of its microarray technologies for a multipathogen- and chemical-detection system.

Under previously funded programs with the DoD, CombiMatrix has demonstrated that its products can simultaneously detect toxins, viruses, and bacteria using its semiconductor-based microarrays. Unique to this platform is its "on chip" electrochemical detection process, which eliminates the need for complex, expensive, and less-portable optical instrumentation. These systems are currently in use at several military and government laboratories as well as civilian installations.

"The events in the UK, in June, underscore the need for better technologies and products to address the constant threat of terrorist activities. Although the terrorist activity utilized explosives, the threat of chemical or biological weapons persists," stated Dr. David Danley, Director of Homeland Security and Defense Programs at CombiMatrix. "We are pleased that our government feels that our technology has value in addressing these concerns. Our products are being designed to address biothreat agents as well as infectious diseases of public-health concern, including influenza A and the 'Bird flu' subtype along with other upper-respiratory infections."

Dr. Amit Kumar, President and CEO of CombiMatrix, said, "CombiMatrix's work with the DoD to address infectious diseases fits nicely with our strategy of developing products for the molecular-diagnostics and the personalized-medicine market segments. We have already launched several microarray-based diagnostics products addressing diseases like childhood abnormalities and hematological cancers. We continue to develop additional products, including those being funded by the US DoD, to ensure a broad and integrated suite of tools to detect and to identify threats to the health of humans and animals regardless of their origin."

[DagobertDuck57]

Antwort auf Beitrag Nr.: 30.938.012 von wiwifant am 30.07.07 16:03:37

Gefällt mir!!!!

[DagobertDuck57]

Antwort auf Beitrag Nr.: 30.938.012 von wiwifant am 30.07.07 16:03:37

Dasselbe nochmal in leidlichem Deutsch

Montag, der 30. Juli, 6 Uhr 00 UND

NEWPORT-STRAND, Calif. - (GESCHÄFTSLEITUNG) - Akazie-Forschungsvereinigung (Nasdaq:CBMX - Nachrichten; Nasdaq:ACTG - Nachrichten) gab heute bekannt, dass das US-amerikanische Verteidigungsministerium (DoD) einen Jahresvertrag von 2.2 Millionen $ zu CombiMatrix für die weitere Entwicklung seiner Mikroreihe-Technologien für einen multipathogen- und System der chemischen Entdeckung zuerkannt hat.

Unter vorher geförderten Programmen mit dem DoD hat CombiMatrix demonstriert, dass seine Produkte gleichzeitig Toxine, Viren, und Bakterien entdecken können, die seine auf den Halbleiter gegründete Mikroreihe verwenden. Einzigartig zu dieser Plattform ist sein "auf dem Span" elektrochemischer Entdeckungsprozess, der das Bedürfnis nach kompliziert, teuer, und weniger - tragbare optische Instrumentierung beseitigt. Diese Systeme sind zurzeit im Gebrauch an mehreren militärischen und Regierungslaboratorien sowie den Zivilinstallationen.

"Die Ereignisse im Vereinigten Königreich unterstreichen im Juni das Bedürfnis nach besseren Technologien und Produkten, um die unveränderliche Drohung von Terroristentätigkeiten zu richten. Obwohl die Terroristentätigkeit Explosivstoffe verwertete, dauert die Drohung von chemischen oder biologischen Waffen an," setzte Dr David Danley, Direktor von Heimatssicherheits- und Verteidigungsprogrammen an CombiMatrix fest. "Wir sind zufrieden, dass unsere Regierung findet, dass unsere Technologie Wert im Wenden dieser Sorgen hat. Unsere Produkte werden dafür entworfen, biothreat Agenten sowie ansteckende Krankheiten der Gesundheitswesen-Sorge, einschließlich Grippe A und der 'Vogel Grippe' Subtyp zusammen mit anderen Ober-Atmungsinfektionen anzureden."

Dr Amit Kumar, Präsident und CEO von CombiMatrix, sagte, "die Arbeit von CombiMatrix mit dem DoD, um ansteckende Krankheiten zu richten, passt nett mit unserer Strategie von sich entwickelnden Produkten für die molekulare Diagnostik und die Marktsegmente der personifizieren-Medizin. Wir haben bereits mehrere auf die Mikroreihe gegründete Diagnostik-Produkte gestartet, Krankheiten wie Kindheitsabnormitäten und hematological Krebse richtend. Wir setzen fort, zusätzliche Produkte, einschließlich derjenigen zu entwickeln, die durch den US-DoD gefördert, ein breites und einheitliches Gefolge von Werkzeugen zu sichern, um Drohungen gegen die Gesundheit von Menschen und Tieren unabhängig von ihrem Ursprung zu entdecken und zu identifizieren."

ÜBER DIE AKAZIE-FORSCHUNGSVEREINIGUNG

Akazie-Forschungsvereinigung umfasst zwei Betriebsgruppen, Akazie-Technologiegruppe und Gruppe von CombiMatrix.

Die Gruppe von CombiMatrix entwickelt eine Plattform-Technologie, um anpassbare Reihe schnell zu erzeugen, die auf den Halbleiter gegründete Werkzeuge für den Gebrauch im Identifizieren und der Bestimmung der Rollen von Genen, Genveränderungen und Proteinen ist. Die Gruppentechnologie von CombiMatrix hat eine breite Reihe von potenziellen Anwendungen in den Gebieten von genomics, proteomics, biosensors, Rauschgift-Entdeckung, Rauschgift-Entwicklung, Diagnostik, kombinatorischer Chemie, materiellen Wissenschaften und Nanotechnologie.

[nort.]

[DagobertDuck57]

Split off of CombiMatrix Corporation Completed Today on August 15, 2007
Wednesday August 15, 6:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CombiMatrix Corporation (Nasdaq:CBMXD - News) and Acacia Research Corporation (Nasdaq:ACTG - News) announced today that CombiMatrix Corporation completed the split off from Acacia Research Corporation through the redemption of all outstanding shares of Acacia Research-CombiMatrix common stock.

Acacia Research Corporation Chairman and CEO Paul Ryan commented, \"Today we completed the split off of CombiMatrix Corporation. On behalf of our shareholders I thank the former members of our Board of Directors, Tom Akin, Rigdon Currie, and Amit Kumar for their years of service to our company. I know they will do a great job as members of the Board of Directors of CombiMatrix Corporation.\"

\"We are pleased with the completion of our split off, and we wish Acacia Research Corporation continued success. As we move forward, we look forward to establishing our own identity in the personalized medicine market,\" said Dr. Amit Kumar, President and CEO of CombiMatrix Corporation.

ABOUT ACACIA RESEARCH CORPORATION

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 77 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Information about the Acacia Technologies group is available at www.acaciatechnologies.com.

ABOUT COMBIMATRIX CORPORATION

CombiMatrix is a diversified biotechnology company that develops and sells proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security, as well as other potential markets where our products and services could be utilized. The technologies we have developed include methods to produce DNA arrays for use in identifying and determining the roles of genes, gene mutations and proteins. These technologies have a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Information about CombiMatrix Corporation is available at www.combimatrix.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



Contact:
Acacia Research Corporation
Rob Stewart, Investor Relations, 949-480-8300
Fax: [phone]
or
CombiMatrix Corporation
Amit Kumar, Investor Relations, 425-493-2000
Fax: [phone]

Source: Acacia Research Corporation

[DagobertDuck57]

Antwort auf Beitrag Nr.: 31.168.460 von DagobertDuck57 am 15.08.07 13:35:13

Day\'s Range: 5.19 - 6.20$
Nun hamse wenigstens mal ganz kurz an den 6$ schnuppern dürfen, und schon gehts wieder in die bekannte Richtung: nämlich abwärts!!!

[italy05]

Antwort auf Beitrag Nr.: 31.174.649 von DagobertDuck57 am 15.08.07 20:21:34

kann mir jemand sagen was da los ist, Fr kei handel ?ausgestzt??

danke für die andwort

[DagobertDuck57]

Antwort auf Beitrag Nr.: 31.180.530 von italy05 am 16.08.07 10:39:50

Siehe Posting #441 und #453
http://finance.yahoo.com/q?s=CBMXD

[italy05]

Antwort auf Beitrag Nr.: 31.181.928 von DagobertDuck57 am 16.08.07 11:48:59

kann kein englisch

wiso ist der Kurs in usa auf über 5 dollar u in fr 0,43?

danke

[murkel58]

Ich kann auch kein Englisch, habe aber was von einem Splitt gehört. Es tut sich aber nichts!!!!

[murkel58]

Ich kann auch kein Englisch, habe aber was von einem Splitt gehört. Es tut sich aber nichts!!!!

Gruss Günther